data_6d10_residue ############################ # Computer software used # ############################ save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 6d10 _Structure_validation_residue.Date_analyzed 2019-04-12 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 99.6 mttt . . . . . 0 C--O 1.23 0.073 0 CA-C-O 120.767 0.318 . . . . 0.0 111.212 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -91.95 143.2 26.73 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.218 174.464 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 68.3 tp -93.06 112.55 24.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.271 177.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 58.5 t -115.44 122.8 70.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.192 -178.434 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 41.8 ttm180 -112.1 144.91 40.69 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.225 177.434 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 92.3 t -114.35 119.94 62.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.205 169.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 66.6 tp60 -107.74 107.36 18.1 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.237 -177.611 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 65.0 t-20 -85.11 103.64 14.3 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.269 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 92.1 mt -102.61 17.44 23.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.228 -179.756 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 30.8 p -103.01 -179.33 3.92 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.215 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -104.82 29.25 12.1 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 111.258 -0.737 . . . . 0.0 111.258 174.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 46.1 t -144.8 147.42 32.86 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.808 0.337 . . . . 0.0 111.229 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -69.18 136.49 52.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.189 179.289 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.413 ' C ' HD12 ' A' ' 139' ' ' LEU . 4.4 pp -149.69 165.91 30.94 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.155 179.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 13.4 t -144.95 150.99 37.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.165 -177.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 64.7 tp -100.64 112.33 24.71 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.2 175.018 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 14.6 ptmm? -140.2 178.72 7.08 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.175 -176.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 57.0 p -83.22 164.9 19.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.167 179.011 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -108.45 4.82 24.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.214 177.079 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 75.7 m-20 -104.04 4.3 34.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.182 -177.539 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 174.55 -161.86 31.81 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.196 -0.762 . . . . 0.0 111.196 -178.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -93.81 -5.16 48.83 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.703 0.287 . . . . 0.0 111.146 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 89.4 m -62.0 130.06 43.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.239 178.31 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 42.3 p30 -93.13 177.57 6.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.215 -177.573 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 90.7 t -113.72 -56.27 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.172 177.609 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 99.0 t -117.46 133.41 64.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.247 178.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -100.77 166.38 10.9 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.173 -176.646 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 29.4 t0 64.32 47.38 3.15 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.204 177.118 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 69.7 t -118.27 121.17 66.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.235 174.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -124.59 -165.61 12.22 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 -177.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -75.77 141.01 24.03 Favored 'Trans proline' 0 N--CA 1.458 -0.563 0 C-N-CA 121.728 1.619 . . . . 0.0 111.182 179.247 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 49.64 50.54 18.1 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.217 175.66 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 17.4 t -161.48 -157.52 0.5 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.193 -178.434 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 57.2 p-80 -156.57 164.66 37.94 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.196 179.002 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -147.05 147.56 18.48 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 111.209 -0.756 . . . . 0.0 111.209 179.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 88.0 m-20 -112.55 155.6 24.08 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.739 0.304 . . . . 0.0 111.202 178.766 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 29.2 tpt180 -159.5 127.6 4.95 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.175 175.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -82.66 123.13 28.98 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.189 173.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 80.9 mt -127.89 137.97 56.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.189 -171.554 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 96.3 m-20 -50.45 147.26 8.04 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.236 178.76 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 81.1 Cg_endo -75.17 68.19 5.93 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 121.687 1.591 . . . . 0.0 111.226 -178.644 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 33.5 m -129.45 -178.12 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.203 -177.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -75.89 116.88 17.04 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.228 173.233 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 95.1 t -119.39 121.16 65.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.204 -175.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 170' ' ' ASN . . . . . 0.427 ' HA ' ' HA ' ' A' ' 185' ' ' PRO . 55.1 t-20 -73.31 111.13 8.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.223 178.821 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 59.5 mt -95.82 142.92 27.52 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.244 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -161.88 143.76 11.29 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.189 175.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 65.5 tp -95.84 120.94 37.0 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.251 -178.404 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -118.77 140.44 49.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.257 175.406 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 39.6 t0 -111.46 94.45 4.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.188 171.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 79.22 -105.04 2.2 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 111.205 -0.758 . . . . 0.0 111.205 -173.104 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 88.9 p -115.75 6.06 14.33 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.771 0.32 . . . . 0.0 111.182 172.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -98.05 120.14 37.91 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.217 -176.116 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -66.47 126.89 30.28 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.241 173.433 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 88.0 t -105.65 -53.14 7.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.218 -177.049 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 44.8 t -147.88 140.31 24.46 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.204 -176.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -100.85 107.08 18.53 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.159 176.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 183' ' ' LEU . . . . . 0.536 ' O ' ' HB2' ' A' ' 184' ' ' LYS . 92.1 mt -89.69 -15.98 31.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.24 -171.793 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 184' ' ' LYS . . . . . 0.536 ' HB2' ' O ' ' A' ' 183' ' ' LEU . 74.9 mmtt 83.33 165.08 0.11 Allowed Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.209 167.113 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 185' ' ' PRO . . . . . 0.427 ' HA ' ' HA ' ' A' ' 170' ' ' ASN . 53.4 Cg_exo -59.92 134.74 58.62 Favored 'Trans proline' 0 N--CA 1.458 -0.598 0 C-N-CA 121.689 1.593 . . . . 0.0 111.189 179.099 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 29.9 m -125.28 152.43 31.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.163 172.144 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 97.2 m -94.28 117.17 29.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.211 -179.197 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 93.4 mt -95.11 153.33 17.7 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.163 178.092 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -131.4 156.82 44.9 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.203 177.47 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 89.9 mtm180 -62.77 123.14 17.67 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.21 -176.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 87.47 -1.07 85.71 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 176.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -70.2 133.2 46.83 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.698 0.285 . . . . 0.0 111.231 -179.306 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 98.4 t -113.24 118.28 57.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.218 178.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 33.4 m -131.89 162.42 39.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.216 177.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 46.1 t -150.73 128.36 11.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.19 -179.111 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 60.9 tp -92.24 117.42 29.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.186 177.76 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -102.43 105.79 16.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.19 -179.737 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 54.2 t -105.22 112.79 40.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.21 -178.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 71.8 p -99.61 163.9 12.3 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.122 -178.519 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -116.39 135.24 11.92 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 111.239 -0.745 . . . . 0.0 111.239 179.022 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.2 t -160.69 120.06 2.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.746 0.308 . . . . 0.0 111.162 179.035 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 74.31 15.16 80.29 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 111.228 -0.749 . . . . 0.0 111.228 176.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 89.98 -0.84 79.68 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 111.179 -0.768 . . . . 0.0 111.179 -177.215 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -106.49 158.92 16.55 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.875 0.369 . . . . 0.0 111.157 -179.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 90.4 mt -107.02 141.51 38.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.146 179.522 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -125.33 92.81 46.37 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.268 179.191 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -74.6 127.36 10.91 Favored 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 121.712 1.608 . . . . 0.0 111.16 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 64.3 t -126.81 106.09 15.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.137 174.327 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 10.8 t90 -80.06 124.29 28.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.215 -177.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 98.7 t -120.63 132.56 69.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.167 -175.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -99.93 133.8 43.76 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.233 175.695 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 41.9 mmt180 . . . . . 0 C--O 1.2 -1.501 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.134 -179.484 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 74.4 mmtt . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.736 0.303 . . . . 0.0 111.229 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -143.91 177.78 8.31 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.241 177.015 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 95.4 mt -122.51 147.92 45.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.236 -177.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 12.2 p -134.35 142.84 39.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.205 178.365 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 38.5 ttm180 -117.53 99.31 6.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.203 179.017 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 96.2 t -84.69 121.37 36.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.169 -171.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 69.3 mm-40 -112.83 78.88 1.17 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.183 173.343 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 -89.33 157.41 18.2 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.197 -174.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 58.0 tp -62.97 -40.9 99.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.159 176.856 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 91.7 p -72.04 155.84 39.88 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.194 -175.085 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -113.84 55.4 0.52 Allowed Glycine 0 CA--C 1.524 0.599 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 -179.281 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 99.4 p -145.18 160.2 41.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.789 0.328 . . . . 0.0 111.213 -178.444 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -64.76 124.78 22.83 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.171 178.288 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 73.5 mt -111.06 157.83 19.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.19 -175.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 92.0 m -110.66 127.77 55.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.186 172.345 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 62.4 tp -95.6 123.66 39.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.153 176.387 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 96.3 mttt -123.61 158.52 31.29 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.181 178.314 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 14.5 t -125.18 -175.76 3.39 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.266 178.18 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' ALA . . . . . 0.43 ' O ' ' HB2' ' A' ' 145' ' ' ASP . . . 56.6 54.02 7.84 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.122 -173.284 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.43 ' HB2' ' O ' ' A' ' 144' ' ' ALA . 65.9 m-20 68.03 34.93 3.9 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.216 -178.533 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 72.84 43.64 41.16 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 111.187 -0.765 . . . . 0.0 111.187 174.064 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -118.6 -50.8 2.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.801 0.334 . . . . 0.0 111.136 -175.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 86.4 m -89.96 127.95 36.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.198 -173.207 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -65.67 114.91 5.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.273 -178.027 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 94.2 t -89.03 -59.99 2.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.253 174.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 14.5 p -156.97 143.71 10.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.199 -179.446 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -109.91 -179.28 3.75 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.168 178.62 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 74.6 m-20 59.09 41.57 20.38 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.127 178.044 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.425 ' O ' ' HD3' ' A' ' 156' ' ' PRO . 85.3 t -77.65 130.41 36.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.097 174.562 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -110.58 100.02 1.22 Allowed Glycine 0 CA--C 1.524 0.605 0 N-CA-C 111.151 -0.78 . . . . 0.0 111.151 -176.322 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . 0.425 ' HD3' ' O ' ' A' ' 154' ' ' VAL . 76.7 Cg_exo -56.02 139.53 85.08 Favored 'Trans proline' 0 N--CA 1.458 -0.608 0 C-N-CA 121.732 1.621 . . . . 0.0 111.205 177.483 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 54.06 45.66 27.08 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.179 174.213 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 83.6 p -116.36 -172.6 2.21 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.222 177.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -116.28 78.28 1.18 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.146 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 173.65 171.1 37.85 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 60.0 m-20 -115.26 168.28 10.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.84 0.352 . . . . 0.0 111.225 -177.335 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 91.4 mmt-85 -132.22 155.2 48.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.266 177.283 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -64.41 131.66 47.83 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.224 178.523 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 21.5 tt -141.89 143.14 27.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.253 176.211 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 91.9 m-20 -73.93 126.45 89.41 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.14 176.099 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -79.83 60.42 7.82 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 121.64 1.56 . . . . 0.0 111.142 -176.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 35.6 m -134.06 150.6 31.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.201 179.315 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -86.06 73.19 10.32 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.175 -177.247 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 84.2 t -131.1 142.92 42.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.22 -176.326 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 90.9 m-20 -49.73 119.94 3.88 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.242 -178.577 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 171' ' ' LEU . . . . . 0.455 ' HB2' ' HB2' ' A' ' 183' ' ' LEU . 65.2 mt -103.94 172.34 6.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.172 175.433 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -160.19 148.16 16.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.218 175.563 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 95.3 mt -107.23 135.73 48.25 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.134 176.197 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 81.5 m-85 -124.37 145.68 49.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.214 -177.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -115.03 87.51 2.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.207 171.573 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 78.98 -106.6 2.39 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 111.254 -0.738 . . . . 0.0 111.254 -177.143 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 95.5 p -105.9 -8.05 17.87 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.877 0.37 . . . . 0.0 111.213 175.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -103.4 117.18 33.88 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.2 -175.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 40.4 ttpt -64.03 130.99 46.23 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.254 176.688 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 69.4 t -82.55 -53.7 11.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.156 178.74 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 44.8 t -171.95 142.45 1.47 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.229 -178.067 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -80.27 145.35 32.22 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.281 174.155 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 183' ' ' LEU . . . . . 0.455 ' HB2' ' HB2' ' A' ' 171' ' ' LEU . 61.1 mt -110.06 159.02 17.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.185 -177.385 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -85.57 151.6 56.06 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.203 176.055 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_exo -55.86 142.78 83.59 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 121.748 1.632 . . . . 0.0 111.135 177.62 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 7.6 p -145.93 136.05 18.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.197 -179.731 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 98.7 m -98.75 129.94 45.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.176 -178.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 5.0 mp -125.21 150.49 46.95 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.218 177.123 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -90.35 169.24 11.25 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.271 169.637 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 -64.14 106.99 1.17 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.186 -179.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 92.62 7.24 63.34 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 111.186 -0.766 . . . . 0.0 111.186 178.311 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -76.06 137.86 40.45 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.797 0.332 . . . . 0.0 111.264 -179.817 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 61.3 t -104.27 116.6 48.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.161 178.179 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 97.6 t -120.86 134.66 63.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.149 177.408 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 76.6 m -95.94 153.37 17.8 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.187 -175.426 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 60.1 tp -126.32 117.49 23.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.201 178.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 91.7 m-85 -112.82 111.51 22.33 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.199 -179.281 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 68.8 t -100.02 113.57 35.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.2 -178.537 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 45.9 p -108.34 172.83 6.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.1 -175.433 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 88.81 -151.86 22.61 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 111.343 -0.703 . . . . 0.0 111.343 177.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 45.0 t -151.89 146.41 25.63 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.723 0.297 . . . . 0.0 111.256 179.699 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . -62.19 147.66 48.93 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.096 -0.802 . . . . 0.0 111.096 -176.209 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -98.58 35.26 4.73 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 5.655 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -122.6 68.89 0.96 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.797 0.332 . . . . 0.0 111.185 178.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 96.0 mt -88.6 148.0 24.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.194 -178.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -123.51 95.73 44.67 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.183 -177.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -72.96 135.9 24.04 Favored 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 121.713 1.609 . . . . 0.0 111.217 178.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 93.5 t -127.11 122.71 60.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.247 178.681 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 98.6 m95 -85.36 127.26 34.29 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.241 177.512 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 96.1 t -125.01 128.68 73.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.29 -0.413 . . . . 0.0 111.232 -176.472 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -124.45 120.46 32.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.219 177.459 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 91.0 mmt-85 . . . . . 0 C--O 1.201 -1.472 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.24 -178.167 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 96.0 mttt . . . . . 0 C--O 1.232 0.178 0 CA-C-O 120.706 0.289 . . . . 0.0 111.285 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -121.98 175.07 6.51 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.193 177.699 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 93.4 mt -119.07 139.33 51.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.256 -178.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 94.1 t -124.87 128.5 73.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.259 173.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -122.98 97.88 5.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.137 -177.4 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 61.7 t -98.06 127.8 50.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.143 -177.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 45.9 tt0 -109.45 126.81 53.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.17 178.328 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 51.5 t-20 -101.99 105.29 16.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.26 -177.092 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 83.5 mt -106.73 32.19 4.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.203 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 53.4 p -115.22 -168.22 1.36 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.225 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -108.11 18.08 34.1 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 177.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 47.4 t -150.38 148.77 29.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.858 0.361 . . . . 0.0 111.12 -179.428 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -76.77 163.55 26.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.19 -178.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 4.4 pp -149.31 165.51 31.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.126 -175.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 9.7 t -147.42 149.27 32.39 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.138 -177.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 83.9 mt -113.35 149.21 34.34 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.237 178.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -125.5 162.91 23.85 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.166 -176.038 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 66.9 p -71.28 153.19 42.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.246 178.607 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -68.06 -33.4 74.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.233 179.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -75.47 -19.74 59.23 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.249 178.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 80.14 28.81 48.17 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 111.286 -0.725 . . . . 0.0 111.286 -178.325 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -86.02 -42.07 14.29 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.777 0.322 . . . . 0.0 111.236 -175.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 14.7 t -156.18 -169.41 3.04 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.208 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -96.58 155.59 16.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.304 177.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . 0.456 HG12 HG23 ' A' ' 151' ' ' VAL . 68.8 t -109.29 -55.52 5.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.254 -178.415 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.456 HG23 HG12 ' A' ' 150' ' ' VAL . 84.2 t -123.82 133.6 68.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.191 178.802 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -137.0 143.92 43.02 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.215 -176.479 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 27.9 t0 56.25 63.53 1.97 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.182 175.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 93.8 t -76.21 125.31 35.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.245 178.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -70.52 146.69 42.6 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 179.544 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -73.74 138.75 26.85 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 121.697 1.598 . . . . 0.0 111.185 -178.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 50.47 48.6 22.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.216 177.128 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 46.5 t -162.24 141.28 9.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.194 179.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -78.35 88.67 4.37 Favored 'General case' 0 C--N 1.364 1.212 0 C-N-CA 119.654 -0.818 . . . . 0.0 111.034 -179.235 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -58.29 88.1 0.02 OUTLIER Glycine 0 CA--C 1.524 0.635 0 CA-C-N 115.378 -0.828 . . . . 0.0 111.178 177.175 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 13.9 t70 -69.4 132.83 46.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.782 0.325 . . . . 0.0 111.107 177.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 91.3 mmt-85 -133.62 140.34 47.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.212 -179.511 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 65.9 tt0 -84.56 103.95 14.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.296 173.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 48.3 mm -118.17 137.59 51.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.163 -169.547 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 95.3 m-20 -62.22 154.56 70.02 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.231 176.517 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -75.14 71.85 4.95 Favored 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 121.687 1.591 . . . . 0.0 111.14 -179.073 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 32.7 m -130.54 167.85 24.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.208 -177.237 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -79.58 130.72 35.64 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.178 174.032 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 33.9 m -122.01 149.93 25.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.166 -172.062 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 61.9 t-20 -97.85 110.2 22.81 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.152 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 86.9 mt -79.8 58.23 2.77 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.205 -176.358 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -104.48 141.1 36.98 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.121 178.06 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 76.1 mt -103.33 136.56 42.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.212 -176.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 84.6 m-85 -128.86 148.55 50.9 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.218 -177.453 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 53.2 t0 -129.77 96.25 4.18 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.213 175.349 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 79.34 -105.5 2.27 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 111.231 -0.748 . . . . 0.0 111.231 -176.136 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 88.8 p -115.41 6.68 14.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.869 0.366 . . . . 0.0 111.219 173.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -103.4 133.8 47.84 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.194 -176.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -81.41 128.03 33.41 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.145 172.086 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 93.5 t -103.37 -52.54 7.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.233 -172.459 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 47.6 t -143.34 149.26 37.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.19 -173.372 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 50.6 t0 -130.73 96.18 4.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.182 -177.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 54.8 tp -95.09 137.36 34.24 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.288 177.021 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -46.21 124.17 6.97 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.189 -172.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -54.91 146.96 54.17 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 121.65 1.567 . . . . 0.0 111.267 176.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 35.1 m -127.86 152.53 36.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.157 -177.588 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 96.8 m -93.08 118.04 30.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.194 178.652 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 69.4 tp -104.89 114.46 28.67 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.137 -178.352 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -94.93 154.9 16.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.269 -179.676 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 53.2 ptt85 -60.9 138.62 58.14 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.191 -178.496 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 95.72 -16.51 61.05 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 111.182 -0.767 . . . . 0.0 111.182 178.595 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 84.9 mt-10 -85.69 147.46 26.35 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.773 0.32 . . . . 0.0 111.203 -178.075 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 61.5 t -121.7 120.08 60.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.175 174.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 35.0 m -123.67 150.38 27.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.216 -177.662 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 82.8 m -122.89 158.64 29.92 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.172 177.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 51.7 tp -134.73 117.34 15.9 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.207 174.752 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -105.76 105.79 16.0 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.198 -176.192 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 97.7 t -103.78 125.56 58.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.242 -177.014 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 14.5 t -127.2 -170.42 2.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.239 178.333 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -108.34 135.67 12.99 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 111.229 -0.749 . . . . 0.0 111.229 -178.493 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.6 t -158.82 117.11 2.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.776 0.322 . . . . 0.0 111.215 178.03 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 75.11 14.88 81.45 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.151 -0.779 . . . . 0.0 111.151 177.488 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 89.44 2.03 77.19 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 -178.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -118.91 167.42 11.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.816 0.341 . . . . 0.0 111.21 -179.383 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 99.1 mt -82.21 140.08 33.91 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.217 178.019 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -124.63 95.08 43.44 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.142 -178.613 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -75.98 138.62 20.95 Favored 'Trans proline' 0 N--CA 1.458 -0.594 0 C-N-CA 121.738 1.625 . . . . 0.0 111.228 -178.717 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 65.0 t -127.8 106.62 15.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.186 173.349 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 24.8 t90 -79.97 127.29 32.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.185 -177.31 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 79.0 t -128.56 108.89 18.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.202 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -84.3 127.03 33.73 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.2 176.085 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 97.0 mtt-85 . . . . . 0 C--O 1.2 -1.529 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.209 -177.699 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 88.1 tttt . . . . . 0 CA--C 1.523 -0.078 0 CA-C-O 120.873 0.368 . . . . 0.0 111.132 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . 0.401 ' HA ' ' HB3' ' A' ' 188' ' ' LEU . . . -104.76 163.97 12.11 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.238 178.112 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 64.1 tp -149.45 120.73 7.84 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.183 -178.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 89.0 t -117.03 131.34 70.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.192 -175.362 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 41.2 ttm180 -102.29 116.46 32.68 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.172 172.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 65.1 t -105.66 125.44 61.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.199 -175.39 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 38.1 tt0 -120.71 127.5 52.07 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.223 -177.052 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 48.1 t-20 -89.86 110.06 21.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.088 176.005 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 95.3 mt -111.61 14.84 21.28 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.11 177.338 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 38.1 p -85.65 -179.73 6.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.177 -179.211 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -98.03 14.11 62.91 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 111.192 -0.763 . . . . 0.0 111.192 177.447 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 18.7 t -136.55 -166.78 1.95 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.849 0.357 . . . . 0.0 111.086 -179.423 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 34.4 mmtp -95.46 136.97 35.16 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.256 -177.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.413 ' HB3' ' HB ' ' A' ' 154' ' ' VAL . 56.8 tp -102.03 131.72 48.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.293 -178.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 98.7 m -130.97 136.2 48.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.143 178.295 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 79.6 mt -125.4 142.87 51.26 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.218 172.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 60.6 mttm -118.78 163.84 16.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.166 -177.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 74.3 p -75.42 162.77 28.07 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.2 -177.347 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -65.17 -40.82 94.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.162 -175.23 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -78.62 -19.21 53.2 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.209 -178.261 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 80.55 21.93 63.25 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 111.2 -0.76 . . . . 0.0 111.2 -177.454 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -77.98 -36.47 48.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.728 0.299 . . . . 0.0 111.172 -178.305 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 14.7 t -154.95 -169.08 3.08 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.246 176.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -99.31 150.92 21.63 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.193 -179.766 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 69.3 t -89.03 -46.31 15.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.234 171.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 12.0 p -161.42 144.04 3.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.176 173.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 64.0 pttt -145.63 158.96 43.78 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.137 -175.303 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 28.4 t0 60.2 43.35 14.08 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.218 178.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.413 ' HB ' ' HB3' ' A' ' 139' ' ' LEU . 98.6 t -87.6 119.08 34.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.251 174.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -81.97 165.91 46.03 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 -175.14 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 63.5 Cg_exo -57.0 147.17 76.32 Favored 'Trans proline' 0 N--CA 1.458 -0.6 0 C-N-CA 121.691 1.594 . . . . 0.0 111.276 177.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 56.53 50.67 12.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.153 178.453 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 77.8 p -150.44 158.19 43.87 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.238 172.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 27.7 p-80 -151.56 167.45 28.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.169 -173.33 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -161.56 162.28 33.8 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 111.219 -0.752 . . . . 0.0 111.219 175.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -101.3 144.42 30.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.73 0.3 . . . . 0.0 111.293 -176.19 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 87.8 mmt-85 -138.91 130.04 26.74 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.17 176.137 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 91.1 mt-10 -84.69 144.91 28.24 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.207 179.26 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 19.5 tt -160.15 151.74 5.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.179 -179.051 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -73.62 142.03 80.26 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.221 175.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -78.75 60.37 7.65 Favored 'Trans proline' 0 N--CA 1.458 -0.59 0 C-N-CA 121.732 1.621 . . . . 0.0 111.2 -178.199 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 33.5 m -131.73 178.71 5.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.175 -178.038 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -69.76 112.52 6.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.169 176.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 35.6 m -129.31 164.35 32.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.211 -178.651 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 49.7 t30 -97.89 99.93 11.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.287 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 82.3 mt -104.69 146.64 28.65 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.229 178.008 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -147.59 152.67 38.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.19 -177.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 51.8 tp -112.95 121.38 44.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.215 -173.132 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 72.8 m-85 -118.76 140.2 50.33 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.157 -176.558 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 64.2 t0 -104.33 98.2 8.03 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.122 170.674 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 77.59 -103.38 1.85 Allowed Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.129 -0.788 . . . . 0.0 111.129 -173.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 93.4 p -118.31 0.11 11.62 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.824 0.345 . . . . 0.0 111.134 175.21 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -108.38 130.14 55.23 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.244 -177.421 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -69.53 137.74 52.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.208 -179.052 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 88.4 t -99.67 -52.04 9.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.235 174.084 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 19.1 t -163.36 -158.77 0.48 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.205 -178.668 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 74.0 m-20 -114.0 160.8 18.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.203 177.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 93.9 mt -115.99 152.28 33.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.24 178.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -98.08 117.94 64.35 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.301 179.151 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_exo -55.07 130.45 40.8 Favored 'Trans proline' 0 N--CA 1.458 -0.583 0 C-N-CA 121.728 1.619 . . . . 0.0 111.128 177.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 99.2 t -121.73 127.4 75.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.227 175.006 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 71.1 p -84.53 166.61 17.08 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.174 -178.454 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . 0.418 ' C ' HD23 ' A' ' 188' ' ' LEU . 10.4 tt -137.07 123.65 20.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.226 -176.704 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -98.97 164.29 12.25 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.234 177.151 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 79.9 ttt180 -52.97 116.85 2.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.188 178.142 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 100.07 -14.49 59.9 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 178.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -87.56 143.75 27.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.801 0.334 . . . . 0.0 111.21 -179.285 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 193' ' ' VAL . . . . . 0.411 ' HB ' ' HB2' ' A' ' 212' ' ' ARG . 90.2 t -119.38 129.64 75.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.15 174.179 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 89.7 t -115.82 125.25 72.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.191 179.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 74.9 m -125.7 156.85 38.69 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.185 179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 58.0 tp -130.03 118.5 21.67 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.205 175.451 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 88.7 m-85 -111.72 113.0 25.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.299 -178.444 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 80.5 t -107.86 120.27 58.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.177 -177.561 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 14.5 t -124.71 -169.45 1.98 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.203 -178.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -108.18 134.91 12.49 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 111.173 -0.771 . . . . 0.0 111.173 -177.691 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.6 t -160.22 118.32 2.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.787 0.327 . . . . 0.0 111.144 177.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 75.98 14.25 82.39 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 176.366 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 91.33 -0.5 75.03 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 -178.602 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -120.26 169.03 10.64 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.657 0.265 . . . . 0.0 111.229 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 82.6 mt -78.73 141.61 37.73 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.236 176.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -123.99 98.39 39.41 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.253 179.12 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -78.54 141.19 17.46 Favored 'Trans proline' 0 C--N 1.327 -0.587 0 C-N-CA 121.708 1.606 . . . . 0.0 111.212 -177.076 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 66.8 t -129.61 110.67 20.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.253 176.5 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 94.9 m95 -83.47 127.46 33.72 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.182 176.628 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 84.7 t -123.7 125.69 71.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.215 -177.421 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 56.2 mtmt -109.26 135.09 50.92 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.21 174.568 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 212' ' ' ARG . . . . . 0.411 ' HB2' ' HB ' ' A' ' 193' ' ' VAL . 82.2 mtp180 . . . . . 0 C--O 1.2 -1.543 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.142 179.053 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 17.5 ptpt . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.785 0.326 . . . . 0.0 111.186 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -92.85 155.21 17.76 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.226 -176.096 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 60.8 tp -111.11 121.9 46.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.228 175.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 97.9 t -110.38 124.2 66.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.227 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 39.7 ttm180 -115.6 125.9 53.52 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.248 176.619 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 66.1 t -115.53 130.25 70.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.172 -175.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 37.1 tt0 -113.43 130.43 56.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.194 179.446 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 47.2 t30 -114.6 117.4 30.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.206 177.331 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 98.4 mt -102.77 -9.02 20.35 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.24 177.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 73.8 p -81.01 156.11 26.06 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.218 -178.318 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -83.14 -12.61 78.88 Favored Glycine 0 CA--C 1.523 0.571 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 -174.726 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 62.7 p -93.67 169.98 9.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.771 0.319 . . . . 0.0 111.251 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -73.97 135.22 43.17 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.214 -175.526 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 65.7 tp -108.23 121.15 44.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.218 174.24 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 97.7 m -130.4 130.69 44.67 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.175 174.49 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 82.9 mt -112.87 116.11 29.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.223 -178.427 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -119.57 156.24 30.71 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.217 177.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 74.9 p -84.02 154.78 23.08 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.166 -178.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -62.88 116.76 5.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.207 -176.412 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 55.21 33.89 21.54 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.164 177.12 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -106.7 -171.42 22.73 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 177.855 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -130.36 -6.59 4.25 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.832 0.349 . . . . 0.0 111.202 177.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 97.2 m -114.39 127.05 55.65 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.19 179.041 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 42.7 p30 -92.38 -179.37 5.2 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.245 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 26.9 m -128.89 -30.89 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.217 176.068 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 71.5 t -133.91 136.92 53.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.202 174.419 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -148.33 138.48 22.55 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.204 -176.64 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 45.3 t0 56.3 60.43 3.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.213 172.598 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 84.2 t -111.37 128.87 67.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.203 173.118 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -96.79 -164.42 32.77 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 -177.447 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -71.82 148.12 51.51 Favored 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 121.693 1.595 . . . . 0.0 111.176 -178.435 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 77.3 mt-30 52.8 50.6 17.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.204 178.565 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 44.9 t -142.06 148.91 39.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.199 -176.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 71.3 m80 -124.6 149.42 47.07 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.21 -176.053 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -134.6 132.58 6.38 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 174.696 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -106.83 135.1 48.95 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.797 0.332 . . . . 0.0 111.193 177.181 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 24.9 tpp180 -144.04 118.58 9.73 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.224 178.157 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -83.88 127.02 33.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.19 175.486 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 78.8 mt -130.85 137.32 56.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.172 -174.632 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . 0.402 ' HA ' ' HD3' ' A' ' 166' ' ' PRO . 96.3 m-20 -57.67 154.62 24.93 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.233 -178.12 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 166' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 165' ' ' ASN . 47.9 Cg_exo -65.37 78.24 0.24 Allowed 'Trans proline' 0 N--CA 1.458 -0.608 0 C-N-CA 121.675 1.583 . . . . 0.0 111.259 -177.609 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 32.1 m -136.56 167.61 23.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.253 177.154 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 89.0 tttt -77.89 116.48 18.43 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.206 173.166 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 63.9 t -113.15 121.11 64.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.162 -174.285 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 64.6 t-20 -105.12 99.84 9.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.217 176.719 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 94.4 mt -95.03 167.63 11.27 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.196 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -144.19 148.55 35.12 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.194 174.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 73.9 mt -80.1 117.71 21.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.176 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 78.4 m-85 -113.86 152.2 31.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.233 173.487 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -148.29 99.53 3.05 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.175 -178.486 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 80.37 -106.58 2.52 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 111.179 -0.768 . . . . 0.0 111.179 -179.323 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 86.0 p -117.83 8.78 12.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.728 0.299 . . . . 0.0 111.147 -179.468 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 65.3 pttt -128.01 164.43 22.37 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.207 -177.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -102.77 136.08 43.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.227 174.448 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 86.2 t -87.1 -55.32 6.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.155 -178.39 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 43.7 t -172.64 142.23 1.19 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.179 -175.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 93.1 m-20 -70.36 150.38 46.36 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.201 178.427 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 94.8 mt -103.09 153.45 20.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.178 177.387 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -64.93 127.31 92.61 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.187 176.551 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_exo -54.63 135.02 65.27 Favored 'Trans proline' 0 N--CA 1.458 -0.593 0 C-N-CA 121.696 1.597 . . . . 0.0 111.223 177.088 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 85.1 t -120.31 124.29 72.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.213 179.232 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 92.5 m -82.35 118.47 23.19 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.198 174.511 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 92.2 mt -96.76 143.46 27.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.208 -174.261 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -122.73 150.09 43.22 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.196 173.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 190' ' ' ARG . . . . . 0.435 ' HG3' ' O ' ' A' ' 190' ' ' ARG . 18.4 ptp180 -52.79 120.79 6.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.194 177.727 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 93.4 -6.54 75.02 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 175.793 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -74.94 136.51 41.37 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.805 0.336 . . . . 0.0 111.224 -178.134 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 99.1 t -109.08 118.0 55.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.163 177.367 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 85.6 t -121.98 131.55 72.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.143 -177.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 71.0 m -114.73 146.16 41.26 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.245 -179.045 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 65.8 tp -128.0 116.41 20.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.234 175.639 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -106.11 108.06 19.38 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.185 -177.449 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 85.1 t -109.73 121.98 63.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.169 -178.09 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 14.5 t -127.55 -171.02 2.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.192 177.803 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -107.26 135.17 12.6 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 111.184 -0.767 . . . . 0.0 111.184 -177.607 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.7 t -159.19 116.81 2.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.825 0.345 . . . . 0.0 111.222 177.676 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 75.2 14.91 81.46 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 177.084 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 90.19 0.69 76.75 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 -178.17 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -118.88 169.15 10.11 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.826 0.346 . . . . 0.0 111.22 -179.675 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 92.1 mt -82.43 141.95 32.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.187 177.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -122.87 93.27 48.53 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.215 179.367 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -79.7 143.37 16.7 Favored 'Trans proline' 0 N--CA 1.459 -0.549 0 C-N-CA 121.631 1.554 . . . . 0.0 111.168 -177.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 67.9 t -132.39 120.8 44.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.21 172.65 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 95.6 m95 -86.35 125.53 33.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.191 178.115 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 93.4 t -133.59 128.71 54.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.226 177.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 90.4 mttt -108.25 148.2 30.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.206 178.036 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 . . . . . 0 C--O 1.2 -1.54 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.176 179.811 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 96.4 mttt . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.835 0.35 . . . . 0.0 111.181 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -94.72 152.93 18.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.2 -179.463 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 62.4 tp -105.41 120.29 41.23 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.239 174.202 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 91.2 t -119.02 135.59 58.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.2 -178.241 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -128.79 142.02 51.12 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.136 175.283 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 83.8 t -121.82 118.16 54.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.232 176.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 4.1 tp-100 -116.53 107.53 14.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.228 -175.513 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 63.1 t-20 -80.22 106.03 11.93 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.192 179.505 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 92.9 mt -106.08 11.27 31.63 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.15 179.616 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 33.1 p -83.98 179.76 7.45 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.242 -178.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -104.56 23.83 30.35 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 111.166 -0.774 . . . . 0.0 111.166 176.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 27.1 t -150.14 179.74 7.84 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.886 0.374 . . . . 0.0 111.157 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -75.57 138.47 41.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.233 -178.288 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 59.2 tp -92.15 119.1 31.48 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.181 175.604 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' THR . . . . . 0.413 ' HB ' ' HB2' ' A' ' 174' ' ' PHE . 96.5 m -123.56 125.84 45.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.131 174.492 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 85.0 mt -126.4 135.36 51.33 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.247 179.408 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 60.9 mttm -123.38 151.75 42.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.182 177.489 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 8.7 t -63.07 136.53 57.85 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.159 177.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -75.05 -6.67 50.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.181 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -89.6 -0.51 57.57 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.235 178.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -178.23 -121.57 0.71 Allowed Glycine 0 CA--C 1.524 0.626 0 N-CA-C 111.176 -0.769 . . . . 0.0 111.176 178.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -145.79 11.56 1.25 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.864 0.364 . . . . 0.0 111.216 179.356 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 89.0 m -61.5 129.9 43.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.088 -177.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -64.03 129.71 41.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.22 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 89.7 t -113.82 -51.31 5.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.148 173.001 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 95.9 t -124.25 137.03 58.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.095 173.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 62.6 pttt -164.81 161.3 20.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.18 174.655 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 75.3 m-20 57.89 42.95 22.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.397 -179.688 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 92.6 t -112.4 115.62 50.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.185 176.011 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -84.87 -173.31 49.81 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.212 -0.755 . . . . 0.0 111.212 -179.055 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo -72.4 155.98 55.0 Favored 'Trans proline' 0 N--CA 1.457 -0.664 0 C-N-CA 121.791 1.661 . . . . 0.0 111.176 -179.06 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 55.1 52.02 12.4 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.187 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 41.7 t -137.88 126.28 23.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.193 -178.042 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 56.0 p-80 -161.59 173.22 15.08 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.365 -176.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 175.57 170.41 38.4 Favored Glycine 0 CA--C 1.522 0.478 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 177.352 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -73.43 146.29 45.14 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.842 0.353 . . . . 0.0 111.253 -178.541 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 90.9 mmt-85 -132.7 121.33 22.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.253 172.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -86.36 103.1 14.62 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.254 177.652 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 80.2 mt -131.28 134.22 61.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.218 -173.105 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 92.7 m-20 -68.25 153.07 96.04 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.22 178.6 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo -51.26 118.4 4.29 Favored 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 121.749 1.633 . . . . 0.0 111.205 176.345 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.443 ' H ' ' HB2' ' A' ' 188' ' ' LEU . 9.1 p -167.77 149.2 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.15 -177.034 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 40.7 ttmt -72.06 115.59 11.46 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.273 173.235 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 99.2 t -100.08 119.9 48.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.199 -177.577 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 62.2 t-20 -134.2 100.97 4.86 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.175 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 76.7 mt -114.39 152.63 31.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.127 -177.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -90.42 142.73 27.44 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.282 175.11 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 60.9 tp -97.58 117.19 31.31 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.131 -170.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 174' ' ' PHE . . . . . 0.413 ' HB2' ' HB ' ' A' ' 140' ' ' THR . 82.1 m-85 -116.77 137.81 51.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.261 177.467 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -91.72 97.71 11.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.184 166.407 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 69.26 -83.51 0.25 Allowed Glycine 0 CA--C 1.522 0.49 0 N-CA-C 111.177 -0.769 . . . . 0.0 111.177 -171.475 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 93.6 p -135.08 -1.26 2.67 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.849 0.357 . . . . 0.0 111.22 177.516 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -103.63 117.44 34.4 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.258 -177.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -61.86 128.74 37.63 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.19 -176.691 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 92.2 t -96.45 -51.06 11.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.153 174.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 17.9 t -164.51 -157.52 0.37 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.165 -179.159 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 58.1 m-20 -125.27 144.08 50.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.185 172.376 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 94.0 mt -83.13 144.16 30.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.124 -178.138 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -65.08 129.91 94.64 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.187 179.254 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 75.9 Cg_exo -55.25 124.3 15.94 Favored 'Trans proline' 0 N--CA 1.459 -0.542 0 C-N-CA 121.666 1.577 . . . . 0.0 111.129 175.736 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 96.0 t -123.52 124.94 70.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.23 175.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 94.9 m -85.77 122.32 29.68 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.238 178.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . 0.443 ' HB2' ' H ' ' A' ' 167' ' ' VAL . 74.0 mt -85.55 156.08 20.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.061 178.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -150.55 153.09 35.15 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.206 -179.792 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 41.3 ptt180 -57.83 128.37 36.73 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.228 -175.566 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 91.96 -13.52 66.69 Favored Glycine 0 CA--C 1.523 0.556 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 173.033 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 72.6 mm-40 -87.38 149.22 24.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.838 0.351 . . . . 0.0 111.09 -176.08 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 67.3 t -116.09 120.87 66.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.194 177.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 92.4 t -120.91 122.73 68.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.221 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 74.5 m -116.48 144.32 44.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.197 -177.585 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 66.1 tp -114.47 117.01 29.77 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.149 175.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -106.62 99.42 8.99 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.221 -178.697 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . 0.471 ' HA ' ' HA ' ' A' ' 207' ' ' PRO . 90.3 t -83.42 115.94 26.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.301 -0.408 . . . . 0.0 111.188 -174.319 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 28.4 p -110.33 174.3 5.92 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.199 179.332 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -149.71 144.69 12.32 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 111.166 -0.774 . . . . 0.0 111.166 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.7 t -160.75 120.37 2.7 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.779 0.323 . . . . 0.0 111.265 177.137 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 75.31 14.05 82.27 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 111.267 -0.733 . . . . 0.0 111.267 178.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 95.92 -5.86 66.57 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 -178.418 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -103.5 134.6 46.58 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.826 0.346 . . . . 0.0 111.161 -179.261 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 99.4 mt -83.36 150.8 25.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.227 179.318 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -150.09 73.77 9.28 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.203 177.028 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 207' ' ' PRO . . . . . 0.471 ' HA ' ' HA ' ' A' ' 198' ' ' VAL . 46.2 Cg_exo -63.4 147.71 93.24 Favored 'Trans proline' 0 N--CA 1.456 -0.704 0 C-N-CA 121.729 1.619 . . . . 0.0 111.248 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 87.3 t -118.91 127.72 75.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.22 176.674 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 97.1 m95 -84.15 128.5 34.6 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.253 175.113 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 89.7 t -125.96 122.82 62.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.16 178.144 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -106.41 127.78 53.55 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.141 178.104 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 84.8 mtt85 . . . . . 0 C--O 1.2 -1.501 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.257 179.545 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 94.4 mttt . . . . . 0 N--CA 1.457 -0.096 0 CA-C-O 120.752 0.311 . . . . 0.0 111.193 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -74.02 147.88 42.5 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.185 179.263 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 88.7 mt -114.85 149.82 36.5 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.235 175.225 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 86.3 t -125.77 128.34 72.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.28 178.655 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . 0.609 HH21 ' CE1' ' A' ' 159' ' ' HIS . 81.9 mtp180 -117.7 157.72 25.99 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.235 178.281 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 14.2 p -130.95 142.42 43.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.147 175.251 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 66.7 tp60 -148.21 109.4 4.32 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.183 179.374 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . 0.457 ' HA ' ' HB ' ' A' ' 198' ' ' VAL . 64.2 t-20 -86.18 108.97 18.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.166 -175.343 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 87.8 mt -90.99 -4.08 56.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.263 179.564 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 27.4 p -102.24 -178.3 3.66 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.192 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -103.66 8.54 51.37 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 111.201 -0.76 . . . . 0.0 111.201 176.566 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 94.9 p -90.39 160.01 16.29 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.816 0.341 . . . . 0.0 111.166 -175.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 39.4 ttpt -107.95 119.29 39.03 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.275 176.177 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 52.0 mt -131.69 150.56 52.11 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.228 -176.776 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 60.1 m -106.68 129.28 54.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.215 174.253 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 63.0 tp -95.48 121.29 37.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.225 -178.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -145.07 145.31 31.39 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.217 -179.535 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 81.1 p -68.8 150.6 47.65 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.223 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -60.62 121.81 13.14 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.209 -178.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 79.5 m-20 56.19 36.18 27.0 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.286 -179.174 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -86.45 -179.81 49.35 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 111.171 -0.772 . . . . 0.0 111.171 177.059 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -113.4 -23.75 9.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.774 0.321 . . . . 0.0 111.181 -179.483 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 89.9 m -128.87 136.88 51.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.175 -175.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 76.5 m-20 -65.2 145.82 55.76 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.239 178.48 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . 0.473 HG12 HG23 ' A' ' 151' ' ' VAL . 91.7 t -87.51 -57.04 4.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.194 178.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.473 HG23 HG12 ' A' ' 150' ' ' VAL . 46.9 t -130.71 124.33 56.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.178 169.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -94.38 138.06 32.78 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.167 -176.16 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 72.4 m-20 53.84 62.86 2.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.159 171.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 96.7 t -74.26 106.21 3.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.228 176.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -90.09 179.62 43.96 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 -176.564 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -57.39 127.7 26.53 Favored 'Trans proline' 0 C--N 1.327 -0.585 0 C-N-CA 121.702 1.601 . . . . 0.0 111.209 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 94.7 mm-40 66.2 19.32 11.08 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.218 175.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 35.8 t -73.37 145.74 45.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.235 176.772 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 159' ' ' HIS . . . . . 0.609 ' CE1' HH21 ' A' ' 130' ' ' ARG . 82.5 t60 -149.74 143.89 25.72 Favored 'General case' 0 CA--C 1.509 -0.607 0 CA-C-O 122.115 0.959 . . . . 0.0 111.029 178.613 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -158.84 157.43 28.43 Favored Glycine 0 CA--C 1.524 0.602 0 CA-C-N 114.868 -1.06 . . . . 0.0 111.224 -179.425 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 75.8 m-20 -113.01 147.37 37.33 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.849 0.357 . . . . 0.0 111.174 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 90.9 mmt-85 -138.85 148.09 43.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.178 178.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -110.06 134.83 51.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.184 173.731 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 20.2 tt -147.77 149.43 15.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.194 -175.082 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 97.0 m-20 -50.21 142.99 13.5 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.202 174.569 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -78.82 65.21 8.78 Favored 'Trans proline' 0 N--CA 1.457 -0.643 0 C-N-CA 121.764 1.642 . . . . 0.0 111.201 -173.615 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 34.3 m -133.42 160.78 42.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.23 176.343 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -65.91 108.44 2.17 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.061 -179.334 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 93.0 t -121.35 125.35 73.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.289 178.037 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 83.9 m-20 -99.38 141.81 31.68 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.162 177.322 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 5.4 mp -124.67 172.6 9.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.167 -174.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -148.11 166.06 28.96 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.207 -178.296 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 67.4 mt -94.69 135.43 36.17 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.251 177.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 -128.91 156.57 43.5 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.204 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 67.9 t0 -144.43 95.42 2.71 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.237 175.363 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 79.88 -106.38 2.44 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 111.199 -0.76 . . . . 0.0 111.199 179.827 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 88.1 p -115.52 7.87 15.02 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.797 0.332 . . . . 0.0 111.184 178.638 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -125.71 130.34 51.32 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.227 -178.309 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 38.9 ttpt -71.23 135.2 47.39 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.216 176.434 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 70.4 t -83.2 -55.57 7.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.152 -179.239 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 43.6 t -173.9 142.13 0.85 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.223 -176.038 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -69.09 146.84 52.24 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.223 176.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 94.6 mt -95.3 158.95 15.23 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.196 176.307 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -57.74 130.37 82.02 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.161 177.647 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_exo -52.85 140.1 58.42 Favored 'Trans proline' 0 N--CA 1.457 -0.661 0 C-N-CA 121.783 1.655 . . . . 0.0 111.17 177.504 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 8.2 p -143.49 136.24 24.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.119 -175.387 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 97.7 m -95.92 131.14 42.58 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.237 176.335 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 59.7 mt -100.04 96.03 7.25 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.171 -176.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -70.14 142.65 52.51 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.226 -177.448 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 80.6 ttt180 -66.55 125.9 27.19 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.241 -176.005 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 93.0 -10.52 73.71 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 173.549 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -103.22 178.93 4.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.788 0.328 . . . . 0.0 111.144 -178.32 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 7.4 p -135.09 139.6 46.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.148 -177.308 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 33.3 m -113.1 156.55 14.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.158 172.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 49.5 t -134.8 129.23 34.24 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.245 179.46 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 66.0 tp -89.45 115.29 26.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.237 177.133 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -101.47 104.34 15.26 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.194 176.571 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . 0.457 ' HB ' ' HA ' ' A' ' 133' ' ' ASN . 84.8 t -79.05 114.2 19.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.207 -173.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 15.3 t -143.84 -160.85 1.17 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.227 179.361 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 167.33 -171.61 42.05 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 44.3 t -162.35 129.21 3.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.732 0.301 . . . . 0.0 111.191 -179.452 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 75.57 15.9 80.96 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 111.157 -0.777 . . . . 0.0 111.157 177.089 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 99.17 -13.91 61.51 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 111.128 -0.789 . . . . 0.0 111.128 -178.327 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -88.7 123.69 33.39 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.777 0.322 . . . . 0.0 111.136 -179.377 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 96.8 mt -74.28 138.33 43.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.141 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -152.8 70.39 7.19 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.246 173.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -58.31 148.26 80.36 Favored 'Trans proline' 0 N--CA 1.458 -0.575 0 C-N-CA 121.783 1.655 . . . . 0.0 111.201 176.363 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 85.6 t -119.62 129.16 75.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.216 -177.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 92.0 m95 -83.59 128.34 34.44 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.229 172.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 86.7 t -121.41 124.87 72.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.2 175.743 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 28.1 ttpp -97.04 128.22 43.78 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.109 179.524 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 96.4 mtt-85 . . . . . 0 C--O 1.201 -1.484 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.236 -178.834 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 99.9 mttt . . . . . 0 CA--C 1.523 -0.069 0 CA-C-O 120.876 0.37 . . . . 0.0 111.138 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -143.36 173.11 11.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.197 174.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 93.7 mt -127.45 142.43 51.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.136 177.059 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 10.0 p -125.05 133.76 68.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.155 175.143 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 44.3 ttm180 -135.6 146.53 48.02 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.109 -177.163 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 98.8 t -125.85 127.24 71.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.167 176.764 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 62.9 tp60 -95.28 128.18 41.92 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.199 -179.688 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 57.5 t-20 -87.17 110.42 20.14 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.237 173.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 94.3 mt -101.76 7.91 41.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.123 177.119 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 30.5 t -101.35 158.82 15.77 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.178 178.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -79.85 -9.73 86.44 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.274 -0.731 . . . . 0.0 111.274 172.785 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 87.5 p -91.31 169.96 10.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.854 0.359 . . . . 0.0 111.109 173.321 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -89.1 156.08 19.04 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.197 177.536 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 84.7 mt -109.98 152.75 25.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.236 178.102 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 49.7 p -125.47 78.5 1.73 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.22 177.052 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 38.1 tp -70.92 120.88 17.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.116 -170.041 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -142.99 153.44 43.0 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.236 -178.016 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 85.6 m -57.3 125.31 22.23 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.244 174.117 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -59.07 118.3 5.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.233 -177.426 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 57.34 29.85 17.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.172 -179.566 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -113.38 -171.17 17.75 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.229 -0.748 . . . . 0.0 111.229 177.291 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -115.76 -4.19 12.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.829 0.347 . . . . 0.0 111.181 177.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 99.8 m -98.43 117.15 32.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.139 -175.529 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 81.2 m-20 -74.49 146.56 42.63 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.204 172.611 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . 0.493 HG12 HG23 ' A' ' 151' ' ' VAL . 60.1 t -108.95 -64.89 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.146 -175.192 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.493 HG23 HG12 ' A' ' 150' ' ' VAL . 99.4 t -141.47 120.28 10.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.204 172.06 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 54.2 mtmt -113.38 160.11 18.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.179 -178.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 32.1 t0 62.08 47.77 5.5 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.191 178.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 93.9 t -78.25 114.62 19.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.184 175.288 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -66.7 156.59 51.23 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 -171.549 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -55.02 132.79 54.4 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 121.797 1.665 . . . . 0.0 111.103 177.361 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 92.9 mm-40 57.08 33.09 22.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.162 179.506 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 19.2 t -119.06 -161.49 0.85 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.182 175.572 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 34.3 p80 -160.36 170.11 21.73 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.259 179.481 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -156.66 159.88 29.86 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 176.43 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 20.9 p30 -149.32 175.86 11.06 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.793 0.33 . . . . 0.0 111.237 -175.293 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 58.1 ttm-85 -156.05 140.69 16.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.208 -178.22 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -71.26 128.85 37.29 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.307 171.327 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 19.9 tt -159.06 153.93 5.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.147 -172.054 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 95.6 m-20 -62.87 154.08 77.38 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.181 176.433 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -75.16 71.36 5.13 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 121.725 1.617 . . . . 0.0 111.238 -179.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 33.4 m -126.26 179.83 3.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.181 -177.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -76.37 121.08 22.5 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.179 173.732 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 76.9 t -114.18 121.05 65.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.178 -176.367 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 87.3 m-20 -96.36 119.06 34.16 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.196 177.418 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 77.3 mt -113.76 154.19 27.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.206 -174.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -158.39 162.54 37.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.267 179.22 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 68.0 mt -111.73 148.58 33.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.154 173.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 35.0 p90 -142.76 160.1 40.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.198 -174.122 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 67.7 t0 -131.39 91.36 3.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.128 174.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 79.49 -106.73 2.45 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 -177.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 95.1 p -106.29 -9.26 16.89 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.784 0.326 . . . . 0.0 111.168 177.012 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -104.29 117.71 34.88 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.159 -176.138 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 39.0 ttpt -66.59 136.53 55.73 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.249 177.426 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 72.2 t -86.04 -56.29 5.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.251 -178.441 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 43.5 t -171.36 143.63 1.86 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.19 -176.342 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -72.48 150.33 43.37 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.217 176.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 82.4 mt -106.16 159.33 16.17 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.237 175.32 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 56.4 tptt -55.58 116.29 11.58 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.262 -179.802 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 77.1 Cg_exo -56.38 141.95 88.93 Favored 'Trans proline' 0 N--CA 1.459 -0.514 0 C-N-CA 121.602 1.535 . . . . 0.0 111.155 178.26 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 73.3 t -121.32 127.39 75.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.202 -177.415 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 97.1 m -95.33 116.67 29.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.171 170.194 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 83.3 mt -90.84 158.25 16.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.199 -175.539 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -136.53 156.36 48.69 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.198 -179.492 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 75.3 mtp180 -62.51 124.37 20.76 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.157 -174.453 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 78.7 13.32 83.28 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 111.194 -0.762 . . . . 0.0 111.194 173.172 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 92.5 mt-10 -121.29 158.34 28.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.769 0.318 . . . . 0.0 111.149 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 7.3 p -131.91 139.22 50.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.216 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 84.6 t -112.41 136.43 48.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.212 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 44.6 t -114.72 110.85 20.37 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.214 172.223 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 52.7 tp -90.82 110.57 21.78 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.157 -178.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 197' ' ' TYR . . . . . 0.407 ' HB2' ' HB ' ' A' ' 208' ' ' VAL . 85.3 m-85 -86.75 96.77 10.28 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.192 -175.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 97.3 t -86.76 121.58 37.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.178 -174.469 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 14.8 t -153.19 -169.11 3.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.207 178.377 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 144.54 -162.77 27.96 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 111.204 -0.758 . . . . 0.0 111.204 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.3 t -171.5 143.65 1.81 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.833 0.349 . . . . 0.0 111.148 -177.683 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 76.48 16.3 80.83 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 111.192 -0.763 . . . . 0.0 111.192 174.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 94.96 -6.52 69.51 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 111.114 -0.795 . . . . 0.0 111.114 -178.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -98.73 115.72 29.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.766 0.317 . . . . 0.0 111.102 179.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 91.5 mt -98.72 154.25 18.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.086 -177.291 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -150.74 73.96 8.72 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.208 176.449 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_exo -58.05 139.02 88.92 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 121.656 1.571 . . . . 0.0 111.161 178.653 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 208' ' ' VAL . . . . . 0.407 ' HB ' ' HB2' ' A' ' 197' ' ' TYR . 57.5 t -104.73 114.29 43.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.22 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 209' ' ' TRP . . . . . 0.435 ' CD1' ' C ' ' A' ' 209' ' ' TRP . 7.3 t90 -77.76 96.97 5.04 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.199 -178.082 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 98.3 t -106.23 115.41 47.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.219 175.277 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 29.2 ttpp -102.38 132.53 48.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.206 178.56 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 83.0 mtt85 . . . . . 0 C--O 1.202 -1.412 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.174 179.632 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 62.9 pttt . . . . . 0 C--O 1.232 0.183 0 CA-C-O 120.722 0.296 . . . . 0.0 111.271 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -142.13 167.9 21.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.201 -174.792 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 69.3 mt -120.86 154.73 35.42 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.129 176.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 13.1 p -141.39 137.0 32.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.296 177.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -125.82 149.24 48.78 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.166 172.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 87.4 t -128.71 120.12 51.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.128 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 64.7 tt0 -110.41 138.57 46.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.239 -174.366 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 64.7 t-20 -88.72 109.62 20.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.223 177.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 7.8 mp -105.93 34.94 3.08 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.284 178.256 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 59.6 p -132.8 173.1 11.73 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.16 177.445 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -86.71 -12.63 68.75 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 175.295 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 95.9 p -88.47 167.02 13.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.888 0.375 . . . . 0.0 111.207 179.13 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -79.04 135.87 37.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.275 178.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 60.5 tp -107.85 131.41 54.52 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.293 -175.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 93.5 m -133.37 128.43 35.6 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.334 172.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.4 HD23 ' C ' ' A' ' 141' ' ' LEU . 10.3 tt -142.9 132.64 23.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.107 -176.669 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -125.92 165.8 18.07 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.137 179.647 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 14.6 t -150.92 -170.37 3.64 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.211 175.406 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . 55.16 51.63 12.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.19 -175.386 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 75.7 m-20 62.05 27.68 16.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.16 -177.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 84.29 6.67 85.94 Favored Glycine 0 CA--C 1.52 0.367 0 N-CA-C 111.276 -0.73 . . . . 0.0 111.276 176.131 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -81.81 -32.59 31.21 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.805 0.336 . . . . 0.0 111.122 -177.606 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 82.6 m -99.77 120.04 39.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.183 -178.335 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 65.4 t0 -89.32 109.01 19.96 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.192 176.027 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 87.4 t -85.48 -58.0 3.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.202 -176.489 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 27.8 m -132.83 153.33 37.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.209 168.373 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 65.6 tttm -150.55 116.97 5.71 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.337 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 70.8 m-20 56.17 46.98 20.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.266 174.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 33.5 m -101.96 151.24 5.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.142 179.14 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -99.1 -168.98 30.62 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 -171.58 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_exo -58.52 136.97 77.69 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 121.651 1.568 . . . . 0.0 111.153 -178.244 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 96.0 mm-40 68.3 17.12 9.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.249 173.463 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 70.3 m -103.99 151.23 23.44 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.308 170.192 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 56.4 p-80 -152.79 161.56 42.41 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.212 -176.49 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -114.98 160.24 13.31 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 176.481 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 37.4 t0 -136.86 115.5 12.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.609 0.242 . . . . 0.0 111.276 -178.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 89.4 mmt-85 -127.15 144.24 51.08 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.275 -173.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -96.18 124.48 40.2 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.253 175.707 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 46.1 pt -126.15 164.24 26.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.235 -168.1 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 -84.32 160.73 56.42 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.165 177.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -79.02 57.17 6.34 Favored 'Trans proline' 0 N--CA 1.458 -0.604 0 C-N-CA 121.588 1.525 . . . . 0.0 111.148 -179.753 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 33.6 m -130.96 -179.14 3.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.165 -175.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -65.61 104.01 0.96 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.305 174.36 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 91.7 t -104.3 126.56 58.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.25 -178.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 37.7 t-20 -107.26 109.21 20.93 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.089 -178.32 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 65.9 mt -90.64 117.67 29.48 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.218 175.602 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -126.12 140.39 52.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.154 -175.055 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 96.3 mt -87.69 141.18 28.81 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.185 178.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -135.6 156.44 48.86 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.209 179.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 66.9 t0 -136.05 83.78 2.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.193 173.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 79.48 -105.67 2.31 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.224 -0.75 . . . . 0.0 111.224 -173.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 98.0 p -102.95 -6.02 22.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.789 0.328 . . . . 0.0 111.195 172.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -83.82 131.51 34.88 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.196 -176.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 89.1 tttt -86.65 126.32 34.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.151 170.569 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 97.3 t -103.02 -53.02 7.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.195 -171.016 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 47.2 t -146.7 149.06 32.7 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.122 -174.619 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 51.0 t0 -136.2 102.33 4.97 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.228 -175.76 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 94.8 mt -81.56 148.23 29.24 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.148 -177.315 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -62.22 131.48 93.6 Favored Pre-proline 0 C--N 1.327 -0.38 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.244 178.464 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 76.3 Cg_exo -55.05 133.08 56.12 Favored 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 121.611 1.54 . . . . 0.0 111.234 177.031 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 94.0 t -124.21 131.15 73.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.26 178.462 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 98.2 m -88.24 130.01 35.2 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.101 175.584 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 82.0 mt -113.05 153.91 27.38 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.217 -178.635 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -102.41 163.83 12.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.116 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 79.6 ttt180 -51.03 120.21 4.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.147 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 104.74 -16.27 47.67 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 169.387 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 64.7 mt-10 -73.64 136.78 43.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.781 0.324 . . . . 0.0 111.089 -177.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 61.8 t -125.78 123.31 64.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.277 179.148 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 79.2 t -103.44 135.03 42.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.27 -178.411 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 44.3 t -121.78 105.63 10.56 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.249 176.316 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 31.0 tp -81.49 124.16 29.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.215 -176.222 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -105.72 98.52 8.2 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.2 179.196 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . 0.436 ' HA ' ' HA ' ' A' ' 207' ' ' PRO . 62.3 t -90.54 106.99 17.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.216 -176.398 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 44.5 p -105.22 174.77 5.74 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.089 -175.454 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 100.36 -138.26 13.75 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 111.406 -0.678 . . . . 0.0 111.406 176.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 42.1 t -163.88 127.18 2.61 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.823 0.345 . . . . 0.0 111.204 178.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . -54.07 139.15 37.74 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 -174.478 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -91.52 8.34 78.96 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 111.015 -0.834 . . . . 0.0 111.015 7.118 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -89.65 69.9 7.78 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.671 0.272 . . . . 0.0 111.076 -177.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 93.4 mt -97.69 156.81 16.38 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.246 -178.342 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -139.42 84.58 16.07 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.135 -176.444 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 207' ' ' PRO . . . . . 0.436 ' HA ' ' HA ' ' A' ' 198' ' ' VAL . 53.0 Cg_exo -57.61 129.42 33.65 Favored 'Trans proline' 0 N--CA 1.459 -0.55 0 C-N-CA 121.692 1.595 . . . . 0.0 111.139 176.716 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 77.2 t -109.65 115.67 50.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.217 173.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 38.6 t-105 -81.52 105.24 12.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.221 -174.666 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 94.8 t -117.58 119.92 63.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.154 177.063 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -100.31 134.22 43.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.215 178.436 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 40.3 mmt180 . . . . . 0 C--O 1.199 -1.576 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.218 -179.934 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 88.0 tttt . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.77 0.319 . . . . 0.0 111.116 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -150.23 143.63 25.09 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.248 172.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 59.0 tp -101.96 128.65 48.28 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.179 -177.613 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 33.1 m -125.48 152.01 31.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.136 174.452 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 41.7 ttm180 -140.85 124.2 16.7 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.208 178.617 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 57.3 t -105.39 121.33 57.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.257 -177.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 64.7 tp60 -107.76 127.01 53.31 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.173 -177.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 57.9 t-20 -85.63 105.34 16.13 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.153 178.357 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 98.3 mt -110.66 28.85 8.28 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.287 176.539 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 50.3 p -104.64 -175.69 2.87 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.222 -178.448 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -100.1 11.18 60.35 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 176.348 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 21.0 t -137.64 -167.46 2.14 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.802 0.334 . . . . 0.0 111.222 -178.388 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -102.63 142.91 33.02 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.125 178.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 93.8 mt -104.47 148.18 26.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.265 -177.265 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' THR . . . . . 0.409 ' HB ' ' HB2' ' A' ' 174' ' ' PHE . 97.2 m -139.26 128.35 23.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.18 169.352 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 79.9 mt -118.97 114.85 23.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.259 -179.243 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -127.24 133.63 50.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.198 179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 79.4 p -71.83 156.81 38.88 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.134 -172.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -59.93 -30.02 68.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.238 -176.736 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -64.44 -31.65 72.94 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.208 179.625 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 78.18 17.39 78.24 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 -178.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -110.02 -27.31 9.27 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.758 0.313 . . . . 0.0 111.184 -178.029 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 69.1 p -130.36 169.7 15.12 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.262 -179.108 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 20.6 p30 -150.61 175.12 12.22 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.162 -178.633 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 88.1 t -129.25 -40.69 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.247 179.093 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 90.1 t -132.09 137.92 53.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.184 -178.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -135.95 107.83 7.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.201 178.085 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 75.5 m-20 51.5 51.31 17.03 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.243 173.459 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 76.6 t -100.57 127.66 53.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.236 179.194 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -88.84 177.66 44.96 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 111.224 -0.75 . . . . 0.0 111.224 -171.067 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -58.8 147.22 89.69 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 121.652 1.568 . . . . 0.0 111.199 -178.211 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 94.4 mm-40 68.98 17.06 8.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.233 176.707 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 68.1 m -124.87 161.53 26.36 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.168 171.644 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 33.8 p80 -146.41 170.14 17.43 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.206 -176.515 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -143.7 145.7 15.66 Favored Glycine 0 CA--C 1.523 0.571 0 N-CA-C 111.246 -0.742 . . . . 0.0 111.246 179.119 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -111.09 150.34 29.54 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.823 0.344 . . . . 0.0 111.168 -178.324 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 85.1 mmt-85 -143.6 143.6 31.56 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.16 175.433 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -99.53 112.29 24.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.211 170.066 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 76.8 mt -130.78 139.13 51.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.113 -171.183 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . 0.452 ' HA ' ' HD3' ' A' ' 166' ' ' PRO . 95.3 m-20 -61.67 155.01 63.09 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.206 177.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 166' ' ' PRO . . . . . 0.452 ' HD3' ' HA ' ' A' ' 165' ' ' ASN . 51.1 Cg_exo -63.1 80.15 0.12 Allowed 'Trans proline' 0 N--CA 1.458 -0.595 0 C-N-CA 121.65 1.567 . . . . 0.0 111.173 -178.858 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 30.2 m -129.28 179.62 3.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.203 177.487 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -89.95 133.8 34.58 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.227 174.241 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 86.1 t -72.4 87.27 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.178 -176.7 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 62.9 t-20 -88.36 88.98 7.8 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.154 170.416 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 8.7 tt -145.18 140.66 28.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.231 -166.351 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -92.07 141.72 28.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.249 -177.07 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 62.6 tp -101.55 117.87 35.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.193 -172.662 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 174' ' ' PHE . . . . . 0.409 ' HB2' ' HB ' ' A' ' 140' ' ' THR . 70.5 m-85 -113.26 148.2 36.04 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.221 -178.524 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -105.69 94.18 5.06 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.196 167.146 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 77.38 -104.01 1.9 Allowed Glycine 0 CA--C 1.523 0.562 0 N-CA-C 111.232 -0.747 . . . . 0.0 111.232 -173.546 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 92.8 p -115.86 1.29 13.35 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.716 0.293 . . . . 0.0 111.166 172.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -104.64 116.96 32.97 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.306 -177.511 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -63.57 133.08 53.14 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.17 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 93.7 t -102.18 -53.3 7.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.206 176.614 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 19.2 t -163.99 -157.75 0.41 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.187 178.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -105.15 137.16 43.36 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.214 170.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 51.4 tp -74.73 128.75 36.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.252 -178.567 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -51.91 126.78 34.41 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.25 177.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -74.4 150.83 41.87 Favored 'Trans proline' 0 N--CA 1.458 -0.613 0 C-N-CA 121.647 1.565 . . . . 0.0 111.246 -176.516 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 14.5 p -147.42 143.79 19.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.177 176.349 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 92.1 m -81.0 124.58 29.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.168 -177.765 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 80.6 mt -93.78 158.75 15.51 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.218 177.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -159.85 146.02 15.89 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.202 -179.473 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 79.8 ttt180 -71.07 134.22 46.89 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.163 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 101.93 -12.13 57.56 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 111.184 -0.766 . . . . 0.0 111.184 -177.186 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -121.26 146.65 46.59 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.814 0.34 . . . . 0.0 111.168 179.324 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 96.9 t -114.46 123.36 70.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.244 178.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 76.7 t -109.85 114.12 46.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.206 -175.19 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 75.9 m -100.7 152.95 19.86 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.239 -178.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 64.8 tp -125.8 123.07 37.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.236 178.294 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -114.72 108.73 17.18 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.234 -179.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 65.5 t -109.43 124.19 65.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.122 -177.474 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 13.5 t -131.06 -174.29 3.34 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.148 -179.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -89.06 140.73 15.91 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 111.193 -0.763 . . . . 0.0 111.193 -177.615 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 37.3 t -146.38 86.87 1.7 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.798 0.332 . . . . 0.0 111.236 176.68 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 73.35 22.23 78.91 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 177.194 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 100.84 -12.5 59.26 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 111.231 -0.747 . . . . 0.0 111.231 -178.154 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -100.62 165.07 11.59 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.738 0.304 . . . . 0.0 111.239 178.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 96.5 mt -85.96 139.62 31.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.215 177.285 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -124.09 92.23 48.58 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.216 -179.385 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -76.26 138.75 20.43 Favored 'Trans proline' 0 N--CA 1.457 -0.672 0 C-N-CA 121.777 1.651 . . . . 0.0 111.244 -179.433 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 92.3 t -129.82 122.5 54.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.163 174.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 91.8 m95 -86.8 126.46 34.63 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.166 178.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 69.5 t -131.62 113.54 23.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.213 176.244 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 36.2 ttpt -103.51 136.0 44.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.225 -176.29 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 80.4 ttt180 . . . . . 0 C--O 1.198 -1.611 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.18 177.708 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 99.6 mttt . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.823 0.344 . . . . 0.0 111.205 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 99.8 mm-40 -100.38 3.79 43.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.185 179.734 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -124.32 163.2 22.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.212 178.328 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -91.95 143.2 26.73 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.218 174.464 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 68.3 tp -93.06 112.55 24.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.271 177.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 58.5 t -115.44 122.8 70.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.192 -178.434 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 41.8 ttm180 -112.1 144.91 40.69 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.225 177.434 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 92.3 t -114.35 119.94 62.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.205 169.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 66.6 tp60 -107.74 107.36 18.1 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.237 -177.611 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 65.0 t-20 -85.11 103.64 14.3 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.269 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 92.1 mt -102.61 17.44 23.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.228 -179.756 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 30.8 p -103.01 -179.33 3.92 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.215 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -104.82 29.25 12.1 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 111.258 -0.737 . . . . 0.0 111.258 174.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 46.1 t -144.8 147.42 32.86 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.808 0.337 . . . . 0.0 111.229 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -69.18 136.49 52.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.189 179.289 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.413 ' C ' HD12 ' A' ' 139' ' ' LEU . 4.4 pp -149.69 165.91 30.94 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.155 179.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 13.4 t -144.95 150.99 37.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.165 -177.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 64.7 tp -100.64 112.33 24.71 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.2 175.018 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 14.6 ptmm? -140.2 178.72 7.08 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.175 -176.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 57.0 p -83.22 164.9 19.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.167 179.011 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -108.45 4.82 24.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.214 177.079 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 75.7 m-20 -104.04 4.3 34.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.182 -177.539 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 174.55 -161.86 31.81 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.196 -0.762 . . . . 0.0 111.196 -178.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -93.81 -5.16 48.83 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.703 0.287 . . . . 0.0 111.146 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 89.4 m -62.0 130.06 43.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.239 178.31 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 42.3 p30 -93.13 177.57 6.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.215 -177.573 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 90.7 t -113.72 -56.27 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.172 177.609 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 99.0 t -117.46 133.41 64.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.247 178.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -100.77 166.38 10.9 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.173 -176.646 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 29.4 t0 64.32 47.38 3.15 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.204 177.118 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 69.7 t -118.27 121.17 66.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.235 174.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -124.59 -165.61 12.22 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 -177.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -75.77 141.01 24.03 Favored 'Trans proline' 0 N--CA 1.458 -0.563 0 C-N-CA 121.728 1.619 . . . . 0.0 111.182 179.247 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 49.64 50.54 18.1 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.217 175.66 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 17.4 t -161.48 -157.52 0.5 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.193 -178.434 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 57.2 p-80 -156.57 164.66 37.94 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.196 179.002 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -147.05 147.56 18.48 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 111.209 -0.756 . . . . 0.0 111.209 179.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 88.0 m-20 -112.55 155.6 24.08 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.739 0.304 . . . . 0.0 111.202 178.766 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 29.2 tpt180 -159.5 127.6 4.95 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.175 175.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -82.66 123.13 28.98 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.189 173.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 80.9 mt -127.89 137.97 56.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.189 -171.554 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 96.3 m-20 -50.45 147.26 8.04 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.236 178.76 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 81.1 Cg_endo -75.17 68.19 5.93 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 121.687 1.591 . . . . 0.0 111.226 -178.644 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 33.5 m -129.45 -178.12 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.203 -177.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -75.89 116.88 17.04 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.228 173.233 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 95.1 t -119.39 121.16 65.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.204 -175.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 170' ' ' ASN . . . . . 0.427 ' HA ' ' HA ' ' A' ' 185' ' ' PRO . 55.1 t-20 -73.31 111.13 8.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.223 178.821 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 59.5 mt -95.82 142.92 27.52 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.244 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -161.88 143.76 11.29 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.189 175.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 65.5 tp -95.84 120.94 37.0 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.251 -178.404 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -118.77 140.44 49.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.257 175.406 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 39.6 t0 -111.46 94.45 4.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.188 171.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 79.22 -105.04 2.2 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 111.205 -0.758 . . . . 0.0 111.205 -173.104 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 88.9 p -115.75 6.06 14.33 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.771 0.32 . . . . 0.0 111.182 172.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -98.05 120.14 37.91 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.217 -176.116 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -66.47 126.89 30.28 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.241 173.433 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 88.0 t -105.65 -53.14 7.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.218 -177.049 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 44.8 t -147.88 140.31 24.46 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.204 -176.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -100.85 107.08 18.53 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.159 176.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 183' ' ' LEU . . . . . 0.536 ' O ' ' HB2' ' A' ' 184' ' ' LYS . 92.1 mt -89.69 -15.98 31.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.24 -171.793 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 184' ' ' LYS . . . . . 0.536 ' HB2' ' O ' ' A' ' 183' ' ' LEU . 74.9 mmtt 83.33 165.08 0.11 Allowed Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.209 167.113 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 185' ' ' PRO . . . . . 0.427 ' HA ' ' HA ' ' A' ' 170' ' ' ASN . 53.4 Cg_exo -59.92 134.74 58.62 Favored 'Trans proline' 0 N--CA 1.458 -0.598 0 C-N-CA 121.689 1.593 . . . . 0.0 111.189 179.099 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 29.9 m -125.28 152.43 31.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.163 172.144 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 97.2 m -94.28 117.17 29.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.211 -179.197 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 93.4 mt -95.11 153.33 17.7 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.163 178.092 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -131.4 156.82 44.9 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.203 177.47 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 89.9 mtm180 -62.77 123.14 17.67 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.21 -176.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 87.47 -1.07 85.71 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 176.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -70.2 133.2 46.83 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.698 0.285 . . . . 0.0 111.231 -179.306 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 98.4 t -113.24 118.28 57.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.218 178.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 33.4 m -131.89 162.42 39.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.216 177.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 46.1 t -150.73 128.36 11.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.19 -179.111 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 60.9 tp -92.24 117.42 29.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.186 177.76 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -102.43 105.79 16.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.19 -179.737 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 54.2 t -105.22 112.79 40.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.21 -178.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 71.8 p -99.61 163.9 12.3 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.122 -178.519 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -116.39 135.24 11.92 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 111.239 -0.745 . . . . 0.0 111.239 179.022 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.2 t -160.69 120.06 2.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.746 0.308 . . . . 0.0 111.162 179.035 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 74.31 15.16 80.29 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 111.228 -0.749 . . . . 0.0 111.228 176.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 89.98 -0.84 79.68 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 111.179 -0.768 . . . . 0.0 111.179 -177.215 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -106.49 158.92 16.55 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.875 0.369 . . . . 0.0 111.157 -179.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 90.4 mt -107.02 141.51 38.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.146 179.522 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -125.33 92.81 46.37 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.268 179.191 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -74.6 127.36 10.91 Favored 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 121.712 1.608 . . . . 0.0 111.16 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 64.3 t -126.81 106.09 15.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.137 174.327 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 10.8 t90 -80.06 124.29 28.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.215 -177.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 98.7 t -120.63 132.56 69.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.167 -175.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -99.93 133.8 43.76 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.233 175.695 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 41.9 mmt180 . . . . . 0 C--O 1.2 -1.501 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.134 -179.484 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 99.7 mttt . . . . . 0 N--CA 1.457 -0.121 0 CA-C-O 120.713 0.292 . . . . 0.0 111.274 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 85.3 mt-30 -93.19 159.34 15.32 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.146 179.694 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 74.4 mmtt -128.5 154.91 45.63 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.229 178.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -143.91 177.78 8.31 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.241 177.015 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 95.4 mt -122.51 147.92 45.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.236 -177.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 12.2 p -134.35 142.84 39.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.205 178.365 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 38.5 ttm180 -117.53 99.31 6.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.203 179.017 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 96.2 t -84.69 121.37 36.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.169 -171.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 69.3 mm-40 -112.83 78.88 1.17 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.183 173.343 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 -89.33 157.41 18.2 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.197 -174.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 58.0 tp -62.97 -40.9 99.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.159 176.856 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 91.7 p -72.04 155.84 39.88 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.194 -175.085 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -113.84 55.4 0.52 Allowed Glycine 0 CA--C 1.524 0.599 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 -179.281 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 99.4 p -145.18 160.2 41.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.789 0.328 . . . . 0.0 111.213 -178.444 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -64.76 124.78 22.83 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.171 178.288 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 73.5 mt -111.06 157.83 19.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.19 -175.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 92.0 m -110.66 127.77 55.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.186 172.345 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 62.4 tp -95.6 123.66 39.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.153 176.387 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 96.3 mttt -123.61 158.52 31.29 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.181 178.314 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 14.5 t -125.18 -175.76 3.39 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.266 178.18 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' ALA . . . . . 0.43 ' O ' ' HB2' ' A' ' 145' ' ' ASP . . . 56.6 54.02 7.84 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.122 -173.284 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.43 ' HB2' ' O ' ' A' ' 144' ' ' ALA . 65.9 m-20 68.03 34.93 3.9 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.216 -178.533 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 72.84 43.64 41.16 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 111.187 -0.765 . . . . 0.0 111.187 174.064 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -118.6 -50.8 2.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.801 0.334 . . . . 0.0 111.136 -175.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 86.4 m -89.96 127.95 36.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.198 -173.207 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -65.67 114.91 5.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.273 -178.027 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 94.2 t -89.03 -59.99 2.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.253 174.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 14.5 p -156.97 143.71 10.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.199 -179.446 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -109.91 -179.28 3.75 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.168 178.62 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 74.6 m-20 59.09 41.57 20.38 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.127 178.044 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.425 ' O ' ' HD3' ' A' ' 156' ' ' PRO . 85.3 t -77.65 130.41 36.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.097 174.562 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -110.58 100.02 1.22 Allowed Glycine 0 CA--C 1.524 0.605 0 N-CA-C 111.151 -0.78 . . . . 0.0 111.151 -176.322 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . 0.425 ' HD3' ' O ' ' A' ' 154' ' ' VAL . 76.7 Cg_exo -56.02 139.53 85.08 Favored 'Trans proline' 0 N--CA 1.458 -0.608 0 C-N-CA 121.732 1.621 . . . . 0.0 111.205 177.483 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 54.06 45.66 27.08 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.179 174.213 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 83.6 p -116.36 -172.6 2.21 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.222 177.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -116.28 78.28 1.18 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.146 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 173.65 171.1 37.85 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 60.0 m-20 -115.26 168.28 10.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.84 0.352 . . . . 0.0 111.225 -177.335 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 91.4 mmt-85 -132.22 155.2 48.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.266 177.283 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -64.41 131.66 47.83 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.224 178.523 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 21.5 tt -141.89 143.14 27.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.253 176.211 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 91.9 m-20 -73.93 126.45 89.41 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.14 176.099 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -79.83 60.42 7.82 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 121.64 1.56 . . . . 0.0 111.142 -176.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 35.6 m -134.06 150.6 31.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.201 179.315 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -86.06 73.19 10.32 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.175 -177.247 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 84.2 t -131.1 142.92 42.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.22 -176.326 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 90.9 m-20 -49.73 119.94 3.88 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.242 -178.577 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 171' ' ' LEU . . . . . 0.455 ' HB2' ' HB2' ' A' ' 183' ' ' LEU . 65.2 mt -103.94 172.34 6.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.172 175.433 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -160.19 148.16 16.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.218 175.563 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 95.3 mt -107.23 135.73 48.25 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.134 176.197 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 81.5 m-85 -124.37 145.68 49.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.214 -177.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -115.03 87.51 2.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.207 171.573 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 78.98 -106.6 2.39 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 111.254 -0.738 . . . . 0.0 111.254 -177.143 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 95.5 p -105.9 -8.05 17.87 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.877 0.37 . . . . 0.0 111.213 175.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -103.4 117.18 33.88 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.2 -175.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 40.4 ttpt -64.03 130.99 46.23 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.254 176.688 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 69.4 t -82.55 -53.7 11.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.156 178.74 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 44.8 t -171.95 142.45 1.47 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.229 -178.067 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -80.27 145.35 32.22 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.281 174.155 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 183' ' ' LEU . . . . . 0.455 ' HB2' ' HB2' ' A' ' 171' ' ' LEU . 61.1 mt -110.06 159.02 17.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.185 -177.385 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -85.57 151.6 56.06 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.203 176.055 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_exo -55.86 142.78 83.59 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 121.748 1.632 . . . . 0.0 111.135 177.62 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 7.6 p -145.93 136.05 18.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.197 -179.731 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 98.7 m -98.75 129.94 45.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.176 -178.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 5.0 mp -125.21 150.49 46.95 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.218 177.123 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -90.35 169.24 11.25 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.271 169.637 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 -64.14 106.99 1.17 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.186 -179.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 92.62 7.24 63.34 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 111.186 -0.766 . . . . 0.0 111.186 178.311 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -76.06 137.86 40.45 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.797 0.332 . . . . 0.0 111.264 -179.817 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 61.3 t -104.27 116.6 48.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.161 178.179 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 97.6 t -120.86 134.66 63.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.149 177.408 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 76.6 m -95.94 153.37 17.8 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.187 -175.426 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 60.1 tp -126.32 117.49 23.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.201 178.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 91.7 m-85 -112.82 111.51 22.33 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.199 -179.281 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 68.8 t -100.02 113.57 35.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.2 -178.537 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 45.9 p -108.34 172.83 6.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.1 -175.433 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 88.81 -151.86 22.61 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 111.343 -0.703 . . . . 0.0 111.343 177.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 45.0 t -151.89 146.41 25.63 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.723 0.297 . . . . 0.0 111.256 179.699 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . -62.19 147.66 48.93 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.096 -0.802 . . . . 0.0 111.096 -176.209 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -98.58 35.26 4.73 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 5.655 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -122.6 68.89 0.96 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.797 0.332 . . . . 0.0 111.185 178.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 96.0 mt -88.6 148.0 24.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.194 -178.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -123.51 95.73 44.67 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.183 -177.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -72.96 135.9 24.04 Favored 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 121.713 1.609 . . . . 0.0 111.217 178.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 93.5 t -127.11 122.71 60.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.247 178.681 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 98.6 m95 -85.36 127.26 34.29 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.241 177.512 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 96.1 t -125.01 128.68 73.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.29 -0.413 . . . . 0.0 111.232 -176.472 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -124.45 120.46 32.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.219 177.459 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 91.0 mmt-85 . . . . . 0 C--O 1.201 -1.472 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.24 -178.167 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 99.6 mttt . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.868 0.365 . . . . 0.0 111.18 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 99.8 mm-40 -97.92 -3.1 39.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.212 -179.657 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 96.0 mttt -130.11 175.19 9.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.285 -178.72 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -121.98 175.07 6.51 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.193 177.699 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 93.4 mt -119.07 139.33 51.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.256 -178.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 94.1 t -124.87 128.5 73.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.259 173.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -122.98 97.88 5.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.137 -177.4 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 61.7 t -98.06 127.8 50.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.143 -177.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 45.9 tt0 -109.45 126.81 53.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.17 178.328 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 51.5 t-20 -101.99 105.29 16.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.26 -177.092 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 83.5 mt -106.73 32.19 4.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.203 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 53.4 p -115.22 -168.22 1.36 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.225 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -108.11 18.08 34.1 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 177.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 47.4 t -150.38 148.77 29.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.858 0.361 . . . . 0.0 111.12 -179.428 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -76.77 163.55 26.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.19 -178.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 4.4 pp -149.31 165.51 31.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.126 -175.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 9.7 t -147.42 149.27 32.39 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.138 -177.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 83.9 mt -113.35 149.21 34.34 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.237 178.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -125.5 162.91 23.85 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.166 -176.038 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 66.9 p -71.28 153.19 42.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.246 178.607 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -68.06 -33.4 74.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.233 179.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -75.47 -19.74 59.23 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.249 178.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 80.14 28.81 48.17 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 111.286 -0.725 . . . . 0.0 111.286 -178.325 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -86.02 -42.07 14.29 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.777 0.322 . . . . 0.0 111.236 -175.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 14.7 t -156.18 -169.41 3.04 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.208 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -96.58 155.59 16.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.304 177.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . 0.456 HG12 HG23 ' A' ' 151' ' ' VAL . 68.8 t -109.29 -55.52 5.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.254 -178.415 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.456 HG23 HG12 ' A' ' 150' ' ' VAL . 84.2 t -123.82 133.6 68.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.191 178.802 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -137.0 143.92 43.02 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.215 -176.479 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 27.9 t0 56.25 63.53 1.97 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.182 175.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 93.8 t -76.21 125.31 35.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.245 178.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -70.52 146.69 42.6 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 179.544 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -73.74 138.75 26.85 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 121.697 1.598 . . . . 0.0 111.185 -178.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 50.47 48.6 22.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.216 177.128 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 46.5 t -162.24 141.28 9.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.194 179.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -78.35 88.67 4.37 Favored 'General case' 0 C--N 1.364 1.212 0 C-N-CA 119.654 -0.818 . . . . 0.0 111.034 -179.235 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -58.29 88.1 0.02 OUTLIER Glycine 0 CA--C 1.524 0.635 0 CA-C-N 115.378 -0.828 . . . . 0.0 111.178 177.175 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 13.9 t70 -69.4 132.83 46.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.782 0.325 . . . . 0.0 111.107 177.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 91.3 mmt-85 -133.62 140.34 47.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.212 -179.511 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 65.9 tt0 -84.56 103.95 14.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.296 173.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 48.3 mm -118.17 137.59 51.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.163 -169.547 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 95.3 m-20 -62.22 154.56 70.02 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.231 176.517 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -75.14 71.85 4.95 Favored 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 121.687 1.591 . . . . 0.0 111.14 -179.073 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 32.7 m -130.54 167.85 24.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.208 -177.237 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -79.58 130.72 35.64 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.178 174.032 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 33.9 m -122.01 149.93 25.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.166 -172.062 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 61.9 t-20 -97.85 110.2 22.81 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.152 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 86.9 mt -79.8 58.23 2.77 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.205 -176.358 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -104.48 141.1 36.98 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.121 178.06 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 76.1 mt -103.33 136.56 42.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.212 -176.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 84.6 m-85 -128.86 148.55 50.9 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.218 -177.453 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 53.2 t0 -129.77 96.25 4.18 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.213 175.349 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 79.34 -105.5 2.27 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 111.231 -0.748 . . . . 0.0 111.231 -176.136 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 88.8 p -115.41 6.68 14.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.869 0.366 . . . . 0.0 111.219 173.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -103.4 133.8 47.84 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.194 -176.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -81.41 128.03 33.41 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.145 172.086 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 93.5 t -103.37 -52.54 7.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.233 -172.459 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 47.6 t -143.34 149.26 37.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.19 -173.372 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 50.6 t0 -130.73 96.18 4.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.182 -177.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 54.8 tp -95.09 137.36 34.24 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.288 177.021 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -46.21 124.17 6.97 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.189 -172.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -54.91 146.96 54.17 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 121.65 1.567 . . . . 0.0 111.267 176.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 35.1 m -127.86 152.53 36.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.157 -177.588 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 96.8 m -93.08 118.04 30.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.194 178.652 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 69.4 tp -104.89 114.46 28.67 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.137 -178.352 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -94.93 154.9 16.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.269 -179.676 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 53.2 ptt85 -60.9 138.62 58.14 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.191 -178.496 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 95.72 -16.51 61.05 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 111.182 -0.767 . . . . 0.0 111.182 178.595 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 84.9 mt-10 -85.69 147.46 26.35 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.773 0.32 . . . . 0.0 111.203 -178.075 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 61.5 t -121.7 120.08 60.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.175 174.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 35.0 m -123.67 150.38 27.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.216 -177.662 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 82.8 m -122.89 158.64 29.92 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.172 177.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 51.7 tp -134.73 117.34 15.9 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.207 174.752 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -105.76 105.79 16.0 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.198 -176.192 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 97.7 t -103.78 125.56 58.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.242 -177.014 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 14.5 t -127.2 -170.42 2.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.239 178.333 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -108.34 135.67 12.99 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 111.229 -0.749 . . . . 0.0 111.229 -178.493 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.6 t -158.82 117.11 2.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.776 0.322 . . . . 0.0 111.215 178.03 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 75.11 14.88 81.45 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.151 -0.779 . . . . 0.0 111.151 177.488 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 89.44 2.03 77.19 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 -178.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -118.91 167.42 11.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.816 0.341 . . . . 0.0 111.21 -179.383 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 99.1 mt -82.21 140.08 33.91 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.217 178.019 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -124.63 95.08 43.44 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.142 -178.613 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -75.98 138.62 20.95 Favored 'Trans proline' 0 N--CA 1.458 -0.594 0 C-N-CA 121.738 1.625 . . . . 0.0 111.228 -178.717 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 65.0 t -127.8 106.62 15.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.186 173.349 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 24.8 t90 -79.97 127.29 32.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.185 -177.31 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 79.0 t -128.56 108.89 18.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.202 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -84.3 127.03 33.73 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.2 176.085 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 97.0 mtt-85 . . . . . 0 C--O 1.2 -1.529 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.209 -177.699 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 55.0 tptt . . . . . 0 C--O 1.23 0.053 0 CA-C-O 120.797 0.332 . . . . 0.0 111.178 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 -107.42 19.05 20.79 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.181 -176.012 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -145.16 122.89 11.86 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.132 178.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . 0.401 ' HA ' ' HB3' ' A' ' 188' ' ' LEU . . . -104.76 163.97 12.11 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.238 178.112 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 64.1 tp -149.45 120.73 7.84 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.183 -178.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 89.0 t -117.03 131.34 70.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.192 -175.362 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 41.2 ttm180 -102.29 116.46 32.68 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.172 172.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 65.1 t -105.66 125.44 61.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.199 -175.39 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 38.1 tt0 -120.71 127.5 52.07 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.223 -177.052 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 48.1 t-20 -89.86 110.06 21.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.088 176.005 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 95.3 mt -111.61 14.84 21.28 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.11 177.338 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 38.1 p -85.65 -179.73 6.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.177 -179.211 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -98.03 14.11 62.91 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 111.192 -0.763 . . . . 0.0 111.192 177.447 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 18.7 t -136.55 -166.78 1.95 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.849 0.357 . . . . 0.0 111.086 -179.423 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 34.4 mmtp -95.46 136.97 35.16 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.256 -177.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.413 ' HB3' ' HB ' ' A' ' 154' ' ' VAL . 56.8 tp -102.03 131.72 48.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.293 -178.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 98.7 m -130.97 136.2 48.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.143 178.295 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 79.6 mt -125.4 142.87 51.26 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.218 172.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 60.6 mttm -118.78 163.84 16.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.166 -177.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 74.3 p -75.42 162.77 28.07 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.2 -177.347 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -65.17 -40.82 94.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.162 -175.23 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -78.62 -19.21 53.2 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.209 -178.261 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 80.55 21.93 63.25 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 111.2 -0.76 . . . . 0.0 111.2 -177.454 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -77.98 -36.47 48.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.728 0.299 . . . . 0.0 111.172 -178.305 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 14.7 t -154.95 -169.08 3.08 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.246 176.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -99.31 150.92 21.63 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.193 -179.766 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 69.3 t -89.03 -46.31 15.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.234 171.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 12.0 p -161.42 144.04 3.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.176 173.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 64.0 pttt -145.63 158.96 43.78 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.137 -175.303 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 28.4 t0 60.2 43.35 14.08 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.218 178.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.413 ' HB ' ' HB3' ' A' ' 139' ' ' LEU . 98.6 t -87.6 119.08 34.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.251 174.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -81.97 165.91 46.03 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 -175.14 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 63.5 Cg_exo -57.0 147.17 76.32 Favored 'Trans proline' 0 N--CA 1.458 -0.6 0 C-N-CA 121.691 1.594 . . . . 0.0 111.276 177.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 56.53 50.67 12.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.153 178.453 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 77.8 p -150.44 158.19 43.87 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.238 172.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 27.7 p-80 -151.56 167.45 28.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.169 -173.33 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -161.56 162.28 33.8 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 111.219 -0.752 . . . . 0.0 111.219 175.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -101.3 144.42 30.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.73 0.3 . . . . 0.0 111.293 -176.19 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 87.8 mmt-85 -138.91 130.04 26.74 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.17 176.137 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 91.1 mt-10 -84.69 144.91 28.24 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.207 179.26 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 19.5 tt -160.15 151.74 5.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.179 -179.051 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -73.62 142.03 80.26 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.221 175.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -78.75 60.37 7.65 Favored 'Trans proline' 0 N--CA 1.458 -0.59 0 C-N-CA 121.732 1.621 . . . . 0.0 111.2 -178.199 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 33.5 m -131.73 178.71 5.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.175 -178.038 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -69.76 112.52 6.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.169 176.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 35.6 m -129.31 164.35 32.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.211 -178.651 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 49.7 t30 -97.89 99.93 11.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.287 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 82.3 mt -104.69 146.64 28.65 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.229 178.008 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -147.59 152.67 38.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.19 -177.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 51.8 tp -112.95 121.38 44.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.215 -173.132 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 72.8 m-85 -118.76 140.2 50.33 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.157 -176.558 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 64.2 t0 -104.33 98.2 8.03 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.122 170.674 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 77.59 -103.38 1.85 Allowed Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.129 -0.788 . . . . 0.0 111.129 -173.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 93.4 p -118.31 0.11 11.62 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.824 0.345 . . . . 0.0 111.134 175.21 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -108.38 130.14 55.23 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.244 -177.421 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -69.53 137.74 52.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.208 -179.052 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 88.4 t -99.67 -52.04 9.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.235 174.084 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 19.1 t -163.36 -158.77 0.48 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.205 -178.668 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 74.0 m-20 -114.0 160.8 18.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.203 177.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 93.9 mt -115.99 152.28 33.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.24 178.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -98.08 117.94 64.35 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.301 179.151 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_exo -55.07 130.45 40.8 Favored 'Trans proline' 0 N--CA 1.458 -0.583 0 C-N-CA 121.728 1.619 . . . . 0.0 111.128 177.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 99.2 t -121.73 127.4 75.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.227 175.006 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 71.1 p -84.53 166.61 17.08 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.174 -178.454 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . 0.418 ' C ' HD23 ' A' ' 188' ' ' LEU . 10.4 tt -137.07 123.65 20.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.226 -176.704 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -98.97 164.29 12.25 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.234 177.151 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 79.9 ttt180 -52.97 116.85 2.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.188 178.142 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 100.07 -14.49 59.9 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 178.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -87.56 143.75 27.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.801 0.334 . . . . 0.0 111.21 -179.285 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 193' ' ' VAL . . . . . 0.411 ' HB ' ' HB2' ' A' ' 212' ' ' ARG . 90.2 t -119.38 129.64 75.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.15 174.179 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 89.7 t -115.82 125.25 72.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.191 179.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 74.9 m -125.7 156.85 38.69 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.185 179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 58.0 tp -130.03 118.5 21.67 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.205 175.451 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 88.7 m-85 -111.72 113.0 25.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.299 -178.444 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 80.5 t -107.86 120.27 58.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.177 -177.561 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 14.5 t -124.71 -169.45 1.98 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.203 -178.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -108.18 134.91 12.49 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 111.173 -0.771 . . . . 0.0 111.173 -177.691 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.6 t -160.22 118.32 2.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.787 0.327 . . . . 0.0 111.144 177.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 75.98 14.25 82.39 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 176.366 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 91.33 -0.5 75.03 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 -178.602 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -120.26 169.03 10.64 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.657 0.265 . . . . 0.0 111.229 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 82.6 mt -78.73 141.61 37.73 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.236 176.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -123.99 98.39 39.41 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.253 179.12 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -78.54 141.19 17.46 Favored 'Trans proline' 0 C--N 1.327 -0.587 0 C-N-CA 121.708 1.606 . . . . 0.0 111.212 -177.076 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 66.8 t -129.61 110.67 20.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.253 176.5 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 94.9 m95 -83.47 127.46 33.72 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.182 176.628 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 84.7 t -123.7 125.69 71.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.215 -177.421 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 56.2 mtmt -109.26 135.09 50.92 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.21 174.568 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 212' ' ' ARG . . . . . 0.411 ' HB2' ' HB ' ' A' ' 193' ' ' VAL . 82.2 mtp180 . . . . . 0 C--O 1.2 -1.543 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.142 179.053 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 99.6 mttt . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.785 0.326 . . . . 0.0 111.208 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 -111.19 21.37 16.41 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.223 -179.013 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 17.5 ptpt -161.49 166.92 26.43 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.186 -176.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -92.85 155.21 17.76 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.226 -176.096 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 60.8 tp -111.11 121.9 46.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.228 175.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 97.9 t -110.38 124.2 66.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.227 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 39.7 ttm180 -115.6 125.9 53.52 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.248 176.619 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 66.1 t -115.53 130.25 70.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.172 -175.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 37.1 tt0 -113.43 130.43 56.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.194 179.446 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 47.2 t30 -114.6 117.4 30.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.206 177.331 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 98.4 mt -102.77 -9.02 20.35 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.24 177.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 73.8 p -81.01 156.11 26.06 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.218 -178.318 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -83.14 -12.61 78.88 Favored Glycine 0 CA--C 1.523 0.571 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 -174.726 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 62.7 p -93.67 169.98 9.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.771 0.319 . . . . 0.0 111.251 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -73.97 135.22 43.17 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.214 -175.526 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 65.7 tp -108.23 121.15 44.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.218 174.24 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 97.7 m -130.4 130.69 44.67 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.175 174.49 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 82.9 mt -112.87 116.11 29.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.223 -178.427 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -119.57 156.24 30.71 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.217 177.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 74.9 p -84.02 154.78 23.08 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.166 -178.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -62.88 116.76 5.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.207 -176.412 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 55.21 33.89 21.54 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.164 177.12 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -106.7 -171.42 22.73 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 177.855 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -130.36 -6.59 4.25 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.832 0.349 . . . . 0.0 111.202 177.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 97.2 m -114.39 127.05 55.65 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.19 179.041 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 42.7 p30 -92.38 -179.37 5.2 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.245 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 26.9 m -128.89 -30.89 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.217 176.068 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 71.5 t -133.91 136.92 53.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.202 174.419 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -148.33 138.48 22.55 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.204 -176.64 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 45.3 t0 56.3 60.43 3.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.213 172.598 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 84.2 t -111.37 128.87 67.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.203 173.118 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -96.79 -164.42 32.77 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 -177.447 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -71.82 148.12 51.51 Favored 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 121.693 1.595 . . . . 0.0 111.176 -178.435 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 77.3 mt-30 52.8 50.6 17.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.204 178.565 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 44.9 t -142.06 148.91 39.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.199 -176.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 71.3 m80 -124.6 149.42 47.07 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.21 -176.053 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -134.6 132.58 6.38 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 174.696 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -106.83 135.1 48.95 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.797 0.332 . . . . 0.0 111.193 177.181 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 24.9 tpp180 -144.04 118.58 9.73 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.224 178.157 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -83.88 127.02 33.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.19 175.486 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 78.8 mt -130.85 137.32 56.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.172 -174.632 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . 0.402 ' HA ' ' HD3' ' A' ' 166' ' ' PRO . 96.3 m-20 -57.67 154.62 24.93 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.233 -178.12 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 166' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 165' ' ' ASN . 47.9 Cg_exo -65.37 78.24 0.24 Allowed 'Trans proline' 0 N--CA 1.458 -0.608 0 C-N-CA 121.675 1.583 . . . . 0.0 111.259 -177.609 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 32.1 m -136.56 167.61 23.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.253 177.154 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 89.0 tttt -77.89 116.48 18.43 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.206 173.166 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 63.9 t -113.15 121.11 64.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.162 -174.285 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 64.6 t-20 -105.12 99.84 9.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.217 176.719 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 94.4 mt -95.03 167.63 11.27 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.196 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -144.19 148.55 35.12 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.194 174.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 73.9 mt -80.1 117.71 21.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.176 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 78.4 m-85 -113.86 152.2 31.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.233 173.487 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -148.29 99.53 3.05 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.175 -178.486 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 80.37 -106.58 2.52 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 111.179 -0.768 . . . . 0.0 111.179 -179.323 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 86.0 p -117.83 8.78 12.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.728 0.299 . . . . 0.0 111.147 -179.468 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 65.3 pttt -128.01 164.43 22.37 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.207 -177.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -102.77 136.08 43.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.227 174.448 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 86.2 t -87.1 -55.32 6.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.155 -178.39 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 43.7 t -172.64 142.23 1.19 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.179 -175.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 93.1 m-20 -70.36 150.38 46.36 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.201 178.427 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 94.8 mt -103.09 153.45 20.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.178 177.387 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -64.93 127.31 92.61 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.187 176.551 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_exo -54.63 135.02 65.27 Favored 'Trans proline' 0 N--CA 1.458 -0.593 0 C-N-CA 121.696 1.597 . . . . 0.0 111.223 177.088 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 85.1 t -120.31 124.29 72.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.213 179.232 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 92.5 m -82.35 118.47 23.19 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.198 174.511 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 92.2 mt -96.76 143.46 27.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.208 -174.261 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -122.73 150.09 43.22 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.196 173.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 190' ' ' ARG . . . . . 0.435 ' HG3' ' O ' ' A' ' 190' ' ' ARG . 18.4 ptp180 -52.79 120.79 6.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.194 177.727 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 93.4 -6.54 75.02 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 175.793 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -74.94 136.51 41.37 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.805 0.336 . . . . 0.0 111.224 -178.134 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 99.1 t -109.08 118.0 55.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.163 177.367 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 85.6 t -121.98 131.55 72.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.143 -177.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 71.0 m -114.73 146.16 41.26 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.245 -179.045 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 65.8 tp -128.0 116.41 20.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.234 175.639 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -106.11 108.06 19.38 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.185 -177.449 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 85.1 t -109.73 121.98 63.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.169 -178.09 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 14.5 t -127.55 -171.02 2.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.192 177.803 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -107.26 135.17 12.6 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 111.184 -0.767 . . . . 0.0 111.184 -177.607 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.7 t -159.19 116.81 2.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.825 0.345 . . . . 0.0 111.222 177.676 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 75.2 14.91 81.46 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 177.084 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 90.19 0.69 76.75 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 -178.17 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -118.88 169.15 10.11 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.826 0.346 . . . . 0.0 111.22 -179.675 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 92.1 mt -82.43 141.95 32.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.187 177.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -122.87 93.27 48.53 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.215 179.367 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -79.7 143.37 16.7 Favored 'Trans proline' 0 N--CA 1.459 -0.549 0 C-N-CA 121.631 1.554 . . . . 0.0 111.168 -177.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 67.9 t -132.39 120.8 44.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.21 172.65 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 95.6 m95 -86.35 125.53 33.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.191 178.115 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 93.4 t -133.59 128.71 54.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.226 177.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 90.4 mttt -108.25 148.2 30.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.206 178.036 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 . . . . . 0 C--O 1.2 -1.54 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.176 179.811 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 99.7 mttt . . . . . 0 N--CA 1.456 -0.174 0 CA-C-O 120.725 0.298 . . . . 0.0 111.177 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -101.26 7.17 43.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.18 178.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -123.08 165.27 17.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.181 -179.552 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -94.72 152.93 18.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.2 -179.463 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 62.4 tp -105.41 120.29 41.23 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.239 174.202 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 91.2 t -119.02 135.59 58.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.2 -178.241 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -128.79 142.02 51.12 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.136 175.283 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 83.8 t -121.82 118.16 54.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.232 176.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 4.1 tp-100 -116.53 107.53 14.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.228 -175.513 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 63.1 t-20 -80.22 106.03 11.93 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.192 179.505 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 92.9 mt -106.08 11.27 31.63 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.15 179.616 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 33.1 p -83.98 179.76 7.45 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.242 -178.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -104.56 23.83 30.35 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 111.166 -0.774 . . . . 0.0 111.166 176.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 27.1 t -150.14 179.74 7.84 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.886 0.374 . . . . 0.0 111.157 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -75.57 138.47 41.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.233 -178.288 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 59.2 tp -92.15 119.1 31.48 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.181 175.604 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' THR . . . . . 0.413 ' HB ' ' HB2' ' A' ' 174' ' ' PHE . 96.5 m -123.56 125.84 45.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.131 174.492 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 85.0 mt -126.4 135.36 51.33 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.247 179.408 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 60.9 mttm -123.38 151.75 42.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.182 177.489 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 8.7 t -63.07 136.53 57.85 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.159 177.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -75.05 -6.67 50.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.181 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -89.6 -0.51 57.57 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.235 178.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -178.23 -121.57 0.71 Allowed Glycine 0 CA--C 1.524 0.626 0 N-CA-C 111.176 -0.769 . . . . 0.0 111.176 178.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -145.79 11.56 1.25 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.864 0.364 . . . . 0.0 111.216 179.356 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 89.0 m -61.5 129.9 43.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.088 -177.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -64.03 129.71 41.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.22 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 89.7 t -113.82 -51.31 5.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.148 173.001 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 95.9 t -124.25 137.03 58.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.095 173.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 62.6 pttt -164.81 161.3 20.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.18 174.655 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 75.3 m-20 57.89 42.95 22.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.397 -179.688 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 92.6 t -112.4 115.62 50.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.185 176.011 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -84.87 -173.31 49.81 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.212 -0.755 . . . . 0.0 111.212 -179.055 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo -72.4 155.98 55.0 Favored 'Trans proline' 0 N--CA 1.457 -0.664 0 C-N-CA 121.791 1.661 . . . . 0.0 111.176 -179.06 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 55.1 52.02 12.4 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.187 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 41.7 t -137.88 126.28 23.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.193 -178.042 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 56.0 p-80 -161.59 173.22 15.08 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.365 -176.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 175.57 170.41 38.4 Favored Glycine 0 CA--C 1.522 0.478 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 177.352 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -73.43 146.29 45.14 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.842 0.353 . . . . 0.0 111.253 -178.541 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 90.9 mmt-85 -132.7 121.33 22.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.253 172.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -86.36 103.1 14.62 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.254 177.652 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 80.2 mt -131.28 134.22 61.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.218 -173.105 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 92.7 m-20 -68.25 153.07 96.04 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.22 178.6 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo -51.26 118.4 4.29 Favored 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 121.749 1.633 . . . . 0.0 111.205 176.345 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.443 ' H ' ' HB2' ' A' ' 188' ' ' LEU . 9.1 p -167.77 149.2 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.15 -177.034 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 40.7 ttmt -72.06 115.59 11.46 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.273 173.235 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 99.2 t -100.08 119.9 48.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.199 -177.577 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 62.2 t-20 -134.2 100.97 4.86 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.175 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 76.7 mt -114.39 152.63 31.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.127 -177.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -90.42 142.73 27.44 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.282 175.11 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 60.9 tp -97.58 117.19 31.31 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.131 -170.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 174' ' ' PHE . . . . . 0.413 ' HB2' ' HB ' ' A' ' 140' ' ' THR . 82.1 m-85 -116.77 137.81 51.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.261 177.467 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -91.72 97.71 11.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.184 166.407 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 69.26 -83.51 0.25 Allowed Glycine 0 CA--C 1.522 0.49 0 N-CA-C 111.177 -0.769 . . . . 0.0 111.177 -171.475 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 93.6 p -135.08 -1.26 2.67 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.849 0.357 . . . . 0.0 111.22 177.516 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -103.63 117.44 34.4 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.258 -177.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -61.86 128.74 37.63 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.19 -176.691 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 92.2 t -96.45 -51.06 11.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.153 174.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 17.9 t -164.51 -157.52 0.37 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.165 -179.159 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 58.1 m-20 -125.27 144.08 50.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.185 172.376 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 94.0 mt -83.13 144.16 30.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.124 -178.138 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -65.08 129.91 94.64 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.187 179.254 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 75.9 Cg_exo -55.25 124.3 15.94 Favored 'Trans proline' 0 N--CA 1.459 -0.542 0 C-N-CA 121.666 1.577 . . . . 0.0 111.129 175.736 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 96.0 t -123.52 124.94 70.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.23 175.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 94.9 m -85.77 122.32 29.68 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.238 178.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . 0.443 ' HB2' ' H ' ' A' ' 167' ' ' VAL . 74.0 mt -85.55 156.08 20.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.061 178.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -150.55 153.09 35.15 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.206 -179.792 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 41.3 ptt180 -57.83 128.37 36.73 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.228 -175.566 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 91.96 -13.52 66.69 Favored Glycine 0 CA--C 1.523 0.556 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 173.033 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 72.6 mm-40 -87.38 149.22 24.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.838 0.351 . . . . 0.0 111.09 -176.08 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 67.3 t -116.09 120.87 66.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.194 177.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 92.4 t -120.91 122.73 68.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.221 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 74.5 m -116.48 144.32 44.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.197 -177.585 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 66.1 tp -114.47 117.01 29.77 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.149 175.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -106.62 99.42 8.99 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.221 -178.697 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . 0.471 ' HA ' ' HA ' ' A' ' 207' ' ' PRO . 90.3 t -83.42 115.94 26.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.301 -0.408 . . . . 0.0 111.188 -174.319 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 28.4 p -110.33 174.3 5.92 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.199 179.332 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -149.71 144.69 12.32 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 111.166 -0.774 . . . . 0.0 111.166 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.7 t -160.75 120.37 2.7 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.779 0.323 . . . . 0.0 111.265 177.137 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 75.31 14.05 82.27 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 111.267 -0.733 . . . . 0.0 111.267 178.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 95.92 -5.86 66.57 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 -178.418 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -103.5 134.6 46.58 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.826 0.346 . . . . 0.0 111.161 -179.261 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 99.4 mt -83.36 150.8 25.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.227 179.318 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -150.09 73.77 9.28 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.203 177.028 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 207' ' ' PRO . . . . . 0.471 ' HA ' ' HA ' ' A' ' 198' ' ' VAL . 46.2 Cg_exo -63.4 147.71 93.24 Favored 'Trans proline' 0 N--CA 1.456 -0.704 0 C-N-CA 121.729 1.619 . . . . 0.0 111.248 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 87.3 t -118.91 127.72 75.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.22 176.674 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 97.1 m95 -84.15 128.5 34.6 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.253 175.113 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 89.7 t -125.96 122.82 62.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.16 178.144 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -106.41 127.78 53.55 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.141 178.104 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 84.8 mtt85 . . . . . 0 C--O 1.2 -1.501 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.257 179.545 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 76.0 mmtt . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.695 0.283 . . . . 0.0 111.195 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -95.43 -24.73 16.55 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.15 176.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 94.4 mttt -124.88 166.69 15.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.193 176.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -74.02 147.88 42.5 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.185 179.263 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 88.7 mt -114.85 149.82 36.5 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.235 175.225 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 86.3 t -125.77 128.34 72.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.28 178.655 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . 0.609 HH21 ' CE1' ' A' ' 159' ' ' HIS . 81.9 mtp180 -117.7 157.72 25.99 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.235 178.281 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 14.2 p -130.95 142.42 43.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.147 175.251 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 66.7 tp60 -148.21 109.4 4.32 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.183 179.374 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . 0.457 ' HA ' ' HB ' ' A' ' 198' ' ' VAL . 64.2 t-20 -86.18 108.97 18.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.166 -175.343 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 87.8 mt -90.99 -4.08 56.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.263 179.564 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 27.4 p -102.24 -178.3 3.66 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.192 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -103.66 8.54 51.37 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 111.201 -0.76 . . . . 0.0 111.201 176.566 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 94.9 p -90.39 160.01 16.29 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.816 0.341 . . . . 0.0 111.166 -175.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 39.4 ttpt -107.95 119.29 39.03 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.275 176.177 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 52.0 mt -131.69 150.56 52.11 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.228 -176.776 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 60.1 m -106.68 129.28 54.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.215 174.253 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 63.0 tp -95.48 121.29 37.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.225 -178.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -145.07 145.31 31.39 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.217 -179.535 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 81.1 p -68.8 150.6 47.65 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.223 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -60.62 121.81 13.14 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.209 -178.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 79.5 m-20 56.19 36.18 27.0 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.286 -179.174 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -86.45 -179.81 49.35 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 111.171 -0.772 . . . . 0.0 111.171 177.059 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -113.4 -23.75 9.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.774 0.321 . . . . 0.0 111.181 -179.483 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 89.9 m -128.87 136.88 51.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.175 -175.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 76.5 m-20 -65.2 145.82 55.76 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.239 178.48 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . 0.473 HG12 HG23 ' A' ' 151' ' ' VAL . 91.7 t -87.51 -57.04 4.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.194 178.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.473 HG23 HG12 ' A' ' 150' ' ' VAL . 46.9 t -130.71 124.33 56.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.178 169.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -94.38 138.06 32.78 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.167 -176.16 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 72.4 m-20 53.84 62.86 2.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.159 171.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 96.7 t -74.26 106.21 3.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.228 176.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -90.09 179.62 43.96 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 -176.564 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -57.39 127.7 26.53 Favored 'Trans proline' 0 C--N 1.327 -0.585 0 C-N-CA 121.702 1.601 . . . . 0.0 111.209 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 94.7 mm-40 66.2 19.32 11.08 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.218 175.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 35.8 t -73.37 145.74 45.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.235 176.772 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' HIS . . . . . 0.609 ' CE1' HH21 ' A' ' 130' ' ' ARG . 82.5 t60 -149.74 143.89 25.72 Favored 'General case' 0 CA--C 1.509 -0.607 0 CA-C-O 122.115 0.959 . . . . 0.0 111.029 178.613 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -158.84 157.43 28.43 Favored Glycine 0 CA--C 1.524 0.602 0 CA-C-N 114.868 -1.06 . . . . 0.0 111.224 -179.425 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 75.8 m-20 -113.01 147.37 37.33 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.849 0.357 . . . . 0.0 111.174 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 90.9 mmt-85 -138.85 148.09 43.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.178 178.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -110.06 134.83 51.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.184 173.731 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 20.2 tt -147.77 149.43 15.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.194 -175.082 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 97.0 m-20 -50.21 142.99 13.5 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.202 174.569 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -78.82 65.21 8.78 Favored 'Trans proline' 0 N--CA 1.457 -0.643 0 C-N-CA 121.764 1.642 . . . . 0.0 111.201 -173.615 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 34.3 m -133.42 160.78 42.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.23 176.343 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -65.91 108.44 2.17 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.061 -179.334 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 93.0 t -121.35 125.35 73.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.289 178.037 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 83.9 m-20 -99.38 141.81 31.68 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.162 177.322 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 5.4 mp -124.67 172.6 9.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.167 -174.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -148.11 166.06 28.96 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.207 -178.296 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 67.4 mt -94.69 135.43 36.17 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.251 177.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 -128.91 156.57 43.5 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.204 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 67.9 t0 -144.43 95.42 2.71 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.237 175.363 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 79.88 -106.38 2.44 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 111.199 -0.76 . . . . 0.0 111.199 179.827 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 88.1 p -115.52 7.87 15.02 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.797 0.332 . . . . 0.0 111.184 178.638 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -125.71 130.34 51.32 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.227 -178.309 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 38.9 ttpt -71.23 135.2 47.39 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.216 176.434 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 70.4 t -83.2 -55.57 7.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.152 -179.239 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 43.6 t -173.9 142.13 0.85 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.223 -176.038 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -69.09 146.84 52.24 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.223 176.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 94.6 mt -95.3 158.95 15.23 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.196 176.307 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -57.74 130.37 82.02 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.161 177.647 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_exo -52.85 140.1 58.42 Favored 'Trans proline' 0 N--CA 1.457 -0.661 0 C-N-CA 121.783 1.655 . . . . 0.0 111.17 177.504 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 8.2 p -143.49 136.24 24.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.119 -175.387 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 97.7 m -95.92 131.14 42.58 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.237 176.335 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 59.7 mt -100.04 96.03 7.25 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.171 -176.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -70.14 142.65 52.51 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.226 -177.448 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 80.6 ttt180 -66.55 125.9 27.19 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.241 -176.005 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 93.0 -10.52 73.71 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 173.549 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -103.22 178.93 4.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.788 0.328 . . . . 0.0 111.144 -178.32 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 7.4 p -135.09 139.6 46.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.148 -177.308 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 33.3 m -113.1 156.55 14.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.158 172.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 49.5 t -134.8 129.23 34.24 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.245 179.46 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 66.0 tp -89.45 115.29 26.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.237 177.133 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -101.47 104.34 15.26 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.194 176.571 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . 0.457 ' HB ' ' HA ' ' A' ' 133' ' ' ASN . 84.8 t -79.05 114.2 19.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.207 -173.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 15.3 t -143.84 -160.85 1.17 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.227 179.361 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 167.33 -171.61 42.05 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 44.3 t -162.35 129.21 3.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.732 0.301 . . . . 0.0 111.191 -179.452 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 75.57 15.9 80.96 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 111.157 -0.777 . . . . 0.0 111.157 177.089 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 99.17 -13.91 61.51 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 111.128 -0.789 . . . . 0.0 111.128 -178.327 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -88.7 123.69 33.39 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.777 0.322 . . . . 0.0 111.136 -179.377 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 96.8 mt -74.28 138.33 43.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.141 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -152.8 70.39 7.19 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.246 173.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -58.31 148.26 80.36 Favored 'Trans proline' 0 N--CA 1.458 -0.575 0 C-N-CA 121.783 1.655 . . . . 0.0 111.201 176.363 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 85.6 t -119.62 129.16 75.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.216 -177.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 92.0 m95 -83.59 128.34 34.44 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.229 172.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 86.7 t -121.41 124.87 72.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.2 175.743 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 28.1 ttpp -97.04 128.22 43.78 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.109 179.524 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 96.4 mtt-85 . . . . . 0 C--O 1.201 -1.484 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.236 -178.834 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 99.6 mttt . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.828 0.347 . . . . 0.0 111.206 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' GLN . . . . . 0.458 ' OE1' ' N ' ' A' ' 125' ' ' GLN . 18.3 pm0 -86.56 -6.54 58.85 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.136 176.643 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 99.9 mttt -111.31 -179.14 3.63 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.138 -178.313 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -143.36 173.11 11.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.197 174.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 93.7 mt -127.45 142.43 51.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.136 177.059 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 10.0 p -125.05 133.76 68.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.155 175.143 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 44.3 ttm180 -135.6 146.53 48.02 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.109 -177.163 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 98.8 t -125.85 127.24 71.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.167 176.764 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 62.9 tp60 -95.28 128.18 41.92 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.199 -179.688 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 57.5 t-20 -87.17 110.42 20.14 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.237 173.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 94.3 mt -101.76 7.91 41.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.123 177.119 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 30.5 t -101.35 158.82 15.77 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.178 178.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -79.85 -9.73 86.44 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.274 -0.731 . . . . 0.0 111.274 172.785 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 87.5 p -91.31 169.96 10.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.854 0.359 . . . . 0.0 111.109 173.321 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -89.1 156.08 19.04 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.197 177.536 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 84.7 mt -109.98 152.75 25.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.236 178.102 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 49.7 p -125.47 78.5 1.73 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.22 177.052 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 38.1 tp -70.92 120.88 17.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.116 -170.041 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -142.99 153.44 43.0 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.236 -178.016 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 85.6 m -57.3 125.31 22.23 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.244 174.117 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -59.07 118.3 5.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.233 -177.426 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 57.34 29.85 17.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.172 -179.566 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -113.38 -171.17 17.75 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.229 -0.748 . . . . 0.0 111.229 177.291 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -115.76 -4.19 12.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.829 0.347 . . . . 0.0 111.181 177.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 99.8 m -98.43 117.15 32.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.139 -175.529 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 81.2 m-20 -74.49 146.56 42.63 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.204 172.611 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . 0.493 HG12 HG23 ' A' ' 151' ' ' VAL . 60.1 t -108.95 -64.89 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.146 -175.192 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.493 HG23 HG12 ' A' ' 150' ' ' VAL . 99.4 t -141.47 120.28 10.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.204 172.06 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 54.2 mtmt -113.38 160.11 18.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.179 -178.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 32.1 t0 62.08 47.77 5.5 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.191 178.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 93.9 t -78.25 114.62 19.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.184 175.288 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -66.7 156.59 51.23 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 -171.549 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -55.02 132.79 54.4 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 121.797 1.665 . . . . 0.0 111.103 177.361 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 92.9 mm-40 57.08 33.09 22.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.162 179.506 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 19.2 t -119.06 -161.49 0.85 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.182 175.572 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 34.3 p80 -160.36 170.11 21.73 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.259 179.481 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -156.66 159.88 29.86 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 176.43 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 20.9 p30 -149.32 175.86 11.06 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.793 0.33 . . . . 0.0 111.237 -175.293 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 58.1 ttm-85 -156.05 140.69 16.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.208 -178.22 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -71.26 128.85 37.29 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.307 171.327 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 19.9 tt -159.06 153.93 5.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.147 -172.054 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 95.6 m-20 -62.87 154.08 77.38 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.181 176.433 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -75.16 71.36 5.13 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 121.725 1.617 . . . . 0.0 111.238 -179.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 33.4 m -126.26 179.83 3.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.181 -177.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -76.37 121.08 22.5 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.179 173.732 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 76.9 t -114.18 121.05 65.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.178 -176.367 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 87.3 m-20 -96.36 119.06 34.16 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.196 177.418 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 77.3 mt -113.76 154.19 27.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.206 -174.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -158.39 162.54 37.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.267 179.22 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 68.0 mt -111.73 148.58 33.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.154 173.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 35.0 p90 -142.76 160.1 40.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.198 -174.122 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 67.7 t0 -131.39 91.36 3.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.128 174.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 79.49 -106.73 2.45 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 -177.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 95.1 p -106.29 -9.26 16.89 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.784 0.326 . . . . 0.0 111.168 177.012 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -104.29 117.71 34.88 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.159 -176.138 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 39.0 ttpt -66.59 136.53 55.73 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.249 177.426 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 72.2 t -86.04 -56.29 5.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.251 -178.441 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 43.5 t -171.36 143.63 1.86 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.19 -176.342 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -72.48 150.33 43.37 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.217 176.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 82.4 mt -106.16 159.33 16.17 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.237 175.32 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 56.4 tptt -55.58 116.29 11.58 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.262 -179.802 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 77.1 Cg_exo -56.38 141.95 88.93 Favored 'Trans proline' 0 N--CA 1.459 -0.514 0 C-N-CA 121.602 1.535 . . . . 0.0 111.155 178.26 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 73.3 t -121.32 127.39 75.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.202 -177.415 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 97.1 m -95.33 116.67 29.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.171 170.194 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 83.3 mt -90.84 158.25 16.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.199 -175.539 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -136.53 156.36 48.69 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.198 -179.492 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 75.3 mtp180 -62.51 124.37 20.76 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.157 -174.453 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 78.7 13.32 83.28 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 111.194 -0.762 . . . . 0.0 111.194 173.172 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 92.5 mt-10 -121.29 158.34 28.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.769 0.318 . . . . 0.0 111.149 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 7.3 p -131.91 139.22 50.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.216 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 84.6 t -112.41 136.43 48.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.212 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 44.6 t -114.72 110.85 20.37 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.214 172.223 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 52.7 tp -90.82 110.57 21.78 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.157 -178.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 197' ' ' TYR . . . . . 0.407 ' HB2' ' HB ' ' A' ' 208' ' ' VAL . 85.3 m-85 -86.75 96.77 10.28 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.192 -175.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 97.3 t -86.76 121.58 37.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.178 -174.469 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 14.8 t -153.19 -169.11 3.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.207 178.377 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 144.54 -162.77 27.96 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 111.204 -0.758 . . . . 0.0 111.204 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.3 t -171.5 143.65 1.81 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.833 0.349 . . . . 0.0 111.148 -177.683 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 76.48 16.3 80.83 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 111.192 -0.763 . . . . 0.0 111.192 174.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 94.96 -6.52 69.51 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 111.114 -0.795 . . . . 0.0 111.114 -178.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -98.73 115.72 29.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.766 0.317 . . . . 0.0 111.102 179.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 91.5 mt -98.72 154.25 18.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.086 -177.291 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -150.74 73.96 8.72 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.208 176.449 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_exo -58.05 139.02 88.92 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 121.656 1.571 . . . . 0.0 111.161 178.653 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 208' ' ' VAL . . . . . 0.407 ' HB ' ' HB2' ' A' ' 197' ' ' TYR . 57.5 t -104.73 114.29 43.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.22 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 209' ' ' TRP . . . . . 0.435 ' CD1' ' C ' ' A' ' 209' ' ' TRP . 7.3 t90 -77.76 96.97 5.04 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.199 -178.082 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 98.3 t -106.23 115.41 47.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.219 175.277 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 29.2 ttpp -102.38 132.53 48.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.206 178.56 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 83.0 mtt85 . . . . . 0 C--O 1.202 -1.412 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.174 179.632 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 88.5 tttt . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.842 0.353 . . . . 0.0 111.282 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 61.7 mt-30 -103.59 150.02 24.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.2 179.368 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 62.9 pttt -164.33 166.29 20.95 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.271 174.253 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -142.13 167.9 21.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.201 -174.792 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 69.3 mt -120.86 154.73 35.42 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.129 176.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 13.1 p -141.39 137.0 32.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.296 177.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -125.82 149.24 48.78 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.166 172.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 87.4 t -128.71 120.12 51.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.128 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 64.7 tt0 -110.41 138.57 46.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.239 -174.366 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 64.7 t-20 -88.72 109.62 20.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.223 177.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 7.8 mp -105.93 34.94 3.08 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.284 178.256 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 59.6 p -132.8 173.1 11.73 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.16 177.445 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -86.71 -12.63 68.75 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 175.295 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 95.9 p -88.47 167.02 13.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.888 0.375 . . . . 0.0 111.207 179.13 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -79.04 135.87 37.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.275 178.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 60.5 tp -107.85 131.41 54.52 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.293 -175.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 93.5 m -133.37 128.43 35.6 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.334 172.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.4 HD23 ' C ' ' A' ' 141' ' ' LEU . 10.3 tt -142.9 132.64 23.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.107 -176.669 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -125.92 165.8 18.07 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.137 179.647 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 14.6 t -150.92 -170.37 3.64 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.211 175.406 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . 55.16 51.63 12.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.19 -175.386 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 75.7 m-20 62.05 27.68 16.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.16 -177.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 84.29 6.67 85.94 Favored Glycine 0 CA--C 1.52 0.367 0 N-CA-C 111.276 -0.73 . . . . 0.0 111.276 176.131 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -81.81 -32.59 31.21 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.805 0.336 . . . . 0.0 111.122 -177.606 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 82.6 m -99.77 120.04 39.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.183 -178.335 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 65.4 t0 -89.32 109.01 19.96 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.192 176.027 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 87.4 t -85.48 -58.0 3.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.202 -176.489 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 27.8 m -132.83 153.33 37.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.209 168.373 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 65.6 tttm -150.55 116.97 5.71 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.337 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 70.8 m-20 56.17 46.98 20.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.266 174.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 33.5 m -101.96 151.24 5.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.142 179.14 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -99.1 -168.98 30.62 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 -171.58 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_exo -58.52 136.97 77.69 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 121.651 1.568 . . . . 0.0 111.153 -178.244 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 96.0 mm-40 68.3 17.12 9.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.249 173.463 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 70.3 m -103.99 151.23 23.44 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.308 170.192 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 56.4 p-80 -152.79 161.56 42.41 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.212 -176.49 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -114.98 160.24 13.31 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 176.481 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 37.4 t0 -136.86 115.5 12.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.609 0.242 . . . . 0.0 111.276 -178.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 89.4 mmt-85 -127.15 144.24 51.08 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.275 -173.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -96.18 124.48 40.2 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.253 175.707 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 46.1 pt -126.15 164.24 26.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.235 -168.1 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 -84.32 160.73 56.42 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.165 177.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -79.02 57.17 6.34 Favored 'Trans proline' 0 N--CA 1.458 -0.604 0 C-N-CA 121.588 1.525 . . . . 0.0 111.148 -179.753 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 33.6 m -130.96 -179.14 3.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.165 -175.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -65.61 104.01 0.96 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.305 174.36 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 91.7 t -104.3 126.56 58.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.25 -178.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 37.7 t-20 -107.26 109.21 20.93 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.089 -178.32 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 65.9 mt -90.64 117.67 29.48 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.218 175.602 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -126.12 140.39 52.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.154 -175.055 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 96.3 mt -87.69 141.18 28.81 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.185 178.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -135.6 156.44 48.86 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.209 179.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 66.9 t0 -136.05 83.78 2.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.193 173.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 79.48 -105.67 2.31 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.224 -0.75 . . . . 0.0 111.224 -173.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 98.0 p -102.95 -6.02 22.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.789 0.328 . . . . 0.0 111.195 172.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -83.82 131.51 34.88 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.196 -176.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 89.1 tttt -86.65 126.32 34.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.151 170.569 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 97.3 t -103.02 -53.02 7.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.195 -171.016 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 47.2 t -146.7 149.06 32.7 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.122 -174.619 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 51.0 t0 -136.2 102.33 4.97 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.228 -175.76 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 94.8 mt -81.56 148.23 29.24 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.148 -177.315 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -62.22 131.48 93.6 Favored Pre-proline 0 C--N 1.327 -0.38 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.244 178.464 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 76.3 Cg_exo -55.05 133.08 56.12 Favored 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 121.611 1.54 . . . . 0.0 111.234 177.031 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 94.0 t -124.21 131.15 73.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.26 178.462 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 98.2 m -88.24 130.01 35.2 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.101 175.584 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 82.0 mt -113.05 153.91 27.38 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.217 -178.635 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -102.41 163.83 12.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.116 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 79.6 ttt180 -51.03 120.21 4.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.147 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 104.74 -16.27 47.67 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 169.387 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 64.7 mt-10 -73.64 136.78 43.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.781 0.324 . . . . 0.0 111.089 -177.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 61.8 t -125.78 123.31 64.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.277 179.148 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 79.2 t -103.44 135.03 42.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.27 -178.411 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 44.3 t -121.78 105.63 10.56 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.249 176.316 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 31.0 tp -81.49 124.16 29.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.215 -176.222 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -105.72 98.52 8.2 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.2 179.196 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . 0.436 ' HA ' ' HA ' ' A' ' 207' ' ' PRO . 62.3 t -90.54 106.99 17.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.216 -176.398 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 44.5 p -105.22 174.77 5.74 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.089 -175.454 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 100.36 -138.26 13.75 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 111.406 -0.678 . . . . 0.0 111.406 176.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 42.1 t -163.88 127.18 2.61 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.823 0.345 . . . . 0.0 111.204 178.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . -54.07 139.15 37.74 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 -174.478 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -91.52 8.34 78.96 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 111.015 -0.834 . . . . 0.0 111.015 7.118 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -89.65 69.9 7.78 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.671 0.272 . . . . 0.0 111.076 -177.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 93.4 mt -97.69 156.81 16.38 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.246 -178.342 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -139.42 84.58 16.07 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.135 -176.444 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 207' ' ' PRO . . . . . 0.436 ' HA ' ' HA ' ' A' ' 198' ' ' VAL . 53.0 Cg_exo -57.61 129.42 33.65 Favored 'Trans proline' 0 N--CA 1.459 -0.55 0 C-N-CA 121.692 1.595 . . . . 0.0 111.139 176.716 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 77.2 t -109.65 115.67 50.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.217 173.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 38.6 t-105 -81.52 105.24 12.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.221 -174.666 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 94.8 t -117.58 119.92 63.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.154 177.063 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -100.31 134.22 43.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.215 178.436 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 40.3 mmt180 . . . . . 0 C--O 1.199 -1.576 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.218 -179.934 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 99.3 mttt . . . . . 0 C--O 1.23 0.078 0 CA-C-O 120.795 0.331 . . . . 0.0 111.239 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 94.7 mt-30 -140.29 54.28 1.63 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.181 178.307 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -170.23 125.41 0.76 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.116 -178.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -150.23 143.63 25.09 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.248 172.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 59.0 tp -101.96 128.65 48.28 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.179 -177.613 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 33.1 m -125.48 152.01 31.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.136 174.452 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 41.7 ttm180 -140.85 124.2 16.7 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.208 178.617 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 57.3 t -105.39 121.33 57.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.257 -177.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 64.7 tp60 -107.76 127.01 53.31 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.173 -177.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 57.9 t-20 -85.63 105.34 16.13 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.153 178.357 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 98.3 mt -110.66 28.85 8.28 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.287 176.539 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 50.3 p -104.64 -175.69 2.87 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.222 -178.448 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -100.1 11.18 60.35 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 176.348 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 21.0 t -137.64 -167.46 2.14 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.802 0.334 . . . . 0.0 111.222 -178.388 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -102.63 142.91 33.02 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.125 178.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 93.8 mt -104.47 148.18 26.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.265 -177.265 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' THR . . . . . 0.409 ' HB ' ' HB2' ' A' ' 174' ' ' PHE . 97.2 m -139.26 128.35 23.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.18 169.352 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 79.9 mt -118.97 114.85 23.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.259 -179.243 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -127.24 133.63 50.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.198 179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 79.4 p -71.83 156.81 38.88 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.134 -172.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -59.93 -30.02 68.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.238 -176.736 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -64.44 -31.65 72.94 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.208 179.625 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 78.18 17.39 78.24 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 -178.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -110.02 -27.31 9.27 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.758 0.313 . . . . 0.0 111.184 -178.029 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 69.1 p -130.36 169.7 15.12 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.262 -179.108 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 20.6 p30 -150.61 175.12 12.22 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.162 -178.633 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 88.1 t -129.25 -40.69 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.247 179.093 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 90.1 t -132.09 137.92 53.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.184 -178.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -135.95 107.83 7.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.201 178.085 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 75.5 m-20 51.5 51.31 17.03 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.243 173.459 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 76.6 t -100.57 127.66 53.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.236 179.194 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -88.84 177.66 44.96 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 111.224 -0.75 . . . . 0.0 111.224 -171.067 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -58.8 147.22 89.69 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 121.652 1.568 . . . . 0.0 111.199 -178.211 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 94.4 mm-40 68.98 17.06 8.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.233 176.707 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 68.1 m -124.87 161.53 26.36 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.168 171.644 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 33.8 p80 -146.41 170.14 17.43 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.206 -176.515 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -143.7 145.7 15.66 Favored Glycine 0 CA--C 1.523 0.571 0 N-CA-C 111.246 -0.742 . . . . 0.0 111.246 179.119 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -111.09 150.34 29.54 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.823 0.344 . . . . 0.0 111.168 -178.324 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 85.1 mmt-85 -143.6 143.6 31.56 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.16 175.433 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -99.53 112.29 24.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.211 170.066 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 76.8 mt -130.78 139.13 51.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.113 -171.183 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . 0.452 ' HA ' ' HD3' ' A' ' 166' ' ' PRO . 95.3 m-20 -61.67 155.01 63.09 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.206 177.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 166' ' ' PRO . . . . . 0.452 ' HD3' ' HA ' ' A' ' 165' ' ' ASN . 51.1 Cg_exo -63.1 80.15 0.12 Allowed 'Trans proline' 0 N--CA 1.458 -0.595 0 C-N-CA 121.65 1.567 . . . . 0.0 111.173 -178.858 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 30.2 m -129.28 179.62 3.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.203 177.487 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -89.95 133.8 34.58 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.227 174.241 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 86.1 t -72.4 87.27 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.178 -176.7 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 62.9 t-20 -88.36 88.98 7.8 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.154 170.416 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 8.7 tt -145.18 140.66 28.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.231 -166.351 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -92.07 141.72 28.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.249 -177.07 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 62.6 tp -101.55 117.87 35.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.193 -172.662 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 174' ' ' PHE . . . . . 0.409 ' HB2' ' HB ' ' A' ' 140' ' ' THR . 70.5 m-85 -113.26 148.2 36.04 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.221 -178.524 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -105.69 94.18 5.06 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.196 167.146 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 77.38 -104.01 1.9 Allowed Glycine 0 CA--C 1.523 0.562 0 N-CA-C 111.232 -0.747 . . . . 0.0 111.232 -173.546 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 92.8 p -115.86 1.29 13.35 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.716 0.293 . . . . 0.0 111.166 172.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -104.64 116.96 32.97 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.306 -177.511 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -63.57 133.08 53.14 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.17 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 93.7 t -102.18 -53.3 7.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.206 176.614 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 19.2 t -163.99 -157.75 0.41 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.187 178.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -105.15 137.16 43.36 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.214 170.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 51.4 tp -74.73 128.75 36.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.252 -178.567 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -51.91 126.78 34.41 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.25 177.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -74.4 150.83 41.87 Favored 'Trans proline' 0 N--CA 1.458 -0.613 0 C-N-CA 121.647 1.565 . . . . 0.0 111.246 -176.516 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 14.5 p -147.42 143.79 19.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.177 176.349 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 92.1 m -81.0 124.58 29.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.168 -177.765 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 80.6 mt -93.78 158.75 15.51 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.218 177.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -159.85 146.02 15.89 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.202 -179.473 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 79.8 ttt180 -71.07 134.22 46.89 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.163 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 101.93 -12.13 57.56 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 111.184 -0.766 . . . . 0.0 111.184 -177.186 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -121.26 146.65 46.59 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.814 0.34 . . . . 0.0 111.168 179.324 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 96.9 t -114.46 123.36 70.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.244 178.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 76.7 t -109.85 114.12 46.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.206 -175.19 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 75.9 m -100.7 152.95 19.86 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.239 -178.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 64.8 tp -125.8 123.07 37.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.236 178.294 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -114.72 108.73 17.18 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.234 -179.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 65.5 t -109.43 124.19 65.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.122 -177.474 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 13.5 t -131.06 -174.29 3.34 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.148 -179.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -89.06 140.73 15.91 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 111.193 -0.763 . . . . 0.0 111.193 -177.615 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 37.3 t -146.38 86.87 1.7 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.798 0.332 . . . . 0.0 111.236 176.68 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 73.35 22.23 78.91 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 177.194 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 100.84 -12.5 59.26 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 111.231 -0.747 . . . . 0.0 111.231 -178.154 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -100.62 165.07 11.59 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.738 0.304 . . . . 0.0 111.239 178.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 96.5 mt -85.96 139.62 31.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.215 177.285 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -124.09 92.23 48.58 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.216 -179.385 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -76.26 138.75 20.43 Favored 'Trans proline' 0 N--CA 1.457 -0.672 0 C-N-CA 121.777 1.651 . . . . 0.0 111.244 -179.433 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 92.3 t -129.82 122.5 54.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.163 174.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 91.8 m95 -86.8 126.46 34.63 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.166 178.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 69.5 t -131.62 113.54 23.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.213 176.244 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 36.2 ttpt -103.51 136.0 44.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.225 -176.29 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 80.4 ttt180 . . . . . 0 C--O 1.198 -1.611 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.18 177.708 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 99.6 mttt . . . . . 0 C--O 1.23 0.073 0 CA-C-O 120.767 0.318 . . . . 0.0 111.212 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -91.95 143.2 26.73 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.218 174.464 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 68.3 tp -93.06 112.55 24.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.271 177.926 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 58.5 t -115.44 122.8 70.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.192 -178.434 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 41.8 ttm180 -112.1 144.91 40.69 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.225 177.434 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 92.3 t -114.35 119.94 62.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.205 169.877 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 66.6 tp60 -107.74 107.36 18.1 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.237 -177.611 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 65.0 t-20 -85.11 103.64 14.3 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.269 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 92.1 mt -102.61 17.44 23.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.228 -179.756 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 30.8 p -103.01 -179.33 3.92 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.215 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -104.82 29.25 12.1 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 111.258 -0.737 . . . . 0.0 111.258 174.919 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 46.1 t -144.8 147.42 32.86 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.808 0.337 . . . . 0.0 111.229 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -69.18 136.49 52.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.189 179.289 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.413 ' C ' HD12 ' A' ' 139' ' ' LEU . 4.4 pp -149.69 165.91 30.94 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.155 179.803 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 13.4 t -144.95 150.99 37.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.165 -177.223 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 64.7 tp -100.64 112.33 24.71 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.2 175.018 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 14.6 ptmm? -140.2 178.72 7.08 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.175 -176.837 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 57.0 p -83.22 164.9 19.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.167 179.011 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -108.45 4.82 24.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.214 177.079 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 75.7 m-20 -104.04 4.3 34.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.182 -177.539 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 174.55 -161.86 31.81 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.196 -0.762 . . . . 0.0 111.196 -178.729 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -93.81 -5.16 48.83 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.703 0.287 . . . . 0.0 111.146 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 89.4 m -62.0 130.06 43.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.239 178.31 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 42.3 p30 -93.13 177.57 6.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.215 -177.573 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 90.7 t -113.72 -56.27 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.172 177.609 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 99.0 t -117.46 133.41 64.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.247 178.843 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -100.77 166.38 10.9 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.173 -176.646 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 29.4 t0 64.32 47.38 3.15 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.204 177.118 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 69.7 t -118.27 121.17 66.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.235 174.905 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -124.59 -165.61 12.22 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 -177.463 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -75.77 141.01 24.03 Favored 'Trans proline' 0 N--CA 1.458 -0.563 0 C-N-CA 121.728 1.619 . . . . 0.0 111.182 179.247 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 49.64 50.54 18.1 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.217 175.66 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 17.4 t -161.48 -157.52 0.5 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.193 -178.434 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 57.2 p-80 -156.57 164.66 37.94 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.196 179.002 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -147.05 147.56 18.48 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 111.209 -0.756 . . . . 0.0 111.209 179.632 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 88.0 m-20 -112.55 155.6 24.08 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.739 0.304 . . . . 0.0 111.202 178.766 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 29.2 tpt180 -159.5 127.6 4.95 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.175 175.792 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -82.66 123.13 28.98 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.189 173.85 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 80.9 mt -127.89 137.97 56.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.189 -171.554 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 96.3 m-20 -50.45 147.26 8.04 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.236 178.76 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 81.1 Cg_endo -75.17 68.19 5.93 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 121.687 1.591 . . . . 0.0 111.226 -178.644 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 33.5 m -129.45 -178.12 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.203 -177.923 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -75.89 116.88 17.04 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.228 173.233 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 95.1 t -119.39 121.16 65.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.204 -175.845 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 55.1 t-20 -73.31 111.13 8.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.223 178.821 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 59.5 mt -95.82 142.92 27.52 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.244 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -161.88 143.76 11.29 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.189 175.662 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 65.5 tp -95.84 120.94 37.0 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.251 -178.404 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -118.77 140.44 49.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.257 175.406 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 39.6 t0 -111.46 94.45 4.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.188 171.803 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 79.22 -105.04 2.2 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 111.205 -0.758 . . . . 0.0 111.205 -173.104 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 88.9 p -115.75 6.06 14.33 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.771 0.32 . . . . 0.0 111.182 172.841 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -98.05 120.14 37.91 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.217 -176.116 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -66.47 126.89 30.28 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.241 173.433 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 88.0 t -105.65 -53.14 7.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.218 -177.049 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 44.8 t -147.88 140.31 24.46 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.204 -176.299 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -100.85 107.08 18.53 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.159 176.223 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 183' ' ' LEU . . . . . 0.538 ' O ' ' HB2' ' A' ' 184' ' ' LYS . 92.1 mt -89.69 -15.98 31.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.24 -171.793 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 184' ' ' LYS . . . . . 0.538 ' HB2' ' O ' ' A' ' 183' ' ' LEU . 74.9 mmtt 83.33 165.08 0.11 Allowed Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.209 167.113 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_exo -59.92 134.74 58.62 Favored 'Trans proline' 0 N--CA 1.458 -0.598 0 C-N-CA 121.689 1.593 . . . . 0.0 111.189 179.099 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 29.9 m -125.28 152.43 31.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.163 172.144 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 97.2 m -94.28 117.17 29.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.211 -179.197 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 93.4 mt -95.11 153.33 17.7 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.163 178.092 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -131.4 156.82 44.9 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.203 177.47 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 89.9 mtm180 -62.77 123.14 17.67 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.21 -176.678 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 87.47 -1.07 85.71 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 176.705 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -70.2 133.2 46.83 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.698 0.285 . . . . 0.0 111.231 -179.306 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 98.4 t -113.24 118.28 57.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.218 178.684 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 33.4 m -131.89 162.42 39.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.216 177.857 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 46.1 t -150.73 128.36 11.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.19 -179.111 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 60.9 tp -92.24 117.42 29.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.186 177.76 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -102.43 105.79 16.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.19 -179.737 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 54.2 t -105.22 112.79 40.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.21 -178.937 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 71.8 p -99.61 163.9 12.3 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.122 -178.519 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -116.39 135.24 11.92 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 111.239 -0.745 . . . . 0.0 111.239 179.022 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.2 t -160.69 120.06 2.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.746 0.308 . . . . 0.0 111.162 179.035 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 74.31 15.16 80.29 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 111.228 -0.749 . . . . 0.0 111.228 176.798 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 89.98 -0.84 79.68 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 111.179 -0.768 . . . . 0.0 111.179 -177.215 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -106.49 158.92 16.55 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.875 0.369 . . . . 0.0 111.157 -179.335 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 90.4 mt -107.02 141.51 38.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.146 179.522 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -125.33 92.81 46.37 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.268 179.191 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -74.6 127.36 10.91 Favored 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 121.712 1.608 . . . . 0.0 111.16 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 64.3 t -126.81 106.09 15.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.137 174.327 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 10.8 t90 -80.06 124.29 28.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.215 -177.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 98.7 t -120.63 132.56 69.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.167 -175.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -99.93 133.8 43.76 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.233 175.695 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 41.9 mmt180 . . . . . 0 C--O 1.2 -1.501 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.134 -179.484 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 74.4 mmtt . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.736 0.303 . . . . 0.0 111.229 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -143.91 177.78 8.31 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.241 177.015 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 95.4 mt -122.51 147.92 45.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.236 -177.979 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 12.2 p -134.35 142.84 39.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.205 178.365 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 38.5 ttm180 -117.53 99.31 6.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.203 179.017 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 96.2 t -84.69 121.37 36.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.169 -171.712 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 69.3 mm-40 -112.83 78.88 1.17 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.183 173.343 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 -89.33 157.41 18.2 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.197 -174.846 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 58.0 tp -62.97 -40.9 99.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.159 176.856 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 91.7 p -72.04 155.84 39.88 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.194 -175.085 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -113.84 55.4 0.52 Allowed Glycine 0 CA--C 1.524 0.599 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 -179.281 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 99.4 p -145.18 160.2 41.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.789 0.328 . . . . 0.0 111.213 -178.444 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -64.76 124.78 22.83 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.171 178.288 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 73.5 mt -111.06 157.83 19.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.19 -175.777 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 92.0 m -110.66 127.77 55.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.186 172.345 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 62.4 tp -95.6 123.66 39.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.153 176.387 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 96.3 mttt -123.61 158.52 31.29 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.181 178.314 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 14.5 t -125.18 -175.76 3.39 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.266 178.18 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 144' ' ' ALA . . . . . 0.432 ' O ' ' HB2' ' A' ' 145' ' ' ASP . . . 56.6 54.02 7.84 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.122 -173.284 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.432 ' HB2' ' O ' ' A' ' 144' ' ' ALA . 65.9 m-20 68.03 34.93 3.9 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.216 -178.533 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 72.84 43.64 41.16 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 111.187 -0.765 . . . . 0.0 111.187 174.064 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -118.6 -50.8 2.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.801 0.334 . . . . 0.0 111.136 -175.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 86.4 m -89.96 127.95 36.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.198 -173.207 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -65.67 114.91 5.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.273 -178.027 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 94.2 t -89.03 -59.99 2.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.253 174.878 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 14.5 p -156.97 143.71 10.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.199 -179.446 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -109.91 -179.28 3.75 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.168 178.62 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 74.6 m-20 59.09 41.57 20.38 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.127 178.044 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.439 ' O ' ' HD3' ' A' ' 156' ' ' PRO . 85.3 t -77.65 130.41 36.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.097 174.562 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -110.58 100.02 1.22 Allowed Glycine 0 CA--C 1.524 0.605 0 N-CA-C 111.151 -0.78 . . . . 0.0 111.151 -176.322 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 156' ' ' PRO . . . . . 0.439 ' HD3' ' O ' ' A' ' 154' ' ' VAL . 76.7 Cg_exo -56.02 139.53 85.08 Favored 'Trans proline' 0 N--CA 1.458 -0.608 0 C-N-CA 121.732 1.621 . . . . 0.0 111.205 177.483 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 54.06 45.66 27.08 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.179 174.213 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 83.6 p -116.36 -172.6 2.21 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.222 177.818 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -116.28 78.28 1.18 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.146 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 173.65 171.1 37.85 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 60.0 m-20 -115.26 168.28 10.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.84 0.352 . . . . 0.0 111.225 -177.335 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 91.4 mmt-85 -132.22 155.2 48.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.266 177.283 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -64.41 131.66 47.83 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.224 178.523 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 21.5 tt -141.89 143.14 27.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.253 176.211 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 91.9 m-20 -73.93 126.45 89.41 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.14 176.099 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -79.83 60.42 7.82 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 121.64 1.56 . . . . 0.0 111.142 -176.717 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 35.6 m -134.06 150.6 31.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.201 179.315 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -86.06 73.19 10.32 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.175 -177.247 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 84.2 t -131.1 142.92 42.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.22 -176.326 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 90.9 m-20 -49.73 119.94 3.88 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.242 -178.577 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 171' ' ' LEU . . . . . 0.458 ' HB2' ' HB2' ' A' ' 183' ' ' LEU . 65.2 mt -103.94 172.34 6.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.172 175.433 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -160.19 148.16 16.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.218 175.563 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 95.3 mt -107.23 135.73 48.25 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.134 176.197 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 81.5 m-85 -124.37 145.68 49.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.214 -177.924 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -115.03 87.51 2.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.207 171.573 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 78.98 -106.6 2.39 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 111.254 -0.738 . . . . 0.0 111.254 -177.143 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 95.5 p -105.9 -8.05 17.87 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.877 0.37 . . . . 0.0 111.213 175.581 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -103.4 117.18 33.88 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.2 -175.852 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 40.4 ttpt -64.03 130.99 46.23 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.254 176.688 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 69.4 t -82.55 -53.7 11.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.156 178.74 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 44.8 t -171.95 142.45 1.47 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.229 -178.067 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -80.27 145.35 32.22 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.281 174.155 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 183' ' ' LEU . . . . . 0.458 ' HB2' ' HB2' ' A' ' 171' ' ' LEU . 61.1 mt -110.06 159.02 17.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.185 -177.385 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 184' ' ' LYS . . . . . 0.404 ' HA ' ' HD3' ' A' ' 185' ' ' PRO . 99.6 mttt -85.57 151.6 56.06 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.203 176.055 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 185' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 184' ' ' LYS . 76.8 Cg_exo -55.86 142.78 83.59 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 121.748 1.632 . . . . 0.0 111.135 177.62 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 7.6 p -145.93 136.05 18.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.197 -179.731 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 98.7 m -98.75 129.94 45.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.176 -178.65 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 5.0 mp -125.21 150.49 46.95 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.218 177.123 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -90.35 169.24 11.25 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.271 169.637 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 -64.14 106.99 1.17 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.186 -179.671 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 92.62 7.24 63.34 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 111.186 -0.766 . . . . 0.0 111.186 178.311 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -76.06 137.86 40.45 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.797 0.332 . . . . 0.0 111.264 -179.817 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 61.3 t -104.27 116.6 48.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.161 178.179 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 97.6 t -120.86 134.66 63.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.149 177.408 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 76.6 m -95.94 153.37 17.8 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.187 -175.426 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 60.1 tp -126.32 117.49 23.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.201 178.898 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 91.7 m-85 -112.82 111.51 22.33 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.199 -179.281 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 68.8 t -100.02 113.57 35.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.2 -178.537 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 45.9 p -108.34 172.83 6.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.1 -175.433 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 88.81 -151.86 22.61 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 111.343 -0.703 . . . . 0.0 111.343 177.92 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 45.0 t -151.89 146.41 25.63 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.723 0.297 . . . . 0.0 111.256 179.699 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . -62.19 147.66 48.93 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.096 -0.802 . . . . 0.0 111.096 -176.209 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -98.58 35.26 4.73 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 5.655 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -122.6 68.89 0.96 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.797 0.332 . . . . 0.0 111.185 178.722 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 96.0 mt -88.6 148.0 24.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.194 -178.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 206' ' ' ALA . . . . . 0.409 ' HA ' ' HD2' ' A' ' 207' ' ' PRO . . . -123.51 95.73 44.67 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.183 -177.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 207' ' ' PRO . . . . . 0.409 ' HD2' ' HA ' ' A' ' 206' ' ' ALA . 72.9 Cg_endo -72.96 135.9 24.04 Favored 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 121.713 1.609 . . . . 0.0 111.217 178.95 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 93.5 t -127.11 122.71 60.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.247 178.681 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 98.6 m95 -85.36 127.26 34.29 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.241 177.512 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 96.1 t -125.01 128.68 73.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.29 -0.413 . . . . 0.0 111.232 -176.472 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -124.45 120.46 32.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.219 177.459 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 91.0 mmt-85 . . . . . 0 C--O 1.201 -1.472 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.24 -178.167 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 96.0 mttt . . . . . 0 C--O 1.232 0.178 0 CA-C-O 120.706 0.289 . . . . 0.0 111.285 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -121.98 175.07 6.51 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.193 177.699 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 93.4 mt -119.07 139.33 51.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.256 -178.879 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 94.1 t -124.87 128.5 73.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.259 173.915 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -122.98 97.88 5.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.137 -177.4 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 61.7 t -98.06 127.8 50.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.143 -177.71 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 45.9 tt0 -109.45 126.81 53.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.17 178.328 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 51.5 t-20 -101.99 105.29 16.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.26 -177.092 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 83.5 mt -106.73 32.19 4.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.203 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 53.4 p -115.22 -168.22 1.36 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.225 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -108.11 18.08 34.1 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 177.721 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 47.4 t -150.38 148.77 29.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.858 0.361 . . . . 0.0 111.12 -179.428 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -76.77 163.55 26.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.19 -178.885 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 4.4 pp -149.31 165.51 31.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.126 -175.781 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 9.7 t -147.42 149.27 32.39 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.138 -177.939 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 83.9 mt -113.35 149.21 34.34 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.237 178.971 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -125.5 162.91 23.85 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.166 -176.038 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 66.9 p -71.28 153.19 42.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.246 178.607 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -68.06 -33.4 74.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.233 179.743 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -75.47 -19.74 59.23 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.249 178.542 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 80.14 28.81 48.17 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 111.286 -0.725 . . . . 0.0 111.286 -178.325 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -86.02 -42.07 14.29 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.777 0.322 . . . . 0.0 111.236 -175.792 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 14.7 t -156.18 -169.41 3.04 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.208 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -96.58 155.59 16.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.304 177.94 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 150' ' ' VAL . . . . . 0.459 HG12 HG23 ' A' ' 151' ' ' VAL . 68.8 t -109.29 -55.52 5.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.254 -178.415 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.459 HG23 HG12 ' A' ' 150' ' ' VAL . 84.2 t -123.82 133.6 68.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.191 178.802 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -137.0 143.92 43.02 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.215 -176.479 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 27.9 t0 56.25 63.53 1.97 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.182 175.939 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 93.8 t -76.21 125.31 35.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.245 178.874 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -70.52 146.69 42.6 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 179.544 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -73.74 138.75 26.85 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 121.697 1.598 . . . . 0.0 111.185 -178.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 50.47 48.6 22.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.216 177.128 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 46.5 t -162.24 141.28 9.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.194 179.817 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 60.0 m80 -78.35 88.67 4.37 Favored 'General case' 0 C--N 1.364 1.212 0 C-N-CA 119.654 -0.818 . . . . 0.0 111.034 -179.235 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -58.29 88.1 0.02 OUTLIER Glycine 0 CA--C 1.524 0.635 0 CA-C-N 115.378 -0.828 . . . . 0.0 111.178 177.175 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 13.9 t70 -69.4 132.83 46.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.782 0.325 . . . . 0.0 111.107 177.675 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 91.3 mmt-85 -133.62 140.34 47.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.212 -179.511 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 65.9 tt0 -84.56 103.95 14.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.296 173.804 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 48.3 mm -118.17 137.59 51.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.163 -169.547 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 95.3 m-20 -62.22 154.56 70.02 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.231 176.517 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -75.14 71.85 4.95 Favored 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 121.687 1.591 . . . . 0.0 111.14 -179.073 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 32.7 m -130.54 167.85 24.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.208 -177.237 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -79.58 130.72 35.64 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.178 174.032 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 33.9 m -122.01 149.93 25.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.166 -172.062 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 61.9 t-20 -97.85 110.2 22.81 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.152 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 86.9 mt -79.8 58.23 2.77 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.205 -176.358 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -104.48 141.1 36.98 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.121 178.06 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 76.1 mt -103.33 136.56 42.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.212 -176.805 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 84.6 m-85 -128.86 148.55 50.9 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.218 -177.453 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 53.2 t0 -129.77 96.25 4.18 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.213 175.349 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 79.34 -105.5 2.27 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 111.231 -0.748 . . . . 0.0 111.231 -176.136 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 88.8 p -115.41 6.68 14.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.869 0.366 . . . . 0.0 111.219 173.843 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -103.4 133.8 47.84 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.194 -176.882 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -81.41 128.03 33.41 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.145 172.086 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 93.5 t -103.37 -52.54 7.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.233 -172.459 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 47.6 t -143.34 149.26 37.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.19 -173.372 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 50.6 t0 -130.73 96.18 4.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.182 -177.512 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 54.8 tp -95.09 137.36 34.24 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.288 177.021 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -46.21 124.17 6.97 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.189 -172.989 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -54.91 146.96 54.17 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 121.65 1.567 . . . . 0.0 111.267 176.753 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 35.1 m -127.86 152.53 36.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.157 -177.588 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 96.8 m -93.08 118.04 30.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.194 178.652 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 69.4 tp -104.89 114.46 28.67 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.137 -178.352 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -94.93 154.9 16.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.269 -179.676 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 53.2 ptt85 -60.9 138.62 58.14 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.191 -178.496 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 95.72 -16.51 61.05 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 111.182 -0.767 . . . . 0.0 111.182 178.595 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 84.9 mt-10 -85.69 147.46 26.35 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.773 0.32 . . . . 0.0 111.203 -178.075 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 61.5 t -121.7 120.08 60.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.175 174.807 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 35.0 m -123.67 150.38 27.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.216 -177.662 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 82.8 m -122.89 158.64 29.92 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.172 177.965 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 51.7 tp -134.73 117.34 15.9 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.207 174.752 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -105.76 105.79 16.0 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.198 -176.192 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 97.7 t -103.78 125.56 58.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.242 -177.014 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 14.5 t -127.2 -170.42 2.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.239 178.333 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -108.34 135.67 12.99 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 111.229 -0.749 . . . . 0.0 111.229 -178.493 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.6 t -158.82 117.11 2.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.776 0.322 . . . . 0.0 111.215 178.03 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 75.11 14.88 81.45 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.151 -0.779 . . . . 0.0 111.151 177.488 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 89.44 2.03 77.19 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 -178.0 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -118.91 167.42 11.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.816 0.341 . . . . 0.0 111.21 -179.383 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 99.1 mt -82.21 140.08 33.91 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.217 178.019 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -124.63 95.08 43.44 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.142 -178.613 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -75.98 138.62 20.95 Favored 'Trans proline' 0 N--CA 1.458 -0.594 0 C-N-CA 121.738 1.625 . . . . 0.0 111.228 -178.717 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 65.0 t -127.8 106.62 15.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.186 173.349 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 24.8 t90 -79.97 127.29 32.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.185 -177.31 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 79.0 t -128.56 108.89 18.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.202 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -84.3 127.03 33.73 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.2 176.085 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 97.0 mtt-85 . . . . . 0 C--O 1.2 -1.529 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.209 -177.699 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 88.1 tttt . . . . . 0 CA--C 1.523 -0.078 0 CA-C-O 120.873 0.368 . . . . 0.0 111.132 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -104.76 163.97 12.11 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.238 178.112 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 64.1 tp -149.45 120.73 7.84 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.183 -178.994 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 89.0 t -117.03 131.34 70.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.192 -175.362 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 41.2 ttm180 -102.29 116.46 32.68 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.172 172.786 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 65.1 t -105.66 125.44 61.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.199 -175.39 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 38.1 tt0 -120.71 127.5 52.07 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.223 -177.052 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 48.1 t-20 -89.86 110.06 21.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.088 176.005 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 95.3 mt -111.61 14.84 21.28 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.11 177.338 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 38.1 p -85.65 -179.73 6.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.177 -179.211 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -98.03 14.11 62.91 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 111.192 -0.763 . . . . 0.0 111.192 177.447 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 18.7 t -136.55 -166.78 1.95 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.849 0.357 . . . . 0.0 111.086 -179.423 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 34.4 mmtp -95.46 136.97 35.16 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.256 -177.65 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.407 ' HB3' ' HB ' ' A' ' 154' ' ' VAL . 56.8 tp -102.03 131.72 48.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.293 -178.931 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 98.7 m -130.97 136.2 48.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.143 178.295 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 79.6 mt -125.4 142.87 51.26 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.218 172.606 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 60.6 mttm -118.78 163.84 16.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.166 -177.886 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 74.3 p -75.42 162.77 28.07 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.2 -177.347 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -65.17 -40.82 94.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.162 -175.23 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -78.62 -19.21 53.2 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.209 -178.261 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 80.55 21.93 63.25 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 111.2 -0.76 . . . . 0.0 111.2 -177.454 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -77.98 -36.47 48.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.728 0.299 . . . . 0.0 111.172 -178.305 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 14.7 t -154.95 -169.08 3.08 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.246 176.889 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -99.31 150.92 21.63 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.193 -179.766 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 69.3 t -89.03 -46.31 15.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.234 171.791 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 12.0 p -161.42 144.04 3.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.176 173.486 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 64.0 pttt -145.63 158.96 43.78 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.137 -175.303 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 28.4 t0 60.2 43.35 14.08 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.218 178.939 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.407 ' HB ' ' HB3' ' A' ' 139' ' ' LEU . 98.6 t -87.6 119.08 34.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.251 174.957 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -81.97 165.91 46.03 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 -175.14 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 63.5 Cg_exo -57.0 147.17 76.32 Favored 'Trans proline' 0 N--CA 1.458 -0.6 0 C-N-CA 121.691 1.594 . . . . 0.0 111.276 177.949 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 56.53 50.67 12.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.153 178.453 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 77.8 p -150.44 158.19 43.87 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.238 172.606 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 27.7 p-80 -151.56 167.45 28.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.169 -173.33 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -161.56 162.28 33.8 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 111.219 -0.752 . . . . 0.0 111.219 175.752 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -101.3 144.42 30.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.73 0.3 . . . . 0.0 111.293 -176.19 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 87.8 mmt-85 -138.91 130.04 26.74 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.17 176.137 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 91.1 mt-10 -84.69 144.91 28.24 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.207 179.26 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 19.5 tt -160.15 151.74 5.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.179 -179.051 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -73.62 142.03 80.26 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.221 175.527 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -78.75 60.37 7.65 Favored 'Trans proline' 0 N--CA 1.458 -0.59 0 C-N-CA 121.732 1.621 . . . . 0.0 111.2 -178.199 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 33.5 m -131.73 178.71 5.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.175 -178.038 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -69.76 112.52 6.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.169 176.958 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.404 HG23 ' HG ' ' A' ' 171' ' ' LEU . 35.6 m -129.31 164.35 32.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.211 -178.651 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 49.7 t30 -97.89 99.93 11.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.287 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 171' ' ' LEU . . . . . 0.404 ' HG ' HG23 ' A' ' 169' ' ' VAL . 82.3 mt -104.69 146.64 28.65 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.229 178.008 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -147.59 152.67 38.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.19 -177.877 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 51.8 tp -112.95 121.38 44.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.215 -173.132 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 72.8 m-85 -118.76 140.2 50.33 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.157 -176.558 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 64.2 t0 -104.33 98.2 8.03 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.122 170.674 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 77.59 -103.38 1.85 Allowed Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.129 -0.788 . . . . 0.0 111.129 -173.809 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 93.4 p -118.31 0.11 11.62 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.824 0.345 . . . . 0.0 111.134 175.21 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -108.38 130.14 55.23 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.244 -177.421 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -69.53 137.74 52.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.208 -179.052 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 88.4 t -99.67 -52.04 9.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.235 174.084 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 19.1 t -163.36 -158.77 0.48 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.205 -178.668 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 74.0 m-20 -114.0 160.8 18.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.203 177.894 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 93.9 mt -115.99 152.28 33.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.24 178.84 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -98.08 117.94 64.35 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.301 179.151 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_exo -55.07 130.45 40.8 Favored 'Trans proline' 0 N--CA 1.458 -0.583 0 C-N-CA 121.728 1.619 . . . . 0.0 111.128 177.801 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 99.2 t -121.73 127.4 75.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.227 175.006 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 71.1 p -84.53 166.61 17.08 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.174 -178.454 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 188' ' ' LEU . . . . . 0.418 ' C ' HD23 ' A' ' 188' ' ' LEU . 10.4 tt -137.07 123.65 20.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.226 -176.704 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -98.97 164.29 12.25 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.234 177.151 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 79.9 ttt180 -52.97 116.85 2.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.188 178.142 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 100.07 -14.49 59.9 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 178.857 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -87.56 143.75 27.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.801 0.334 . . . . 0.0 111.21 -179.285 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 193' ' ' VAL . . . . . 0.409 ' HB ' ' HB2' ' A' ' 212' ' ' ARG . 90.2 t -119.38 129.64 75.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.15 174.179 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 89.7 t -115.82 125.25 72.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.191 179.741 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 74.9 m -125.7 156.85 38.69 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.185 179.83 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 58.0 tp -130.03 118.5 21.67 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.205 175.451 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 88.7 m-85 -111.72 113.0 25.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.299 -178.444 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 80.5 t -107.86 120.27 58.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.177 -177.561 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 14.5 t -124.71 -169.45 1.98 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.203 -178.852 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -108.18 134.91 12.49 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 111.173 -0.771 . . . . 0.0 111.173 -177.691 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.6 t -160.22 118.32 2.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.787 0.327 . . . . 0.0 111.144 177.684 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 75.98 14.25 82.39 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 176.366 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 91.33 -0.5 75.03 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 -178.602 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -120.26 169.03 10.64 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.657 0.265 . . . . 0.0 111.229 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 82.6 mt -78.73 141.61 37.73 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.236 176.942 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -123.99 98.39 39.41 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.253 179.12 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -78.54 141.19 17.46 Favored 'Trans proline' 0 C--N 1.327 -0.587 0 C-N-CA 121.708 1.606 . . . . 0.0 111.212 -177.076 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 66.8 t -129.61 110.67 20.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.253 176.5 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 94.9 m95 -83.47 127.46 33.72 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.182 176.628 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 84.7 t -123.7 125.69 71.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.215 -177.421 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 56.2 mtmt -109.26 135.09 50.92 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.21 174.568 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 212' ' ' ARG . . . . . 0.409 ' HB2' ' HB ' ' A' ' 193' ' ' VAL . 82.2 mtp180 . . . . . 0 C--O 1.2 -1.543 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.142 179.053 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 17.5 ptpt . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.785 0.326 . . . . 0.0 111.186 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -92.85 155.21 17.76 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.226 -176.096 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 60.8 tp -111.11 121.9 46.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.228 175.99 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 97.9 t -110.38 124.2 66.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.227 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 39.7 ttm180 -115.6 125.9 53.52 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.248 176.619 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 66.1 t -115.53 130.25 70.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.172 -175.857 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 37.1 tt0 -113.43 130.43 56.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.194 179.446 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 47.2 t30 -114.6 117.4 30.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.206 177.331 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 98.4 mt -102.77 -9.02 20.35 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.24 177.767 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 73.8 p -81.01 156.11 26.06 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.218 -178.318 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -83.14 -12.61 78.88 Favored Glycine 0 CA--C 1.523 0.571 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 -174.726 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 62.7 p -93.67 169.98 9.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.771 0.319 . . . . 0.0 111.251 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -73.97 135.22 43.17 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.214 -175.526 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 65.7 tp -108.23 121.15 44.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.218 174.24 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 97.7 m -130.4 130.69 44.67 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.175 174.49 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 82.9 mt -112.87 116.11 29.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.223 -178.427 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -119.57 156.24 30.71 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.217 177.973 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 74.9 p -84.02 154.78 23.08 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.166 -178.796 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -62.88 116.76 5.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.207 -176.412 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 55.21 33.89 21.54 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.164 177.12 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -106.7 -171.42 22.73 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 177.855 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -130.36 -6.59 4.25 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.832 0.349 . . . . 0.0 111.202 177.857 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 97.2 m -114.39 127.05 55.65 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.19 179.041 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 42.7 p30 -92.38 -179.37 5.2 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.245 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 26.9 m -128.89 -30.89 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.217 176.068 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 71.5 t -133.91 136.92 53.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.202 174.419 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -148.33 138.48 22.55 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.204 -176.64 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 45.3 t0 56.3 60.43 3.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.213 172.598 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 84.2 t -111.37 128.87 67.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.203 173.118 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -96.79 -164.42 32.77 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 -177.447 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -71.82 148.12 51.51 Favored 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 121.693 1.595 . . . . 0.0 111.176 -178.435 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 77.3 mt-30 52.8 50.6 17.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.204 178.565 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 44.9 t -142.06 148.91 39.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.199 -176.846 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 71.3 m80 -124.6 149.42 47.07 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.21 -176.053 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -134.6 132.58 6.38 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 174.696 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -106.83 135.1 48.95 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.797 0.332 . . . . 0.0 111.193 177.181 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 24.9 tpp180 -144.04 118.58 9.73 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.224 178.157 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -83.88 127.02 33.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.19 175.486 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 78.8 mt -130.85 137.32 56.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.172 -174.632 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 165' ' ' ASN . . . . . 0.435 ' HA ' ' HD3' ' A' ' 166' ' ' PRO . 96.3 m-20 -57.67 154.62 24.93 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.233 -178.12 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 166' ' ' PRO . . . . . 0.435 ' HD3' ' HA ' ' A' ' 165' ' ' ASN . 47.9 Cg_exo -65.37 78.24 0.24 Allowed 'Trans proline' 0 N--CA 1.458 -0.608 0 C-N-CA 121.675 1.583 . . . . 0.0 111.259 -177.609 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 32.1 m -136.56 167.61 23.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.253 177.154 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 89.0 tttt -77.89 116.48 18.43 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.206 173.166 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 63.9 t -113.15 121.11 64.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.162 -174.285 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 64.6 t-20 -105.12 99.84 9.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.217 176.719 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 94.4 mt -95.03 167.63 11.27 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.196 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -144.19 148.55 35.12 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.194 174.948 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 73.9 mt -80.1 117.71 21.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.176 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 78.4 m-85 -113.86 152.2 31.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.233 173.487 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -148.29 99.53 3.05 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.175 -178.486 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 80.37 -106.58 2.52 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 111.179 -0.768 . . . . 0.0 111.179 -179.323 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 86.0 p -117.83 8.78 12.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.728 0.299 . . . . 0.0 111.147 -179.468 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 65.3 pttt -128.01 164.43 22.37 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.207 -177.816 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -102.77 136.08 43.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.227 174.448 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 86.2 t -87.1 -55.32 6.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.155 -178.39 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 43.7 t -172.64 142.23 1.19 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.179 -175.707 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 93.1 m-20 -70.36 150.38 46.36 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.201 178.427 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 94.8 mt -103.09 153.45 20.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.178 177.387 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 184' ' ' LYS . . . . . 0.41 ' HA ' ' HD3' ' A' ' 185' ' ' PRO . 88.3 tttt -64.93 127.31 92.61 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.187 176.551 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 185' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 184' ' ' LYS . 73.5 Cg_exo -54.63 135.02 65.27 Favored 'Trans proline' 0 N--CA 1.458 -0.593 0 C-N-CA 121.696 1.597 . . . . 0.0 111.223 177.088 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 85.1 t -120.31 124.29 72.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.213 179.232 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 92.5 m -82.35 118.47 23.19 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.198 174.511 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 92.2 mt -96.76 143.46 27.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.208 -174.261 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -122.73 150.09 43.22 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.196 173.882 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 190' ' ' ARG . . . . . 0.452 ' HG3' ' O ' ' A' ' 190' ' ' ARG . 18.4 ptp180 -52.79 120.79 6.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.194 177.727 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 93.4 -6.54 75.02 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 175.793 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -74.94 136.51 41.37 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.805 0.336 . . . . 0.0 111.224 -178.134 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 99.1 t -109.08 118.0 55.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.163 177.367 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 85.6 t -121.98 131.55 72.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.143 -177.844 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 71.0 m -114.73 146.16 41.26 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.245 -179.045 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 65.8 tp -128.0 116.41 20.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.234 175.639 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -106.11 108.06 19.38 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.185 -177.449 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 85.1 t -109.73 121.98 63.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.169 -178.09 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 14.5 t -127.55 -171.02 2.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.192 177.803 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -107.26 135.17 12.6 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 111.184 -0.767 . . . . 0.0 111.184 -177.607 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.7 t -159.19 116.81 2.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.825 0.345 . . . . 0.0 111.222 177.676 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 75.2 14.91 81.46 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 177.084 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 90.19 0.69 76.75 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 -178.17 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -118.88 169.15 10.11 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.826 0.346 . . . . 0.0 111.22 -179.675 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 92.1 mt -82.43 141.95 32.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.187 177.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -122.87 93.27 48.53 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.215 179.367 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -79.7 143.37 16.7 Favored 'Trans proline' 0 N--CA 1.459 -0.549 0 C-N-CA 121.631 1.554 . . . . 0.0 111.168 -177.549 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 67.9 t -132.39 120.8 44.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.21 172.65 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 95.6 m95 -86.35 125.53 33.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.191 178.115 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 93.4 t -133.59 128.71 54.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.226 177.888 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 90.4 mttt -108.25 148.2 30.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.206 178.036 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 . . . . . 0 C--O 1.2 -1.54 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.176 179.811 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 96.4 mttt . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.835 0.35 . . . . 0.0 111.181 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -94.72 152.93 18.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.2 -179.463 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 62.4 tp -105.41 120.29 41.23 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.239 174.202 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 91.2 t -119.02 135.59 58.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.2 -178.241 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -128.79 142.02 51.12 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.136 175.283 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 83.8 t -121.82 118.16 54.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.232 176.63 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 4.1 tp-100 -116.53 107.53 14.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.228 -175.513 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 63.1 t-20 -80.22 106.03 11.93 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.192 179.505 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 92.9 mt -106.08 11.27 31.63 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.15 179.616 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 33.1 p -83.98 179.76 7.45 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.242 -178.836 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -104.56 23.83 30.35 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 111.166 -0.774 . . . . 0.0 111.166 176.878 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 27.1 t -150.14 179.74 7.84 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.886 0.374 . . . . 0.0 111.157 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -75.57 138.47 41.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.233 -178.288 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 59.2 tp -92.15 119.1 31.48 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.181 175.604 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 140' ' ' THR . . . . . 0.437 ' HB ' ' HB2' ' A' ' 174' ' ' PHE . 96.5 m -123.56 125.84 45.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.131 174.492 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 85.0 mt -126.4 135.36 51.33 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.247 179.408 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 60.9 mttm -123.38 151.75 42.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.182 177.489 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 8.7 t -63.07 136.53 57.85 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.159 177.675 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -75.05 -6.67 50.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.181 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -89.6 -0.51 57.57 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.235 178.982 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -178.23 -121.57 0.71 Allowed Glycine 0 CA--C 1.524 0.626 0 N-CA-C 111.176 -0.769 . . . . 0.0 111.176 178.98 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -145.79 11.56 1.25 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.864 0.364 . . . . 0.0 111.216 179.356 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 89.0 m -61.5 129.9 43.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.088 -177.851 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -64.03 129.71 41.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.22 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 89.7 t -113.82 -51.31 5.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.148 173.001 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 95.9 t -124.25 137.03 58.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.095 173.766 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 62.6 pttt -164.81 161.3 20.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.18 174.655 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 75.3 m-20 57.89 42.95 22.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.397 -179.688 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 92.6 t -112.4 115.62 50.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.185 176.011 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -84.87 -173.31 49.81 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.212 -0.755 . . . . 0.0 111.212 -179.055 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo -72.4 155.98 55.0 Favored 'Trans proline' 0 N--CA 1.457 -0.664 0 C-N-CA 121.791 1.661 . . . . 0.0 111.176 -179.06 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 55.1 52.02 12.4 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.187 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 41.7 t -137.88 126.28 23.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.193 -178.042 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 56.0 p-80 -161.59 173.22 15.08 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.365 -176.913 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 175.57 170.41 38.4 Favored Glycine 0 CA--C 1.522 0.478 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 177.352 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -73.43 146.29 45.14 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.842 0.353 . . . . 0.0 111.253 -178.541 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 90.9 mmt-85 -132.7 121.33 22.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.253 172.899 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -86.36 103.1 14.62 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.254 177.652 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 80.2 mt -131.28 134.22 61.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.218 -173.105 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 92.7 m-20 -68.25 153.07 96.04 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.22 178.6 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo -51.26 118.4 4.29 Favored 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 121.749 1.633 . . . . 0.0 111.205 176.345 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.425 ' H ' ' HB2' ' A' ' 188' ' ' LEU . 9.1 p -167.77 149.2 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.15 -177.034 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 168' ' ' LYS . . . . . 0.403 ' HA ' ' HA ' ' A' ' 187' ' ' THR . 40.7 ttmt -72.06 115.59 11.46 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.273 173.235 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 99.2 t -100.08 119.9 48.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.199 -177.577 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 62.2 t-20 -134.2 100.97 4.86 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.175 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 76.7 mt -114.39 152.63 31.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.127 -177.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -90.42 142.73 27.44 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.282 175.11 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 60.9 tp -97.58 117.19 31.31 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.131 -170.77 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 174' ' ' PHE . . . . . 0.437 ' HB2' ' HB ' ' A' ' 140' ' ' THR . 82.1 m-85 -116.77 137.81 51.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.261 177.467 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -91.72 97.71 11.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.184 166.407 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 69.26 -83.51 0.25 Allowed Glycine 0 CA--C 1.522 0.49 0 N-CA-C 111.177 -0.769 . . . . 0.0 111.177 -171.475 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 93.6 p -135.08 -1.26 2.67 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.849 0.357 . . . . 0.0 111.22 177.516 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -103.63 117.44 34.4 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.258 -177.939 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -61.86 128.74 37.63 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.19 -176.691 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 92.2 t -96.45 -51.06 11.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.153 174.612 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 17.9 t -164.51 -157.52 0.37 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.165 -179.159 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 58.1 m-20 -125.27 144.08 50.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.185 172.376 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 94.0 mt -83.13 144.16 30.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.124 -178.138 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 184' ' ' LYS . . . . . 0.419 ' HA ' ' HD3' ' A' ' 185' ' ' PRO . 88.1 tttt -65.08 129.91 94.64 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.187 179.254 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 185' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 184' ' ' LYS . 75.9 Cg_exo -55.25 124.3 15.94 Favored 'Trans proline' 0 N--CA 1.459 -0.542 0 C-N-CA 121.666 1.577 . . . . 0.0 111.129 175.736 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 96.0 t -123.52 124.94 70.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.23 175.807 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 187' ' ' THR . . . . . 0.403 ' HA ' ' HA ' ' A' ' 168' ' ' LYS . 94.9 m -85.77 122.32 29.68 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.238 178.998 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 188' ' ' LEU . . . . . 0.425 ' HB2' ' H ' ' A' ' 167' ' ' VAL . 74.0 mt -85.55 156.08 20.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.061 178.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -150.55 153.09 35.15 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.206 -179.792 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 41.3 ptt180 -57.83 128.37 36.73 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.228 -175.566 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 91.96 -13.52 66.69 Favored Glycine 0 CA--C 1.523 0.556 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 173.033 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 72.6 mm-40 -87.38 149.22 24.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.838 0.351 . . . . 0.0 111.09 -176.08 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 67.3 t -116.09 120.87 66.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.194 177.963 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 92.4 t -120.91 122.73 68.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.221 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 74.5 m -116.48 144.32 44.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.197 -177.585 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 66.1 tp -114.47 117.01 29.77 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.149 175.659 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -106.62 99.42 8.99 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.221 -178.697 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 198' ' ' VAL . . . . . 0.407 ' HA ' ' HA ' ' A' ' 207' ' ' PRO . 90.3 t -83.42 115.94 26.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.301 -0.408 . . . . 0.0 111.188 -174.319 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 28.4 p -110.33 174.3 5.92 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.199 179.332 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -149.71 144.69 12.32 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 111.166 -0.774 . . . . 0.0 111.166 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.7 t -160.75 120.37 2.7 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.779 0.323 . . . . 0.0 111.265 177.137 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 75.31 14.05 82.27 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 111.267 -0.733 . . . . 0.0 111.267 178.999 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 95.92 -5.86 66.57 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 -178.418 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -103.5 134.6 46.58 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.826 0.346 . . . . 0.0 111.161 -179.261 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 99.4 mt -83.36 150.8 25.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.227 179.318 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -150.09 73.77 9.28 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.203 177.028 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 207' ' ' PRO . . . . . 0.407 ' HA ' ' HA ' ' A' ' 198' ' ' VAL . 46.2 Cg_exo -63.4 147.71 93.24 Favored 'Trans proline' 0 N--CA 1.456 -0.704 0 C-N-CA 121.729 1.619 . . . . 0.0 111.248 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 87.3 t -118.91 127.72 75.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.22 176.674 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 97.1 m95 -84.15 128.5 34.6 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.253 175.113 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 89.7 t -125.96 122.82 62.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.16 178.144 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -106.41 127.78 53.55 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.141 178.104 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 84.8 mtt85 . . . . . 0 C--O 1.2 -1.501 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.257 179.545 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 94.4 mttt . . . . . 0 N--CA 1.457 -0.096 0 CA-C-O 120.752 0.311 . . . . 0.0 111.193 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -74.02 147.88 42.5 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.185 179.263 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 88.7 mt -114.85 149.82 36.5 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.235 175.225 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 86.3 t -125.77 128.34 72.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.28 178.655 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 130' ' ' ARG . . . . . 0.431 HH21 ' CE1' ' A' ' 159' ' ' HIS . 81.9 mtp180 -117.7 157.72 25.99 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.235 178.281 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.55 ' O ' ' CD2' ' A' ' 159' ' ' HIS . 14.2 p -130.95 142.42 43.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.147 175.251 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 66.7 tp60 -148.21 109.4 4.32 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.183 179.374 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 133' ' ' ASN . . . . . 0.461 ' HA ' ' HB ' ' A' ' 198' ' ' VAL . 64.2 t-20 -86.18 108.97 18.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.166 -175.343 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 87.8 mt -90.99 -4.08 56.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.263 179.564 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 27.4 p -102.24 -178.3 3.66 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.192 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -103.66 8.54 51.37 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 111.201 -0.76 . . . . 0.0 111.201 176.566 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 94.9 p -90.39 160.01 16.29 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.816 0.341 . . . . 0.0 111.166 -175.977 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 39.4 ttpt -107.95 119.29 39.03 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.275 176.177 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 52.0 mt -131.69 150.56 52.11 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.228 -176.776 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 60.1 m -106.68 129.28 54.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.215 174.253 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 63.0 tp -95.48 121.29 37.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.225 -178.782 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -145.07 145.31 31.39 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.217 -179.535 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 81.1 p -68.8 150.6 47.65 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.223 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -60.62 121.81 13.14 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.209 -178.862 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 79.5 m-20 56.19 36.18 27.0 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.286 -179.174 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -86.45 -179.81 49.35 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 111.171 -0.772 . . . . 0.0 111.171 177.059 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -113.4 -23.75 9.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.774 0.321 . . . . 0.0 111.181 -179.483 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 89.9 m -128.87 136.88 51.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.175 -175.905 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 76.5 m-20 -65.2 145.82 55.76 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.239 178.48 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 150' ' ' VAL . . . . . 0.474 HG12 HG23 ' A' ' 151' ' ' VAL . 91.7 t -87.51 -57.04 4.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.194 178.819 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.474 HG23 HG12 ' A' ' 150' ' ' VAL . 46.9 t -130.71 124.33 56.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.178 169.937 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -94.38 138.06 32.78 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.167 -176.16 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 72.4 m-20 53.84 62.86 2.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.159 171.869 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 96.7 t -74.26 106.21 3.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.228 176.978 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -90.09 179.62 43.96 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 -176.564 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -57.39 127.7 26.53 Favored 'Trans proline' 0 C--N 1.327 -0.585 0 C-N-CA 121.702 1.601 . . . . 0.0 111.209 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 94.7 mm-40 66.2 19.32 11.08 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.218 175.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 35.8 t -73.37 145.74 45.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.235 176.772 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 159' ' ' HIS . . . . . 0.55 ' CD2' ' O ' ' A' ' 131' ' ' VAL . 50.3 t-80 -149.74 143.89 25.72 Favored 'General case' 0 CA--C 1.509 -0.607 0 CA-C-O 122.115 0.959 . . . . 0.0 111.029 178.613 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -158.84 157.43 28.43 Favored Glycine 0 CA--C 1.524 0.602 0 CA-C-N 114.868 -1.06 . . . . 0.0 111.224 -179.425 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 75.8 m-20 -113.01 147.37 37.33 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.849 0.357 . . . . 0.0 111.174 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 90.9 mmt-85 -138.85 148.09 43.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.178 178.314 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -110.06 134.83 51.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.184 173.731 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 20.2 tt -147.77 149.43 15.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.194 -175.082 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 97.0 m-20 -50.21 142.99 13.5 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.202 174.569 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -78.82 65.21 8.78 Favored 'Trans proline' 0 N--CA 1.457 -0.643 0 C-N-CA 121.764 1.642 . . . . 0.0 111.201 -173.615 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 34.3 m -133.42 160.78 42.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.23 176.343 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -65.91 108.44 2.17 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.061 -179.334 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 93.0 t -121.35 125.35 73.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.289 178.037 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 83.9 m-20 -99.38 141.81 31.68 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.162 177.322 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 5.4 mp -124.67 172.6 9.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.167 -174.902 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -148.11 166.06 28.96 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.207 -178.296 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 67.4 mt -94.69 135.43 36.17 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.251 177.79 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 -128.91 156.57 43.5 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.204 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 67.9 t0 -144.43 95.42 2.71 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.237 175.363 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 79.88 -106.38 2.44 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 111.199 -0.76 . . . . 0.0 111.199 179.827 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 88.1 p -115.52 7.87 15.02 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.797 0.332 . . . . 0.0 111.184 178.638 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -125.71 130.34 51.32 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.227 -178.309 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 38.9 ttpt -71.23 135.2 47.39 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.216 176.434 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 70.4 t -83.2 -55.57 7.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.152 -179.239 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 43.6 t -173.9 142.13 0.85 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.223 -176.038 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -69.09 146.84 52.24 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.223 176.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 94.6 mt -95.3 158.95 15.23 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.196 176.307 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -57.74 130.37 82.02 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.161 177.647 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_exo -52.85 140.1 58.42 Favored 'Trans proline' 0 N--CA 1.457 -0.661 0 C-N-CA 121.783 1.655 . . . . 0.0 111.17 177.504 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 8.2 p -143.49 136.24 24.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.119 -175.387 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 97.7 m -95.92 131.14 42.58 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.237 176.335 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 59.7 mt -100.04 96.03 7.25 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.171 -176.964 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -70.14 142.65 52.51 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.226 -177.448 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 80.6 ttt180 -66.55 125.9 27.19 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.241 -176.005 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 93.0 -10.52 73.71 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 173.549 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -103.22 178.93 4.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.788 0.328 . . . . 0.0 111.144 -178.32 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 7.4 p -135.09 139.6 46.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.148 -177.308 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 33.3 m -113.1 156.55 14.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.158 172.876 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 49.5 t -134.8 129.23 34.24 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.245 179.46 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 66.0 tp -89.45 115.29 26.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.237 177.133 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -101.47 104.34 15.26 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.194 176.571 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 198' ' ' VAL . . . . . 0.461 ' HB ' ' HA ' ' A' ' 133' ' ' ASN . 84.8 t -79.05 114.2 19.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.207 -173.905 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 15.3 t -143.84 -160.85 1.17 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.227 179.361 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 167.33 -171.61 42.05 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 44.3 t -162.35 129.21 3.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.732 0.301 . . . . 0.0 111.191 -179.452 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 75.57 15.9 80.96 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 111.157 -0.777 . . . . 0.0 111.157 177.089 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 99.17 -13.91 61.51 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 111.128 -0.789 . . . . 0.0 111.128 -178.327 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -88.7 123.69 33.39 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.777 0.322 . . . . 0.0 111.136 -179.377 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 96.8 mt -74.28 138.33 43.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.141 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -152.8 70.39 7.19 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.246 173.872 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -58.31 148.26 80.36 Favored 'Trans proline' 0 N--CA 1.458 -0.575 0 C-N-CA 121.783 1.655 . . . . 0.0 111.201 176.363 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 85.6 t -119.62 129.16 75.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.216 -177.79 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 92.0 m95 -83.59 128.34 34.44 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.229 172.901 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 86.7 t -121.41 124.87 72.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.2 175.743 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 28.1 ttpp -97.04 128.22 43.78 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.109 179.524 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 96.4 mtt-85 . . . . . 0 C--O 1.201 -1.484 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.236 -178.834 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 99.9 mttt . . . . . 0 CA--C 1.523 -0.069 0 CA-C-O 120.876 0.37 . . . . 0.0 111.138 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -143.36 173.11 11.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.197 174.807 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 93.7 mt -127.45 142.43 51.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.136 177.059 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 10.0 p -125.05 133.76 68.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.155 175.143 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 44.3 ttm180 -135.6 146.53 48.02 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.109 -177.163 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 98.8 t -125.85 127.24 71.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.167 176.764 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 62.9 tp60 -95.28 128.18 41.92 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.199 -179.688 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 57.5 t-20 -87.17 110.42 20.14 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.237 173.863 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 94.3 mt -101.76 7.91 41.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.123 177.119 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 30.5 t -101.35 158.82 15.77 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.178 178.793 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -79.85 -9.73 86.44 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.274 -0.731 . . . . 0.0 111.274 172.785 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 87.5 p -91.31 169.96 10.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.854 0.359 . . . . 0.0 111.109 173.321 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -89.1 156.08 19.04 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.197 177.536 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 84.7 mt -109.98 152.75 25.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.236 178.102 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 49.7 p -125.47 78.5 1.73 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.22 177.052 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 38.1 tp -70.92 120.88 17.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.116 -170.041 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -142.99 153.44 43.0 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.236 -178.016 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 85.6 m -57.3 125.31 22.23 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.244 174.117 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -59.07 118.3 5.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.233 -177.426 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 57.34 29.85 17.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.172 -179.566 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -113.38 -171.17 17.75 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.229 -0.748 . . . . 0.0 111.229 177.291 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -115.76 -4.19 12.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.829 0.347 . . . . 0.0 111.181 177.822 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 99.8 m -98.43 117.15 32.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.139 -175.529 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 81.2 m-20 -74.49 146.56 42.63 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.204 172.611 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 150' ' ' VAL . . . . . 0.494 HG12 HG23 ' A' ' 151' ' ' VAL . 60.1 t -108.95 -64.89 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.146 -175.192 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.494 HG23 HG12 ' A' ' 150' ' ' VAL . 99.4 t -141.47 120.28 10.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.204 172.06 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 54.2 mtmt -113.38 160.11 18.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.179 -178.855 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 32.1 t0 62.08 47.77 5.5 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.191 178.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 93.9 t -78.25 114.62 19.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.184 175.288 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -66.7 156.59 51.23 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 -171.549 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -55.02 132.79 54.4 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 121.797 1.665 . . . . 0.0 111.103 177.361 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 92.9 mm-40 57.08 33.09 22.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.162 179.506 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 19.2 t -119.06 -161.49 0.85 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.182 175.572 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 34.3 p80 -160.36 170.11 21.73 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.259 179.481 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -156.66 159.88 29.86 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 176.43 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 20.9 p30 -149.32 175.86 11.06 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.793 0.33 . . . . 0.0 111.237 -175.293 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 58.1 ttm-85 -156.05 140.69 16.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.208 -178.22 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -71.26 128.85 37.29 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.307 171.327 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 19.9 tt -159.06 153.93 5.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.147 -172.054 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 95.6 m-20 -62.87 154.08 77.38 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.181 176.433 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -75.16 71.36 5.13 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 121.725 1.617 . . . . 0.0 111.238 -179.55 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 33.4 m -126.26 179.83 3.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.181 -177.891 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -76.37 121.08 22.5 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.179 173.732 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 76.9 t -114.18 121.05 65.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.178 -176.367 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 87.3 m-20 -96.36 119.06 34.16 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.196 177.418 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 77.3 mt -113.76 154.19 27.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.206 -174.234 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -158.39 162.54 37.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.267 179.22 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 68.0 mt -111.73 148.58 33.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.154 173.417 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 35.0 p90 -142.76 160.1 40.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.198 -174.122 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 67.7 t0 -131.39 91.36 3.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.128 174.868 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 79.49 -106.73 2.45 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 -177.837 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 95.1 p -106.29 -9.26 16.89 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.784 0.326 . . . . 0.0 111.168 177.012 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -104.29 117.71 34.88 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.159 -176.138 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 39.0 ttpt -66.59 136.53 55.73 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.249 177.426 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 72.2 t -86.04 -56.29 5.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.251 -178.441 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 43.5 t -171.36 143.63 1.86 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.19 -176.342 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -72.48 150.33 43.37 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.217 176.788 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 82.4 mt -106.16 159.33 16.17 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.237 175.32 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 56.4 tptt -55.58 116.29 11.58 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.262 -179.802 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 77.1 Cg_exo -56.38 141.95 88.93 Favored 'Trans proline' 0 N--CA 1.459 -0.514 0 C-N-CA 121.602 1.535 . . . . 0.0 111.155 178.26 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 73.3 t -121.32 127.39 75.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.202 -177.415 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 97.1 m -95.33 116.67 29.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.171 170.194 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 83.3 mt -90.84 158.25 16.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.199 -175.539 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -136.53 156.36 48.69 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.198 -179.492 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 75.3 mtp180 -62.51 124.37 20.76 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.157 -174.453 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 78.7 13.32 83.28 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 111.194 -0.762 . . . . 0.0 111.194 173.172 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 92.5 mt-10 -121.29 158.34 28.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.769 0.318 . . . . 0.0 111.149 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 7.3 p -131.91 139.22 50.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.216 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 84.6 t -112.41 136.43 48.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.212 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 44.6 t -114.72 110.85 20.37 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.214 172.223 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 52.7 tp -90.82 110.57 21.78 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.157 -178.805 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 197' ' ' TYR . . . . . 0.409 ' HB2' ' HB ' ' A' ' 208' ' ' VAL . 85.3 m-85 -86.75 96.77 10.28 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.192 -175.982 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 97.3 t -86.76 121.58 37.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.178 -174.469 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 14.8 t -153.19 -169.11 3.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.207 178.377 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 144.54 -162.77 27.96 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 111.204 -0.758 . . . . 0.0 111.204 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.3 t -171.5 143.65 1.81 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.833 0.349 . . . . 0.0 111.148 -177.683 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 76.48 16.3 80.83 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 111.192 -0.763 . . . . 0.0 111.192 174.933 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 94.96 -6.52 69.51 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 111.114 -0.795 . . . . 0.0 111.114 -178.863 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -98.73 115.72 29.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.766 0.317 . . . . 0.0 111.102 179.55 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 91.5 mt -98.72 154.25 18.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.086 -177.291 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -150.74 73.96 8.72 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.208 176.449 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_exo -58.05 139.02 88.92 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 121.656 1.571 . . . . 0.0 111.161 178.653 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 208' ' ' VAL . . . . . 0.409 ' HB ' ' HB2' ' A' ' 197' ' ' TYR . 57.5 t -104.73 114.29 43.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.22 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 209' ' ' TRP . . . . . 0.435 ' CD1' ' C ' ' A' ' 209' ' ' TRP . 7.3 t90 -77.76 96.97 5.04 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.199 -178.082 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 98.3 t -106.23 115.41 47.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.219 175.277 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 29.2 ttpp -102.38 132.53 48.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.206 178.56 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 83.0 mtt85 . . . . . 0 C--O 1.202 -1.412 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.174 179.632 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 62.9 pttt . . . . . 0 C--O 1.232 0.183 0 CA-C-O 120.722 0.296 . . . . 0.0 111.271 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -142.13 167.9 21.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.201 -174.792 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 69.3 mt -120.86 154.73 35.42 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.129 176.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 13.1 p -141.39 137.0 32.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.296 177.787 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -125.82 149.24 48.78 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.166 172.732 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 87.4 t -128.71 120.12 51.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.128 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 64.7 tt0 -110.41 138.57 46.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.239 -174.366 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 64.7 t-20 -88.72 109.62 20.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.223 177.941 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 7.8 mp -105.93 34.94 3.08 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.284 178.256 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 59.6 p -132.8 173.1 11.73 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.16 177.445 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -86.71 -12.63 68.75 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 175.295 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 95.9 p -88.47 167.02 13.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.888 0.375 . . . . 0.0 111.207 179.13 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -79.04 135.87 37.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.275 178.812 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 60.5 tp -107.85 131.41 54.52 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.293 -175.758 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 93.5 m -133.37 128.43 35.6 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.334 172.874 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 10.3 tt -142.9 132.64 23.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.107 -176.669 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -125.92 165.8 18.07 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.137 179.647 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 14.6 t -150.92 -170.37 3.64 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.211 175.406 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . 55.16 51.63 12.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.19 -175.386 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 75.7 m-20 62.05 27.68 16.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.16 -177.617 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 84.29 6.67 85.94 Favored Glycine 0 CA--C 1.52 0.367 0 N-CA-C 111.276 -0.73 . . . . 0.0 111.276 176.131 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -81.81 -32.59 31.21 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.805 0.336 . . . . 0.0 111.122 -177.606 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 82.6 m -99.77 120.04 39.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.183 -178.335 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 65.4 t0 -89.32 109.01 19.96 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.192 176.027 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 87.4 t -85.48 -58.0 3.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.202 -176.489 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 27.8 m -132.83 153.33 37.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.209 168.373 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 65.6 tttm -150.55 116.97 5.71 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.337 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 70.8 m-20 56.17 46.98 20.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.266 174.88 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 33.5 m -101.96 151.24 5.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.142 179.14 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -99.1 -168.98 30.62 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 -171.58 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_exo -58.52 136.97 77.69 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 121.651 1.568 . . . . 0.0 111.153 -178.244 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 96.0 mm-40 68.3 17.12 9.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.249 173.463 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 70.3 m -103.99 151.23 23.44 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.308 170.192 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 56.4 p-80 -152.79 161.56 42.41 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.212 -176.49 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -114.98 160.24 13.31 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 176.481 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 37.4 t0 -136.86 115.5 12.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.609 0.242 . . . . 0.0 111.276 -178.873 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 89.4 mmt-85 -127.15 144.24 51.08 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.275 -173.815 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -96.18 124.48 40.2 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.253 175.707 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 46.1 pt -126.15 164.24 26.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.235 -168.1 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 -84.32 160.73 56.42 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.165 177.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -79.02 57.17 6.34 Favored 'Trans proline' 0 N--CA 1.458 -0.604 0 C-N-CA 121.588 1.525 . . . . 0.0 111.148 -179.753 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 33.6 m -130.96 -179.14 3.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.165 -175.774 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -65.61 104.01 0.96 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.305 174.36 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 91.7 t -104.3 126.56 58.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.25 -178.626 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 37.7 t-20 -107.26 109.21 20.93 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.089 -178.32 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 65.9 mt -90.64 117.67 29.48 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.218 175.602 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -126.12 140.39 52.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.154 -175.055 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 96.3 mt -87.69 141.18 28.81 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.185 178.716 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -135.6 156.44 48.86 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.209 179.739 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 66.9 t0 -136.05 83.78 2.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.193 173.806 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 79.48 -105.67 2.31 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.224 -0.75 . . . . 0.0 111.224 -173.922 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 98.0 p -102.95 -6.02 22.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.789 0.328 . . . . 0.0 111.195 172.371 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -83.82 131.51 34.88 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.196 -176.571 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 89.1 tttt -86.65 126.32 34.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.151 170.569 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 97.3 t -103.02 -53.02 7.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.195 -171.016 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 47.2 t -146.7 149.06 32.7 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.122 -174.619 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 51.0 t0 -136.2 102.33 4.97 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.228 -175.76 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 94.8 mt -81.56 148.23 29.24 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.148 -177.315 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -62.22 131.48 93.6 Favored Pre-proline 0 C--N 1.327 -0.38 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.244 178.464 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 76.3 Cg_exo -55.05 133.08 56.12 Favored 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 121.611 1.54 . . . . 0.0 111.234 177.031 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 94.0 t -124.21 131.15 73.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.26 178.462 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 98.2 m -88.24 130.01 35.2 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.101 175.584 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 82.0 mt -113.05 153.91 27.38 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.217 -178.635 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -102.41 163.83 12.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.116 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 79.6 ttt180 -51.03 120.21 4.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.147 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 104.74 -16.27 47.67 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 169.387 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 64.7 mt-10 -73.64 136.78 43.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.781 0.324 . . . . 0.0 111.089 -177.727 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 61.8 t -125.78 123.31 64.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.277 179.148 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 79.2 t -103.44 135.03 42.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.27 -178.411 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 44.3 t -121.78 105.63 10.56 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.249 176.316 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 31.0 tp -81.49 124.16 29.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.215 -176.222 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -105.72 98.52 8.2 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.2 179.196 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 62.3 t -90.54 106.99 17.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.216 -176.398 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 44.5 p -105.22 174.77 5.74 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.089 -175.454 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 100.36 -138.26 13.75 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 111.406 -0.678 . . . . 0.0 111.406 176.994 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 42.1 t -163.88 127.18 2.61 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.823 0.345 . . . . 0.0 111.204 178.828 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . -54.07 139.15 37.74 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 -174.478 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -91.52 8.34 78.96 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 111.015 -0.834 . . . . 0.0 111.015 7.118 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -89.65 69.9 7.78 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.671 0.272 . . . . 0.0 111.076 -177.835 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 93.4 mt -97.69 156.81 16.38 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.246 -178.342 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -139.42 84.58 16.07 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.135 -176.444 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -57.61 129.42 33.65 Favored 'Trans proline' 0 N--CA 1.459 -0.55 0 C-N-CA 121.692 1.595 . . . . 0.0 111.139 176.716 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 77.2 t -109.65 115.67 50.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.217 173.719 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 38.6 t-105 -81.52 105.24 12.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.221 -174.666 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 94.8 t -117.58 119.92 63.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.154 177.063 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -100.31 134.22 43.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.215 178.436 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 40.3 mmt180 . . . . . 0 C--O 1.199 -1.576 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.218 -179.934 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 88.0 tttt . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.77 0.319 . . . . 0.0 111.116 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -150.23 143.63 25.09 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.248 172.903 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 59.0 tp -101.96 128.65 48.28 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.179 -177.613 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 33.1 m -125.48 152.01 31.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.136 174.452 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 41.7 ttm180 -140.85 124.2 16.7 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.208 178.617 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 57.3 t -105.39 121.33 57.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.257 -177.954 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 64.7 tp60 -107.76 127.01 53.31 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.173 -177.82 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 57.9 t-20 -85.63 105.34 16.13 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.153 178.357 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 98.3 mt -110.66 28.85 8.28 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.287 176.539 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 50.3 p -104.64 -175.69 2.87 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.222 -178.448 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -100.1 11.18 60.35 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 176.348 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 21.0 t -137.64 -167.46 2.14 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.802 0.334 . . . . 0.0 111.222 -178.388 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -102.63 142.91 33.02 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.125 178.953 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 93.8 mt -104.47 148.18 26.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.265 -177.265 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 140' ' ' THR . . . . . 0.423 ' HB ' ' HB2' ' A' ' 174' ' ' PHE . 97.2 m -139.26 128.35 23.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.18 169.352 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 79.9 mt -118.97 114.85 23.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.259 -179.243 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -127.24 133.63 50.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.198 179.9 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 79.4 p -71.83 156.81 38.88 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.134 -172.963 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -59.93 -30.02 68.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.238 -176.736 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -64.44 -31.65 72.94 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.208 179.625 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 78.18 17.39 78.24 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 -178.734 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -110.02 -27.31 9.27 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.758 0.313 . . . . 0.0 111.184 -178.029 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 69.1 p -130.36 169.7 15.12 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.262 -179.108 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 20.6 p30 -150.61 175.12 12.22 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.162 -178.633 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 88.1 t -129.25 -40.69 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.247 179.093 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 90.1 t -132.09 137.92 53.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.184 -178.915 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -135.95 107.83 7.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.201 178.085 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 75.5 m-20 51.5 51.31 17.03 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.243 173.459 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 76.6 t -100.57 127.66 53.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.236 179.194 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -88.84 177.66 44.96 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 111.224 -0.75 . . . . 0.0 111.224 -171.067 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -58.8 147.22 89.69 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 121.652 1.568 . . . . 0.0 111.199 -178.211 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 94.4 mm-40 68.98 17.06 8.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.233 176.707 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 68.1 m -124.87 161.53 26.36 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.168 171.644 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 33.8 p80 -146.41 170.14 17.43 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.206 -176.515 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -143.7 145.7 15.66 Favored Glycine 0 CA--C 1.523 0.571 0 N-CA-C 111.246 -0.742 . . . . 0.0 111.246 179.119 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -111.09 150.34 29.54 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.823 0.344 . . . . 0.0 111.168 -178.324 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 85.1 mmt-85 -143.6 143.6 31.56 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.16 175.433 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -99.53 112.29 24.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.211 170.066 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 76.8 mt -130.78 139.13 51.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.113 -171.183 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 95.3 m-20 -61.67 155.01 63.09 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.206 177.941 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -63.1 80.15 0.12 Allowed 'Trans proline' 0 N--CA 1.458 -0.595 0 C-N-CA 121.65 1.567 . . . . 0.0 111.173 -178.858 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 30.2 m -129.28 179.62 3.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.203 177.487 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -89.95 133.8 34.58 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.227 174.241 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 86.1 t -72.4 87.27 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.178 -176.7 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 62.9 t-20 -88.36 88.98 7.8 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.154 170.416 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 8.7 tt -145.18 140.66 28.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.231 -166.351 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -92.07 141.72 28.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.249 -177.07 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 62.6 tp -101.55 117.87 35.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.193 -172.662 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 174' ' ' PHE . . . . . 0.423 ' HB2' ' HB ' ' A' ' 140' ' ' THR . 70.5 m-85 -113.26 148.2 36.04 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.221 -178.524 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -105.69 94.18 5.06 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.196 167.146 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 77.38 -104.01 1.9 Allowed Glycine 0 CA--C 1.523 0.562 0 N-CA-C 111.232 -0.747 . . . . 0.0 111.232 -173.546 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 92.8 p -115.86 1.29 13.35 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.716 0.293 . . . . 0.0 111.166 172.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -104.64 116.96 32.97 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.306 -177.511 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -63.57 133.08 53.14 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.17 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 93.7 t -102.18 -53.3 7.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.206 176.614 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 19.2 t -163.99 -157.75 0.41 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.187 178.974 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -105.15 137.16 43.36 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.214 170.957 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 51.4 tp -74.73 128.75 36.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.252 -178.567 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -51.91 126.78 34.41 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.25 177.91 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -74.4 150.83 41.87 Favored 'Trans proline' 0 N--CA 1.458 -0.613 0 C-N-CA 121.647 1.565 . . . . 0.0 111.246 -176.516 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 14.5 p -147.42 143.79 19.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.177 176.349 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 92.1 m -81.0 124.58 29.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.168 -177.765 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 80.6 mt -93.78 158.75 15.51 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.218 177.853 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -159.85 146.02 15.89 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.202 -179.473 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 79.8 ttt180 -71.07 134.22 46.89 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.163 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 101.93 -12.13 57.56 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 111.184 -0.766 . . . . 0.0 111.184 -177.186 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -121.26 146.65 46.59 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.814 0.34 . . . . 0.0 111.168 179.324 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 96.9 t -114.46 123.36 70.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.244 178.93 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 76.7 t -109.85 114.12 46.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.206 -175.19 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 75.9 m -100.7 152.95 19.86 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.239 -178.598 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 64.8 tp -125.8 123.07 37.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.236 178.294 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -114.72 108.73 17.18 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.234 -179.543 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 65.5 t -109.43 124.19 65.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.122 -177.474 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 13.5 t -131.06 -174.29 3.34 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.148 -179.705 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -89.06 140.73 15.91 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 111.193 -0.763 . . . . 0.0 111.193 -177.615 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 37.3 t -146.38 86.87 1.7 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.798 0.332 . . . . 0.0 111.236 176.68 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 73.35 22.23 78.91 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 177.194 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 100.84 -12.5 59.26 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 111.231 -0.747 . . . . 0.0 111.231 -178.154 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -100.62 165.07 11.59 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.738 0.304 . . . . 0.0 111.239 178.873 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 96.5 mt -85.96 139.62 31.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.215 177.285 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -124.09 92.23 48.58 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.216 -179.385 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -76.26 138.75 20.43 Favored 'Trans proline' 0 N--CA 1.457 -0.672 0 C-N-CA 121.777 1.651 . . . . 0.0 111.244 -179.433 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 92.3 t -129.82 122.5 54.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.163 174.813 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 91.8 m95 -86.8 126.46 34.63 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.166 178.754 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 69.5 t -131.62 113.54 23.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.213 176.244 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 36.2 ttpt -103.51 136.0 44.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.225 -176.29 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 80.4 ttt180 . . . . . 0 C--O 1.198 -1.611 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.18 177.708 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 99.6 mttt . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.823 0.344 . . . . 0.0 111.205 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 99.8 mm-40 -100.38 3.79 43.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.185 179.734 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -124.32 163.2 22.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.212 178.328 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -91.95 143.2 26.73 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.218 174.464 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 68.3 tp -93.06 112.55 24.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.271 177.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 58.5 t -115.44 122.8 70.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.192 -178.434 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 41.8 ttm180 -112.1 144.91 40.69 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.225 177.434 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 92.3 t -114.35 119.94 62.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.205 169.877 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 66.6 tp60 -107.74 107.36 18.1 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.237 -177.611 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 65.0 t-20 -85.11 103.64 14.3 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.269 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 92.1 mt -102.61 17.44 23.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.228 -179.756 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 30.8 p -103.01 -179.33 3.92 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.215 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -104.82 29.25 12.1 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 111.258 -0.737 . . . . 0.0 111.258 174.919 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 46.1 t -144.8 147.42 32.86 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.808 0.337 . . . . 0.0 111.229 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -69.18 136.49 52.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.189 179.289 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.413 ' C ' HD12 ' A' ' 139' ' ' LEU . 4.4 pp -149.69 165.91 30.94 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.155 179.803 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 13.4 t -144.95 150.99 37.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.165 -177.223 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 64.7 tp -100.64 112.33 24.71 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.2 175.018 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 14.6 ptmm? -140.2 178.72 7.08 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.175 -176.837 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 57.0 p -83.22 164.9 19.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.167 179.011 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -108.45 4.82 24.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.214 177.079 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 75.7 m-20 -104.04 4.3 34.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.182 -177.539 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 174.55 -161.86 31.81 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.196 -0.762 . . . . 0.0 111.196 -178.729 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -93.81 -5.16 48.83 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.703 0.287 . . . . 0.0 111.146 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 89.4 m -62.0 130.06 43.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.239 178.31 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 42.3 p30 -93.13 177.57 6.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.215 -177.573 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 90.7 t -113.72 -56.27 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.172 177.609 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 99.0 t -117.46 133.41 64.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.247 178.843 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -100.77 166.38 10.9 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.173 -176.646 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 29.4 t0 64.32 47.38 3.15 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.204 177.118 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 69.7 t -118.27 121.17 66.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.235 174.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -124.59 -165.61 12.22 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 -177.463 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -75.77 141.01 24.03 Favored 'Trans proline' 0 N--CA 1.458 -0.563 0 C-N-CA 121.728 1.619 . . . . 0.0 111.182 179.247 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 49.64 50.54 18.1 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.217 175.66 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 17.4 t -161.48 -157.52 0.5 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.193 -178.434 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 57.2 p-80 -156.57 164.66 37.94 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.196 179.002 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -147.05 147.56 18.48 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 111.209 -0.756 . . . . 0.0 111.209 179.632 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 88.0 m-20 -112.55 155.6 24.08 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.739 0.304 . . . . 0.0 111.202 178.766 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 29.2 tpt180 -159.5 127.6 4.95 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.175 175.792 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -82.66 123.13 28.98 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.189 173.85 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 80.9 mt -127.89 137.97 56.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.189 -171.554 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 96.3 m-20 -50.45 147.26 8.04 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.236 178.76 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 81.1 Cg_endo -75.17 68.19 5.93 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 121.687 1.591 . . . . 0.0 111.226 -178.644 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 33.5 m -129.45 -178.12 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.203 -177.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -75.89 116.88 17.04 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.228 173.233 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 95.1 t -119.39 121.16 65.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.204 -175.845 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 55.1 t-20 -73.31 111.13 8.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.223 178.821 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 59.5 mt -95.82 142.92 27.52 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.244 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -161.88 143.76 11.29 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.189 175.662 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 65.5 tp -95.84 120.94 37.0 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.251 -178.404 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -118.77 140.44 49.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.257 175.406 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 39.6 t0 -111.46 94.45 4.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.188 171.803 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 79.22 -105.04 2.2 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 111.205 -0.758 . . . . 0.0 111.205 -173.104 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 88.9 p -115.75 6.06 14.33 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.771 0.32 . . . . 0.0 111.182 172.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -98.05 120.14 37.91 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.217 -176.116 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -66.47 126.89 30.28 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.241 173.433 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 88.0 t -105.65 -53.14 7.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.218 -177.049 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 44.8 t -147.88 140.31 24.46 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.204 -176.299 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -100.85 107.08 18.53 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.159 176.223 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 183' ' ' LEU . . . . . 0.538 ' O ' ' HB2' ' A' ' 184' ' ' LYS . 92.1 mt -89.69 -15.98 31.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.24 -171.793 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 184' ' ' LYS . . . . . 0.538 ' HB2' ' O ' ' A' ' 183' ' ' LEU . 74.9 mmtt 83.33 165.08 0.11 Allowed Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.209 167.113 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_exo -59.92 134.74 58.62 Favored 'Trans proline' 0 N--CA 1.458 -0.598 0 C-N-CA 121.689 1.593 . . . . 0.0 111.189 179.099 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 29.9 m -125.28 152.43 31.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.163 172.144 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 97.2 m -94.28 117.17 29.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.211 -179.197 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 93.4 mt -95.11 153.33 17.7 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.163 178.092 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -131.4 156.82 44.9 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.203 177.47 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 89.9 mtm180 -62.77 123.14 17.67 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.21 -176.678 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 87.47 -1.07 85.71 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 176.705 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -70.2 133.2 46.83 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.698 0.285 . . . . 0.0 111.231 -179.306 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 98.4 t -113.24 118.28 57.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.218 178.684 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 33.4 m -131.89 162.42 39.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.216 177.857 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 46.1 t -150.73 128.36 11.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.19 -179.111 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 60.9 tp -92.24 117.42 29.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.186 177.76 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -102.43 105.79 16.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.19 -179.737 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 54.2 t -105.22 112.79 40.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.21 -178.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 71.8 p -99.61 163.9 12.3 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.122 -178.519 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -116.39 135.24 11.92 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 111.239 -0.745 . . . . 0.0 111.239 179.022 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.2 t -160.69 120.06 2.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.746 0.308 . . . . 0.0 111.162 179.035 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 74.31 15.16 80.29 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 111.228 -0.749 . . . . 0.0 111.228 176.798 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 89.98 -0.84 79.68 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 111.179 -0.768 . . . . 0.0 111.179 -177.215 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -106.49 158.92 16.55 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.875 0.369 . . . . 0.0 111.157 -179.335 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 90.4 mt -107.02 141.51 38.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.146 179.522 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -125.33 92.81 46.37 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.268 179.191 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -74.6 127.36 10.91 Favored 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 121.712 1.608 . . . . 0.0 111.16 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 64.3 t -126.81 106.09 15.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.137 174.327 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 10.8 t90 -80.06 124.29 28.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.215 -177.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 98.7 t -120.63 132.56 69.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.167 -175.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -99.93 133.8 43.76 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.233 175.695 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 41.9 mmt180 . . . . . 0 C--O 1.2 -1.501 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.134 -179.484 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 99.7 mttt . . . . . 0 N--CA 1.457 -0.121 0 CA-C-O 120.713 0.292 . . . . 0.0 111.274 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 85.3 mt-30 -93.19 159.34 15.32 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.146 179.694 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 74.4 mmtt -128.5 154.91 45.63 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.229 178.675 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -143.91 177.78 8.31 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.241 177.015 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 95.4 mt -122.51 147.92 45.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.236 -177.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 12.2 p -134.35 142.84 39.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.205 178.365 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 38.5 ttm180 -117.53 99.31 6.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.203 179.017 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 96.2 t -84.69 121.37 36.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.169 -171.712 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 69.3 mm-40 -112.83 78.88 1.17 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.183 173.343 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 -89.33 157.41 18.2 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.197 -174.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 58.0 tp -62.97 -40.9 99.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.159 176.856 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 91.7 p -72.04 155.84 39.88 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.194 -175.085 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -113.84 55.4 0.52 Allowed Glycine 0 CA--C 1.524 0.599 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 -179.281 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 99.4 p -145.18 160.2 41.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.789 0.328 . . . . 0.0 111.213 -178.444 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -64.76 124.78 22.83 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.171 178.288 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 73.5 mt -111.06 157.83 19.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.19 -175.777 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 92.0 m -110.66 127.77 55.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.186 172.345 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 62.4 tp -95.6 123.66 39.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.153 176.387 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 96.3 mttt -123.61 158.52 31.29 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.181 178.314 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 14.5 t -125.18 -175.76 3.39 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.266 178.18 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 144' ' ' ALA . . . . . 0.432 ' O ' ' HB2' ' A' ' 145' ' ' ASP . . . 56.6 54.02 7.84 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.122 -173.284 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.432 ' HB2' ' O ' ' A' ' 144' ' ' ALA . 65.9 m-20 68.03 34.93 3.9 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.216 -178.533 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 72.84 43.64 41.16 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 111.187 -0.765 . . . . 0.0 111.187 174.064 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -118.6 -50.8 2.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.801 0.334 . . . . 0.0 111.136 -175.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 86.4 m -89.96 127.95 36.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.198 -173.207 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -65.67 114.91 5.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.273 -178.027 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 94.2 t -89.03 -59.99 2.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.253 174.878 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 14.5 p -156.97 143.71 10.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.199 -179.446 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -109.91 -179.28 3.75 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.168 178.62 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 74.6 m-20 59.09 41.57 20.38 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.127 178.044 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.439 ' O ' ' HD3' ' A' ' 156' ' ' PRO . 85.3 t -77.65 130.41 36.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.097 174.562 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -110.58 100.02 1.22 Allowed Glycine 0 CA--C 1.524 0.605 0 N-CA-C 111.151 -0.78 . . . . 0.0 111.151 -176.322 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 156' ' ' PRO . . . . . 0.439 ' HD3' ' O ' ' A' ' 154' ' ' VAL . 76.7 Cg_exo -56.02 139.53 85.08 Favored 'Trans proline' 0 N--CA 1.458 -0.608 0 C-N-CA 121.732 1.621 . . . . 0.0 111.205 177.483 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 54.06 45.66 27.08 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.179 174.213 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 83.6 p -116.36 -172.6 2.21 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.222 177.818 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -116.28 78.28 1.18 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.146 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 173.65 171.1 37.85 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 60.0 m-20 -115.26 168.28 10.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.84 0.352 . . . . 0.0 111.225 -177.335 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 91.4 mmt-85 -132.22 155.2 48.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.266 177.283 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -64.41 131.66 47.83 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.224 178.523 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 21.5 tt -141.89 143.14 27.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.253 176.211 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 91.9 m-20 -73.93 126.45 89.41 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.14 176.099 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -79.83 60.42 7.82 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 121.64 1.56 . . . . 0.0 111.142 -176.717 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 35.6 m -134.06 150.6 31.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.201 179.315 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -86.06 73.19 10.32 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.175 -177.247 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 84.2 t -131.1 142.92 42.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.22 -176.326 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 90.9 m-20 -49.73 119.94 3.88 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.242 -178.577 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 171' ' ' LEU . . . . . 0.458 ' HB2' ' HB2' ' A' ' 183' ' ' LEU . 65.2 mt -103.94 172.34 6.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.172 175.433 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -160.19 148.16 16.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.218 175.563 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 95.3 mt -107.23 135.73 48.25 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.134 176.197 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 81.5 m-85 -124.37 145.68 49.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.214 -177.924 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -115.03 87.51 2.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.207 171.573 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 78.98 -106.6 2.39 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 111.254 -0.738 . . . . 0.0 111.254 -177.143 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 95.5 p -105.9 -8.05 17.87 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.877 0.37 . . . . 0.0 111.213 175.581 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -103.4 117.18 33.88 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.2 -175.852 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 40.4 ttpt -64.03 130.99 46.23 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.254 176.688 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 69.4 t -82.55 -53.7 11.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.156 178.74 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 44.8 t -171.95 142.45 1.47 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.229 -178.067 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -80.27 145.35 32.22 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.281 174.155 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 183' ' ' LEU . . . . . 0.458 ' HB2' ' HB2' ' A' ' 171' ' ' LEU . 61.1 mt -110.06 159.02 17.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.185 -177.385 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 184' ' ' LYS . . . . . 0.404 ' HA ' ' HD3' ' A' ' 185' ' ' PRO . 99.6 mttt -85.57 151.6 56.06 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.203 176.055 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 185' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 184' ' ' LYS . 76.8 Cg_exo -55.86 142.78 83.59 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 121.748 1.632 . . . . 0.0 111.135 177.62 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 7.6 p -145.93 136.05 18.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.197 -179.731 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 98.7 m -98.75 129.94 45.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.176 -178.65 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 5.0 mp -125.21 150.49 46.95 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.218 177.123 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -90.35 169.24 11.25 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.271 169.637 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 -64.14 106.99 1.17 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.186 -179.671 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 92.62 7.24 63.34 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 111.186 -0.766 . . . . 0.0 111.186 178.311 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -76.06 137.86 40.45 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.797 0.332 . . . . 0.0 111.264 -179.817 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 61.3 t -104.27 116.6 48.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.161 178.179 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 97.6 t -120.86 134.66 63.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.149 177.408 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 76.6 m -95.94 153.37 17.8 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.187 -175.426 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 60.1 tp -126.32 117.49 23.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.201 178.898 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 91.7 m-85 -112.82 111.51 22.33 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.199 -179.281 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 68.8 t -100.02 113.57 35.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.2 -178.537 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 45.9 p -108.34 172.83 6.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.1 -175.433 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 88.81 -151.86 22.61 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 111.343 -0.703 . . . . 0.0 111.343 177.92 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 45.0 t -151.89 146.41 25.63 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.723 0.297 . . . . 0.0 111.256 179.699 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . -62.19 147.66 48.93 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.096 -0.802 . . . . 0.0 111.096 -176.209 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -98.58 35.26 4.73 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 5.655 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -122.6 68.89 0.96 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.797 0.332 . . . . 0.0 111.185 178.722 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 96.0 mt -88.6 148.0 24.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.194 -178.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 206' ' ' ALA . . . . . 0.409 ' HA ' ' HD2' ' A' ' 207' ' ' PRO . . . -123.51 95.73 44.67 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.183 -177.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 207' ' ' PRO . . . . . 0.409 ' HD2' ' HA ' ' A' ' 206' ' ' ALA . 72.9 Cg_endo -72.96 135.9 24.04 Favored 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 121.713 1.609 . . . . 0.0 111.217 178.95 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 93.5 t -127.11 122.71 60.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.247 178.681 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 98.6 m95 -85.36 127.26 34.29 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.241 177.512 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 96.1 t -125.01 128.68 73.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.29 -0.413 . . . . 0.0 111.232 -176.472 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -124.45 120.46 32.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.219 177.459 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 91.0 mmt-85 . . . . . 0 C--O 1.201 -1.472 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.24 -178.167 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 99.6 mttt . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.868 0.365 . . . . 0.0 111.18 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 99.8 mm-40 -97.92 -3.1 39.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.212 -179.657 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 96.0 mttt -130.11 175.19 9.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.285 -178.72 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -121.98 175.07 6.51 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.193 177.699 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 93.4 mt -119.07 139.33 51.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.256 -178.879 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 94.1 t -124.87 128.5 73.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.259 173.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -122.98 97.88 5.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.137 -177.4 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 61.7 t -98.06 127.8 50.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.143 -177.71 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 45.9 tt0 -109.45 126.81 53.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.17 178.328 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 51.5 t-20 -101.99 105.29 16.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.26 -177.092 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 83.5 mt -106.73 32.19 4.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.203 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 53.4 p -115.22 -168.22 1.36 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.225 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -108.11 18.08 34.1 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 177.721 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 47.4 t -150.38 148.77 29.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.858 0.361 . . . . 0.0 111.12 -179.428 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -76.77 163.55 26.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.19 -178.885 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 4.4 pp -149.31 165.51 31.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.126 -175.781 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 9.7 t -147.42 149.27 32.39 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.138 -177.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 83.9 mt -113.35 149.21 34.34 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.237 178.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -125.5 162.91 23.85 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.166 -176.038 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 66.9 p -71.28 153.19 42.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.246 178.607 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -68.06 -33.4 74.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.233 179.743 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -75.47 -19.74 59.23 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.249 178.542 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 80.14 28.81 48.17 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 111.286 -0.725 . . . . 0.0 111.286 -178.325 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -86.02 -42.07 14.29 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.777 0.322 . . . . 0.0 111.236 -175.792 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 14.7 t -156.18 -169.41 3.04 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.208 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -96.58 155.59 16.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.304 177.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 150' ' ' VAL . . . . . 0.459 HG12 HG23 ' A' ' 151' ' ' VAL . 68.8 t -109.29 -55.52 5.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.254 -178.415 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.459 HG23 HG12 ' A' ' 150' ' ' VAL . 84.2 t -123.82 133.6 68.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.191 178.802 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -137.0 143.92 43.02 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.215 -176.479 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 27.9 t0 56.25 63.53 1.97 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.182 175.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 93.8 t -76.21 125.31 35.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.245 178.874 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -70.52 146.69 42.6 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 179.544 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -73.74 138.75 26.85 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 121.697 1.598 . . . . 0.0 111.185 -178.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 50.47 48.6 22.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.216 177.128 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 46.5 t -162.24 141.28 9.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.194 179.817 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 60.0 m80 -78.35 88.67 4.37 Favored 'General case' 0 C--N 1.364 1.212 0 C-N-CA 119.654 -0.818 . . . . 0.0 111.034 -179.235 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -58.29 88.1 0.02 OUTLIER Glycine 0 CA--C 1.524 0.635 0 CA-C-N 115.378 -0.828 . . . . 0.0 111.178 177.175 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 13.9 t70 -69.4 132.83 46.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.782 0.325 . . . . 0.0 111.107 177.675 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 91.3 mmt-85 -133.62 140.34 47.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.212 -179.511 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 65.9 tt0 -84.56 103.95 14.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.296 173.804 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 48.3 mm -118.17 137.59 51.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.163 -169.547 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 95.3 m-20 -62.22 154.56 70.02 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.231 176.517 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -75.14 71.85 4.95 Favored 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 121.687 1.591 . . . . 0.0 111.14 -179.073 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 32.7 m -130.54 167.85 24.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.208 -177.237 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -79.58 130.72 35.64 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.178 174.032 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 33.9 m -122.01 149.93 25.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.166 -172.062 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 61.9 t-20 -97.85 110.2 22.81 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.152 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 86.9 mt -79.8 58.23 2.77 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.205 -176.358 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -104.48 141.1 36.98 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.121 178.06 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 76.1 mt -103.33 136.56 42.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.212 -176.805 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 84.6 m-85 -128.86 148.55 50.9 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.218 -177.453 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 53.2 t0 -129.77 96.25 4.18 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.213 175.349 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 79.34 -105.5 2.27 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 111.231 -0.748 . . . . 0.0 111.231 -176.136 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 88.8 p -115.41 6.68 14.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.869 0.366 . . . . 0.0 111.219 173.843 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -103.4 133.8 47.84 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.194 -176.882 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -81.41 128.03 33.41 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.145 172.086 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 93.5 t -103.37 -52.54 7.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.233 -172.459 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 47.6 t -143.34 149.26 37.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.19 -173.372 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 50.6 t0 -130.73 96.18 4.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.182 -177.512 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 54.8 tp -95.09 137.36 34.24 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.288 177.021 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -46.21 124.17 6.97 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.189 -172.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -54.91 146.96 54.17 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 121.65 1.567 . . . . 0.0 111.267 176.753 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 35.1 m -127.86 152.53 36.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.157 -177.588 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 96.8 m -93.08 118.04 30.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.194 178.652 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 69.4 tp -104.89 114.46 28.67 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.137 -178.352 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -94.93 154.9 16.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.269 -179.676 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 53.2 ptt85 -60.9 138.62 58.14 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.191 -178.496 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 95.72 -16.51 61.05 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 111.182 -0.767 . . . . 0.0 111.182 178.595 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 84.9 mt-10 -85.69 147.46 26.35 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.773 0.32 . . . . 0.0 111.203 -178.075 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 61.5 t -121.7 120.08 60.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.175 174.807 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 35.0 m -123.67 150.38 27.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.216 -177.662 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 82.8 m -122.89 158.64 29.92 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.172 177.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 51.7 tp -134.73 117.34 15.9 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.207 174.752 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -105.76 105.79 16.0 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.198 -176.192 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 97.7 t -103.78 125.56 58.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.242 -177.014 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 14.5 t -127.2 -170.42 2.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.239 178.333 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -108.34 135.67 12.99 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 111.229 -0.749 . . . . 0.0 111.229 -178.493 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.6 t -158.82 117.11 2.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.776 0.322 . . . . 0.0 111.215 178.03 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 75.11 14.88 81.45 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.151 -0.779 . . . . 0.0 111.151 177.488 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 89.44 2.03 77.19 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 -178.0 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -118.91 167.42 11.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.816 0.341 . . . . 0.0 111.21 -179.383 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 99.1 mt -82.21 140.08 33.91 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.217 178.019 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -124.63 95.08 43.44 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.142 -178.613 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -75.98 138.62 20.95 Favored 'Trans proline' 0 N--CA 1.458 -0.594 0 C-N-CA 121.738 1.625 . . . . 0.0 111.228 -178.717 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 65.0 t -127.8 106.62 15.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.186 173.349 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 24.8 t90 -79.97 127.29 32.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.185 -177.31 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 79.0 t -128.56 108.89 18.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.202 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -84.3 127.03 33.73 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.2 176.085 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 97.0 mtt-85 . . . . . 0 C--O 1.2 -1.529 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.209 -177.699 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 55.0 tptt . . . . . 0 C--O 1.23 0.053 0 CA-C-O 120.797 0.332 . . . . 0.0 111.178 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 -107.42 19.05 20.79 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.181 -176.012 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -145.16 122.89 11.86 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.132 178.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -104.76 163.97 12.11 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.238 178.112 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 64.1 tp -149.45 120.73 7.84 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.183 -178.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 89.0 t -117.03 131.34 70.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.192 -175.362 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 41.2 ttm180 -102.29 116.46 32.68 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.172 172.786 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 65.1 t -105.66 125.44 61.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.199 -175.39 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 38.1 tt0 -120.71 127.5 52.07 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.223 -177.052 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 48.1 t-20 -89.86 110.06 21.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.088 176.005 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 95.3 mt -111.61 14.84 21.28 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.11 177.338 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 38.1 p -85.65 -179.73 6.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.177 -179.211 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -98.03 14.11 62.91 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 111.192 -0.763 . . . . 0.0 111.192 177.447 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 18.7 t -136.55 -166.78 1.95 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.849 0.357 . . . . 0.0 111.086 -179.423 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 34.4 mmtp -95.46 136.97 35.16 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.256 -177.65 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.407 ' HB3' ' HB ' ' A' ' 154' ' ' VAL . 56.8 tp -102.03 131.72 48.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.293 -178.931 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 98.7 m -130.97 136.2 48.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.143 178.295 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 79.6 mt -125.4 142.87 51.26 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.218 172.606 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 60.6 mttm -118.78 163.84 16.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.166 -177.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 74.3 p -75.42 162.77 28.07 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.2 -177.347 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -65.17 -40.82 94.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.162 -175.23 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -78.62 -19.21 53.2 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.209 -178.261 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 80.55 21.93 63.25 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 111.2 -0.76 . . . . 0.0 111.2 -177.454 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -77.98 -36.47 48.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.728 0.299 . . . . 0.0 111.172 -178.305 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 14.7 t -154.95 -169.08 3.08 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.246 176.889 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -99.31 150.92 21.63 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.193 -179.766 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 69.3 t -89.03 -46.31 15.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.234 171.791 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 12.0 p -161.42 144.04 3.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.176 173.486 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 64.0 pttt -145.63 158.96 43.78 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.137 -175.303 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 28.4 t0 60.2 43.35 14.08 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.218 178.939 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.407 ' HB ' ' HB3' ' A' ' 139' ' ' LEU . 98.6 t -87.6 119.08 34.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.251 174.957 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -81.97 165.91 46.03 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 -175.14 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 63.5 Cg_exo -57.0 147.17 76.32 Favored 'Trans proline' 0 N--CA 1.458 -0.6 0 C-N-CA 121.691 1.594 . . . . 0.0 111.276 177.949 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 56.53 50.67 12.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.153 178.453 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 77.8 p -150.44 158.19 43.87 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.238 172.606 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 27.7 p-80 -151.56 167.45 28.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.169 -173.33 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -161.56 162.28 33.8 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 111.219 -0.752 . . . . 0.0 111.219 175.752 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -101.3 144.42 30.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.73 0.3 . . . . 0.0 111.293 -176.19 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 87.8 mmt-85 -138.91 130.04 26.74 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.17 176.137 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 91.1 mt-10 -84.69 144.91 28.24 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.207 179.26 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 19.5 tt -160.15 151.74 5.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.179 -179.051 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -73.62 142.03 80.26 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.221 175.527 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -78.75 60.37 7.65 Favored 'Trans proline' 0 N--CA 1.458 -0.59 0 C-N-CA 121.732 1.621 . . . . 0.0 111.2 -178.199 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 33.5 m -131.73 178.71 5.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.175 -178.038 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -69.76 112.52 6.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.169 176.958 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.404 HG23 ' HG ' ' A' ' 171' ' ' LEU . 35.6 m -129.31 164.35 32.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.211 -178.651 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 49.7 t30 -97.89 99.93 11.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.287 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 171' ' ' LEU . . . . . 0.404 ' HG ' HG23 ' A' ' 169' ' ' VAL . 82.3 mt -104.69 146.64 28.65 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.229 178.008 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -147.59 152.67 38.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.19 -177.877 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 51.8 tp -112.95 121.38 44.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.215 -173.132 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 72.8 m-85 -118.76 140.2 50.33 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.157 -176.558 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 64.2 t0 -104.33 98.2 8.03 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.122 170.674 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 77.59 -103.38 1.85 Allowed Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.129 -0.788 . . . . 0.0 111.129 -173.809 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 93.4 p -118.31 0.11 11.62 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.824 0.345 . . . . 0.0 111.134 175.21 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -108.38 130.14 55.23 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.244 -177.421 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -69.53 137.74 52.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.208 -179.052 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 88.4 t -99.67 -52.04 9.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.235 174.084 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 19.1 t -163.36 -158.77 0.48 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.205 -178.668 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 74.0 m-20 -114.0 160.8 18.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.203 177.894 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 93.9 mt -115.99 152.28 33.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.24 178.84 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -98.08 117.94 64.35 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.301 179.151 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_exo -55.07 130.45 40.8 Favored 'Trans proline' 0 N--CA 1.458 -0.583 0 C-N-CA 121.728 1.619 . . . . 0.0 111.128 177.801 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 99.2 t -121.73 127.4 75.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.227 175.006 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 71.1 p -84.53 166.61 17.08 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.174 -178.454 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 188' ' ' LEU . . . . . 0.418 ' C ' HD23 ' A' ' 188' ' ' LEU . 10.4 tt -137.07 123.65 20.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.226 -176.704 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -98.97 164.29 12.25 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.234 177.151 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 79.9 ttt180 -52.97 116.85 2.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.188 178.142 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 100.07 -14.49 59.9 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 178.857 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -87.56 143.75 27.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.801 0.334 . . . . 0.0 111.21 -179.285 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 193' ' ' VAL . . . . . 0.409 ' HB ' ' HB2' ' A' ' 212' ' ' ARG . 90.2 t -119.38 129.64 75.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.15 174.179 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 89.7 t -115.82 125.25 72.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.191 179.741 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 74.9 m -125.7 156.85 38.69 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.185 179.83 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 58.0 tp -130.03 118.5 21.67 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.205 175.451 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 88.7 m-85 -111.72 113.0 25.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.299 -178.444 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 80.5 t -107.86 120.27 58.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.177 -177.561 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 14.5 t -124.71 -169.45 1.98 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.203 -178.852 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -108.18 134.91 12.49 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 111.173 -0.771 . . . . 0.0 111.173 -177.691 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.6 t -160.22 118.32 2.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.787 0.327 . . . . 0.0 111.144 177.684 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 75.98 14.25 82.39 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 176.366 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 91.33 -0.5 75.03 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 -178.602 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -120.26 169.03 10.64 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.657 0.265 . . . . 0.0 111.229 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 82.6 mt -78.73 141.61 37.73 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.236 176.942 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -123.99 98.39 39.41 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.253 179.12 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -78.54 141.19 17.46 Favored 'Trans proline' 0 C--N 1.327 -0.587 0 C-N-CA 121.708 1.606 . . . . 0.0 111.212 -177.076 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 66.8 t -129.61 110.67 20.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.253 176.5 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 94.9 m95 -83.47 127.46 33.72 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.182 176.628 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 84.7 t -123.7 125.69 71.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.215 -177.421 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 56.2 mtmt -109.26 135.09 50.92 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.21 174.568 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 212' ' ' ARG . . . . . 0.409 ' HB2' ' HB ' ' A' ' 193' ' ' VAL . 82.2 mtp180 . . . . . 0 C--O 1.2 -1.543 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.142 179.053 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 99.6 mttt . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.785 0.326 . . . . 0.0 111.208 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 -111.19 21.37 16.41 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.223 -179.013 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 17.5 ptpt -161.49 166.92 26.43 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.186 -176.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -92.85 155.21 17.76 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.226 -176.096 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 60.8 tp -111.11 121.9 46.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.228 175.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 97.9 t -110.38 124.2 66.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.227 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 39.7 ttm180 -115.6 125.9 53.52 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.248 176.619 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 66.1 t -115.53 130.25 70.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.172 -175.857 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 37.1 tt0 -113.43 130.43 56.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.194 179.446 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 47.2 t30 -114.6 117.4 30.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.206 177.331 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 98.4 mt -102.77 -9.02 20.35 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.24 177.767 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 73.8 p -81.01 156.11 26.06 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.218 -178.318 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -83.14 -12.61 78.88 Favored Glycine 0 CA--C 1.523 0.571 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 -174.726 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 62.7 p -93.67 169.98 9.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.771 0.319 . . . . 0.0 111.251 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -73.97 135.22 43.17 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.214 -175.526 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 65.7 tp -108.23 121.15 44.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.218 174.24 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 97.7 m -130.4 130.69 44.67 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.175 174.49 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 82.9 mt -112.87 116.11 29.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.223 -178.427 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -119.57 156.24 30.71 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.217 177.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 74.9 p -84.02 154.78 23.08 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.166 -178.796 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -62.88 116.76 5.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.207 -176.412 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 55.21 33.89 21.54 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.164 177.12 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -106.7 -171.42 22.73 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 177.855 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -130.36 -6.59 4.25 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.832 0.349 . . . . 0.0 111.202 177.857 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 97.2 m -114.39 127.05 55.65 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.19 179.041 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 42.7 p30 -92.38 -179.37 5.2 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.245 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 26.9 m -128.89 -30.89 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.217 176.068 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 71.5 t -133.91 136.92 53.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.202 174.419 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -148.33 138.48 22.55 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.204 -176.64 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 45.3 t0 56.3 60.43 3.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.213 172.598 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 84.2 t -111.37 128.87 67.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.203 173.118 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -96.79 -164.42 32.77 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 -177.447 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -71.82 148.12 51.51 Favored 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 121.693 1.595 . . . . 0.0 111.176 -178.435 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 77.3 mt-30 52.8 50.6 17.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.204 178.565 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 44.9 t -142.06 148.91 39.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.199 -176.846 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 71.3 m80 -124.6 149.42 47.07 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.21 -176.053 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -134.6 132.58 6.38 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 174.696 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -106.83 135.1 48.95 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.797 0.332 . . . . 0.0 111.193 177.181 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 24.9 tpp180 -144.04 118.58 9.73 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.224 178.157 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -83.88 127.02 33.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.19 175.486 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 78.8 mt -130.85 137.32 56.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.172 -174.632 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 165' ' ' ASN . . . . . 0.435 ' HA ' ' HD3' ' A' ' 166' ' ' PRO . 96.3 m-20 -57.67 154.62 24.93 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.233 -178.12 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 166' ' ' PRO . . . . . 0.435 ' HD3' ' HA ' ' A' ' 165' ' ' ASN . 47.9 Cg_exo -65.37 78.24 0.24 Allowed 'Trans proline' 0 N--CA 1.458 -0.608 0 C-N-CA 121.675 1.583 . . . . 0.0 111.259 -177.609 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 32.1 m -136.56 167.61 23.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.253 177.154 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 89.0 tttt -77.89 116.48 18.43 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.206 173.166 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 63.9 t -113.15 121.11 64.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.162 -174.285 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 64.6 t-20 -105.12 99.84 9.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.217 176.719 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 94.4 mt -95.03 167.63 11.27 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.196 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -144.19 148.55 35.12 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.194 174.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 73.9 mt -80.1 117.71 21.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.176 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 78.4 m-85 -113.86 152.2 31.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.233 173.487 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -148.29 99.53 3.05 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.175 -178.486 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 80.37 -106.58 2.52 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 111.179 -0.768 . . . . 0.0 111.179 -179.323 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 86.0 p -117.83 8.78 12.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.728 0.299 . . . . 0.0 111.147 -179.468 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 65.3 pttt -128.01 164.43 22.37 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.207 -177.816 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -102.77 136.08 43.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.227 174.448 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 86.2 t -87.1 -55.32 6.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.155 -178.39 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 43.7 t -172.64 142.23 1.19 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.179 -175.707 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 93.1 m-20 -70.36 150.38 46.36 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.201 178.427 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 94.8 mt -103.09 153.45 20.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.178 177.387 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 184' ' ' LYS . . . . . 0.41 ' HA ' ' HD3' ' A' ' 185' ' ' PRO . 88.3 tttt -64.93 127.31 92.61 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.187 176.551 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 185' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 184' ' ' LYS . 73.5 Cg_exo -54.63 135.02 65.27 Favored 'Trans proline' 0 N--CA 1.458 -0.593 0 C-N-CA 121.696 1.597 . . . . 0.0 111.223 177.088 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 85.1 t -120.31 124.29 72.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.213 179.232 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 92.5 m -82.35 118.47 23.19 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.198 174.511 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 92.2 mt -96.76 143.46 27.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.208 -174.261 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -122.73 150.09 43.22 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.196 173.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 190' ' ' ARG . . . . . 0.452 ' HG3' ' O ' ' A' ' 190' ' ' ARG . 18.4 ptp180 -52.79 120.79 6.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.194 177.727 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 93.4 -6.54 75.02 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 175.793 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -74.94 136.51 41.37 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.805 0.336 . . . . 0.0 111.224 -178.134 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 99.1 t -109.08 118.0 55.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.163 177.367 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 85.6 t -121.98 131.55 72.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.143 -177.844 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 71.0 m -114.73 146.16 41.26 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.245 -179.045 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 65.8 tp -128.0 116.41 20.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.234 175.639 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -106.11 108.06 19.38 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.185 -177.449 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 85.1 t -109.73 121.98 63.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.169 -178.09 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 14.5 t -127.55 -171.02 2.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.192 177.803 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -107.26 135.17 12.6 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 111.184 -0.767 . . . . 0.0 111.184 -177.607 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.7 t -159.19 116.81 2.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.825 0.345 . . . . 0.0 111.222 177.676 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 75.2 14.91 81.46 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 177.084 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 90.19 0.69 76.75 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 -178.17 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -118.88 169.15 10.11 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.826 0.346 . . . . 0.0 111.22 -179.675 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 92.1 mt -82.43 141.95 32.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.187 177.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -122.87 93.27 48.53 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.215 179.367 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -79.7 143.37 16.7 Favored 'Trans proline' 0 N--CA 1.459 -0.549 0 C-N-CA 121.631 1.554 . . . . 0.0 111.168 -177.549 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 67.9 t -132.39 120.8 44.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.21 172.65 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 95.6 m95 -86.35 125.53 33.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.191 178.115 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 93.4 t -133.59 128.71 54.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.226 177.888 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 90.4 mttt -108.25 148.2 30.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.206 178.036 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 . . . . . 0 C--O 1.2 -1.54 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.176 179.811 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 99.7 mttt . . . . . 0 N--CA 1.456 -0.174 0 CA-C-O 120.725 0.298 . . . . 0.0 111.177 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -101.26 7.17 43.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.18 178.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -123.08 165.27 17.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.181 -179.552 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -94.72 152.93 18.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.2 -179.463 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 62.4 tp -105.41 120.29 41.23 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.239 174.202 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 91.2 t -119.02 135.59 58.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.2 -178.241 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -128.79 142.02 51.12 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.136 175.283 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 83.8 t -121.82 118.16 54.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.232 176.63 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 4.1 tp-100 -116.53 107.53 14.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.228 -175.513 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 63.1 t-20 -80.22 106.03 11.93 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.192 179.505 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 92.9 mt -106.08 11.27 31.63 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.15 179.616 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 33.1 p -83.98 179.76 7.45 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.242 -178.836 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -104.56 23.83 30.35 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 111.166 -0.774 . . . . 0.0 111.166 176.878 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 27.1 t -150.14 179.74 7.84 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.886 0.374 . . . . 0.0 111.157 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -75.57 138.47 41.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.233 -178.288 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 59.2 tp -92.15 119.1 31.48 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.181 175.604 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 140' ' ' THR . . . . . 0.437 ' HB ' ' HB2' ' A' ' 174' ' ' PHE . 96.5 m -123.56 125.84 45.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.131 174.492 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 85.0 mt -126.4 135.36 51.33 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.247 179.408 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 60.9 mttm -123.38 151.75 42.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.182 177.489 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 8.7 t -63.07 136.53 57.85 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.159 177.675 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -75.05 -6.67 50.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.181 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -89.6 -0.51 57.57 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.235 178.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -178.23 -121.57 0.71 Allowed Glycine 0 CA--C 1.524 0.626 0 N-CA-C 111.176 -0.769 . . . . 0.0 111.176 178.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -145.79 11.56 1.25 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.864 0.364 . . . . 0.0 111.216 179.356 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 89.0 m -61.5 129.9 43.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.088 -177.851 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -64.03 129.71 41.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.22 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 89.7 t -113.82 -51.31 5.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.148 173.001 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 95.9 t -124.25 137.03 58.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.095 173.766 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 62.6 pttt -164.81 161.3 20.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.18 174.655 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 75.3 m-20 57.89 42.95 22.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.397 -179.688 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 92.6 t -112.4 115.62 50.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.185 176.011 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -84.87 -173.31 49.81 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.212 -0.755 . . . . 0.0 111.212 -179.055 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo -72.4 155.98 55.0 Favored 'Trans proline' 0 N--CA 1.457 -0.664 0 C-N-CA 121.791 1.661 . . . . 0.0 111.176 -179.06 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 55.1 52.02 12.4 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.187 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 41.7 t -137.88 126.28 23.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.193 -178.042 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 56.0 p-80 -161.59 173.22 15.08 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.365 -176.913 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 175.57 170.41 38.4 Favored Glycine 0 CA--C 1.522 0.478 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 177.352 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -73.43 146.29 45.14 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.842 0.353 . . . . 0.0 111.253 -178.541 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 90.9 mmt-85 -132.7 121.33 22.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.253 172.899 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -86.36 103.1 14.62 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.254 177.652 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 80.2 mt -131.28 134.22 61.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.218 -173.105 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 92.7 m-20 -68.25 153.07 96.04 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.22 178.6 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo -51.26 118.4 4.29 Favored 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 121.749 1.633 . . . . 0.0 111.205 176.345 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.425 ' H ' ' HB2' ' A' ' 188' ' ' LEU . 9.1 p -167.77 149.2 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.15 -177.034 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 168' ' ' LYS . . . . . 0.403 ' HA ' ' HA ' ' A' ' 187' ' ' THR . 40.7 ttmt -72.06 115.59 11.46 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.273 173.235 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 99.2 t -100.08 119.9 48.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.199 -177.577 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 62.2 t-20 -134.2 100.97 4.86 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.175 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 76.7 mt -114.39 152.63 31.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.127 -177.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -90.42 142.73 27.44 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.282 175.11 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 60.9 tp -97.58 117.19 31.31 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.131 -170.77 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 174' ' ' PHE . . . . . 0.437 ' HB2' ' HB ' ' A' ' 140' ' ' THR . 82.1 m-85 -116.77 137.81 51.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.261 177.467 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -91.72 97.71 11.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.184 166.407 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 69.26 -83.51 0.25 Allowed Glycine 0 CA--C 1.522 0.49 0 N-CA-C 111.177 -0.769 . . . . 0.0 111.177 -171.475 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 93.6 p -135.08 -1.26 2.67 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.849 0.357 . . . . 0.0 111.22 177.516 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -103.63 117.44 34.4 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.258 -177.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -61.86 128.74 37.63 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.19 -176.691 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 92.2 t -96.45 -51.06 11.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.153 174.612 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 17.9 t -164.51 -157.52 0.37 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.165 -179.159 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 58.1 m-20 -125.27 144.08 50.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.185 172.376 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 94.0 mt -83.13 144.16 30.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.124 -178.138 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 184' ' ' LYS . . . . . 0.419 ' HA ' ' HD3' ' A' ' 185' ' ' PRO . 88.1 tttt -65.08 129.91 94.64 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.187 179.254 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 185' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 184' ' ' LYS . 75.9 Cg_exo -55.25 124.3 15.94 Favored 'Trans proline' 0 N--CA 1.459 -0.542 0 C-N-CA 121.666 1.577 . . . . 0.0 111.129 175.736 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 96.0 t -123.52 124.94 70.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.23 175.807 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 187' ' ' THR . . . . . 0.403 ' HA ' ' HA ' ' A' ' 168' ' ' LYS . 94.9 m -85.77 122.32 29.68 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.238 178.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 188' ' ' LEU . . . . . 0.425 ' HB2' ' H ' ' A' ' 167' ' ' VAL . 74.0 mt -85.55 156.08 20.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.061 178.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -150.55 153.09 35.15 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.206 -179.792 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 41.3 ptt180 -57.83 128.37 36.73 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.228 -175.566 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 91.96 -13.52 66.69 Favored Glycine 0 CA--C 1.523 0.556 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 173.033 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 72.6 mm-40 -87.38 149.22 24.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.838 0.351 . . . . 0.0 111.09 -176.08 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 67.3 t -116.09 120.87 66.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.194 177.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 92.4 t -120.91 122.73 68.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.221 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 74.5 m -116.48 144.32 44.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.197 -177.585 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 66.1 tp -114.47 117.01 29.77 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.149 175.659 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -106.62 99.42 8.99 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.221 -178.697 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 198' ' ' VAL . . . . . 0.407 ' HA ' ' HA ' ' A' ' 207' ' ' PRO . 90.3 t -83.42 115.94 26.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.301 -0.408 . . . . 0.0 111.188 -174.319 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 28.4 p -110.33 174.3 5.92 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.199 179.332 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -149.71 144.69 12.32 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 111.166 -0.774 . . . . 0.0 111.166 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.7 t -160.75 120.37 2.7 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.779 0.323 . . . . 0.0 111.265 177.137 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 75.31 14.05 82.27 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 111.267 -0.733 . . . . 0.0 111.267 178.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 95.92 -5.86 66.57 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 -178.418 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -103.5 134.6 46.58 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.826 0.346 . . . . 0.0 111.161 -179.261 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 99.4 mt -83.36 150.8 25.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.227 179.318 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -150.09 73.77 9.28 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.203 177.028 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 207' ' ' PRO . . . . . 0.407 ' HA ' ' HA ' ' A' ' 198' ' ' VAL . 46.2 Cg_exo -63.4 147.71 93.24 Favored 'Trans proline' 0 N--CA 1.456 -0.704 0 C-N-CA 121.729 1.619 . . . . 0.0 111.248 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 87.3 t -118.91 127.72 75.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.22 176.674 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 97.1 m95 -84.15 128.5 34.6 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.253 175.113 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 89.7 t -125.96 122.82 62.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.16 178.144 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -106.41 127.78 53.55 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.141 178.104 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 84.8 mtt85 . . . . . 0 C--O 1.2 -1.501 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.257 179.545 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 76.0 mmtt . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.695 0.283 . . . . 0.0 111.195 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -95.43 -24.73 16.55 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.15 176.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 94.4 mttt -124.88 166.69 15.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.193 176.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -74.02 147.88 42.5 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.185 179.263 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 88.7 mt -114.85 149.82 36.5 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.235 175.225 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 86.3 t -125.77 128.34 72.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.28 178.655 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 130' ' ' ARG . . . . . 0.431 HH21 ' CE1' ' A' ' 159' ' ' HIS . 81.9 mtp180 -117.7 157.72 25.99 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.235 178.281 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.55 ' O ' ' CD2' ' A' ' 159' ' ' HIS . 14.2 p -130.95 142.42 43.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.147 175.251 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 66.7 tp60 -148.21 109.4 4.32 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.183 179.374 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 133' ' ' ASN . . . . . 0.461 ' HA ' ' HB ' ' A' ' 198' ' ' VAL . 64.2 t-20 -86.18 108.97 18.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.166 -175.343 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 87.8 mt -90.99 -4.08 56.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.263 179.564 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 27.4 p -102.24 -178.3 3.66 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.192 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -103.66 8.54 51.37 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 111.201 -0.76 . . . . 0.0 111.201 176.566 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 94.9 p -90.39 160.01 16.29 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.816 0.341 . . . . 0.0 111.166 -175.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 39.4 ttpt -107.95 119.29 39.03 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.275 176.177 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 52.0 mt -131.69 150.56 52.11 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.228 -176.776 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 60.1 m -106.68 129.28 54.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.215 174.253 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 63.0 tp -95.48 121.29 37.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.225 -178.782 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -145.07 145.31 31.39 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.217 -179.535 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 81.1 p -68.8 150.6 47.65 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.223 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -60.62 121.81 13.14 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.209 -178.862 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 79.5 m-20 56.19 36.18 27.0 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.286 -179.174 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -86.45 -179.81 49.35 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 111.171 -0.772 . . . . 0.0 111.171 177.059 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -113.4 -23.75 9.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.774 0.321 . . . . 0.0 111.181 -179.483 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 89.9 m -128.87 136.88 51.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.175 -175.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 76.5 m-20 -65.2 145.82 55.76 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.239 178.48 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 150' ' ' VAL . . . . . 0.474 HG12 HG23 ' A' ' 151' ' ' VAL . 91.7 t -87.51 -57.04 4.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.194 178.819 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.474 HG23 HG12 ' A' ' 150' ' ' VAL . 46.9 t -130.71 124.33 56.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.178 169.937 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -94.38 138.06 32.78 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.167 -176.16 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 72.4 m-20 53.84 62.86 2.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.159 171.869 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 96.7 t -74.26 106.21 3.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.228 176.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -90.09 179.62 43.96 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 -176.564 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -57.39 127.7 26.53 Favored 'Trans proline' 0 C--N 1.327 -0.585 0 C-N-CA 121.702 1.601 . . . . 0.0 111.209 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 94.7 mm-40 66.2 19.32 11.08 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.218 175.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 35.8 t -73.37 145.74 45.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.235 176.772 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 159' ' ' HIS . . . . . 0.55 ' CD2' ' O ' ' A' ' 131' ' ' VAL . 50.3 t-80 -149.74 143.89 25.72 Favored 'General case' 0 CA--C 1.509 -0.607 0 CA-C-O 122.115 0.959 . . . . 0.0 111.029 178.613 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -158.84 157.43 28.43 Favored Glycine 0 CA--C 1.524 0.602 0 CA-C-N 114.868 -1.06 . . . . 0.0 111.224 -179.425 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 75.8 m-20 -113.01 147.37 37.33 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.849 0.357 . . . . 0.0 111.174 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 90.9 mmt-85 -138.85 148.09 43.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.178 178.314 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -110.06 134.83 51.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.184 173.731 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 20.2 tt -147.77 149.43 15.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.194 -175.082 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 97.0 m-20 -50.21 142.99 13.5 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.202 174.569 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -78.82 65.21 8.78 Favored 'Trans proline' 0 N--CA 1.457 -0.643 0 C-N-CA 121.764 1.642 . . . . 0.0 111.201 -173.615 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 34.3 m -133.42 160.78 42.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.23 176.343 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -65.91 108.44 2.17 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.061 -179.334 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 93.0 t -121.35 125.35 73.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.289 178.037 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 83.9 m-20 -99.38 141.81 31.68 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.162 177.322 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 5.4 mp -124.67 172.6 9.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.167 -174.902 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -148.11 166.06 28.96 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.207 -178.296 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 67.4 mt -94.69 135.43 36.17 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.251 177.79 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 -128.91 156.57 43.5 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.204 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 67.9 t0 -144.43 95.42 2.71 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.237 175.363 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 79.88 -106.38 2.44 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 111.199 -0.76 . . . . 0.0 111.199 179.827 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 88.1 p -115.52 7.87 15.02 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.797 0.332 . . . . 0.0 111.184 178.638 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -125.71 130.34 51.32 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.227 -178.309 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 38.9 ttpt -71.23 135.2 47.39 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.216 176.434 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 70.4 t -83.2 -55.57 7.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.152 -179.239 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 43.6 t -173.9 142.13 0.85 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.223 -176.038 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -69.09 146.84 52.24 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.223 176.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 94.6 mt -95.3 158.95 15.23 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.196 176.307 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -57.74 130.37 82.02 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.161 177.647 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_exo -52.85 140.1 58.42 Favored 'Trans proline' 0 N--CA 1.457 -0.661 0 C-N-CA 121.783 1.655 . . . . 0.0 111.17 177.504 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 8.2 p -143.49 136.24 24.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.119 -175.387 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 97.7 m -95.92 131.14 42.58 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.237 176.335 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 59.7 mt -100.04 96.03 7.25 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.171 -176.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -70.14 142.65 52.51 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.226 -177.448 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 80.6 ttt180 -66.55 125.9 27.19 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.241 -176.005 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 93.0 -10.52 73.71 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 173.549 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -103.22 178.93 4.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.788 0.328 . . . . 0.0 111.144 -178.32 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 7.4 p -135.09 139.6 46.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.148 -177.308 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 33.3 m -113.1 156.55 14.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.158 172.876 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 49.5 t -134.8 129.23 34.24 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.245 179.46 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 66.0 tp -89.45 115.29 26.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.237 177.133 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -101.47 104.34 15.26 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.194 176.571 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 198' ' ' VAL . . . . . 0.461 ' HB ' ' HA ' ' A' ' 133' ' ' ASN . 84.8 t -79.05 114.2 19.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.207 -173.905 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 15.3 t -143.84 -160.85 1.17 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.227 179.361 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 167.33 -171.61 42.05 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 44.3 t -162.35 129.21 3.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.732 0.301 . . . . 0.0 111.191 -179.452 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 75.57 15.9 80.96 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 111.157 -0.777 . . . . 0.0 111.157 177.089 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 99.17 -13.91 61.51 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 111.128 -0.789 . . . . 0.0 111.128 -178.327 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -88.7 123.69 33.39 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.777 0.322 . . . . 0.0 111.136 -179.377 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 96.8 mt -74.28 138.33 43.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.141 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -152.8 70.39 7.19 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.246 173.872 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -58.31 148.26 80.36 Favored 'Trans proline' 0 N--CA 1.458 -0.575 0 C-N-CA 121.783 1.655 . . . . 0.0 111.201 176.363 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 85.6 t -119.62 129.16 75.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.216 -177.79 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 92.0 m95 -83.59 128.34 34.44 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.229 172.901 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 86.7 t -121.41 124.87 72.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.2 175.743 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 28.1 ttpp -97.04 128.22 43.78 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.109 179.524 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 96.4 mtt-85 . . . . . 0 C--O 1.201 -1.484 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.236 -178.834 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 99.6 mttt . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.828 0.347 . . . . 0.0 111.206 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 125' ' ' GLN . . . . . 0.446 ' OE1' ' N ' ' A' ' 125' ' ' GLN . 18.3 pm0 -86.56 -6.54 58.85 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.136 176.643 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 99.9 mttt -111.31 -179.14 3.63 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.138 -178.313 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -143.36 173.11 11.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.197 174.807 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 93.7 mt -127.45 142.43 51.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.136 177.059 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 10.0 p -125.05 133.76 68.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.155 175.143 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 44.3 ttm180 -135.6 146.53 48.02 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.109 -177.163 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 98.8 t -125.85 127.24 71.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.167 176.764 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 62.9 tp60 -95.28 128.18 41.92 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.199 -179.688 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 57.5 t-20 -87.17 110.42 20.14 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.237 173.863 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 94.3 mt -101.76 7.91 41.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.123 177.119 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 30.5 t -101.35 158.82 15.77 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.178 178.793 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -79.85 -9.73 86.44 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.274 -0.731 . . . . 0.0 111.274 172.785 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 87.5 p -91.31 169.96 10.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.854 0.359 . . . . 0.0 111.109 173.321 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -89.1 156.08 19.04 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.197 177.536 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 84.7 mt -109.98 152.75 25.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.236 178.102 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 49.7 p -125.47 78.5 1.73 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.22 177.052 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 38.1 tp -70.92 120.88 17.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.116 -170.041 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -142.99 153.44 43.0 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.236 -178.016 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 85.6 m -57.3 125.31 22.23 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.244 174.117 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -59.07 118.3 5.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.233 -177.426 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 57.34 29.85 17.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.172 -179.566 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -113.38 -171.17 17.75 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.229 -0.748 . . . . 0.0 111.229 177.291 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -115.76 -4.19 12.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.829 0.347 . . . . 0.0 111.181 177.822 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 99.8 m -98.43 117.15 32.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.139 -175.529 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 81.2 m-20 -74.49 146.56 42.63 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.204 172.611 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 150' ' ' VAL . . . . . 0.494 HG12 HG23 ' A' ' 151' ' ' VAL . 60.1 t -108.95 -64.89 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.146 -175.192 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.494 HG23 HG12 ' A' ' 150' ' ' VAL . 99.4 t -141.47 120.28 10.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.204 172.06 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 54.2 mtmt -113.38 160.11 18.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.179 -178.855 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 32.1 t0 62.08 47.77 5.5 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.191 178.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 93.9 t -78.25 114.62 19.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.184 175.288 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -66.7 156.59 51.23 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 -171.549 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -55.02 132.79 54.4 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 121.797 1.665 . . . . 0.0 111.103 177.361 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 92.9 mm-40 57.08 33.09 22.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.162 179.506 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 19.2 t -119.06 -161.49 0.85 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.182 175.572 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 34.3 p80 -160.36 170.11 21.73 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.259 179.481 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -156.66 159.88 29.86 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 176.43 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 20.9 p30 -149.32 175.86 11.06 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.793 0.33 . . . . 0.0 111.237 -175.293 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 58.1 ttm-85 -156.05 140.69 16.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.208 -178.22 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -71.26 128.85 37.29 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.307 171.327 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 19.9 tt -159.06 153.93 5.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.147 -172.054 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 95.6 m-20 -62.87 154.08 77.38 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.181 176.433 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -75.16 71.36 5.13 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 121.725 1.617 . . . . 0.0 111.238 -179.55 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 33.4 m -126.26 179.83 3.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.181 -177.891 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -76.37 121.08 22.5 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.179 173.732 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 76.9 t -114.18 121.05 65.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.178 -176.367 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 87.3 m-20 -96.36 119.06 34.16 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.196 177.418 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 77.3 mt -113.76 154.19 27.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.206 -174.234 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -158.39 162.54 37.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.267 179.22 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 68.0 mt -111.73 148.58 33.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.154 173.417 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 35.0 p90 -142.76 160.1 40.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.198 -174.122 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 67.7 t0 -131.39 91.36 3.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.128 174.868 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 79.49 -106.73 2.45 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 -177.837 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 95.1 p -106.29 -9.26 16.89 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.784 0.326 . . . . 0.0 111.168 177.012 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -104.29 117.71 34.88 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.159 -176.138 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 39.0 ttpt -66.59 136.53 55.73 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.249 177.426 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 72.2 t -86.04 -56.29 5.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.251 -178.441 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 43.5 t -171.36 143.63 1.86 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.19 -176.342 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -72.48 150.33 43.37 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.217 176.788 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 82.4 mt -106.16 159.33 16.17 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.237 175.32 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 56.4 tptt -55.58 116.29 11.58 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.262 -179.802 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 77.1 Cg_exo -56.38 141.95 88.93 Favored 'Trans proline' 0 N--CA 1.459 -0.514 0 C-N-CA 121.602 1.535 . . . . 0.0 111.155 178.26 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 73.3 t -121.32 127.39 75.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.202 -177.415 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 97.1 m -95.33 116.67 29.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.171 170.194 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 83.3 mt -90.84 158.25 16.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.199 -175.539 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -136.53 156.36 48.69 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.198 -179.492 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 75.3 mtp180 -62.51 124.37 20.76 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.157 -174.453 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 78.7 13.32 83.28 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 111.194 -0.762 . . . . 0.0 111.194 173.172 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 92.5 mt-10 -121.29 158.34 28.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.769 0.318 . . . . 0.0 111.149 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 7.3 p -131.91 139.22 50.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.216 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 84.6 t -112.41 136.43 48.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.212 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 44.6 t -114.72 110.85 20.37 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.214 172.223 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 52.7 tp -90.82 110.57 21.78 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.157 -178.805 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 197' ' ' TYR . . . . . 0.409 ' HB2' ' HB ' ' A' ' 208' ' ' VAL . 85.3 m-85 -86.75 96.77 10.28 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.192 -175.982 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 97.3 t -86.76 121.58 37.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.178 -174.469 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 14.8 t -153.19 -169.11 3.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.207 178.377 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 144.54 -162.77 27.96 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 111.204 -0.758 . . . . 0.0 111.204 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.3 t -171.5 143.65 1.81 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.833 0.349 . . . . 0.0 111.148 -177.683 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 76.48 16.3 80.83 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 111.192 -0.763 . . . . 0.0 111.192 174.933 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 94.96 -6.52 69.51 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 111.114 -0.795 . . . . 0.0 111.114 -178.863 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -98.73 115.72 29.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.766 0.317 . . . . 0.0 111.102 179.55 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 91.5 mt -98.72 154.25 18.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.086 -177.291 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -150.74 73.96 8.72 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.208 176.449 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_exo -58.05 139.02 88.92 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 121.656 1.571 . . . . 0.0 111.161 178.653 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 208' ' ' VAL . . . . . 0.409 ' HB ' ' HB2' ' A' ' 197' ' ' TYR . 57.5 t -104.73 114.29 43.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.22 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 209' ' ' TRP . . . . . 0.435 ' CD1' ' C ' ' A' ' 209' ' ' TRP . 7.3 t90 -77.76 96.97 5.04 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.199 -178.082 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 98.3 t -106.23 115.41 47.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.219 175.277 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 29.2 ttpp -102.38 132.53 48.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.206 178.56 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 83.0 mtt85 . . . . . 0 C--O 1.202 -1.412 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.174 179.632 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 88.5 tttt . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.842 0.353 . . . . 0.0 111.282 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 61.7 mt-30 -103.59 150.02 24.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.2 179.368 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 62.9 pttt -164.33 166.29 20.95 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.271 174.253 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -142.13 167.9 21.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.201 -174.792 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 69.3 mt -120.86 154.73 35.42 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.129 176.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 13.1 p -141.39 137.0 32.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.296 177.787 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -125.82 149.24 48.78 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.166 172.732 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 87.4 t -128.71 120.12 51.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.128 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 64.7 tt0 -110.41 138.57 46.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.239 -174.366 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 64.7 t-20 -88.72 109.62 20.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.223 177.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 7.8 mp -105.93 34.94 3.08 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.284 178.256 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 59.6 p -132.8 173.1 11.73 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.16 177.445 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -86.71 -12.63 68.75 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 175.295 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 95.9 p -88.47 167.02 13.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.888 0.375 . . . . 0.0 111.207 179.13 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -79.04 135.87 37.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.275 178.812 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 60.5 tp -107.85 131.41 54.52 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.293 -175.758 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 93.5 m -133.37 128.43 35.6 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.334 172.874 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 10.3 tt -142.9 132.64 23.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.107 -176.669 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -125.92 165.8 18.07 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.137 179.647 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 14.6 t -150.92 -170.37 3.64 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.211 175.406 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . 55.16 51.63 12.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.19 -175.386 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 75.7 m-20 62.05 27.68 16.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.16 -177.617 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 84.29 6.67 85.94 Favored Glycine 0 CA--C 1.52 0.367 0 N-CA-C 111.276 -0.73 . . . . 0.0 111.276 176.131 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -81.81 -32.59 31.21 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.805 0.336 . . . . 0.0 111.122 -177.606 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 82.6 m -99.77 120.04 39.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.183 -178.335 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 65.4 t0 -89.32 109.01 19.96 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.192 176.027 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 87.4 t -85.48 -58.0 3.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.202 -176.489 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 27.8 m -132.83 153.33 37.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.209 168.373 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 65.6 tttm -150.55 116.97 5.71 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.337 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 70.8 m-20 56.17 46.98 20.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.266 174.88 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 33.5 m -101.96 151.24 5.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.142 179.14 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -99.1 -168.98 30.62 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 -171.58 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_exo -58.52 136.97 77.69 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 121.651 1.568 . . . . 0.0 111.153 -178.244 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 96.0 mm-40 68.3 17.12 9.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.249 173.463 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 70.3 m -103.99 151.23 23.44 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.308 170.192 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 56.4 p-80 -152.79 161.56 42.41 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.212 -176.49 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -114.98 160.24 13.31 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 176.481 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 37.4 t0 -136.86 115.5 12.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.609 0.242 . . . . 0.0 111.276 -178.873 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 89.4 mmt-85 -127.15 144.24 51.08 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.275 -173.815 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -96.18 124.48 40.2 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.253 175.707 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 46.1 pt -126.15 164.24 26.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.235 -168.1 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 -84.32 160.73 56.42 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.165 177.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -79.02 57.17 6.34 Favored 'Trans proline' 0 N--CA 1.458 -0.604 0 C-N-CA 121.588 1.525 . . . . 0.0 111.148 -179.753 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 33.6 m -130.96 -179.14 3.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.165 -175.774 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -65.61 104.01 0.96 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.305 174.36 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 91.7 t -104.3 126.56 58.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.25 -178.626 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 37.7 t-20 -107.26 109.21 20.93 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.089 -178.32 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 65.9 mt -90.64 117.67 29.48 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.218 175.602 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -126.12 140.39 52.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.154 -175.055 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 96.3 mt -87.69 141.18 28.81 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.185 178.716 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -135.6 156.44 48.86 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.209 179.739 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 66.9 t0 -136.05 83.78 2.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.193 173.806 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 79.48 -105.67 2.31 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.224 -0.75 . . . . 0.0 111.224 -173.922 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 98.0 p -102.95 -6.02 22.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.789 0.328 . . . . 0.0 111.195 172.371 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -83.82 131.51 34.88 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.196 -176.571 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 89.1 tttt -86.65 126.32 34.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.151 170.569 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 97.3 t -103.02 -53.02 7.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.195 -171.016 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 47.2 t -146.7 149.06 32.7 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.122 -174.619 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 51.0 t0 -136.2 102.33 4.97 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.228 -175.76 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 94.8 mt -81.56 148.23 29.24 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.148 -177.315 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -62.22 131.48 93.6 Favored Pre-proline 0 C--N 1.327 -0.38 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.244 178.464 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 76.3 Cg_exo -55.05 133.08 56.12 Favored 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 121.611 1.54 . . . . 0.0 111.234 177.031 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 94.0 t -124.21 131.15 73.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.26 178.462 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 98.2 m -88.24 130.01 35.2 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.101 175.584 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 82.0 mt -113.05 153.91 27.38 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.217 -178.635 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -102.41 163.83 12.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.116 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 79.6 ttt180 -51.03 120.21 4.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.147 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 104.74 -16.27 47.67 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 169.387 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 64.7 mt-10 -73.64 136.78 43.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.781 0.324 . . . . 0.0 111.089 -177.727 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 61.8 t -125.78 123.31 64.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.277 179.148 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 79.2 t -103.44 135.03 42.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.27 -178.411 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 44.3 t -121.78 105.63 10.56 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.249 176.316 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 31.0 tp -81.49 124.16 29.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.215 -176.222 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -105.72 98.52 8.2 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.2 179.196 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 62.3 t -90.54 106.99 17.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.216 -176.398 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 44.5 p -105.22 174.77 5.74 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.089 -175.454 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 100.36 -138.26 13.75 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 111.406 -0.678 . . . . 0.0 111.406 176.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 42.1 t -163.88 127.18 2.61 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.823 0.345 . . . . 0.0 111.204 178.828 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . -54.07 139.15 37.74 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 -174.478 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -91.52 8.34 78.96 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 111.015 -0.834 . . . . 0.0 111.015 7.118 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -89.65 69.9 7.78 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.671 0.272 . . . . 0.0 111.076 -177.835 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 93.4 mt -97.69 156.81 16.38 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.246 -178.342 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -139.42 84.58 16.07 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.135 -176.444 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -57.61 129.42 33.65 Favored 'Trans proline' 0 N--CA 1.459 -0.55 0 C-N-CA 121.692 1.595 . . . . 0.0 111.139 176.716 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 77.2 t -109.65 115.67 50.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.217 173.719 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 38.6 t-105 -81.52 105.24 12.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.221 -174.666 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 94.8 t -117.58 119.92 63.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.154 177.063 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -100.31 134.22 43.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.215 178.436 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 40.3 mmt180 . . . . . 0 C--O 1.199 -1.576 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.218 -179.934 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 99.3 mttt . . . . . 0 C--O 1.23 0.078 0 CA-C-O 120.795 0.331 . . . . 0.0 111.239 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 94.7 mt-30 -140.29 54.28 1.63 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.181 178.307 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -170.23 125.41 0.76 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.116 -178.842 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -150.23 143.63 25.09 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.248 172.903 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 59.0 tp -101.96 128.65 48.28 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.179 -177.613 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 33.1 m -125.48 152.01 31.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.136 174.452 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 41.7 ttm180 -140.85 124.2 16.7 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.208 178.617 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 57.3 t -105.39 121.33 57.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.257 -177.954 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 64.7 tp60 -107.76 127.01 53.31 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.173 -177.82 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 57.9 t-20 -85.63 105.34 16.13 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.153 178.357 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 98.3 mt -110.66 28.85 8.28 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.287 176.539 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 50.3 p -104.64 -175.69 2.87 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.222 -178.448 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -100.1 11.18 60.35 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 176.348 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 21.0 t -137.64 -167.46 2.14 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.802 0.334 . . . . 0.0 111.222 -178.388 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -102.63 142.91 33.02 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.125 178.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 93.8 mt -104.47 148.18 26.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.265 -177.265 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 140' ' ' THR . . . . . 0.423 ' HB ' ' HB2' ' A' ' 174' ' ' PHE . 97.2 m -139.26 128.35 23.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.18 169.352 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 79.9 mt -118.97 114.85 23.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.259 -179.243 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -127.24 133.63 50.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.198 179.9 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 79.4 p -71.83 156.81 38.88 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.134 -172.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -59.93 -30.02 68.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.238 -176.736 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -64.44 -31.65 72.94 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.208 179.625 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 78.18 17.39 78.24 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 -178.734 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -110.02 -27.31 9.27 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.758 0.313 . . . . 0.0 111.184 -178.029 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 69.1 p -130.36 169.7 15.12 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.262 -179.108 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 20.6 p30 -150.61 175.12 12.22 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.162 -178.633 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 88.1 t -129.25 -40.69 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.247 179.093 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 90.1 t -132.09 137.92 53.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.184 -178.915 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -135.95 107.83 7.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.201 178.085 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 75.5 m-20 51.5 51.31 17.03 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.243 173.459 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 76.6 t -100.57 127.66 53.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.236 179.194 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -88.84 177.66 44.96 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 111.224 -0.75 . . . . 0.0 111.224 -171.067 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -58.8 147.22 89.69 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 121.652 1.568 . . . . 0.0 111.199 -178.211 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 94.4 mm-40 68.98 17.06 8.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.233 176.707 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 68.1 m -124.87 161.53 26.36 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.168 171.644 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 33.8 p80 -146.41 170.14 17.43 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.206 -176.515 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -143.7 145.7 15.66 Favored Glycine 0 CA--C 1.523 0.571 0 N-CA-C 111.246 -0.742 . . . . 0.0 111.246 179.119 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -111.09 150.34 29.54 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.823 0.344 . . . . 0.0 111.168 -178.324 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 85.1 mmt-85 -143.6 143.6 31.56 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.16 175.433 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -99.53 112.29 24.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.211 170.066 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 76.8 mt -130.78 139.13 51.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.113 -171.183 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 95.3 m-20 -61.67 155.01 63.09 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.206 177.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -63.1 80.15 0.12 Allowed 'Trans proline' 0 N--CA 1.458 -0.595 0 C-N-CA 121.65 1.567 . . . . 0.0 111.173 -178.858 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 30.2 m -129.28 179.62 3.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.203 177.487 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -89.95 133.8 34.58 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.227 174.241 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 86.1 t -72.4 87.27 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.178 -176.7 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 62.9 t-20 -88.36 88.98 7.8 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.154 170.416 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 8.7 tt -145.18 140.66 28.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.231 -166.351 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -92.07 141.72 28.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.249 -177.07 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 62.6 tp -101.55 117.87 35.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.193 -172.662 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 174' ' ' PHE . . . . . 0.423 ' HB2' ' HB ' ' A' ' 140' ' ' THR . 70.5 m-85 -113.26 148.2 36.04 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.221 -178.524 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -105.69 94.18 5.06 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.196 167.146 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 77.38 -104.01 1.9 Allowed Glycine 0 CA--C 1.523 0.562 0 N-CA-C 111.232 -0.747 . . . . 0.0 111.232 -173.546 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 92.8 p -115.86 1.29 13.35 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.716 0.293 . . . . 0.0 111.166 172.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -104.64 116.96 32.97 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.306 -177.511 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -63.57 133.08 53.14 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.17 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 93.7 t -102.18 -53.3 7.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.206 176.614 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 19.2 t -163.99 -157.75 0.41 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.187 178.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -105.15 137.16 43.36 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.214 170.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 51.4 tp -74.73 128.75 36.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.252 -178.567 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -51.91 126.78 34.41 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.25 177.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -74.4 150.83 41.87 Favored 'Trans proline' 0 N--CA 1.458 -0.613 0 C-N-CA 121.647 1.565 . . . . 0.0 111.246 -176.516 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 14.5 p -147.42 143.79 19.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.177 176.349 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 92.1 m -81.0 124.58 29.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.168 -177.765 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 80.6 mt -93.78 158.75 15.51 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.218 177.853 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -159.85 146.02 15.89 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.202 -179.473 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 79.8 ttt180 -71.07 134.22 46.89 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.163 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 101.93 -12.13 57.56 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 111.184 -0.766 . . . . 0.0 111.184 -177.186 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -121.26 146.65 46.59 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.814 0.34 . . . . 0.0 111.168 179.324 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 96.9 t -114.46 123.36 70.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.244 178.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 76.7 t -109.85 114.12 46.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.206 -175.19 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 75.9 m -100.7 152.95 19.86 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.239 -178.598 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 64.8 tp -125.8 123.07 37.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.236 178.294 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -114.72 108.73 17.18 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.234 -179.543 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 65.5 t -109.43 124.19 65.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.122 -177.474 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 13.5 t -131.06 -174.29 3.34 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.148 -179.705 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -89.06 140.73 15.91 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 111.193 -0.763 . . . . 0.0 111.193 -177.615 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 37.3 t -146.38 86.87 1.7 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.798 0.332 . . . . 0.0 111.236 176.68 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 73.35 22.23 78.91 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 177.194 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 100.84 -12.5 59.26 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 111.231 -0.747 . . . . 0.0 111.231 -178.154 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -100.62 165.07 11.59 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.738 0.304 . . . . 0.0 111.239 178.873 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 96.5 mt -85.96 139.62 31.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.215 177.285 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -124.09 92.23 48.58 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.216 -179.385 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -76.26 138.75 20.43 Favored 'Trans proline' 0 N--CA 1.457 -0.672 0 C-N-CA 121.777 1.651 . . . . 0.0 111.244 -179.433 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 92.3 t -129.82 122.5 54.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.163 174.813 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 91.8 m95 -86.8 126.46 34.63 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.166 178.754 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 69.5 t -131.62 113.54 23.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.213 176.244 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 36.2 ttpt -103.51 136.0 44.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.225 -176.29 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 80.4 ttt180 . . . . . 0 C--O 1.198 -1.611 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.18 177.708 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 99.6 mttt . . . . . 0 C--O 1.23 0.073 0 CA-C-O 120.767 0.318 . . . . 0.0 111.212 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -91.95 143.2 26.73 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.218 174.464 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 68.3 tp -93.06 112.55 24.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.271 177.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 58.5 t -115.44 122.8 70.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.192 -178.434 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 41.8 ttm180 -112.1 144.91 40.69 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.225 177.434 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 92.3 t -114.35 119.94 62.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.205 169.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 66.6 tp60 -107.74 107.36 18.1 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.237 -177.611 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 65.0 t-20 -85.11 103.64 14.3 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.269 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 92.1 mt -102.61 17.44 23.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.228 -179.756 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 30.8 p -103.01 -179.33 3.92 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.215 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -104.82 29.25 12.1 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 111.258 -0.737 . . . . 0.0 111.258 174.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 46.1 t -144.8 147.42 32.86 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.808 0.337 . . . . 0.0 111.229 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -69.18 136.49 52.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.189 179.289 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.413 ' C ' HD12 ' A' ' 139' ' ' LEU . 4.4 pp -149.69 165.91 30.94 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.155 179.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 13.4 t -144.95 150.99 37.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.165 -177.223 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 64.7 tp -100.64 112.33 24.71 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.2 175.018 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 14.6 ptmm? -140.2 178.72 7.08 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.175 -176.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 57.0 p -83.22 164.9 19.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.167 179.011 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -108.45 4.82 24.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.214 177.079 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 75.7 m-20 -104.04 4.3 34.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.182 -177.539 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 174.55 -161.86 31.81 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.196 -0.762 . . . . 0.0 111.196 -178.729 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -93.81 -5.16 48.83 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.703 0.287 . . . . 0.0 111.146 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 89.4 m -62.0 130.06 43.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.239 178.31 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 42.3 p30 -93.13 177.57 6.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.215 -177.573 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 90.7 t -113.72 -56.27 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.172 177.609 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 99.0 t -117.46 133.41 64.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.247 178.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -100.77 166.38 10.9 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.173 -176.646 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 29.4 t0 64.32 47.38 3.15 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.204 177.118 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 69.7 t -118.27 121.17 66.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.235 174.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -124.59 -165.61 12.22 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 -177.463 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -75.77 141.01 24.03 Favored 'Trans proline' 0 N--CA 1.458 -0.563 0 C-N-CA 121.728 1.619 . . . . 0.0 111.182 179.247 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 49.64 50.54 18.1 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.217 175.66 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 17.4 t -161.48 -157.52 0.5 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.193 -178.434 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 57.2 p-80 -156.57 164.66 37.94 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.196 179.002 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -147.05 147.56 18.48 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 111.209 -0.756 . . . . 0.0 111.209 179.632 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 88.0 m-20 -112.55 155.6 24.08 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.739 0.304 . . . . 0.0 111.202 178.766 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 29.2 tpt180 -159.5 127.6 4.95 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.175 175.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -82.66 123.13 28.98 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.189 173.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 80.9 mt -127.89 137.97 56.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.189 -171.554 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 96.3 m-20 -50.45 147.26 8.04 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.236 178.76 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 81.1 Cg_endo -75.17 68.19 5.93 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 121.687 1.591 . . . . 0.0 111.226 -178.644 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 33.5 m -129.45 -178.12 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.203 -177.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -75.89 116.88 17.04 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.228 173.233 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 95.1 t -119.39 121.16 65.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.204 -175.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 55.1 t-20 -73.31 111.13 8.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.223 178.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 59.5 mt -95.82 142.92 27.52 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.244 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -161.88 143.76 11.29 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.189 175.662 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 65.5 tp -95.84 120.94 37.0 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.251 -178.404 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -118.77 140.44 49.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.257 175.406 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 39.6 t0 -111.46 94.45 4.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.188 171.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 79.22 -105.04 2.2 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 111.205 -0.758 . . . . 0.0 111.205 -173.104 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 88.9 p -115.75 6.06 14.33 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.771 0.32 . . . . 0.0 111.182 172.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -98.05 120.14 37.91 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.217 -176.116 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -66.47 126.89 30.28 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.241 173.433 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 88.0 t -105.65 -53.14 7.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.218 -177.049 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 44.8 t -147.88 140.31 24.46 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.204 -176.299 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -100.85 107.08 18.53 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.159 176.223 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 183' ' ' LEU . . . . . 0.538 ' O ' ' HB2' ' A' ' 184' ' ' LYS . 92.1 mt -89.69 -15.98 31.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.24 -171.793 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 184' ' ' LYS . . . . . 0.538 ' HB2' ' O ' ' A' ' 183' ' ' LEU . 74.9 mmtt 83.33 165.08 0.11 Allowed Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.209 167.113 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_exo -59.92 134.74 58.62 Favored 'Trans proline' 0 N--CA 1.458 -0.598 0 C-N-CA 121.689 1.593 . . . . 0.0 111.189 179.099 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 29.9 m -125.28 152.43 31.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.163 172.144 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 97.2 m -94.28 117.17 29.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.211 -179.197 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 93.4 mt -95.11 153.33 17.7 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.163 178.092 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -131.4 156.82 44.9 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.203 177.47 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 89.9 mtm180 -62.77 123.14 17.67 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.21 -176.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 87.47 -1.07 85.71 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 176.705 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -70.2 133.2 46.83 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.698 0.285 . . . . 0.0 111.231 -179.306 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 98.4 t -113.24 118.28 57.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.218 178.684 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 33.4 m -131.89 162.42 39.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.216 177.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 46.1 t -150.73 128.36 11.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.19 -179.111 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 60.9 tp -92.24 117.42 29.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.186 177.76 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -102.43 105.79 16.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.19 -179.737 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 54.2 t -105.22 112.79 40.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.21 -178.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 71.8 p -99.61 163.9 12.3 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.122 -178.519 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -116.39 135.24 11.92 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 111.239 -0.745 . . . . 0.0 111.239 179.022 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.2 t -160.69 120.06 2.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.746 0.308 . . . . 0.0 111.162 179.035 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 74.31 15.16 80.29 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 111.228 -0.749 . . . . 0.0 111.228 176.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 89.98 -0.84 79.68 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 111.179 -0.768 . . . . 0.0 111.179 -177.215 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -106.49 158.92 16.55 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.875 0.369 . . . . 0.0 111.157 -179.335 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 90.4 mt -107.02 141.51 38.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.146 179.522 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -125.33 92.81 46.37 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.268 179.191 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -74.6 127.36 10.91 Favored 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 121.712 1.608 . . . . 0.0 111.16 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 64.3 t -126.81 106.09 15.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.137 174.327 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 10.8 t90 -80.06 124.29 28.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.215 -177.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 98.7 t -120.63 132.56 69.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.167 -175.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -99.93 133.8 43.76 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.233 175.695 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 41.9 mmt180 . . . . . 0 C--O 1.2 -1.501 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.134 -179.484 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 74.4 mmtt . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.736 0.303 . . . . 0.0 111.229 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -143.91 177.78 8.31 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.241 177.015 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 95.4 mt -122.51 147.92 45.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.236 -177.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 12.2 p -134.35 142.84 39.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.205 178.365 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 38.5 ttm180 -117.53 99.31 6.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.203 179.017 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 96.2 t -84.69 121.37 36.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.169 -171.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 69.3 mm-40 -112.83 78.88 1.17 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.183 173.343 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 -89.33 157.41 18.2 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.197 -174.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 58.0 tp -62.97 -40.9 99.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.159 176.856 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 91.7 p -72.04 155.84 39.88 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.194 -175.085 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -113.84 55.4 0.52 Allowed Glycine 0 CA--C 1.524 0.599 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 -179.281 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 99.4 p -145.18 160.2 41.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.789 0.328 . . . . 0.0 111.213 -178.444 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -64.76 124.78 22.83 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.171 178.288 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 73.5 mt -111.06 157.83 19.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.19 -175.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 92.0 m -110.66 127.77 55.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.186 172.345 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 62.4 tp -95.6 123.66 39.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.153 176.387 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 96.3 mttt -123.61 158.52 31.29 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.181 178.314 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 14.5 t -125.18 -175.76 3.39 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.266 178.18 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' ALA . . . . . 0.432 ' O ' ' HB2' ' A' ' 145' ' ' ASP . . . 56.6 54.02 7.84 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.122 -173.284 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.432 ' HB2' ' O ' ' A' ' 144' ' ' ALA . 65.9 m-20 68.03 34.93 3.9 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.216 -178.533 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 72.84 43.64 41.16 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 111.187 -0.765 . . . . 0.0 111.187 174.064 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -118.6 -50.8 2.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.801 0.334 . . . . 0.0 111.136 -175.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 86.4 m -89.96 127.95 36.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.198 -173.207 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -65.67 114.91 5.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.273 -178.027 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 94.2 t -89.03 -59.99 2.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.253 174.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 14.5 p -156.97 143.71 10.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.199 -179.446 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -109.91 -179.28 3.75 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.168 178.62 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 74.6 m-20 59.09 41.57 20.38 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.127 178.044 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.439 ' O ' ' HD3' ' A' ' 156' ' ' PRO . 85.3 t -77.65 130.41 36.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.097 174.562 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -110.58 100.02 1.22 Allowed Glycine 0 CA--C 1.524 0.605 0 N-CA-C 111.151 -0.78 . . . . 0.0 111.151 -176.322 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . 0.439 ' HD3' ' O ' ' A' ' 154' ' ' VAL . 76.7 Cg_exo -56.02 139.53 85.08 Favored 'Trans proline' 0 N--CA 1.458 -0.608 0 C-N-CA 121.732 1.621 . . . . 0.0 111.205 177.483 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 54.06 45.66 27.08 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.179 174.213 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 83.6 p -116.36 -172.6 2.21 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.222 177.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -116.28 78.28 1.18 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.146 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 173.65 171.1 37.85 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 60.0 m-20 -115.26 168.28 10.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.84 0.352 . . . . 0.0 111.225 -177.335 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 91.4 mmt-85 -132.22 155.2 48.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.266 177.283 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -64.41 131.66 47.83 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.224 178.523 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 21.5 tt -141.89 143.14 27.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.253 176.211 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 91.9 m-20 -73.93 126.45 89.41 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.14 176.099 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -79.83 60.42 7.82 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 121.64 1.56 . . . . 0.0 111.142 -176.717 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 35.6 m -134.06 150.6 31.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.201 179.315 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -86.06 73.19 10.32 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.175 -177.247 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 84.2 t -131.1 142.92 42.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.22 -176.326 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 90.9 m-20 -49.73 119.94 3.88 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.242 -178.577 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 171' ' ' LEU . . . . . 0.458 ' HB2' ' HB2' ' A' ' 183' ' ' LEU . 65.2 mt -103.94 172.34 6.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.172 175.433 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -160.19 148.16 16.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.218 175.563 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 95.3 mt -107.23 135.73 48.25 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.134 176.197 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 81.5 m-85 -124.37 145.68 49.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.214 -177.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -115.03 87.51 2.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.207 171.573 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 78.98 -106.6 2.39 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 111.254 -0.738 . . . . 0.0 111.254 -177.143 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 95.5 p -105.9 -8.05 17.87 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.877 0.37 . . . . 0.0 111.213 175.581 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -103.4 117.18 33.88 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.2 -175.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 40.4 ttpt -64.03 130.99 46.23 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.254 176.688 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 69.4 t -82.55 -53.7 11.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.156 178.74 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 44.8 t -171.95 142.45 1.47 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.229 -178.067 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -80.27 145.35 32.22 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.281 174.155 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 183' ' ' LEU . . . . . 0.458 ' HB2' ' HB2' ' A' ' 171' ' ' LEU . 61.1 mt -110.06 159.02 17.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.185 -177.385 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 184' ' ' LYS . . . . . 0.404 ' HA ' ' HD3' ' A' ' 185' ' ' PRO . 99.6 mttt -85.57 151.6 56.06 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.203 176.055 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 185' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 184' ' ' LYS . 76.8 Cg_exo -55.86 142.78 83.59 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 121.748 1.632 . . . . 0.0 111.135 177.62 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 7.6 p -145.93 136.05 18.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.197 -179.731 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 98.7 m -98.75 129.94 45.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.176 -178.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 5.0 mp -125.21 150.49 46.95 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.218 177.123 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -90.35 169.24 11.25 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.271 169.637 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 -64.14 106.99 1.17 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.186 -179.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 92.62 7.24 63.34 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 111.186 -0.766 . . . . 0.0 111.186 178.311 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -76.06 137.86 40.45 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.797 0.332 . . . . 0.0 111.264 -179.817 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 61.3 t -104.27 116.6 48.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.161 178.179 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 97.6 t -120.86 134.66 63.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.149 177.408 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 76.6 m -95.94 153.37 17.8 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.187 -175.426 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 60.1 tp -126.32 117.49 23.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.201 178.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 91.7 m-85 -112.82 111.51 22.33 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.199 -179.281 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 68.8 t -100.02 113.57 35.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.2 -178.537 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 45.9 p -108.34 172.83 6.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.1 -175.433 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 88.81 -151.86 22.61 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 111.343 -0.703 . . . . 0.0 111.343 177.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 45.0 t -151.89 146.41 25.63 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.723 0.297 . . . . 0.0 111.256 179.699 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . -62.19 147.66 48.93 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.096 -0.802 . . . . 0.0 111.096 -176.209 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -98.58 35.26 4.73 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 5.655 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -122.6 68.89 0.96 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.797 0.332 . . . . 0.0 111.185 178.722 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 96.0 mt -88.6 148.0 24.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.194 -178.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 206' ' ' ALA . . . . . 0.409 ' HA ' ' HD2' ' A' ' 207' ' ' PRO . . . -123.51 95.73 44.67 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.183 -177.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 207' ' ' PRO . . . . . 0.409 ' HD2' ' HA ' ' A' ' 206' ' ' ALA . 72.9 Cg_endo -72.96 135.9 24.04 Favored 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 121.713 1.609 . . . . 0.0 111.217 178.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 93.5 t -127.11 122.71 60.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.247 178.681 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 98.6 m95 -85.36 127.26 34.29 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.241 177.512 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 96.1 t -125.01 128.68 73.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.29 -0.413 . . . . 0.0 111.232 -176.472 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -124.45 120.46 32.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.219 177.459 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 91.0 mmt-85 . . . . . 0 C--O 1.201 -1.472 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.24 -178.167 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 96.0 mttt . . . . . 0 C--O 1.232 0.178 0 CA-C-O 120.706 0.289 . . . . 0.0 111.285 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -121.98 175.07 6.51 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.193 177.699 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 93.4 mt -119.07 139.33 51.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.256 -178.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 94.1 t -124.87 128.5 73.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.259 173.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -122.98 97.88 5.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.137 -177.4 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 61.7 t -98.06 127.8 50.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.143 -177.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 45.9 tt0 -109.45 126.81 53.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.17 178.328 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 51.5 t-20 -101.99 105.29 16.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.26 -177.092 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 83.5 mt -106.73 32.19 4.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.203 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 53.4 p -115.22 -168.22 1.36 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.225 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -108.11 18.08 34.1 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 177.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 47.4 t -150.38 148.77 29.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.858 0.361 . . . . 0.0 111.12 -179.428 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -76.77 163.55 26.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.19 -178.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 4.4 pp -149.31 165.51 31.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.126 -175.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 9.7 t -147.42 149.27 32.39 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.138 -177.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 83.9 mt -113.35 149.21 34.34 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.237 178.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -125.5 162.91 23.85 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.166 -176.038 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 66.9 p -71.28 153.19 42.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.246 178.607 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -68.06 -33.4 74.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.233 179.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -75.47 -19.74 59.23 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.249 178.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 80.14 28.81 48.17 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 111.286 -0.725 . . . . 0.0 111.286 -178.325 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -86.02 -42.07 14.29 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.777 0.322 . . . . 0.0 111.236 -175.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 14.7 t -156.18 -169.41 3.04 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.208 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -96.58 155.59 16.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.304 177.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . 0.459 HG12 HG23 ' A' ' 151' ' ' VAL . 68.8 t -109.29 -55.52 5.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.254 -178.415 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.459 HG23 HG12 ' A' ' 150' ' ' VAL . 84.2 t -123.82 133.6 68.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.191 178.802 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -137.0 143.92 43.02 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.215 -176.479 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 27.9 t0 56.25 63.53 1.97 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.182 175.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 93.8 t -76.21 125.31 35.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.245 178.874 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -70.52 146.69 42.6 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 179.544 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -73.74 138.75 26.85 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 121.697 1.598 . . . . 0.0 111.185 -178.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 50.47 48.6 22.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.216 177.128 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 46.5 t -162.24 141.28 9.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.194 179.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -78.35 88.67 4.37 Favored 'General case' 0 C--N 1.364 1.212 0 C-N-CA 119.654 -0.818 . . . . 0.0 111.034 -179.235 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -58.29 88.1 0.02 OUTLIER Glycine 0 CA--C 1.524 0.635 0 CA-C-N 115.378 -0.828 . . . . 0.0 111.178 177.175 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 13.9 t70 -69.4 132.83 46.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.782 0.325 . . . . 0.0 111.107 177.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 91.3 mmt-85 -133.62 140.34 47.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.212 -179.511 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 65.9 tt0 -84.56 103.95 14.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.296 173.804 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 48.3 mm -118.17 137.59 51.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.163 -169.547 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 95.3 m-20 -62.22 154.56 70.02 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.231 176.517 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -75.14 71.85 4.95 Favored 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 121.687 1.591 . . . . 0.0 111.14 -179.073 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 32.7 m -130.54 167.85 24.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.208 -177.237 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -79.58 130.72 35.64 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.178 174.032 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 33.9 m -122.01 149.93 25.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.166 -172.062 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 61.9 t-20 -97.85 110.2 22.81 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.152 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 86.9 mt -79.8 58.23 2.77 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.205 -176.358 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -104.48 141.1 36.98 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.121 178.06 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 76.1 mt -103.33 136.56 42.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.212 -176.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 84.6 m-85 -128.86 148.55 50.9 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.218 -177.453 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 53.2 t0 -129.77 96.25 4.18 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.213 175.349 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 79.34 -105.5 2.27 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 111.231 -0.748 . . . . 0.0 111.231 -176.136 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 88.8 p -115.41 6.68 14.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.869 0.366 . . . . 0.0 111.219 173.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -103.4 133.8 47.84 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.194 -176.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -81.41 128.03 33.41 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.145 172.086 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 93.5 t -103.37 -52.54 7.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.233 -172.459 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 47.6 t -143.34 149.26 37.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.19 -173.372 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 50.6 t0 -130.73 96.18 4.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.182 -177.512 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 54.8 tp -95.09 137.36 34.24 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.288 177.021 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -46.21 124.17 6.97 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.189 -172.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -54.91 146.96 54.17 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 121.65 1.567 . . . . 0.0 111.267 176.753 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 35.1 m -127.86 152.53 36.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.157 -177.588 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 96.8 m -93.08 118.04 30.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.194 178.652 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 69.4 tp -104.89 114.46 28.67 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.137 -178.352 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -94.93 154.9 16.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.269 -179.676 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 53.2 ptt85 -60.9 138.62 58.14 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.191 -178.496 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 95.72 -16.51 61.05 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 111.182 -0.767 . . . . 0.0 111.182 178.595 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 84.9 mt-10 -85.69 147.46 26.35 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.773 0.32 . . . . 0.0 111.203 -178.075 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 61.5 t -121.7 120.08 60.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.175 174.807 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 35.0 m -123.67 150.38 27.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.216 -177.662 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 82.8 m -122.89 158.64 29.92 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.172 177.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 51.7 tp -134.73 117.34 15.9 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.207 174.752 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -105.76 105.79 16.0 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.198 -176.192 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 97.7 t -103.78 125.56 58.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.242 -177.014 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 14.5 t -127.2 -170.42 2.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.239 178.333 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -108.34 135.67 12.99 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 111.229 -0.749 . . . . 0.0 111.229 -178.493 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.6 t -158.82 117.11 2.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.776 0.322 . . . . 0.0 111.215 178.03 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 75.11 14.88 81.45 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.151 -0.779 . . . . 0.0 111.151 177.488 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 89.44 2.03 77.19 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 -178.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -118.91 167.42 11.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.816 0.341 . . . . 0.0 111.21 -179.383 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 99.1 mt -82.21 140.08 33.91 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.217 178.019 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -124.63 95.08 43.44 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.142 -178.613 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -75.98 138.62 20.95 Favored 'Trans proline' 0 N--CA 1.458 -0.594 0 C-N-CA 121.738 1.625 . . . . 0.0 111.228 -178.717 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 65.0 t -127.8 106.62 15.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.186 173.349 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 24.8 t90 -79.97 127.29 32.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.185 -177.31 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 79.0 t -128.56 108.89 18.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.202 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -84.3 127.03 33.73 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.2 176.085 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 97.0 mtt-85 . . . . . 0 C--O 1.2 -1.529 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.209 -177.699 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 88.1 tttt . . . . . 0 CA--C 1.523 -0.078 0 CA-C-O 120.873 0.368 . . . . 0.0 111.132 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -104.76 163.97 12.11 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.238 178.112 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 64.1 tp -149.45 120.73 7.84 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.183 -178.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 89.0 t -117.03 131.34 70.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.192 -175.362 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 41.2 ttm180 -102.29 116.46 32.68 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.172 172.786 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 65.1 t -105.66 125.44 61.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.199 -175.39 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 38.1 tt0 -120.71 127.5 52.07 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.223 -177.052 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 48.1 t-20 -89.86 110.06 21.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.088 176.005 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 95.3 mt -111.61 14.84 21.28 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.11 177.338 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 38.1 p -85.65 -179.73 6.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.177 -179.211 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -98.03 14.11 62.91 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 111.192 -0.763 . . . . 0.0 111.192 177.447 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 18.7 t -136.55 -166.78 1.95 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.849 0.357 . . . . 0.0 111.086 -179.423 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 34.4 mmtp -95.46 136.97 35.16 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.256 -177.65 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.407 ' HB3' ' HB ' ' A' ' 154' ' ' VAL . 56.8 tp -102.03 131.72 48.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.293 -178.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 98.7 m -130.97 136.2 48.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.143 178.295 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 79.6 mt -125.4 142.87 51.26 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.218 172.606 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 60.6 mttm -118.78 163.84 16.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.166 -177.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 74.3 p -75.42 162.77 28.07 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.2 -177.347 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -65.17 -40.82 94.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.162 -175.23 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -78.62 -19.21 53.2 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.209 -178.261 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 80.55 21.93 63.25 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 111.2 -0.76 . . . . 0.0 111.2 -177.454 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -77.98 -36.47 48.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.728 0.299 . . . . 0.0 111.172 -178.305 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 14.7 t -154.95 -169.08 3.08 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.246 176.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -99.31 150.92 21.63 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.193 -179.766 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 69.3 t -89.03 -46.31 15.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.234 171.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 12.0 p -161.42 144.04 3.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.176 173.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 64.0 pttt -145.63 158.96 43.78 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.137 -175.303 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 28.4 t0 60.2 43.35 14.08 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.218 178.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.407 ' HB ' ' HB3' ' A' ' 139' ' ' LEU . 98.6 t -87.6 119.08 34.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.251 174.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -81.97 165.91 46.03 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 -175.14 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 63.5 Cg_exo -57.0 147.17 76.32 Favored 'Trans proline' 0 N--CA 1.458 -0.6 0 C-N-CA 121.691 1.594 . . . . 0.0 111.276 177.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 56.53 50.67 12.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.153 178.453 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 77.8 p -150.44 158.19 43.87 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.238 172.606 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 27.7 p-80 -151.56 167.45 28.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.169 -173.33 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -161.56 162.28 33.8 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 111.219 -0.752 . . . . 0.0 111.219 175.752 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -101.3 144.42 30.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.73 0.3 . . . . 0.0 111.293 -176.19 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 87.8 mmt-85 -138.91 130.04 26.74 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.17 176.137 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 91.1 mt-10 -84.69 144.91 28.24 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.207 179.26 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 19.5 tt -160.15 151.74 5.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.179 -179.051 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -73.62 142.03 80.26 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.221 175.527 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -78.75 60.37 7.65 Favored 'Trans proline' 0 N--CA 1.458 -0.59 0 C-N-CA 121.732 1.621 . . . . 0.0 111.2 -178.199 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 33.5 m -131.73 178.71 5.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.175 -178.038 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -69.76 112.52 6.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.169 176.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.404 HG23 ' HG ' ' A' ' 171' ' ' LEU . 35.6 m -129.31 164.35 32.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.211 -178.651 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 49.7 t30 -97.89 99.93 11.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.287 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 171' ' ' LEU . . . . . 0.404 ' HG ' HG23 ' A' ' 169' ' ' VAL . 82.3 mt -104.69 146.64 28.65 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.229 178.008 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -147.59 152.67 38.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.19 -177.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 51.8 tp -112.95 121.38 44.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.215 -173.132 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 72.8 m-85 -118.76 140.2 50.33 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.157 -176.558 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 64.2 t0 -104.33 98.2 8.03 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.122 170.674 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 77.59 -103.38 1.85 Allowed Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.129 -0.788 . . . . 0.0 111.129 -173.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 93.4 p -118.31 0.11 11.62 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.824 0.345 . . . . 0.0 111.134 175.21 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -108.38 130.14 55.23 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.244 -177.421 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -69.53 137.74 52.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.208 -179.052 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 88.4 t -99.67 -52.04 9.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.235 174.084 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 19.1 t -163.36 -158.77 0.48 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.205 -178.668 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 74.0 m-20 -114.0 160.8 18.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.203 177.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 93.9 mt -115.99 152.28 33.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.24 178.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -98.08 117.94 64.35 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.301 179.151 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_exo -55.07 130.45 40.8 Favored 'Trans proline' 0 N--CA 1.458 -0.583 0 C-N-CA 121.728 1.619 . . . . 0.0 111.128 177.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 99.2 t -121.73 127.4 75.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.227 175.006 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 71.1 p -84.53 166.61 17.08 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.174 -178.454 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . 0.418 ' C ' HD23 ' A' ' 188' ' ' LEU . 10.4 tt -137.07 123.65 20.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.226 -176.704 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -98.97 164.29 12.25 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.234 177.151 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 79.9 ttt180 -52.97 116.85 2.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.188 178.142 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 100.07 -14.49 59.9 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 178.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -87.56 143.75 27.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.801 0.334 . . . . 0.0 111.21 -179.285 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 193' ' ' VAL . . . . . 0.409 ' HB ' ' HB2' ' A' ' 212' ' ' ARG . 90.2 t -119.38 129.64 75.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.15 174.179 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 89.7 t -115.82 125.25 72.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.191 179.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 74.9 m -125.7 156.85 38.69 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.185 179.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 58.0 tp -130.03 118.5 21.67 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.205 175.451 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 88.7 m-85 -111.72 113.0 25.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.299 -178.444 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 80.5 t -107.86 120.27 58.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.177 -177.561 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 14.5 t -124.71 -169.45 1.98 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.203 -178.852 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -108.18 134.91 12.49 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 111.173 -0.771 . . . . 0.0 111.173 -177.691 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.6 t -160.22 118.32 2.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.787 0.327 . . . . 0.0 111.144 177.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 75.98 14.25 82.39 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 176.366 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 91.33 -0.5 75.03 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 -178.602 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -120.26 169.03 10.64 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.657 0.265 . . . . 0.0 111.229 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 82.6 mt -78.73 141.61 37.73 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.236 176.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -123.99 98.39 39.41 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.253 179.12 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -78.54 141.19 17.46 Favored 'Trans proline' 0 C--N 1.327 -0.587 0 C-N-CA 121.708 1.606 . . . . 0.0 111.212 -177.076 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 66.8 t -129.61 110.67 20.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.253 176.5 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 94.9 m95 -83.47 127.46 33.72 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.182 176.628 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 84.7 t -123.7 125.69 71.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.215 -177.421 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 56.2 mtmt -109.26 135.09 50.92 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.21 174.568 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 212' ' ' ARG . . . . . 0.409 ' HB2' ' HB ' ' A' ' 193' ' ' VAL . 82.2 mtp180 . . . . . 0 C--O 1.2 -1.543 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.142 179.053 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 17.5 ptpt . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.785 0.326 . . . . 0.0 111.186 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -92.85 155.21 17.76 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.226 -176.096 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 60.8 tp -111.11 121.9 46.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.228 175.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 97.9 t -110.38 124.2 66.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.227 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 39.7 ttm180 -115.6 125.9 53.52 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.248 176.619 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 66.1 t -115.53 130.25 70.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.172 -175.857 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 37.1 tt0 -113.43 130.43 56.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.194 179.446 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 47.2 t30 -114.6 117.4 30.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.206 177.331 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 98.4 mt -102.77 -9.02 20.35 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.24 177.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 73.8 p -81.01 156.11 26.06 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.218 -178.318 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -83.14 -12.61 78.88 Favored Glycine 0 CA--C 1.523 0.571 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 -174.726 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 62.7 p -93.67 169.98 9.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.771 0.319 . . . . 0.0 111.251 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -73.97 135.22 43.17 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.214 -175.526 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 65.7 tp -108.23 121.15 44.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.218 174.24 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 97.7 m -130.4 130.69 44.67 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.175 174.49 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 82.9 mt -112.87 116.11 29.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.223 -178.427 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -119.57 156.24 30.71 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.217 177.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 74.9 p -84.02 154.78 23.08 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.166 -178.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -62.88 116.76 5.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.207 -176.412 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 55.21 33.89 21.54 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.164 177.12 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -106.7 -171.42 22.73 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 177.855 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -130.36 -6.59 4.25 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.832 0.349 . . . . 0.0 111.202 177.857 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 97.2 m -114.39 127.05 55.65 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.19 179.041 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 42.7 p30 -92.38 -179.37 5.2 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.245 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 26.9 m -128.89 -30.89 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.217 176.068 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 71.5 t -133.91 136.92 53.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.202 174.419 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -148.33 138.48 22.55 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.204 -176.64 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 45.3 t0 56.3 60.43 3.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.213 172.598 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 84.2 t -111.37 128.87 67.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.203 173.118 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -96.79 -164.42 32.77 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 -177.447 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -71.82 148.12 51.51 Favored 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 121.693 1.595 . . . . 0.0 111.176 -178.435 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 77.3 mt-30 52.8 50.6 17.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.204 178.565 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 44.9 t -142.06 148.91 39.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.199 -176.846 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 71.3 m80 -124.6 149.42 47.07 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.21 -176.053 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -134.6 132.58 6.38 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 174.696 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -106.83 135.1 48.95 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.797 0.332 . . . . 0.0 111.193 177.181 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 24.9 tpp180 -144.04 118.58 9.73 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.224 178.157 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -83.88 127.02 33.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.19 175.486 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 78.8 mt -130.85 137.32 56.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.172 -174.632 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . 0.435 ' HA ' ' HD3' ' A' ' 166' ' ' PRO . 96.3 m-20 -57.67 154.62 24.93 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.233 -178.12 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 166' ' ' PRO . . . . . 0.435 ' HD3' ' HA ' ' A' ' 165' ' ' ASN . 47.9 Cg_exo -65.37 78.24 0.24 Allowed 'Trans proline' 0 N--CA 1.458 -0.608 0 C-N-CA 121.675 1.583 . . . . 0.0 111.259 -177.609 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 32.1 m -136.56 167.61 23.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.253 177.154 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 89.0 tttt -77.89 116.48 18.43 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.206 173.166 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 63.9 t -113.15 121.11 64.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.162 -174.285 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 64.6 t-20 -105.12 99.84 9.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.217 176.719 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 94.4 mt -95.03 167.63 11.27 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.196 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -144.19 148.55 35.12 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.194 174.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 73.9 mt -80.1 117.71 21.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.176 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 78.4 m-85 -113.86 152.2 31.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.233 173.487 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -148.29 99.53 3.05 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.175 -178.486 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 80.37 -106.58 2.52 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 111.179 -0.768 . . . . 0.0 111.179 -179.323 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 86.0 p -117.83 8.78 12.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.728 0.299 . . . . 0.0 111.147 -179.468 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 65.3 pttt -128.01 164.43 22.37 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.207 -177.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -102.77 136.08 43.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.227 174.448 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 86.2 t -87.1 -55.32 6.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.155 -178.39 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 43.7 t -172.64 142.23 1.19 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.179 -175.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 93.1 m-20 -70.36 150.38 46.36 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.201 178.427 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 94.8 mt -103.09 153.45 20.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.178 177.387 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 184' ' ' LYS . . . . . 0.41 ' HA ' ' HD3' ' A' ' 185' ' ' PRO . 88.3 tttt -64.93 127.31 92.61 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.187 176.551 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 185' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 184' ' ' LYS . 73.5 Cg_exo -54.63 135.02 65.27 Favored 'Trans proline' 0 N--CA 1.458 -0.593 0 C-N-CA 121.696 1.597 . . . . 0.0 111.223 177.088 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 85.1 t -120.31 124.29 72.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.213 179.232 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 92.5 m -82.35 118.47 23.19 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.198 174.511 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 92.2 mt -96.76 143.46 27.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.208 -174.261 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -122.73 150.09 43.22 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.196 173.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 190' ' ' ARG . . . . . 0.452 ' HG3' ' O ' ' A' ' 190' ' ' ARG . 18.4 ptp180 -52.79 120.79 6.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.194 177.727 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 93.4 -6.54 75.02 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 175.793 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -74.94 136.51 41.37 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.805 0.336 . . . . 0.0 111.224 -178.134 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 99.1 t -109.08 118.0 55.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.163 177.367 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 85.6 t -121.98 131.55 72.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.143 -177.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 71.0 m -114.73 146.16 41.26 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.245 -179.045 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 65.8 tp -128.0 116.41 20.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.234 175.639 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -106.11 108.06 19.38 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.185 -177.449 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 85.1 t -109.73 121.98 63.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.169 -178.09 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 14.5 t -127.55 -171.02 2.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.192 177.803 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -107.26 135.17 12.6 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 111.184 -0.767 . . . . 0.0 111.184 -177.607 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.7 t -159.19 116.81 2.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.825 0.345 . . . . 0.0 111.222 177.676 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 75.2 14.91 81.46 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 177.084 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 90.19 0.69 76.75 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 -178.17 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -118.88 169.15 10.11 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.826 0.346 . . . . 0.0 111.22 -179.675 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 92.1 mt -82.43 141.95 32.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.187 177.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -122.87 93.27 48.53 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.215 179.367 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -79.7 143.37 16.7 Favored 'Trans proline' 0 N--CA 1.459 -0.549 0 C-N-CA 121.631 1.554 . . . . 0.0 111.168 -177.549 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 67.9 t -132.39 120.8 44.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.21 172.65 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 95.6 m95 -86.35 125.53 33.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.191 178.115 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 93.4 t -133.59 128.71 54.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.226 177.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 90.4 mttt -108.25 148.2 30.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.206 178.036 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 . . . . . 0 C--O 1.2 -1.54 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.176 179.811 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 96.4 mttt . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.835 0.35 . . . . 0.0 111.181 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -94.72 152.93 18.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.2 -179.463 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 62.4 tp -105.41 120.29 41.23 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.239 174.202 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 91.2 t -119.02 135.59 58.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.2 -178.241 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -128.79 142.02 51.12 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.136 175.283 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 83.8 t -121.82 118.16 54.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.232 176.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 4.1 tp-100 -116.53 107.53 14.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.228 -175.513 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 63.1 t-20 -80.22 106.03 11.93 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.192 179.505 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 92.9 mt -106.08 11.27 31.63 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.15 179.616 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 33.1 p -83.98 179.76 7.45 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.242 -178.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -104.56 23.83 30.35 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 111.166 -0.774 . . . . 0.0 111.166 176.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 27.1 t -150.14 179.74 7.84 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.886 0.374 . . . . 0.0 111.157 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -75.57 138.47 41.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.233 -178.288 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 59.2 tp -92.15 119.1 31.48 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.181 175.604 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' THR . . . . . 0.437 ' HB ' ' HB2' ' A' ' 174' ' ' PHE . 96.5 m -123.56 125.84 45.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.131 174.492 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 85.0 mt -126.4 135.36 51.33 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.247 179.408 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 60.9 mttm -123.38 151.75 42.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.182 177.489 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 8.7 t -63.07 136.53 57.85 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.159 177.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -75.05 -6.67 50.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.181 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -89.6 -0.51 57.57 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.235 178.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -178.23 -121.57 0.71 Allowed Glycine 0 CA--C 1.524 0.626 0 N-CA-C 111.176 -0.769 . . . . 0.0 111.176 178.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -145.79 11.56 1.25 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.864 0.364 . . . . 0.0 111.216 179.356 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 89.0 m -61.5 129.9 43.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.088 -177.851 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -64.03 129.71 41.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.22 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 89.7 t -113.82 -51.31 5.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.148 173.001 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 95.9 t -124.25 137.03 58.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.095 173.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 62.6 pttt -164.81 161.3 20.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.18 174.655 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 75.3 m-20 57.89 42.95 22.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.397 -179.688 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 92.6 t -112.4 115.62 50.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.185 176.011 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -84.87 -173.31 49.81 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.212 -0.755 . . . . 0.0 111.212 -179.055 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo -72.4 155.98 55.0 Favored 'Trans proline' 0 N--CA 1.457 -0.664 0 C-N-CA 121.791 1.661 . . . . 0.0 111.176 -179.06 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 55.1 52.02 12.4 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.187 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 41.7 t -137.88 126.28 23.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.193 -178.042 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 56.0 p-80 -161.59 173.22 15.08 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.365 -176.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 175.57 170.41 38.4 Favored Glycine 0 CA--C 1.522 0.478 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 177.352 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -73.43 146.29 45.14 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.842 0.353 . . . . 0.0 111.253 -178.541 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 90.9 mmt-85 -132.7 121.33 22.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.253 172.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -86.36 103.1 14.62 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.254 177.652 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 80.2 mt -131.28 134.22 61.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.218 -173.105 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 92.7 m-20 -68.25 153.07 96.04 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.22 178.6 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo -51.26 118.4 4.29 Favored 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 121.749 1.633 . . . . 0.0 111.205 176.345 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.425 ' H ' ' HB2' ' A' ' 188' ' ' LEU . 9.1 p -167.77 149.2 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.15 -177.034 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 168' ' ' LYS . . . . . 0.403 ' HA ' ' HA ' ' A' ' 187' ' ' THR . 40.7 ttmt -72.06 115.59 11.46 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.273 173.235 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 99.2 t -100.08 119.9 48.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.199 -177.577 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 62.2 t-20 -134.2 100.97 4.86 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.175 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 76.7 mt -114.39 152.63 31.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.127 -177.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -90.42 142.73 27.44 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.282 175.11 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 60.9 tp -97.58 117.19 31.31 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.131 -170.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 174' ' ' PHE . . . . . 0.437 ' HB2' ' HB ' ' A' ' 140' ' ' THR . 82.1 m-85 -116.77 137.81 51.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.261 177.467 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -91.72 97.71 11.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.184 166.407 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 69.26 -83.51 0.25 Allowed Glycine 0 CA--C 1.522 0.49 0 N-CA-C 111.177 -0.769 . . . . 0.0 111.177 -171.475 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 93.6 p -135.08 -1.26 2.67 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.849 0.357 . . . . 0.0 111.22 177.516 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -103.63 117.44 34.4 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.258 -177.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -61.86 128.74 37.63 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.19 -176.691 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 92.2 t -96.45 -51.06 11.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.153 174.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 17.9 t -164.51 -157.52 0.37 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.165 -179.159 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 58.1 m-20 -125.27 144.08 50.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.185 172.376 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 94.0 mt -83.13 144.16 30.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.124 -178.138 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 184' ' ' LYS . . . . . 0.419 ' HA ' ' HD3' ' A' ' 185' ' ' PRO . 88.1 tttt -65.08 129.91 94.64 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.187 179.254 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 185' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 184' ' ' LYS . 75.9 Cg_exo -55.25 124.3 15.94 Favored 'Trans proline' 0 N--CA 1.459 -0.542 0 C-N-CA 121.666 1.577 . . . . 0.0 111.129 175.736 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 96.0 t -123.52 124.94 70.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.23 175.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 187' ' ' THR . . . . . 0.403 ' HA ' ' HA ' ' A' ' 168' ' ' LYS . 94.9 m -85.77 122.32 29.68 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.238 178.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . 0.425 ' HB2' ' H ' ' A' ' 167' ' ' VAL . 74.0 mt -85.55 156.08 20.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.061 178.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -150.55 153.09 35.15 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.206 -179.792 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 41.3 ptt180 -57.83 128.37 36.73 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.228 -175.566 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 91.96 -13.52 66.69 Favored Glycine 0 CA--C 1.523 0.556 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 173.033 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 72.6 mm-40 -87.38 149.22 24.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.838 0.351 . . . . 0.0 111.09 -176.08 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 67.3 t -116.09 120.87 66.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.194 177.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 92.4 t -120.91 122.73 68.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.221 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 74.5 m -116.48 144.32 44.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.197 -177.585 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 66.1 tp -114.47 117.01 29.77 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.149 175.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -106.62 99.42 8.99 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.221 -178.697 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . 0.407 ' HA ' ' HA ' ' A' ' 207' ' ' PRO . 90.3 t -83.42 115.94 26.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.301 -0.408 . . . . 0.0 111.188 -174.319 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 28.4 p -110.33 174.3 5.92 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.199 179.332 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -149.71 144.69 12.32 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 111.166 -0.774 . . . . 0.0 111.166 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.7 t -160.75 120.37 2.7 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.779 0.323 . . . . 0.0 111.265 177.137 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 75.31 14.05 82.27 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 111.267 -0.733 . . . . 0.0 111.267 178.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 95.92 -5.86 66.57 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 -178.418 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -103.5 134.6 46.58 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.826 0.346 . . . . 0.0 111.161 -179.261 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 99.4 mt -83.36 150.8 25.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.227 179.318 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -150.09 73.77 9.28 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.203 177.028 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 207' ' ' PRO . . . . . 0.407 ' HA ' ' HA ' ' A' ' 198' ' ' VAL . 46.2 Cg_exo -63.4 147.71 93.24 Favored 'Trans proline' 0 N--CA 1.456 -0.704 0 C-N-CA 121.729 1.619 . . . . 0.0 111.248 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 87.3 t -118.91 127.72 75.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.22 176.674 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 97.1 m95 -84.15 128.5 34.6 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.253 175.113 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 89.7 t -125.96 122.82 62.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.16 178.144 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -106.41 127.78 53.55 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.141 178.104 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 84.8 mtt85 . . . . . 0 C--O 1.2 -1.501 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.257 179.545 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 94.4 mttt . . . . . 0 N--CA 1.457 -0.096 0 CA-C-O 120.752 0.311 . . . . 0.0 111.193 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -74.02 147.88 42.5 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.185 179.263 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 88.7 mt -114.85 149.82 36.5 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.235 175.225 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 86.3 t -125.77 128.34 72.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.28 178.655 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . 0.617 HH21 ' CE1' ' A' ' 159' ' ' HIS . 81.9 mtp180 -117.7 157.72 25.99 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.235 178.281 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.428 ' O ' ' HA ' ' A' ' 159' ' ' HIS . 14.2 p -130.95 142.42 43.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.147 175.251 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 66.7 tp60 -148.21 109.4 4.32 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.183 179.374 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . 0.461 ' HA ' ' HB ' ' A' ' 198' ' ' VAL . 64.2 t-20 -86.18 108.97 18.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.166 -175.343 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 87.8 mt -90.99 -4.08 56.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.263 179.564 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 27.4 p -102.24 -178.3 3.66 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.192 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -103.66 8.54 51.37 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 111.201 -0.76 . . . . 0.0 111.201 176.566 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 94.9 p -90.39 160.01 16.29 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.816 0.341 . . . . 0.0 111.166 -175.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 39.4 ttpt -107.95 119.29 39.03 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.275 176.177 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 52.0 mt -131.69 150.56 52.11 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.228 -176.776 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 60.1 m -106.68 129.28 54.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.215 174.253 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 63.0 tp -95.48 121.29 37.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.225 -178.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -145.07 145.31 31.39 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.217 -179.535 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 81.1 p -68.8 150.6 47.65 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.223 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -60.62 121.81 13.14 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.209 -178.862 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 79.5 m-20 56.19 36.18 27.0 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.286 -179.174 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -86.45 -179.81 49.35 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 111.171 -0.772 . . . . 0.0 111.171 177.059 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -113.4 -23.75 9.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.774 0.321 . . . . 0.0 111.181 -179.483 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 89.9 m -128.87 136.88 51.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.175 -175.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 76.5 m-20 -65.2 145.82 55.76 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.239 178.48 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . 0.474 HG12 HG23 ' A' ' 151' ' ' VAL . 91.7 t -87.51 -57.04 4.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.194 178.819 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.474 HG23 HG12 ' A' ' 150' ' ' VAL . 46.9 t -130.71 124.33 56.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.178 169.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -94.38 138.06 32.78 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.167 -176.16 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 72.4 m-20 53.84 62.86 2.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.159 171.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 96.7 t -74.26 106.21 3.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.228 176.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -90.09 179.62 43.96 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 -176.564 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -57.39 127.7 26.53 Favored 'Trans proline' 0 C--N 1.327 -0.585 0 C-N-CA 121.702 1.601 . . . . 0.0 111.209 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 94.7 mm-40 66.2 19.32 11.08 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.218 175.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 35.8 t -73.37 145.74 45.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.235 176.772 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 159' ' ' HIS . . . . . 0.617 ' CE1' HH21 ' A' ' 130' ' ' ARG . 82.5 t60 -149.74 143.89 25.72 Favored 'General case' 0 CA--C 1.509 -0.607 0 CA-C-O 122.115 0.959 . . . . 0.0 111.029 178.613 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -158.84 157.43 28.43 Favored Glycine 0 CA--C 1.524 0.602 0 CA-C-N 114.868 -1.06 . . . . 0.0 111.224 -179.425 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 75.8 m-20 -113.01 147.37 37.33 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.849 0.357 . . . . 0.0 111.174 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 90.9 mmt-85 -138.85 148.09 43.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.178 178.314 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -110.06 134.83 51.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.184 173.731 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 20.2 tt -147.77 149.43 15.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.194 -175.082 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 97.0 m-20 -50.21 142.99 13.5 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.202 174.569 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -78.82 65.21 8.78 Favored 'Trans proline' 0 N--CA 1.457 -0.643 0 C-N-CA 121.764 1.642 . . . . 0.0 111.201 -173.615 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 34.3 m -133.42 160.78 42.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.23 176.343 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -65.91 108.44 2.17 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.061 -179.334 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 93.0 t -121.35 125.35 73.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.289 178.037 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 83.9 m-20 -99.38 141.81 31.68 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.162 177.322 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 5.4 mp -124.67 172.6 9.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.167 -174.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -148.11 166.06 28.96 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.207 -178.296 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 67.4 mt -94.69 135.43 36.17 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.251 177.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 -128.91 156.57 43.5 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.204 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 67.9 t0 -144.43 95.42 2.71 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.237 175.363 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 79.88 -106.38 2.44 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 111.199 -0.76 . . . . 0.0 111.199 179.827 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 88.1 p -115.52 7.87 15.02 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.797 0.332 . . . . 0.0 111.184 178.638 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -125.71 130.34 51.32 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.227 -178.309 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 38.9 ttpt -71.23 135.2 47.39 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.216 176.434 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 70.4 t -83.2 -55.57 7.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.152 -179.239 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 43.6 t -173.9 142.13 0.85 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.223 -176.038 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -69.09 146.84 52.24 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.223 176.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 94.6 mt -95.3 158.95 15.23 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.196 176.307 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -57.74 130.37 82.02 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.161 177.647 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_exo -52.85 140.1 58.42 Favored 'Trans proline' 0 N--CA 1.457 -0.661 0 C-N-CA 121.783 1.655 . . . . 0.0 111.17 177.504 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 8.2 p -143.49 136.24 24.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.119 -175.387 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 97.7 m -95.92 131.14 42.58 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.237 176.335 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 59.7 mt -100.04 96.03 7.25 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.171 -176.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -70.14 142.65 52.51 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.226 -177.448 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 80.6 ttt180 -66.55 125.9 27.19 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.241 -176.005 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 93.0 -10.52 73.71 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 173.549 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -103.22 178.93 4.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.788 0.328 . . . . 0.0 111.144 -178.32 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 7.4 p -135.09 139.6 46.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.148 -177.308 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 33.3 m -113.1 156.55 14.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.158 172.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 49.5 t -134.8 129.23 34.24 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.245 179.46 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 66.0 tp -89.45 115.29 26.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.237 177.133 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -101.47 104.34 15.26 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.194 176.571 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . 0.461 ' HB ' ' HA ' ' A' ' 133' ' ' ASN . 84.8 t -79.05 114.2 19.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.207 -173.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 15.3 t -143.84 -160.85 1.17 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.227 179.361 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 167.33 -171.61 42.05 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 44.3 t -162.35 129.21 3.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.732 0.301 . . . . 0.0 111.191 -179.452 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 75.57 15.9 80.96 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 111.157 -0.777 . . . . 0.0 111.157 177.089 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 99.17 -13.91 61.51 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 111.128 -0.789 . . . . 0.0 111.128 -178.327 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -88.7 123.69 33.39 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.777 0.322 . . . . 0.0 111.136 -179.377 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 96.8 mt -74.28 138.33 43.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.141 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -152.8 70.39 7.19 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.246 173.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -58.31 148.26 80.36 Favored 'Trans proline' 0 N--CA 1.458 -0.575 0 C-N-CA 121.783 1.655 . . . . 0.0 111.201 176.363 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 85.6 t -119.62 129.16 75.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.216 -177.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 92.0 m95 -83.59 128.34 34.44 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.229 172.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 86.7 t -121.41 124.87 72.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.2 175.743 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 28.1 ttpp -97.04 128.22 43.78 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.109 179.524 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 96.4 mtt-85 . . . . . 0 C--O 1.201 -1.484 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.236 -178.834 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 99.9 mttt . . . . . 0 CA--C 1.523 -0.069 0 CA-C-O 120.876 0.37 . . . . 0.0 111.138 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -143.36 173.11 11.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.197 174.807 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 93.7 mt -127.45 142.43 51.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.136 177.059 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 10.0 p -125.05 133.76 68.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.155 175.143 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 44.3 ttm180 -135.6 146.53 48.02 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.109 -177.163 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 98.8 t -125.85 127.24 71.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.167 176.764 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 62.9 tp60 -95.28 128.18 41.92 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.199 -179.688 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 57.5 t-20 -87.17 110.42 20.14 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.237 173.863 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 94.3 mt -101.76 7.91 41.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.123 177.119 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 30.5 t -101.35 158.82 15.77 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.178 178.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -79.85 -9.73 86.44 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.274 -0.731 . . . . 0.0 111.274 172.785 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 87.5 p -91.31 169.96 10.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.854 0.359 . . . . 0.0 111.109 173.321 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -89.1 156.08 19.04 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.197 177.536 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 84.7 mt -109.98 152.75 25.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.236 178.102 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 49.7 p -125.47 78.5 1.73 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.22 177.052 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 38.1 tp -70.92 120.88 17.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.116 -170.041 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -142.99 153.44 43.0 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.236 -178.016 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 85.6 m -57.3 125.31 22.23 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.244 174.117 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -59.07 118.3 5.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.233 -177.426 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 57.34 29.85 17.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.172 -179.566 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -113.38 -171.17 17.75 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.229 -0.748 . . . . 0.0 111.229 177.291 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -115.76 -4.19 12.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.829 0.347 . . . . 0.0 111.181 177.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 99.8 m -98.43 117.15 32.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.139 -175.529 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 81.2 m-20 -74.49 146.56 42.63 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.204 172.611 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . 0.494 HG12 HG23 ' A' ' 151' ' ' VAL . 60.1 t -108.95 -64.89 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.146 -175.192 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.494 HG23 HG12 ' A' ' 150' ' ' VAL . 99.4 t -141.47 120.28 10.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.204 172.06 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 54.2 mtmt -113.38 160.11 18.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.179 -178.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 32.1 t0 62.08 47.77 5.5 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.191 178.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 93.9 t -78.25 114.62 19.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.184 175.288 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -66.7 156.59 51.23 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 -171.549 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -55.02 132.79 54.4 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 121.797 1.665 . . . . 0.0 111.103 177.361 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 92.9 mm-40 57.08 33.09 22.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.162 179.506 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 19.2 t -119.06 -161.49 0.85 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.182 175.572 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 34.3 p80 -160.36 170.11 21.73 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.259 179.481 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -156.66 159.88 29.86 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 176.43 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 20.9 p30 -149.32 175.86 11.06 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.793 0.33 . . . . 0.0 111.237 -175.293 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 58.1 ttm-85 -156.05 140.69 16.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.208 -178.22 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -71.26 128.85 37.29 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.307 171.327 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 19.9 tt -159.06 153.93 5.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.147 -172.054 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 95.6 m-20 -62.87 154.08 77.38 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.181 176.433 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -75.16 71.36 5.13 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 121.725 1.617 . . . . 0.0 111.238 -179.55 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 33.4 m -126.26 179.83 3.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.181 -177.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -76.37 121.08 22.5 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.179 173.732 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 76.9 t -114.18 121.05 65.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.178 -176.367 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 87.3 m-20 -96.36 119.06 34.16 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.196 177.418 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 77.3 mt -113.76 154.19 27.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.206 -174.234 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -158.39 162.54 37.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.267 179.22 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 68.0 mt -111.73 148.58 33.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.154 173.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 35.0 p90 -142.76 160.1 40.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.198 -174.122 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 67.7 t0 -131.39 91.36 3.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.128 174.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 79.49 -106.73 2.45 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 -177.837 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 95.1 p -106.29 -9.26 16.89 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.784 0.326 . . . . 0.0 111.168 177.012 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -104.29 117.71 34.88 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.159 -176.138 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 39.0 ttpt -66.59 136.53 55.73 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.249 177.426 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 72.2 t -86.04 -56.29 5.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.251 -178.441 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 43.5 t -171.36 143.63 1.86 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.19 -176.342 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -72.48 150.33 43.37 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.217 176.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 82.4 mt -106.16 159.33 16.17 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.237 175.32 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 56.4 tptt -55.58 116.29 11.58 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.262 -179.802 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 77.1 Cg_exo -56.38 141.95 88.93 Favored 'Trans proline' 0 N--CA 1.459 -0.514 0 C-N-CA 121.602 1.535 . . . . 0.0 111.155 178.26 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 73.3 t -121.32 127.39 75.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.202 -177.415 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 97.1 m -95.33 116.67 29.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.171 170.194 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 83.3 mt -90.84 158.25 16.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.199 -175.539 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -136.53 156.36 48.69 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.198 -179.492 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 75.3 mtp180 -62.51 124.37 20.76 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.157 -174.453 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 78.7 13.32 83.28 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 111.194 -0.762 . . . . 0.0 111.194 173.172 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 92.5 mt-10 -121.29 158.34 28.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.769 0.318 . . . . 0.0 111.149 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 7.3 p -131.91 139.22 50.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.216 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 84.6 t -112.41 136.43 48.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.212 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 44.6 t -114.72 110.85 20.37 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.214 172.223 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 52.7 tp -90.82 110.57 21.78 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.157 -178.805 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 197' ' ' TYR . . . . . 0.409 ' HB2' ' HB ' ' A' ' 208' ' ' VAL . 85.3 m-85 -86.75 96.77 10.28 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.192 -175.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 97.3 t -86.76 121.58 37.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.178 -174.469 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 14.8 t -153.19 -169.11 3.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.207 178.377 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 144.54 -162.77 27.96 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 111.204 -0.758 . . . . 0.0 111.204 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.3 t -171.5 143.65 1.81 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.833 0.349 . . . . 0.0 111.148 -177.683 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 76.48 16.3 80.83 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 111.192 -0.763 . . . . 0.0 111.192 174.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 94.96 -6.52 69.51 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 111.114 -0.795 . . . . 0.0 111.114 -178.863 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -98.73 115.72 29.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.766 0.317 . . . . 0.0 111.102 179.55 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 91.5 mt -98.72 154.25 18.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.086 -177.291 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -150.74 73.96 8.72 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.208 176.449 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_exo -58.05 139.02 88.92 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 121.656 1.571 . . . . 0.0 111.161 178.653 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 208' ' ' VAL . . . . . 0.409 ' HB ' ' HB2' ' A' ' 197' ' ' TYR . 57.5 t -104.73 114.29 43.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.22 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 209' ' ' TRP . . . . . 0.435 ' CD1' ' C ' ' A' ' 209' ' ' TRP . 7.3 t90 -77.76 96.97 5.04 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.199 -178.082 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 98.3 t -106.23 115.41 47.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.219 175.277 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 29.2 ttpp -102.38 132.53 48.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.206 178.56 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 83.0 mtt85 . . . . . 0 C--O 1.202 -1.412 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.174 179.632 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 62.9 pttt . . . . . 0 C--O 1.232 0.183 0 CA-C-O 120.722 0.296 . . . . 0.0 111.271 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -142.13 167.9 21.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.201 -174.792 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 69.3 mt -120.86 154.73 35.42 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.129 176.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 13.1 p -141.39 137.0 32.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.296 177.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -125.82 149.24 48.78 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.166 172.732 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 87.4 t -128.71 120.12 51.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.128 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 64.7 tt0 -110.41 138.57 46.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.239 -174.366 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 64.7 t-20 -88.72 109.62 20.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.223 177.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 7.8 mp -105.93 34.94 3.08 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.284 178.256 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 59.6 p -132.8 173.1 11.73 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.16 177.445 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -86.71 -12.63 68.75 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 175.295 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 95.9 p -88.47 167.02 13.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.888 0.375 . . . . 0.0 111.207 179.13 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -79.04 135.87 37.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.275 178.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 60.5 tp -107.85 131.41 54.52 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.293 -175.758 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 93.5 m -133.37 128.43 35.6 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.334 172.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 10.3 tt -142.9 132.64 23.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.107 -176.669 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -125.92 165.8 18.07 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.137 179.647 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 14.6 t -150.92 -170.37 3.64 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.211 175.406 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . 55.16 51.63 12.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.19 -175.386 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 75.7 m-20 62.05 27.68 16.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.16 -177.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 84.29 6.67 85.94 Favored Glycine 0 CA--C 1.52 0.367 0 N-CA-C 111.276 -0.73 . . . . 0.0 111.276 176.131 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -81.81 -32.59 31.21 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.805 0.336 . . . . 0.0 111.122 -177.606 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 82.6 m -99.77 120.04 39.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.183 -178.335 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 65.4 t0 -89.32 109.01 19.96 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.192 176.027 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 87.4 t -85.48 -58.0 3.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.202 -176.489 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 27.8 m -132.83 153.33 37.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.209 168.373 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 65.6 tttm -150.55 116.97 5.71 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.337 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 70.8 m-20 56.17 46.98 20.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.266 174.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 33.5 m -101.96 151.24 5.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.142 179.14 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -99.1 -168.98 30.62 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 -171.58 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_exo -58.52 136.97 77.69 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 121.651 1.568 . . . . 0.0 111.153 -178.244 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 96.0 mm-40 68.3 17.12 9.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.249 173.463 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 70.3 m -103.99 151.23 23.44 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.308 170.192 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 56.4 p-80 -152.79 161.56 42.41 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.212 -176.49 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -114.98 160.24 13.31 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 176.481 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 37.4 t0 -136.86 115.5 12.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.609 0.242 . . . . 0.0 111.276 -178.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 89.4 mmt-85 -127.15 144.24 51.08 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.275 -173.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -96.18 124.48 40.2 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.253 175.707 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 46.1 pt -126.15 164.24 26.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.235 -168.1 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 -84.32 160.73 56.42 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.165 177.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -79.02 57.17 6.34 Favored 'Trans proline' 0 N--CA 1.458 -0.604 0 C-N-CA 121.588 1.525 . . . . 0.0 111.148 -179.753 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 33.6 m -130.96 -179.14 3.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.165 -175.774 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -65.61 104.01 0.96 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.305 174.36 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 91.7 t -104.3 126.56 58.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.25 -178.626 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 37.7 t-20 -107.26 109.21 20.93 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.089 -178.32 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 65.9 mt -90.64 117.67 29.48 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.218 175.602 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -126.12 140.39 52.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.154 -175.055 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 96.3 mt -87.69 141.18 28.81 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.185 178.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -135.6 156.44 48.86 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.209 179.739 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 66.9 t0 -136.05 83.78 2.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.193 173.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 79.48 -105.67 2.31 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.224 -0.75 . . . . 0.0 111.224 -173.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 98.0 p -102.95 -6.02 22.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.789 0.328 . . . . 0.0 111.195 172.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -83.82 131.51 34.88 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.196 -176.571 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 89.1 tttt -86.65 126.32 34.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.151 170.569 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 97.3 t -103.02 -53.02 7.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.195 -171.016 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 47.2 t -146.7 149.06 32.7 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.122 -174.619 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 51.0 t0 -136.2 102.33 4.97 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.228 -175.76 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 94.8 mt -81.56 148.23 29.24 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.148 -177.315 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -62.22 131.48 93.6 Favored Pre-proline 0 C--N 1.327 -0.38 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.244 178.464 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 76.3 Cg_exo -55.05 133.08 56.12 Favored 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 121.611 1.54 . . . . 0.0 111.234 177.031 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 94.0 t -124.21 131.15 73.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.26 178.462 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 98.2 m -88.24 130.01 35.2 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.101 175.584 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 82.0 mt -113.05 153.91 27.38 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.217 -178.635 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -102.41 163.83 12.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.116 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 79.6 ttt180 -51.03 120.21 4.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.147 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 104.74 -16.27 47.67 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 169.387 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 64.7 mt-10 -73.64 136.78 43.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.781 0.324 . . . . 0.0 111.089 -177.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 61.8 t -125.78 123.31 64.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.277 179.148 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 79.2 t -103.44 135.03 42.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.27 -178.411 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 44.3 t -121.78 105.63 10.56 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.249 176.316 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 31.0 tp -81.49 124.16 29.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.215 -176.222 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -105.72 98.52 8.2 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.2 179.196 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 62.3 t -90.54 106.99 17.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.216 -176.398 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 44.5 p -105.22 174.77 5.74 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.089 -175.454 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 100.36 -138.26 13.75 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 111.406 -0.678 . . . . 0.0 111.406 176.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 42.1 t -163.88 127.18 2.61 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.823 0.345 . . . . 0.0 111.204 178.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . -54.07 139.15 37.74 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 -174.478 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -91.52 8.34 78.96 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 111.015 -0.834 . . . . 0.0 111.015 7.118 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -89.65 69.9 7.78 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.671 0.272 . . . . 0.0 111.076 -177.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 93.4 mt -97.69 156.81 16.38 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.246 -178.342 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -139.42 84.58 16.07 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.135 -176.444 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -57.61 129.42 33.65 Favored 'Trans proline' 0 N--CA 1.459 -0.55 0 C-N-CA 121.692 1.595 . . . . 0.0 111.139 176.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 77.2 t -109.65 115.67 50.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.217 173.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 38.6 t-105 -81.52 105.24 12.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.221 -174.666 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 94.8 t -117.58 119.92 63.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.154 177.063 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -100.31 134.22 43.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.215 178.436 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 40.3 mmt180 . . . . . 0 C--O 1.199 -1.576 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.218 -179.934 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 88.0 tttt . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.77 0.319 . . . . 0.0 111.116 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -150.23 143.63 25.09 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.248 172.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 59.0 tp -101.96 128.65 48.28 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.179 -177.613 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 33.1 m -125.48 152.01 31.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.136 174.452 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 41.7 ttm180 -140.85 124.2 16.7 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.208 178.617 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 57.3 t -105.39 121.33 57.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.257 -177.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 64.7 tp60 -107.76 127.01 53.31 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.173 -177.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 57.9 t-20 -85.63 105.34 16.13 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.153 178.357 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 98.3 mt -110.66 28.85 8.28 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.287 176.539 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 50.3 p -104.64 -175.69 2.87 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.222 -178.448 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -100.1 11.18 60.35 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 176.348 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 21.0 t -137.64 -167.46 2.14 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.802 0.334 . . . . 0.0 111.222 -178.388 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -102.63 142.91 33.02 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.125 178.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 93.8 mt -104.47 148.18 26.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.265 -177.265 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' THR . . . . . 0.423 ' HB ' ' HB2' ' A' ' 174' ' ' PHE . 97.2 m -139.26 128.35 23.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.18 169.352 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 79.9 mt -118.97 114.85 23.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.259 -179.243 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -127.24 133.63 50.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.198 179.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 79.4 p -71.83 156.81 38.88 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.134 -172.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -59.93 -30.02 68.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.238 -176.736 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -64.44 -31.65 72.94 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.208 179.625 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 78.18 17.39 78.24 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 -178.734 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -110.02 -27.31 9.27 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.758 0.313 . . . . 0.0 111.184 -178.029 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 69.1 p -130.36 169.7 15.12 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.262 -179.108 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 20.6 p30 -150.61 175.12 12.22 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.162 -178.633 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 88.1 t -129.25 -40.69 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.247 179.093 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 90.1 t -132.09 137.92 53.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.184 -178.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -135.95 107.83 7.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.201 178.085 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 75.5 m-20 51.5 51.31 17.03 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.243 173.459 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 76.6 t -100.57 127.66 53.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.236 179.194 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -88.84 177.66 44.96 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 111.224 -0.75 . . . . 0.0 111.224 -171.067 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -58.8 147.22 89.69 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 121.652 1.568 . . . . 0.0 111.199 -178.211 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 94.4 mm-40 68.98 17.06 8.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.233 176.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 68.1 m -124.87 161.53 26.36 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.168 171.644 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 33.8 p80 -146.41 170.14 17.43 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.206 -176.515 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -143.7 145.7 15.66 Favored Glycine 0 CA--C 1.523 0.571 0 N-CA-C 111.246 -0.742 . . . . 0.0 111.246 179.119 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -111.09 150.34 29.54 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.823 0.344 . . . . 0.0 111.168 -178.324 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 85.1 mmt-85 -143.6 143.6 31.56 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.16 175.433 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -99.53 112.29 24.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.211 170.066 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 76.8 mt -130.78 139.13 51.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.113 -171.183 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 95.3 m-20 -61.67 155.01 63.09 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.206 177.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -63.1 80.15 0.12 Allowed 'Trans proline' 0 N--CA 1.458 -0.595 0 C-N-CA 121.65 1.567 . . . . 0.0 111.173 -178.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 30.2 m -129.28 179.62 3.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.203 177.487 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -89.95 133.8 34.58 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.227 174.241 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 86.1 t -72.4 87.27 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.178 -176.7 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 62.9 t-20 -88.36 88.98 7.8 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.154 170.416 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 8.7 tt -145.18 140.66 28.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.231 -166.351 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -92.07 141.72 28.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.249 -177.07 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 62.6 tp -101.55 117.87 35.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.193 -172.662 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 174' ' ' PHE . . . . . 0.423 ' HB2' ' HB ' ' A' ' 140' ' ' THR . 70.5 m-85 -113.26 148.2 36.04 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.221 -178.524 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -105.69 94.18 5.06 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.196 167.146 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 77.38 -104.01 1.9 Allowed Glycine 0 CA--C 1.523 0.562 0 N-CA-C 111.232 -0.747 . . . . 0.0 111.232 -173.546 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 92.8 p -115.86 1.29 13.35 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.716 0.293 . . . . 0.0 111.166 172.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -104.64 116.96 32.97 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.306 -177.511 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -63.57 133.08 53.14 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.17 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 93.7 t -102.18 -53.3 7.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.206 176.614 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 19.2 t -163.99 -157.75 0.41 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.187 178.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -105.15 137.16 43.36 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.214 170.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 51.4 tp -74.73 128.75 36.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.252 -178.567 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -51.91 126.78 34.41 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.25 177.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -74.4 150.83 41.87 Favored 'Trans proline' 0 N--CA 1.458 -0.613 0 C-N-CA 121.647 1.565 . . . . 0.0 111.246 -176.516 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 14.5 p -147.42 143.79 19.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.177 176.349 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 92.1 m -81.0 124.58 29.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.168 -177.765 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 80.6 mt -93.78 158.75 15.51 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.218 177.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -159.85 146.02 15.89 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.202 -179.473 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 79.8 ttt180 -71.07 134.22 46.89 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.163 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 101.93 -12.13 57.56 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 111.184 -0.766 . . . . 0.0 111.184 -177.186 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -121.26 146.65 46.59 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.814 0.34 . . . . 0.0 111.168 179.324 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 96.9 t -114.46 123.36 70.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.244 178.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 76.7 t -109.85 114.12 46.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.206 -175.19 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 75.9 m -100.7 152.95 19.86 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.239 -178.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 64.8 tp -125.8 123.07 37.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.236 178.294 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -114.72 108.73 17.18 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.234 -179.543 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 65.5 t -109.43 124.19 65.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.122 -177.474 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 13.5 t -131.06 -174.29 3.34 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.148 -179.705 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -89.06 140.73 15.91 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 111.193 -0.763 . . . . 0.0 111.193 -177.615 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 37.3 t -146.38 86.87 1.7 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.798 0.332 . . . . 0.0 111.236 176.68 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 73.35 22.23 78.91 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 177.194 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 100.84 -12.5 59.26 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 111.231 -0.747 . . . . 0.0 111.231 -178.154 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -100.62 165.07 11.59 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.738 0.304 . . . . 0.0 111.239 178.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 96.5 mt -85.96 139.62 31.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.215 177.285 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -124.09 92.23 48.58 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.216 -179.385 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -76.26 138.75 20.43 Favored 'Trans proline' 0 N--CA 1.457 -0.672 0 C-N-CA 121.777 1.651 . . . . 0.0 111.244 -179.433 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 92.3 t -129.82 122.5 54.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.163 174.813 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 91.8 m95 -86.8 126.46 34.63 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.166 178.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 69.5 t -131.62 113.54 23.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.213 176.244 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 36.2 ttpt -103.51 136.0 44.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.225 -176.29 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 80.4 ttt180 . . . . . 0 C--O 1.198 -1.611 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.18 177.708 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 99.6 mttt . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.823 0.344 . . . . 0.0 111.205 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 99.8 mm-40 -100.38 3.79 43.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.185 179.734 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -124.32 163.2 22.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.212 178.328 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -91.95 143.2 26.73 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.218 174.464 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 68.3 tp -93.06 112.55 24.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.271 177.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 58.5 t -115.44 122.8 70.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.192 -178.434 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 41.8 ttm180 -112.1 144.91 40.69 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.225 177.434 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 92.3 t -114.35 119.94 62.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.205 169.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 66.6 tp60 -107.74 107.36 18.1 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.237 -177.611 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 65.0 t-20 -85.11 103.64 14.3 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.269 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 92.1 mt -102.61 17.44 23.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.228 -179.756 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 30.8 p -103.01 -179.33 3.92 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.215 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -104.82 29.25 12.1 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 111.258 -0.737 . . . . 0.0 111.258 174.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 46.1 t -144.8 147.42 32.86 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.808 0.337 . . . . 0.0 111.229 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -69.18 136.49 52.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.189 179.289 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.413 ' C ' HD12 ' A' ' 139' ' ' LEU . 4.4 pp -149.69 165.91 30.94 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.155 179.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 13.4 t -144.95 150.99 37.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.165 -177.223 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 64.7 tp -100.64 112.33 24.71 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.2 175.018 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 14.6 ptmm? -140.2 178.72 7.08 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.175 -176.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 57.0 p -83.22 164.9 19.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.167 179.011 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -108.45 4.82 24.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.214 177.079 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 75.7 m-20 -104.04 4.3 34.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.182 -177.539 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 174.55 -161.86 31.81 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.196 -0.762 . . . . 0.0 111.196 -178.729 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -93.81 -5.16 48.83 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.703 0.287 . . . . 0.0 111.146 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 89.4 m -62.0 130.06 43.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.239 178.31 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 42.3 p30 -93.13 177.57 6.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.215 -177.573 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 90.7 t -113.72 -56.27 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.172 177.609 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 99.0 t -117.46 133.41 64.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.247 178.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -100.77 166.38 10.9 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.173 -176.646 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 29.4 t0 64.32 47.38 3.15 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.204 177.118 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 69.7 t -118.27 121.17 66.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.235 174.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -124.59 -165.61 12.22 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 -177.463 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -75.77 141.01 24.03 Favored 'Trans proline' 0 N--CA 1.458 -0.563 0 C-N-CA 121.728 1.619 . . . . 0.0 111.182 179.247 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 49.64 50.54 18.1 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.217 175.66 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 17.4 t -161.48 -157.52 0.5 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.193 -178.434 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 57.2 p-80 -156.57 164.66 37.94 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.196 179.002 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -147.05 147.56 18.48 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 111.209 -0.756 . . . . 0.0 111.209 179.632 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 88.0 m-20 -112.55 155.6 24.08 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.739 0.304 . . . . 0.0 111.202 178.766 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 29.2 tpt180 -159.5 127.6 4.95 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.175 175.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -82.66 123.13 28.98 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.189 173.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 80.9 mt -127.89 137.97 56.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.189 -171.554 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 96.3 m-20 -50.45 147.26 8.04 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.236 178.76 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 81.1 Cg_endo -75.17 68.19 5.93 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 121.687 1.591 . . . . 0.0 111.226 -178.644 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 33.5 m -129.45 -178.12 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.203 -177.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -75.89 116.88 17.04 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.228 173.233 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 95.1 t -119.39 121.16 65.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.204 -175.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 55.1 t-20 -73.31 111.13 8.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.223 178.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 59.5 mt -95.82 142.92 27.52 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.244 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -161.88 143.76 11.29 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.189 175.662 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 65.5 tp -95.84 120.94 37.0 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.251 -178.404 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -118.77 140.44 49.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.257 175.406 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 39.6 t0 -111.46 94.45 4.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.188 171.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 79.22 -105.04 2.2 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 111.205 -0.758 . . . . 0.0 111.205 -173.104 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 88.9 p -115.75 6.06 14.33 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.771 0.32 . . . . 0.0 111.182 172.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -98.05 120.14 37.91 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.217 -176.116 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -66.47 126.89 30.28 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.241 173.433 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 88.0 t -105.65 -53.14 7.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.218 -177.049 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 44.8 t -147.88 140.31 24.46 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.204 -176.299 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -100.85 107.08 18.53 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.159 176.223 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 183' ' ' LEU . . . . . 0.538 ' O ' ' HB2' ' A' ' 184' ' ' LYS . 92.1 mt -89.69 -15.98 31.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.24 -171.793 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 184' ' ' LYS . . . . . 0.538 ' HB2' ' O ' ' A' ' 183' ' ' LEU . 74.9 mmtt 83.33 165.08 0.11 Allowed Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.209 167.113 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_exo -59.92 134.74 58.62 Favored 'Trans proline' 0 N--CA 1.458 -0.598 0 C-N-CA 121.689 1.593 . . . . 0.0 111.189 179.099 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 29.9 m -125.28 152.43 31.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.163 172.144 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 97.2 m -94.28 117.17 29.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.211 -179.197 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 93.4 mt -95.11 153.33 17.7 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.163 178.092 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -131.4 156.82 44.9 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.203 177.47 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 89.9 mtm180 -62.77 123.14 17.67 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.21 -176.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 87.47 -1.07 85.71 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 176.705 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -70.2 133.2 46.83 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.698 0.285 . . . . 0.0 111.231 -179.306 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 98.4 t -113.24 118.28 57.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.218 178.684 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 33.4 m -131.89 162.42 39.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.216 177.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 46.1 t -150.73 128.36 11.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.19 -179.111 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 60.9 tp -92.24 117.42 29.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.186 177.76 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -102.43 105.79 16.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.19 -179.737 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 54.2 t -105.22 112.79 40.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.21 -178.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 71.8 p -99.61 163.9 12.3 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.122 -178.519 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -116.39 135.24 11.92 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 111.239 -0.745 . . . . 0.0 111.239 179.022 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.2 t -160.69 120.06 2.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.746 0.308 . . . . 0.0 111.162 179.035 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 74.31 15.16 80.29 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 111.228 -0.749 . . . . 0.0 111.228 176.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 89.98 -0.84 79.68 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 111.179 -0.768 . . . . 0.0 111.179 -177.215 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -106.49 158.92 16.55 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.875 0.369 . . . . 0.0 111.157 -179.335 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 90.4 mt -107.02 141.51 38.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.146 179.522 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -125.33 92.81 46.37 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.268 179.191 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -74.6 127.36 10.91 Favored 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 121.712 1.608 . . . . 0.0 111.16 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 64.3 t -126.81 106.09 15.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.137 174.327 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 10.8 t90 -80.06 124.29 28.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.215 -177.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 98.7 t -120.63 132.56 69.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.167 -175.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -99.93 133.8 43.76 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.233 175.695 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 41.9 mmt180 . . . . . 0 C--O 1.2 -1.501 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.134 -179.484 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 99.7 mttt . . . . . 0 N--CA 1.457 -0.121 0 CA-C-O 120.713 0.292 . . . . 0.0 111.274 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 85.3 mt-30 -93.19 159.34 15.32 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.146 179.694 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 74.4 mmtt -128.5 154.91 45.63 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.229 178.675 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -143.91 177.78 8.31 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.241 177.015 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 95.4 mt -122.51 147.92 45.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.236 -177.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 12.2 p -134.35 142.84 39.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.205 178.365 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 38.5 ttm180 -117.53 99.31 6.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.203 179.017 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 96.2 t -84.69 121.37 36.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.169 -171.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 69.3 mm-40 -112.83 78.88 1.17 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.183 173.343 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 -89.33 157.41 18.2 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.197 -174.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 58.0 tp -62.97 -40.9 99.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.159 176.856 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 91.7 p -72.04 155.84 39.88 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.194 -175.085 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -113.84 55.4 0.52 Allowed Glycine 0 CA--C 1.524 0.599 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 -179.281 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 99.4 p -145.18 160.2 41.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.789 0.328 . . . . 0.0 111.213 -178.444 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -64.76 124.78 22.83 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.171 178.288 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 73.5 mt -111.06 157.83 19.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.19 -175.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 92.0 m -110.66 127.77 55.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.186 172.345 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 62.4 tp -95.6 123.66 39.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.153 176.387 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 96.3 mttt -123.61 158.52 31.29 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.181 178.314 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 14.5 t -125.18 -175.76 3.39 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.266 178.18 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' ALA . . . . . 0.432 ' O ' ' HB2' ' A' ' 145' ' ' ASP . . . 56.6 54.02 7.84 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.122 -173.284 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.432 ' HB2' ' O ' ' A' ' 144' ' ' ALA . 65.9 m-20 68.03 34.93 3.9 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.216 -178.533 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 72.84 43.64 41.16 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 111.187 -0.765 . . . . 0.0 111.187 174.064 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -118.6 -50.8 2.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.801 0.334 . . . . 0.0 111.136 -175.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 86.4 m -89.96 127.95 36.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.198 -173.207 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -65.67 114.91 5.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.273 -178.027 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 94.2 t -89.03 -59.99 2.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.253 174.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 14.5 p -156.97 143.71 10.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.199 -179.446 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -109.91 -179.28 3.75 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.168 178.62 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 74.6 m-20 59.09 41.57 20.38 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.127 178.044 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.439 ' O ' ' HD3' ' A' ' 156' ' ' PRO . 85.3 t -77.65 130.41 36.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.097 174.562 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -110.58 100.02 1.22 Allowed Glycine 0 CA--C 1.524 0.605 0 N-CA-C 111.151 -0.78 . . . . 0.0 111.151 -176.322 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . 0.439 ' HD3' ' O ' ' A' ' 154' ' ' VAL . 76.7 Cg_exo -56.02 139.53 85.08 Favored 'Trans proline' 0 N--CA 1.458 -0.608 0 C-N-CA 121.732 1.621 . . . . 0.0 111.205 177.483 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 54.06 45.66 27.08 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.179 174.213 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 83.6 p -116.36 -172.6 2.21 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.222 177.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -116.28 78.28 1.18 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.146 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 173.65 171.1 37.85 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 60.0 m-20 -115.26 168.28 10.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.84 0.352 . . . . 0.0 111.225 -177.335 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 91.4 mmt-85 -132.22 155.2 48.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.266 177.283 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -64.41 131.66 47.83 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.224 178.523 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 21.5 tt -141.89 143.14 27.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.253 176.211 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 91.9 m-20 -73.93 126.45 89.41 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.14 176.099 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -79.83 60.42 7.82 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 121.64 1.56 . . . . 0.0 111.142 -176.717 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 35.6 m -134.06 150.6 31.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.201 179.315 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -86.06 73.19 10.32 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.175 -177.247 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 84.2 t -131.1 142.92 42.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.22 -176.326 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 90.9 m-20 -49.73 119.94 3.88 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.242 -178.577 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 171' ' ' LEU . . . . . 0.458 ' HB2' ' HB2' ' A' ' 183' ' ' LEU . 65.2 mt -103.94 172.34 6.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.172 175.433 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -160.19 148.16 16.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.218 175.563 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 95.3 mt -107.23 135.73 48.25 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.134 176.197 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 81.5 m-85 -124.37 145.68 49.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.214 -177.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -115.03 87.51 2.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.207 171.573 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 78.98 -106.6 2.39 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 111.254 -0.738 . . . . 0.0 111.254 -177.143 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 95.5 p -105.9 -8.05 17.87 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.877 0.37 . . . . 0.0 111.213 175.581 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -103.4 117.18 33.88 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.2 -175.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 40.4 ttpt -64.03 130.99 46.23 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.254 176.688 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 69.4 t -82.55 -53.7 11.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.156 178.74 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 44.8 t -171.95 142.45 1.47 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.229 -178.067 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -80.27 145.35 32.22 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.281 174.155 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 183' ' ' LEU . . . . . 0.458 ' HB2' ' HB2' ' A' ' 171' ' ' LEU . 61.1 mt -110.06 159.02 17.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.185 -177.385 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 184' ' ' LYS . . . . . 0.404 ' HA ' ' HD3' ' A' ' 185' ' ' PRO . 99.6 mttt -85.57 151.6 56.06 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.203 176.055 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 185' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 184' ' ' LYS . 76.8 Cg_exo -55.86 142.78 83.59 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 121.748 1.632 . . . . 0.0 111.135 177.62 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 7.6 p -145.93 136.05 18.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.197 -179.731 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 98.7 m -98.75 129.94 45.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.176 -178.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 5.0 mp -125.21 150.49 46.95 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.218 177.123 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -90.35 169.24 11.25 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.271 169.637 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 -64.14 106.99 1.17 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.186 -179.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 92.62 7.24 63.34 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 111.186 -0.766 . . . . 0.0 111.186 178.311 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -76.06 137.86 40.45 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.797 0.332 . . . . 0.0 111.264 -179.817 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 61.3 t -104.27 116.6 48.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.161 178.179 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 97.6 t -120.86 134.66 63.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.149 177.408 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 76.6 m -95.94 153.37 17.8 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.187 -175.426 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 60.1 tp -126.32 117.49 23.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.201 178.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 91.7 m-85 -112.82 111.51 22.33 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.199 -179.281 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 68.8 t -100.02 113.57 35.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.2 -178.537 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 45.9 p -108.34 172.83 6.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.1 -175.433 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 88.81 -151.86 22.61 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 111.343 -0.703 . . . . 0.0 111.343 177.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 45.0 t -151.89 146.41 25.63 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.723 0.297 . . . . 0.0 111.256 179.699 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . -62.19 147.66 48.93 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.096 -0.802 . . . . 0.0 111.096 -176.209 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -98.58 35.26 4.73 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 5.655 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -122.6 68.89 0.96 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.797 0.332 . . . . 0.0 111.185 178.722 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 96.0 mt -88.6 148.0 24.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.194 -178.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 206' ' ' ALA . . . . . 0.409 ' HA ' ' HD2' ' A' ' 207' ' ' PRO . . . -123.51 95.73 44.67 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.183 -177.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 207' ' ' PRO . . . . . 0.409 ' HD2' ' HA ' ' A' ' 206' ' ' ALA . 72.9 Cg_endo -72.96 135.9 24.04 Favored 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 121.713 1.609 . . . . 0.0 111.217 178.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 93.5 t -127.11 122.71 60.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.247 178.681 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 98.6 m95 -85.36 127.26 34.29 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.241 177.512 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 96.1 t -125.01 128.68 73.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.29 -0.413 . . . . 0.0 111.232 -176.472 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -124.45 120.46 32.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.219 177.459 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 91.0 mmt-85 . . . . . 0 C--O 1.201 -1.472 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.24 -178.167 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 99.6 mttt . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.868 0.365 . . . . 0.0 111.18 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 99.8 mm-40 -97.92 -3.1 39.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.212 -179.657 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 96.0 mttt -130.11 175.19 9.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.285 -178.72 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -121.98 175.07 6.51 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.193 177.699 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 93.4 mt -119.07 139.33 51.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.256 -178.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 94.1 t -124.87 128.5 73.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.259 173.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -122.98 97.88 5.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.137 -177.4 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 61.7 t -98.06 127.8 50.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.143 -177.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 45.9 tt0 -109.45 126.81 53.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.17 178.328 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 51.5 t-20 -101.99 105.29 16.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.26 -177.092 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 83.5 mt -106.73 32.19 4.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.203 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 53.4 p -115.22 -168.22 1.36 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.225 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -108.11 18.08 34.1 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 177.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 47.4 t -150.38 148.77 29.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.858 0.361 . . . . 0.0 111.12 -179.428 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -76.77 163.55 26.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.19 -178.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 4.4 pp -149.31 165.51 31.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.126 -175.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 9.7 t -147.42 149.27 32.39 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.138 -177.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 83.9 mt -113.35 149.21 34.34 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.237 178.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -125.5 162.91 23.85 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.166 -176.038 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 66.9 p -71.28 153.19 42.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.246 178.607 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -68.06 -33.4 74.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.233 179.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -75.47 -19.74 59.23 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.249 178.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 80.14 28.81 48.17 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 111.286 -0.725 . . . . 0.0 111.286 -178.325 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -86.02 -42.07 14.29 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.777 0.322 . . . . 0.0 111.236 -175.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 14.7 t -156.18 -169.41 3.04 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.208 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -96.58 155.59 16.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.304 177.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . 0.459 HG12 HG23 ' A' ' 151' ' ' VAL . 68.8 t -109.29 -55.52 5.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.254 -178.415 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.459 HG23 HG12 ' A' ' 150' ' ' VAL . 84.2 t -123.82 133.6 68.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.191 178.802 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -137.0 143.92 43.02 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.215 -176.479 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 27.9 t0 56.25 63.53 1.97 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.182 175.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 93.8 t -76.21 125.31 35.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.245 178.874 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -70.52 146.69 42.6 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 179.544 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -73.74 138.75 26.85 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 121.697 1.598 . . . . 0.0 111.185 -178.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 50.47 48.6 22.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.216 177.128 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 46.5 t -162.24 141.28 9.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.194 179.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -78.35 88.67 4.37 Favored 'General case' 0 C--N 1.364 1.212 0 C-N-CA 119.654 -0.818 . . . . 0.0 111.034 -179.235 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -58.29 88.1 0.02 OUTLIER Glycine 0 CA--C 1.524 0.635 0 CA-C-N 115.378 -0.828 . . . . 0.0 111.178 177.175 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 13.9 t70 -69.4 132.83 46.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.782 0.325 . . . . 0.0 111.107 177.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 91.3 mmt-85 -133.62 140.34 47.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.212 -179.511 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 65.9 tt0 -84.56 103.95 14.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.296 173.804 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 48.3 mm -118.17 137.59 51.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.163 -169.547 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 95.3 m-20 -62.22 154.56 70.02 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.231 176.517 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -75.14 71.85 4.95 Favored 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 121.687 1.591 . . . . 0.0 111.14 -179.073 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 32.7 m -130.54 167.85 24.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.208 -177.237 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -79.58 130.72 35.64 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.178 174.032 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 33.9 m -122.01 149.93 25.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.166 -172.062 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 61.9 t-20 -97.85 110.2 22.81 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.152 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 86.9 mt -79.8 58.23 2.77 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.205 -176.358 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -104.48 141.1 36.98 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.121 178.06 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 76.1 mt -103.33 136.56 42.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.212 -176.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 84.6 m-85 -128.86 148.55 50.9 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.218 -177.453 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 53.2 t0 -129.77 96.25 4.18 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.213 175.349 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 79.34 -105.5 2.27 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 111.231 -0.748 . . . . 0.0 111.231 -176.136 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 88.8 p -115.41 6.68 14.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.869 0.366 . . . . 0.0 111.219 173.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -103.4 133.8 47.84 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.194 -176.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -81.41 128.03 33.41 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.145 172.086 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 93.5 t -103.37 -52.54 7.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.233 -172.459 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 47.6 t -143.34 149.26 37.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.19 -173.372 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 50.6 t0 -130.73 96.18 4.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.182 -177.512 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 54.8 tp -95.09 137.36 34.24 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.288 177.021 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -46.21 124.17 6.97 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.189 -172.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -54.91 146.96 54.17 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 121.65 1.567 . . . . 0.0 111.267 176.753 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 35.1 m -127.86 152.53 36.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.157 -177.588 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 96.8 m -93.08 118.04 30.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.194 178.652 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 69.4 tp -104.89 114.46 28.67 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.137 -178.352 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -94.93 154.9 16.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.269 -179.676 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 53.2 ptt85 -60.9 138.62 58.14 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.191 -178.496 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 95.72 -16.51 61.05 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 111.182 -0.767 . . . . 0.0 111.182 178.595 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 84.9 mt-10 -85.69 147.46 26.35 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.773 0.32 . . . . 0.0 111.203 -178.075 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 61.5 t -121.7 120.08 60.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.175 174.807 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 35.0 m -123.67 150.38 27.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.216 -177.662 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 82.8 m -122.89 158.64 29.92 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.172 177.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 51.7 tp -134.73 117.34 15.9 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.207 174.752 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -105.76 105.79 16.0 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.198 -176.192 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 97.7 t -103.78 125.56 58.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.242 -177.014 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 14.5 t -127.2 -170.42 2.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.239 178.333 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -108.34 135.67 12.99 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 111.229 -0.749 . . . . 0.0 111.229 -178.493 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.6 t -158.82 117.11 2.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.776 0.322 . . . . 0.0 111.215 178.03 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 75.11 14.88 81.45 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.151 -0.779 . . . . 0.0 111.151 177.488 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 89.44 2.03 77.19 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 -178.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -118.91 167.42 11.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.816 0.341 . . . . 0.0 111.21 -179.383 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 99.1 mt -82.21 140.08 33.91 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.217 178.019 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -124.63 95.08 43.44 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.142 -178.613 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -75.98 138.62 20.95 Favored 'Trans proline' 0 N--CA 1.458 -0.594 0 C-N-CA 121.738 1.625 . . . . 0.0 111.228 -178.717 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 65.0 t -127.8 106.62 15.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.186 173.349 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 24.8 t90 -79.97 127.29 32.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.185 -177.31 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 79.0 t -128.56 108.89 18.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.202 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -84.3 127.03 33.73 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.2 176.085 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 97.0 mtt-85 . . . . . 0 C--O 1.2 -1.529 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.209 -177.699 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 55.0 tptt . . . . . 0 C--O 1.23 0.053 0 CA-C-O 120.797 0.332 . . . . 0.0 111.178 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 -107.42 19.05 20.79 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.181 -176.012 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -145.16 122.89 11.86 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.132 178.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -104.76 163.97 12.11 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.238 178.112 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 64.1 tp -149.45 120.73 7.84 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.183 -178.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 89.0 t -117.03 131.34 70.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.192 -175.362 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 41.2 ttm180 -102.29 116.46 32.68 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.172 172.786 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 65.1 t -105.66 125.44 61.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.199 -175.39 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 38.1 tt0 -120.71 127.5 52.07 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.223 -177.052 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 48.1 t-20 -89.86 110.06 21.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.088 176.005 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 95.3 mt -111.61 14.84 21.28 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.11 177.338 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 38.1 p -85.65 -179.73 6.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.177 -179.211 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -98.03 14.11 62.91 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 111.192 -0.763 . . . . 0.0 111.192 177.447 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 18.7 t -136.55 -166.78 1.95 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.849 0.357 . . . . 0.0 111.086 -179.423 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 34.4 mmtp -95.46 136.97 35.16 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.256 -177.65 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.407 ' HB3' ' HB ' ' A' ' 154' ' ' VAL . 56.8 tp -102.03 131.72 48.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.293 -178.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 98.7 m -130.97 136.2 48.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.143 178.295 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 79.6 mt -125.4 142.87 51.26 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.218 172.606 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 60.6 mttm -118.78 163.84 16.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.166 -177.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 74.3 p -75.42 162.77 28.07 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.2 -177.347 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -65.17 -40.82 94.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.162 -175.23 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -78.62 -19.21 53.2 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.209 -178.261 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 80.55 21.93 63.25 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 111.2 -0.76 . . . . 0.0 111.2 -177.454 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -77.98 -36.47 48.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.728 0.299 . . . . 0.0 111.172 -178.305 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 14.7 t -154.95 -169.08 3.08 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.246 176.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -99.31 150.92 21.63 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.193 -179.766 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 69.3 t -89.03 -46.31 15.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.234 171.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 12.0 p -161.42 144.04 3.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.176 173.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 64.0 pttt -145.63 158.96 43.78 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.137 -175.303 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 28.4 t0 60.2 43.35 14.08 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.218 178.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.407 ' HB ' ' HB3' ' A' ' 139' ' ' LEU . 98.6 t -87.6 119.08 34.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.251 174.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -81.97 165.91 46.03 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 -175.14 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 63.5 Cg_exo -57.0 147.17 76.32 Favored 'Trans proline' 0 N--CA 1.458 -0.6 0 C-N-CA 121.691 1.594 . . . . 0.0 111.276 177.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 56.53 50.67 12.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.153 178.453 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 77.8 p -150.44 158.19 43.87 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.238 172.606 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 27.7 p-80 -151.56 167.45 28.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.169 -173.33 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -161.56 162.28 33.8 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 111.219 -0.752 . . . . 0.0 111.219 175.752 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -101.3 144.42 30.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.73 0.3 . . . . 0.0 111.293 -176.19 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 87.8 mmt-85 -138.91 130.04 26.74 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.17 176.137 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 91.1 mt-10 -84.69 144.91 28.24 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.207 179.26 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 19.5 tt -160.15 151.74 5.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.179 -179.051 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -73.62 142.03 80.26 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.221 175.527 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -78.75 60.37 7.65 Favored 'Trans proline' 0 N--CA 1.458 -0.59 0 C-N-CA 121.732 1.621 . . . . 0.0 111.2 -178.199 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 33.5 m -131.73 178.71 5.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.175 -178.038 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -69.76 112.52 6.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.169 176.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.404 HG23 ' HG ' ' A' ' 171' ' ' LEU . 35.6 m -129.31 164.35 32.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.211 -178.651 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 49.7 t30 -97.89 99.93 11.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.287 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 171' ' ' LEU . . . . . 0.404 ' HG ' HG23 ' A' ' 169' ' ' VAL . 82.3 mt -104.69 146.64 28.65 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.229 178.008 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -147.59 152.67 38.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.19 -177.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 51.8 tp -112.95 121.38 44.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.215 -173.132 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 72.8 m-85 -118.76 140.2 50.33 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.157 -176.558 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 64.2 t0 -104.33 98.2 8.03 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.122 170.674 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 77.59 -103.38 1.85 Allowed Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.129 -0.788 . . . . 0.0 111.129 -173.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 93.4 p -118.31 0.11 11.62 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.824 0.345 . . . . 0.0 111.134 175.21 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -108.38 130.14 55.23 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.244 -177.421 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -69.53 137.74 52.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.208 -179.052 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 88.4 t -99.67 -52.04 9.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.235 174.084 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 19.1 t -163.36 -158.77 0.48 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.205 -178.668 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 74.0 m-20 -114.0 160.8 18.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.203 177.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 93.9 mt -115.99 152.28 33.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.24 178.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -98.08 117.94 64.35 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.301 179.151 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_exo -55.07 130.45 40.8 Favored 'Trans proline' 0 N--CA 1.458 -0.583 0 C-N-CA 121.728 1.619 . . . . 0.0 111.128 177.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 99.2 t -121.73 127.4 75.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.227 175.006 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 71.1 p -84.53 166.61 17.08 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.174 -178.454 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . 0.418 ' C ' HD23 ' A' ' 188' ' ' LEU . 10.4 tt -137.07 123.65 20.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.226 -176.704 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -98.97 164.29 12.25 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.234 177.151 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 79.9 ttt180 -52.97 116.85 2.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.188 178.142 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 100.07 -14.49 59.9 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 178.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -87.56 143.75 27.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.801 0.334 . . . . 0.0 111.21 -179.285 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 193' ' ' VAL . . . . . 0.409 ' HB ' ' HB2' ' A' ' 212' ' ' ARG . 90.2 t -119.38 129.64 75.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.15 174.179 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 89.7 t -115.82 125.25 72.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.191 179.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 74.9 m -125.7 156.85 38.69 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.185 179.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 58.0 tp -130.03 118.5 21.67 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.205 175.451 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 88.7 m-85 -111.72 113.0 25.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.299 -178.444 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 80.5 t -107.86 120.27 58.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.177 -177.561 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 14.5 t -124.71 -169.45 1.98 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.203 -178.852 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -108.18 134.91 12.49 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 111.173 -0.771 . . . . 0.0 111.173 -177.691 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.6 t -160.22 118.32 2.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.787 0.327 . . . . 0.0 111.144 177.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 75.98 14.25 82.39 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 176.366 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 91.33 -0.5 75.03 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 -178.602 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -120.26 169.03 10.64 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.657 0.265 . . . . 0.0 111.229 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 82.6 mt -78.73 141.61 37.73 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.236 176.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -123.99 98.39 39.41 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.253 179.12 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -78.54 141.19 17.46 Favored 'Trans proline' 0 C--N 1.327 -0.587 0 C-N-CA 121.708 1.606 . . . . 0.0 111.212 -177.076 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 66.8 t -129.61 110.67 20.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.253 176.5 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 94.9 m95 -83.47 127.46 33.72 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.182 176.628 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 84.7 t -123.7 125.69 71.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.215 -177.421 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 56.2 mtmt -109.26 135.09 50.92 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.21 174.568 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 212' ' ' ARG . . . . . 0.409 ' HB2' ' HB ' ' A' ' 193' ' ' VAL . 82.2 mtp180 . . . . . 0 C--O 1.2 -1.543 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.142 179.053 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 99.6 mttt . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.785 0.326 . . . . 0.0 111.208 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 -111.19 21.37 16.41 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.223 -179.013 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 17.5 ptpt -161.49 166.92 26.43 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.186 -176.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -92.85 155.21 17.76 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.226 -176.096 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 60.8 tp -111.11 121.9 46.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.228 175.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 97.9 t -110.38 124.2 66.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.227 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 39.7 ttm180 -115.6 125.9 53.52 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.248 176.619 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 66.1 t -115.53 130.25 70.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.172 -175.857 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 37.1 tt0 -113.43 130.43 56.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.194 179.446 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 47.2 t30 -114.6 117.4 30.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.206 177.331 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 98.4 mt -102.77 -9.02 20.35 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.24 177.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 73.8 p -81.01 156.11 26.06 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.218 -178.318 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -83.14 -12.61 78.88 Favored Glycine 0 CA--C 1.523 0.571 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 -174.726 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 62.7 p -93.67 169.98 9.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.771 0.319 . . . . 0.0 111.251 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -73.97 135.22 43.17 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.214 -175.526 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 65.7 tp -108.23 121.15 44.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.218 174.24 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 97.7 m -130.4 130.69 44.67 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.175 174.49 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 82.9 mt -112.87 116.11 29.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.223 -178.427 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -119.57 156.24 30.71 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.217 177.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 74.9 p -84.02 154.78 23.08 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.166 -178.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -62.88 116.76 5.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.207 -176.412 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 55.21 33.89 21.54 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.164 177.12 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -106.7 -171.42 22.73 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 177.855 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -130.36 -6.59 4.25 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.832 0.349 . . . . 0.0 111.202 177.857 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 97.2 m -114.39 127.05 55.65 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.19 179.041 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 42.7 p30 -92.38 -179.37 5.2 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.245 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 26.9 m -128.89 -30.89 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.217 176.068 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 71.5 t -133.91 136.92 53.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.202 174.419 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -148.33 138.48 22.55 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.204 -176.64 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 45.3 t0 56.3 60.43 3.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.213 172.598 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 84.2 t -111.37 128.87 67.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.203 173.118 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -96.79 -164.42 32.77 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 -177.447 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -71.82 148.12 51.51 Favored 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 121.693 1.595 . . . . 0.0 111.176 -178.435 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 77.3 mt-30 52.8 50.6 17.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.204 178.565 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 44.9 t -142.06 148.91 39.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.199 -176.846 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 71.3 m80 -124.6 149.42 47.07 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.21 -176.053 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -134.6 132.58 6.38 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 174.696 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -106.83 135.1 48.95 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.797 0.332 . . . . 0.0 111.193 177.181 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 24.9 tpp180 -144.04 118.58 9.73 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.224 178.157 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -83.88 127.02 33.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.19 175.486 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 78.8 mt -130.85 137.32 56.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.172 -174.632 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . 0.435 ' HA ' ' HD3' ' A' ' 166' ' ' PRO . 96.3 m-20 -57.67 154.62 24.93 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.233 -178.12 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 166' ' ' PRO . . . . . 0.435 ' HD3' ' HA ' ' A' ' 165' ' ' ASN . 47.9 Cg_exo -65.37 78.24 0.24 Allowed 'Trans proline' 0 N--CA 1.458 -0.608 0 C-N-CA 121.675 1.583 . . . . 0.0 111.259 -177.609 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 32.1 m -136.56 167.61 23.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.253 177.154 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 89.0 tttt -77.89 116.48 18.43 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.206 173.166 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 63.9 t -113.15 121.11 64.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.162 -174.285 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 64.6 t-20 -105.12 99.84 9.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.217 176.719 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 94.4 mt -95.03 167.63 11.27 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.196 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -144.19 148.55 35.12 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.194 174.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 73.9 mt -80.1 117.71 21.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.176 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 78.4 m-85 -113.86 152.2 31.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.233 173.487 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -148.29 99.53 3.05 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.175 -178.486 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 80.37 -106.58 2.52 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 111.179 -0.768 . . . . 0.0 111.179 -179.323 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 86.0 p -117.83 8.78 12.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.728 0.299 . . . . 0.0 111.147 -179.468 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 65.3 pttt -128.01 164.43 22.37 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.207 -177.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -102.77 136.08 43.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.227 174.448 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 86.2 t -87.1 -55.32 6.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.155 -178.39 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 43.7 t -172.64 142.23 1.19 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.179 -175.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 93.1 m-20 -70.36 150.38 46.36 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.201 178.427 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 94.8 mt -103.09 153.45 20.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.178 177.387 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 184' ' ' LYS . . . . . 0.41 ' HA ' ' HD3' ' A' ' 185' ' ' PRO . 88.3 tttt -64.93 127.31 92.61 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.187 176.551 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 185' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 184' ' ' LYS . 73.5 Cg_exo -54.63 135.02 65.27 Favored 'Trans proline' 0 N--CA 1.458 -0.593 0 C-N-CA 121.696 1.597 . . . . 0.0 111.223 177.088 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 85.1 t -120.31 124.29 72.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.213 179.232 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 92.5 m -82.35 118.47 23.19 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.198 174.511 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 92.2 mt -96.76 143.46 27.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.208 -174.261 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -122.73 150.09 43.22 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.196 173.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 190' ' ' ARG . . . . . 0.452 ' HG3' ' O ' ' A' ' 190' ' ' ARG . 18.4 ptp180 -52.79 120.79 6.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.194 177.727 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 93.4 -6.54 75.02 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 175.793 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -74.94 136.51 41.37 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.805 0.336 . . . . 0.0 111.224 -178.134 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 99.1 t -109.08 118.0 55.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.163 177.367 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 85.6 t -121.98 131.55 72.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.143 -177.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 71.0 m -114.73 146.16 41.26 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.245 -179.045 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 65.8 tp -128.0 116.41 20.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.234 175.639 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -106.11 108.06 19.38 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.185 -177.449 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 85.1 t -109.73 121.98 63.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.169 -178.09 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 14.5 t -127.55 -171.02 2.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.192 177.803 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -107.26 135.17 12.6 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 111.184 -0.767 . . . . 0.0 111.184 -177.607 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.7 t -159.19 116.81 2.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.825 0.345 . . . . 0.0 111.222 177.676 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 75.2 14.91 81.46 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 177.084 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 90.19 0.69 76.75 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 -178.17 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -118.88 169.15 10.11 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.826 0.346 . . . . 0.0 111.22 -179.675 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 92.1 mt -82.43 141.95 32.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.187 177.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -122.87 93.27 48.53 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.215 179.367 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -79.7 143.37 16.7 Favored 'Trans proline' 0 N--CA 1.459 -0.549 0 C-N-CA 121.631 1.554 . . . . 0.0 111.168 -177.549 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 67.9 t -132.39 120.8 44.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.21 172.65 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 95.6 m95 -86.35 125.53 33.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.191 178.115 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 93.4 t -133.59 128.71 54.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.226 177.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 90.4 mttt -108.25 148.2 30.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.206 178.036 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 . . . . . 0 C--O 1.2 -1.54 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.176 179.811 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 99.7 mttt . . . . . 0 N--CA 1.456 -0.174 0 CA-C-O 120.725 0.298 . . . . 0.0 111.177 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -101.26 7.17 43.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.18 178.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -123.08 165.27 17.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.181 -179.552 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -94.72 152.93 18.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.2 -179.463 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 62.4 tp -105.41 120.29 41.23 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.239 174.202 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 91.2 t -119.02 135.59 58.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.2 -178.241 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -128.79 142.02 51.12 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.136 175.283 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 83.8 t -121.82 118.16 54.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.232 176.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 4.1 tp-100 -116.53 107.53 14.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.228 -175.513 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 63.1 t-20 -80.22 106.03 11.93 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.192 179.505 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 92.9 mt -106.08 11.27 31.63 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.15 179.616 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 33.1 p -83.98 179.76 7.45 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.242 -178.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -104.56 23.83 30.35 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 111.166 -0.774 . . . . 0.0 111.166 176.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 27.1 t -150.14 179.74 7.84 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.886 0.374 . . . . 0.0 111.157 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -75.57 138.47 41.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.233 -178.288 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 59.2 tp -92.15 119.1 31.48 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.181 175.604 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' THR . . . . . 0.437 ' HB ' ' HB2' ' A' ' 174' ' ' PHE . 96.5 m -123.56 125.84 45.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.131 174.492 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 85.0 mt -126.4 135.36 51.33 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.247 179.408 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 60.9 mttm -123.38 151.75 42.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.182 177.489 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 8.7 t -63.07 136.53 57.85 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.159 177.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -75.05 -6.67 50.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.181 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -89.6 -0.51 57.57 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.235 178.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -178.23 -121.57 0.71 Allowed Glycine 0 CA--C 1.524 0.626 0 N-CA-C 111.176 -0.769 . . . . 0.0 111.176 178.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -145.79 11.56 1.25 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.864 0.364 . . . . 0.0 111.216 179.356 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 89.0 m -61.5 129.9 43.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.088 -177.851 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -64.03 129.71 41.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.22 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 89.7 t -113.82 -51.31 5.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.148 173.001 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 95.9 t -124.25 137.03 58.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.095 173.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 62.6 pttt -164.81 161.3 20.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.18 174.655 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 75.3 m-20 57.89 42.95 22.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.397 -179.688 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 92.6 t -112.4 115.62 50.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.185 176.011 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -84.87 -173.31 49.81 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.212 -0.755 . . . . 0.0 111.212 -179.055 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo -72.4 155.98 55.0 Favored 'Trans proline' 0 N--CA 1.457 -0.664 0 C-N-CA 121.791 1.661 . . . . 0.0 111.176 -179.06 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 55.1 52.02 12.4 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.187 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 41.7 t -137.88 126.28 23.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.193 -178.042 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 56.0 p-80 -161.59 173.22 15.08 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.365 -176.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 175.57 170.41 38.4 Favored Glycine 0 CA--C 1.522 0.478 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 177.352 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -73.43 146.29 45.14 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.842 0.353 . . . . 0.0 111.253 -178.541 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 90.9 mmt-85 -132.7 121.33 22.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.253 172.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -86.36 103.1 14.62 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.254 177.652 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 80.2 mt -131.28 134.22 61.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.218 -173.105 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 92.7 m-20 -68.25 153.07 96.04 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.22 178.6 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo -51.26 118.4 4.29 Favored 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 121.749 1.633 . . . . 0.0 111.205 176.345 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.425 ' H ' ' HB2' ' A' ' 188' ' ' LEU . 9.1 p -167.77 149.2 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.15 -177.034 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 168' ' ' LYS . . . . . 0.403 ' HA ' ' HA ' ' A' ' 187' ' ' THR . 40.7 ttmt -72.06 115.59 11.46 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.273 173.235 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 99.2 t -100.08 119.9 48.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.199 -177.577 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 62.2 t-20 -134.2 100.97 4.86 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.175 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 76.7 mt -114.39 152.63 31.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.127 -177.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -90.42 142.73 27.44 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.282 175.11 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 60.9 tp -97.58 117.19 31.31 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.131 -170.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 174' ' ' PHE . . . . . 0.437 ' HB2' ' HB ' ' A' ' 140' ' ' THR . 82.1 m-85 -116.77 137.81 51.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.261 177.467 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -91.72 97.71 11.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.184 166.407 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 69.26 -83.51 0.25 Allowed Glycine 0 CA--C 1.522 0.49 0 N-CA-C 111.177 -0.769 . . . . 0.0 111.177 -171.475 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 93.6 p -135.08 -1.26 2.67 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.849 0.357 . . . . 0.0 111.22 177.516 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -103.63 117.44 34.4 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.258 -177.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -61.86 128.74 37.63 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.19 -176.691 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 92.2 t -96.45 -51.06 11.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.153 174.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 17.9 t -164.51 -157.52 0.37 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.165 -179.159 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 58.1 m-20 -125.27 144.08 50.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.185 172.376 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 94.0 mt -83.13 144.16 30.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.124 -178.138 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 184' ' ' LYS . . . . . 0.419 ' HA ' ' HD3' ' A' ' 185' ' ' PRO . 88.1 tttt -65.08 129.91 94.64 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.187 179.254 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 185' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 184' ' ' LYS . 75.9 Cg_exo -55.25 124.3 15.94 Favored 'Trans proline' 0 N--CA 1.459 -0.542 0 C-N-CA 121.666 1.577 . . . . 0.0 111.129 175.736 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 96.0 t -123.52 124.94 70.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.23 175.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 187' ' ' THR . . . . . 0.403 ' HA ' ' HA ' ' A' ' 168' ' ' LYS . 94.9 m -85.77 122.32 29.68 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.238 178.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . 0.425 ' HB2' ' H ' ' A' ' 167' ' ' VAL . 74.0 mt -85.55 156.08 20.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.061 178.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -150.55 153.09 35.15 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.206 -179.792 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 41.3 ptt180 -57.83 128.37 36.73 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.228 -175.566 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 91.96 -13.52 66.69 Favored Glycine 0 CA--C 1.523 0.556 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 173.033 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 72.6 mm-40 -87.38 149.22 24.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.838 0.351 . . . . 0.0 111.09 -176.08 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 67.3 t -116.09 120.87 66.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.194 177.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 92.4 t -120.91 122.73 68.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.221 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 74.5 m -116.48 144.32 44.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.197 -177.585 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 66.1 tp -114.47 117.01 29.77 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.149 175.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -106.62 99.42 8.99 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.221 -178.697 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . 0.407 ' HA ' ' HA ' ' A' ' 207' ' ' PRO . 90.3 t -83.42 115.94 26.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.301 -0.408 . . . . 0.0 111.188 -174.319 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 28.4 p -110.33 174.3 5.92 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.199 179.332 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -149.71 144.69 12.32 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 111.166 -0.774 . . . . 0.0 111.166 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.7 t -160.75 120.37 2.7 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.779 0.323 . . . . 0.0 111.265 177.137 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 75.31 14.05 82.27 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 111.267 -0.733 . . . . 0.0 111.267 178.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 95.92 -5.86 66.57 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 -178.418 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -103.5 134.6 46.58 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.826 0.346 . . . . 0.0 111.161 -179.261 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 99.4 mt -83.36 150.8 25.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.227 179.318 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -150.09 73.77 9.28 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.203 177.028 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 207' ' ' PRO . . . . . 0.407 ' HA ' ' HA ' ' A' ' 198' ' ' VAL . 46.2 Cg_exo -63.4 147.71 93.24 Favored 'Trans proline' 0 N--CA 1.456 -0.704 0 C-N-CA 121.729 1.619 . . . . 0.0 111.248 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 87.3 t -118.91 127.72 75.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.22 176.674 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 97.1 m95 -84.15 128.5 34.6 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.253 175.113 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 89.7 t -125.96 122.82 62.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.16 178.144 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -106.41 127.78 53.55 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.141 178.104 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 84.8 mtt85 . . . . . 0 C--O 1.2 -1.501 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.257 179.545 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 76.0 mmtt . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.695 0.283 . . . . 0.0 111.195 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -95.43 -24.73 16.55 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.15 176.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 94.4 mttt -124.88 166.69 15.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.193 176.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -74.02 147.88 42.5 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.185 179.263 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 88.7 mt -114.85 149.82 36.5 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.235 175.225 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 86.3 t -125.77 128.34 72.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.28 178.655 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . 0.617 HH21 ' CE1' ' A' ' 159' ' ' HIS . 81.9 mtp180 -117.7 157.72 25.99 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.235 178.281 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.428 ' O ' ' HA ' ' A' ' 159' ' ' HIS . 14.2 p -130.95 142.42 43.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.147 175.251 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 66.7 tp60 -148.21 109.4 4.32 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.183 179.374 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . 0.461 ' HA ' ' HB ' ' A' ' 198' ' ' VAL . 64.2 t-20 -86.18 108.97 18.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.166 -175.343 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 87.8 mt -90.99 -4.08 56.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.263 179.564 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 27.4 p -102.24 -178.3 3.66 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.192 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -103.66 8.54 51.37 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 111.201 -0.76 . . . . 0.0 111.201 176.566 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 94.9 p -90.39 160.01 16.29 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.816 0.341 . . . . 0.0 111.166 -175.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 39.4 ttpt -107.95 119.29 39.03 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.275 176.177 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 52.0 mt -131.69 150.56 52.11 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.228 -176.776 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 60.1 m -106.68 129.28 54.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.215 174.253 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 63.0 tp -95.48 121.29 37.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.225 -178.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -145.07 145.31 31.39 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.217 -179.535 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 81.1 p -68.8 150.6 47.65 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.223 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -60.62 121.81 13.14 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.209 -178.862 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 79.5 m-20 56.19 36.18 27.0 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.286 -179.174 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -86.45 -179.81 49.35 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 111.171 -0.772 . . . . 0.0 111.171 177.059 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -113.4 -23.75 9.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.774 0.321 . . . . 0.0 111.181 -179.483 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 89.9 m -128.87 136.88 51.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.175 -175.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 76.5 m-20 -65.2 145.82 55.76 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.239 178.48 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . 0.474 HG12 HG23 ' A' ' 151' ' ' VAL . 91.7 t -87.51 -57.04 4.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.194 178.819 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.474 HG23 HG12 ' A' ' 150' ' ' VAL . 46.9 t -130.71 124.33 56.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.178 169.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -94.38 138.06 32.78 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.167 -176.16 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 72.4 m-20 53.84 62.86 2.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.159 171.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 96.7 t -74.26 106.21 3.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.228 176.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -90.09 179.62 43.96 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 -176.564 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -57.39 127.7 26.53 Favored 'Trans proline' 0 C--N 1.327 -0.585 0 C-N-CA 121.702 1.601 . . . . 0.0 111.209 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 94.7 mm-40 66.2 19.32 11.08 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.218 175.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 35.8 t -73.37 145.74 45.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.235 176.772 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' HIS . . . . . 0.617 ' CE1' HH21 ' A' ' 130' ' ' ARG . 82.5 t60 -149.74 143.89 25.72 Favored 'General case' 0 CA--C 1.509 -0.607 0 CA-C-O 122.115 0.959 . . . . 0.0 111.029 178.613 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -158.84 157.43 28.43 Favored Glycine 0 CA--C 1.524 0.602 0 CA-C-N 114.868 -1.06 . . . . 0.0 111.224 -179.425 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 75.8 m-20 -113.01 147.37 37.33 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.849 0.357 . . . . 0.0 111.174 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 90.9 mmt-85 -138.85 148.09 43.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.178 178.314 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -110.06 134.83 51.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.184 173.731 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 20.2 tt -147.77 149.43 15.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.194 -175.082 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 97.0 m-20 -50.21 142.99 13.5 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.202 174.569 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -78.82 65.21 8.78 Favored 'Trans proline' 0 N--CA 1.457 -0.643 0 C-N-CA 121.764 1.642 . . . . 0.0 111.201 -173.615 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 34.3 m -133.42 160.78 42.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.23 176.343 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -65.91 108.44 2.17 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.061 -179.334 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 93.0 t -121.35 125.35 73.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.289 178.037 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 83.9 m-20 -99.38 141.81 31.68 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.162 177.322 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 5.4 mp -124.67 172.6 9.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.167 -174.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -148.11 166.06 28.96 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.207 -178.296 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 67.4 mt -94.69 135.43 36.17 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.251 177.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 -128.91 156.57 43.5 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.204 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 67.9 t0 -144.43 95.42 2.71 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.237 175.363 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 79.88 -106.38 2.44 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 111.199 -0.76 . . . . 0.0 111.199 179.827 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 88.1 p -115.52 7.87 15.02 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.797 0.332 . . . . 0.0 111.184 178.638 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -125.71 130.34 51.32 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.227 -178.309 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 38.9 ttpt -71.23 135.2 47.39 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.216 176.434 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 70.4 t -83.2 -55.57 7.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.152 -179.239 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 43.6 t -173.9 142.13 0.85 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.223 -176.038 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -69.09 146.84 52.24 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.223 176.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 94.6 mt -95.3 158.95 15.23 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.196 176.307 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -57.74 130.37 82.02 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.161 177.647 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_exo -52.85 140.1 58.42 Favored 'Trans proline' 0 N--CA 1.457 -0.661 0 C-N-CA 121.783 1.655 . . . . 0.0 111.17 177.504 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 8.2 p -143.49 136.24 24.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.119 -175.387 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 97.7 m -95.92 131.14 42.58 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.237 176.335 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 59.7 mt -100.04 96.03 7.25 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.171 -176.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -70.14 142.65 52.51 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.226 -177.448 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 80.6 ttt180 -66.55 125.9 27.19 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.241 -176.005 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 93.0 -10.52 73.71 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 173.549 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -103.22 178.93 4.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.788 0.328 . . . . 0.0 111.144 -178.32 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 7.4 p -135.09 139.6 46.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.148 -177.308 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 33.3 m -113.1 156.55 14.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.158 172.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 49.5 t -134.8 129.23 34.24 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.245 179.46 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 66.0 tp -89.45 115.29 26.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.237 177.133 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -101.47 104.34 15.26 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.194 176.571 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . 0.461 ' HB ' ' HA ' ' A' ' 133' ' ' ASN . 84.8 t -79.05 114.2 19.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.207 -173.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 15.3 t -143.84 -160.85 1.17 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.227 179.361 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 167.33 -171.61 42.05 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 44.3 t -162.35 129.21 3.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.732 0.301 . . . . 0.0 111.191 -179.452 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 75.57 15.9 80.96 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 111.157 -0.777 . . . . 0.0 111.157 177.089 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 99.17 -13.91 61.51 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 111.128 -0.789 . . . . 0.0 111.128 -178.327 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -88.7 123.69 33.39 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.777 0.322 . . . . 0.0 111.136 -179.377 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 96.8 mt -74.28 138.33 43.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.141 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -152.8 70.39 7.19 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.246 173.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -58.31 148.26 80.36 Favored 'Trans proline' 0 N--CA 1.458 -0.575 0 C-N-CA 121.783 1.655 . . . . 0.0 111.201 176.363 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 85.6 t -119.62 129.16 75.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.216 -177.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 92.0 m95 -83.59 128.34 34.44 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.229 172.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 86.7 t -121.41 124.87 72.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.2 175.743 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 28.1 ttpp -97.04 128.22 43.78 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.109 179.524 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 96.4 mtt-85 . . . . . 0 C--O 1.201 -1.484 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.236 -178.834 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 99.6 mttt . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.828 0.347 . . . . 0.0 111.206 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' GLN . . . . . 0.446 ' OE1' ' N ' ' A' ' 125' ' ' GLN . 18.3 pm0 -86.56 -6.54 58.85 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.136 176.643 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 99.9 mttt -111.31 -179.14 3.63 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.138 -178.313 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -143.36 173.11 11.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.197 174.807 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 93.7 mt -127.45 142.43 51.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.136 177.059 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 10.0 p -125.05 133.76 68.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.155 175.143 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 44.3 ttm180 -135.6 146.53 48.02 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.109 -177.163 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 98.8 t -125.85 127.24 71.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.167 176.764 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 62.9 tp60 -95.28 128.18 41.92 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.199 -179.688 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 57.5 t-20 -87.17 110.42 20.14 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.237 173.863 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 94.3 mt -101.76 7.91 41.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.123 177.119 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 30.5 t -101.35 158.82 15.77 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.178 178.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -79.85 -9.73 86.44 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.274 -0.731 . . . . 0.0 111.274 172.785 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 87.5 p -91.31 169.96 10.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.854 0.359 . . . . 0.0 111.109 173.321 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -89.1 156.08 19.04 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.197 177.536 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 84.7 mt -109.98 152.75 25.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.236 178.102 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 49.7 p -125.47 78.5 1.73 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.22 177.052 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 38.1 tp -70.92 120.88 17.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.116 -170.041 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -142.99 153.44 43.0 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.236 -178.016 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 85.6 m -57.3 125.31 22.23 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.244 174.117 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -59.07 118.3 5.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.233 -177.426 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 57.34 29.85 17.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.172 -179.566 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -113.38 -171.17 17.75 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.229 -0.748 . . . . 0.0 111.229 177.291 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -115.76 -4.19 12.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.829 0.347 . . . . 0.0 111.181 177.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 99.8 m -98.43 117.15 32.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.139 -175.529 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 81.2 m-20 -74.49 146.56 42.63 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.204 172.611 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . 0.494 HG12 HG23 ' A' ' 151' ' ' VAL . 60.1 t -108.95 -64.89 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.146 -175.192 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.494 HG23 HG12 ' A' ' 150' ' ' VAL . 99.4 t -141.47 120.28 10.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.204 172.06 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 54.2 mtmt -113.38 160.11 18.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.179 -178.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 32.1 t0 62.08 47.77 5.5 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.191 178.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 93.9 t -78.25 114.62 19.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.184 175.288 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -66.7 156.59 51.23 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 -171.549 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -55.02 132.79 54.4 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 121.797 1.665 . . . . 0.0 111.103 177.361 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 92.9 mm-40 57.08 33.09 22.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.162 179.506 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 19.2 t -119.06 -161.49 0.85 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.182 175.572 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 34.3 p80 -160.36 170.11 21.73 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.259 179.481 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -156.66 159.88 29.86 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 176.43 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 20.9 p30 -149.32 175.86 11.06 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.793 0.33 . . . . 0.0 111.237 -175.293 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 58.1 ttm-85 -156.05 140.69 16.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.208 -178.22 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -71.26 128.85 37.29 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.307 171.327 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 19.9 tt -159.06 153.93 5.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.147 -172.054 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 95.6 m-20 -62.87 154.08 77.38 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.181 176.433 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -75.16 71.36 5.13 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 121.725 1.617 . . . . 0.0 111.238 -179.55 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 33.4 m -126.26 179.83 3.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.181 -177.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -76.37 121.08 22.5 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.179 173.732 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 76.9 t -114.18 121.05 65.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.178 -176.367 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 87.3 m-20 -96.36 119.06 34.16 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.196 177.418 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 77.3 mt -113.76 154.19 27.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.206 -174.234 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -158.39 162.54 37.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.267 179.22 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 68.0 mt -111.73 148.58 33.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.154 173.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 35.0 p90 -142.76 160.1 40.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.198 -174.122 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 67.7 t0 -131.39 91.36 3.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.128 174.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 79.49 -106.73 2.45 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 -177.837 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 95.1 p -106.29 -9.26 16.89 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.784 0.326 . . . . 0.0 111.168 177.012 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -104.29 117.71 34.88 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.159 -176.138 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 39.0 ttpt -66.59 136.53 55.73 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.249 177.426 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 72.2 t -86.04 -56.29 5.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.251 -178.441 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 43.5 t -171.36 143.63 1.86 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.19 -176.342 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -72.48 150.33 43.37 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.217 176.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 82.4 mt -106.16 159.33 16.17 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.237 175.32 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 56.4 tptt -55.58 116.29 11.58 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.262 -179.802 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 77.1 Cg_exo -56.38 141.95 88.93 Favored 'Trans proline' 0 N--CA 1.459 -0.514 0 C-N-CA 121.602 1.535 . . . . 0.0 111.155 178.26 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 73.3 t -121.32 127.39 75.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.202 -177.415 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 97.1 m -95.33 116.67 29.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.171 170.194 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 83.3 mt -90.84 158.25 16.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.199 -175.539 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -136.53 156.36 48.69 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.198 -179.492 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 75.3 mtp180 -62.51 124.37 20.76 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.157 -174.453 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 78.7 13.32 83.28 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 111.194 -0.762 . . . . 0.0 111.194 173.172 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 92.5 mt-10 -121.29 158.34 28.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.769 0.318 . . . . 0.0 111.149 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 7.3 p -131.91 139.22 50.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.216 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 84.6 t -112.41 136.43 48.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.212 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 44.6 t -114.72 110.85 20.37 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.214 172.223 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 52.7 tp -90.82 110.57 21.78 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.157 -178.805 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 197' ' ' TYR . . . . . 0.409 ' HB2' ' HB ' ' A' ' 208' ' ' VAL . 85.3 m-85 -86.75 96.77 10.28 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.192 -175.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 97.3 t -86.76 121.58 37.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.178 -174.469 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 14.8 t -153.19 -169.11 3.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.207 178.377 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 144.54 -162.77 27.96 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 111.204 -0.758 . . . . 0.0 111.204 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.3 t -171.5 143.65 1.81 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.833 0.349 . . . . 0.0 111.148 -177.683 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 76.48 16.3 80.83 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 111.192 -0.763 . . . . 0.0 111.192 174.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 94.96 -6.52 69.51 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 111.114 -0.795 . . . . 0.0 111.114 -178.863 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -98.73 115.72 29.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.766 0.317 . . . . 0.0 111.102 179.55 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 91.5 mt -98.72 154.25 18.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.086 -177.291 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -150.74 73.96 8.72 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.208 176.449 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_exo -58.05 139.02 88.92 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 121.656 1.571 . . . . 0.0 111.161 178.653 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 208' ' ' VAL . . . . . 0.409 ' HB ' ' HB2' ' A' ' 197' ' ' TYR . 57.5 t -104.73 114.29 43.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.22 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 209' ' ' TRP . . . . . 0.435 ' CD1' ' C ' ' A' ' 209' ' ' TRP . 7.3 t90 -77.76 96.97 5.04 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.199 -178.082 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 98.3 t -106.23 115.41 47.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.219 175.277 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 29.2 ttpp -102.38 132.53 48.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.206 178.56 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 83.0 mtt85 . . . . . 0 C--O 1.202 -1.412 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.174 179.632 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 88.5 tttt . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.842 0.353 . . . . 0.0 111.282 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 61.7 mt-30 -103.59 150.02 24.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.2 179.368 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 62.9 pttt -164.33 166.29 20.95 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.271 174.253 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -142.13 167.9 21.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.201 -174.792 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 69.3 mt -120.86 154.73 35.42 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.129 176.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 13.1 p -141.39 137.0 32.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.296 177.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -125.82 149.24 48.78 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.166 172.732 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 87.4 t -128.71 120.12 51.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.128 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 64.7 tt0 -110.41 138.57 46.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.239 -174.366 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 64.7 t-20 -88.72 109.62 20.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.223 177.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 7.8 mp -105.93 34.94 3.08 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.284 178.256 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 59.6 p -132.8 173.1 11.73 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.16 177.445 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -86.71 -12.63 68.75 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 175.295 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 95.9 p -88.47 167.02 13.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.888 0.375 . . . . 0.0 111.207 179.13 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -79.04 135.87 37.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.275 178.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 60.5 tp -107.85 131.41 54.52 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.293 -175.758 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' THR . . . . . . . . . . . . . 93.5 m -133.37 128.43 35.6 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.334 172.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 10.3 tt -142.9 132.64 23.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.107 -176.669 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -125.92 165.8 18.07 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.137 179.647 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 14.6 t -150.92 -170.37 3.64 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.211 175.406 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . 55.16 51.63 12.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.19 -175.386 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 75.7 m-20 62.05 27.68 16.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.16 -177.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 84.29 6.67 85.94 Favored Glycine 0 CA--C 1.52 0.367 0 N-CA-C 111.276 -0.73 . . . . 0.0 111.276 176.131 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -81.81 -32.59 31.21 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.805 0.336 . . . . 0.0 111.122 -177.606 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 82.6 m -99.77 120.04 39.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.183 -178.335 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 65.4 t0 -89.32 109.01 19.96 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.192 176.027 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 87.4 t -85.48 -58.0 3.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.202 -176.489 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 27.8 m -132.83 153.33 37.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.209 168.373 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 65.6 tttm -150.55 116.97 5.71 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.337 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 70.8 m-20 56.17 46.98 20.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.266 174.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 33.5 m -101.96 151.24 5.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.142 179.14 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -99.1 -168.98 30.62 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 -171.58 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_exo -58.52 136.97 77.69 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 121.651 1.568 . . . . 0.0 111.153 -178.244 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 96.0 mm-40 68.3 17.12 9.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.249 173.463 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 70.3 m -103.99 151.23 23.44 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.308 170.192 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 56.4 p-80 -152.79 161.56 42.41 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.212 -176.49 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -114.98 160.24 13.31 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 176.481 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 37.4 t0 -136.86 115.5 12.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.609 0.242 . . . . 0.0 111.276 -178.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 89.4 mmt-85 -127.15 144.24 51.08 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.275 -173.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -96.18 124.48 40.2 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.253 175.707 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 46.1 pt -126.15 164.24 26.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.235 -168.1 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 -84.32 160.73 56.42 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.165 177.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -79.02 57.17 6.34 Favored 'Trans proline' 0 N--CA 1.458 -0.604 0 C-N-CA 121.588 1.525 . . . . 0.0 111.148 -179.753 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 33.6 m -130.96 -179.14 3.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.165 -175.774 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -65.61 104.01 0.96 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.305 174.36 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 91.7 t -104.3 126.56 58.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.25 -178.626 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 37.7 t-20 -107.26 109.21 20.93 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.089 -178.32 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 65.9 mt -90.64 117.67 29.48 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.218 175.602 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -126.12 140.39 52.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.154 -175.055 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 96.3 mt -87.69 141.18 28.81 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.185 178.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 174' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -135.6 156.44 48.86 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.209 179.739 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 66.9 t0 -136.05 83.78 2.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.193 173.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 79.48 -105.67 2.31 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.224 -0.75 . . . . 0.0 111.224 -173.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 98.0 p -102.95 -6.02 22.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.789 0.328 . . . . 0.0 111.195 172.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -83.82 131.51 34.88 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.196 -176.571 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 89.1 tttt -86.65 126.32 34.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.151 170.569 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 97.3 t -103.02 -53.02 7.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.195 -171.016 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 47.2 t -146.7 149.06 32.7 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.122 -174.619 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 51.0 t0 -136.2 102.33 4.97 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.228 -175.76 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 94.8 mt -81.56 148.23 29.24 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.148 -177.315 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -62.22 131.48 93.6 Favored Pre-proline 0 C--N 1.327 -0.38 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.244 178.464 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 76.3 Cg_exo -55.05 133.08 56.12 Favored 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 121.611 1.54 . . . . 0.0 111.234 177.031 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 94.0 t -124.21 131.15 73.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.26 178.462 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 98.2 m -88.24 130.01 35.2 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.101 175.584 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 82.0 mt -113.05 153.91 27.38 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.217 -178.635 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -102.41 163.83 12.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.116 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 79.6 ttt180 -51.03 120.21 4.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.147 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 104.74 -16.27 47.67 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 169.387 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 64.7 mt-10 -73.64 136.78 43.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.781 0.324 . . . . 0.0 111.089 -177.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 61.8 t -125.78 123.31 64.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.277 179.148 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 79.2 t -103.44 135.03 42.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.27 -178.411 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 44.3 t -121.78 105.63 10.56 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.249 176.316 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 31.0 tp -81.49 124.16 29.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.215 -176.222 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -105.72 98.52 8.2 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.2 179.196 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 62.3 t -90.54 106.99 17.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.216 -176.398 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 44.5 p -105.22 174.77 5.74 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.089 -175.454 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . 100.36 -138.26 13.75 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 111.406 -0.678 . . . . 0.0 111.406 176.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 42.1 t -163.88 127.18 2.61 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.823 0.345 . . . . 0.0 111.204 178.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . -54.07 139.15 37.74 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 -174.478 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -91.52 8.34 78.96 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 111.015 -0.834 . . . . 0.0 111.015 7.118 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -89.65 69.9 7.78 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.671 0.272 . . . . 0.0 111.076 -177.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 93.4 mt -97.69 156.81 16.38 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.246 -178.342 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -139.42 84.58 16.07 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.135 -176.444 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -57.61 129.42 33.65 Favored 'Trans proline' 0 N--CA 1.459 -0.55 0 C-N-CA 121.692 1.595 . . . . 0.0 111.139 176.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 77.2 t -109.65 115.67 50.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.217 173.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 38.6 t-105 -81.52 105.24 12.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.221 -174.666 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 94.8 t -117.58 119.92 63.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.154 177.063 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -100.31 134.22 43.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.215 178.436 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 40.3 mmt180 . . . . . 0 C--O 1.199 -1.576 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.218 -179.934 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 99.3 mttt . . . . . 0 C--O 1.23 0.078 0 CA-C-O 120.795 0.331 . . . . 0.0 111.239 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 94.7 mt-30 -140.29 54.28 1.63 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.181 178.307 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -170.23 125.41 0.76 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.116 -178.842 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -150.23 143.63 25.09 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.248 172.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 59.0 tp -101.96 128.65 48.28 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.179 -177.613 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 33.1 m -125.48 152.01 31.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.136 174.452 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 41.7 ttm180 -140.85 124.2 16.7 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.208 178.617 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 57.3 t -105.39 121.33 57.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.257 -177.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 64.7 tp60 -107.76 127.01 53.31 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.173 -177.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 57.9 t-20 -85.63 105.34 16.13 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.153 178.357 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 98.3 mt -110.66 28.85 8.28 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.287 176.539 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 50.3 p -104.64 -175.69 2.87 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.222 -178.448 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -100.1 11.18 60.35 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 176.348 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 21.0 t -137.64 -167.46 2.14 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.802 0.334 . . . . 0.0 111.222 -178.388 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -102.63 142.91 33.02 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.125 178.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 93.8 mt -104.47 148.18 26.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.265 -177.265 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' THR . . . . . 0.423 ' HB ' ' HB2' ' A' ' 174' ' ' PHE . 97.2 m -139.26 128.35 23.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.18 169.352 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 79.9 mt -118.97 114.85 23.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.259 -179.243 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -127.24 133.63 50.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.198 179.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 79.4 p -71.83 156.81 38.88 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.134 -172.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -59.93 -30.02 68.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.238 -176.736 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -64.44 -31.65 72.94 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.208 179.625 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 78.18 17.39 78.24 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 -178.734 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -110.02 -27.31 9.27 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.758 0.313 . . . . 0.0 111.184 -178.029 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 69.1 p -130.36 169.7 15.12 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.262 -179.108 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 20.6 p30 -150.61 175.12 12.22 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.162 -178.633 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 88.1 t -129.25 -40.69 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.247 179.093 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 90.1 t -132.09 137.92 53.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.184 -178.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -135.95 107.83 7.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.201 178.085 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 75.5 m-20 51.5 51.31 17.03 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.243 173.459 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 76.6 t -100.57 127.66 53.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.236 179.194 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -88.84 177.66 44.96 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 111.224 -0.75 . . . . 0.0 111.224 -171.067 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -58.8 147.22 89.69 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 121.652 1.568 . . . . 0.0 111.199 -178.211 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 94.4 mm-40 68.98 17.06 8.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.233 176.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 68.1 m -124.87 161.53 26.36 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.168 171.644 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' HIS . . . . . . . . . . . . . 33.8 p80 -146.41 170.14 17.43 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.206 -176.515 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -143.7 145.7 15.66 Favored Glycine 0 CA--C 1.523 0.571 0 N-CA-C 111.246 -0.742 . . . . 0.0 111.246 179.119 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 161' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -111.09 150.34 29.54 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.823 0.344 . . . . 0.0 111.168 -178.324 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 85.1 mmt-85 -143.6 143.6 31.56 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.16 175.433 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -99.53 112.29 24.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.211 170.066 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 76.8 mt -130.78 139.13 51.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.113 -171.183 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 95.3 m-20 -61.67 155.01 63.09 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.206 177.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -63.1 80.15 0.12 Allowed 'Trans proline' 0 N--CA 1.458 -0.595 0 C-N-CA 121.65 1.567 . . . . 0.0 111.173 -178.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 30.2 m -129.28 179.62 3.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.203 177.487 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -89.95 133.8 34.58 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.227 174.241 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 86.1 t -72.4 87.27 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.178 -176.7 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 170' ' ' ASN . . . . . . . . . . . . . 62.9 t-20 -88.36 88.98 7.8 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.154 170.416 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 171' ' ' LEU . . . . . . . . . . . . . 8.7 tt -145.18 140.66 28.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.231 -166.351 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -92.07 141.72 28.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.249 -177.07 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 173' ' ' LEU . . . . . . . . . . . . . 62.6 tp -101.55 117.87 35.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.193 -172.662 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 174' ' ' PHE . . . . . 0.423 ' HB2' ' HB ' ' A' ' 140' ' ' THR . 70.5 m-85 -113.26 148.2 36.04 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.221 -178.524 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -105.69 94.18 5.06 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.196 167.146 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . 77.38 -104.01 1.9 Allowed Glycine 0 CA--C 1.523 0.562 0 N-CA-C 111.232 -0.747 . . . . 0.0 111.232 -173.546 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 177' ' ' SER . . . . . . . . . . . . . 92.8 p -115.86 1.29 13.35 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.716 0.293 . . . . 0.0 111.166 172.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -104.64 116.96 32.97 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.306 -177.511 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -63.57 133.08 53.14 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.17 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 93.7 t -102.18 -53.3 7.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.206 176.614 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 181' ' ' SER . . . . . . . . . . . . . 19.2 t -163.99 -157.75 0.41 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.187 178.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -105.15 137.16 43.36 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.214 170.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 183' ' ' LEU . . . . . . . . . . . . . 51.4 tp -74.73 128.75 36.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.252 -178.567 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -51.91 126.78 34.41 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.25 177.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 185' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -74.4 150.83 41.87 Favored 'Trans proline' 0 N--CA 1.458 -0.613 0 C-N-CA 121.647 1.565 . . . . 0.0 111.246 -176.516 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 14.5 p -147.42 143.79 19.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.177 176.349 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 92.1 m -81.0 124.58 29.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.168 -177.765 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 80.6 mt -93.78 158.75 15.51 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.218 177.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 189' ' ' ALA . . . . . . . . . . . . . . . -159.85 146.02 15.89 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.202 -179.473 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 190' ' ' ARG . . . . . . . . . . . . . 79.8 ttt180 -71.07 134.22 46.89 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.163 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 191' ' ' GLY . . . . . . . . . . . . . . . 101.93 -12.13 57.56 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 111.184 -0.766 . . . . 0.0 111.184 -177.186 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 192' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -121.26 146.65 46.59 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.814 0.34 . . . . 0.0 111.168 179.324 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 193' ' ' VAL . . . . . . . . . . . . . 96.9 t -114.46 123.36 70.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.244 178.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 76.7 t -109.85 114.12 46.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.206 -175.19 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 195' ' ' CYS . . . . . . . . . . . . . 75.9 m -100.7 152.95 19.86 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.239 -178.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 64.8 tp -125.8 123.07 37.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.236 178.294 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 197' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -114.72 108.73 17.18 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.234 -179.543 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 65.5 t -109.43 124.19 65.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.122 -177.474 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 199' ' ' THR . . . . . . . . . . . . . 13.5 t -131.06 -174.29 3.34 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.148 -179.705 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 200' ' ' GLY . . . . . . . . . . . . . . . -89.06 140.73 15.91 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 111.193 -0.763 . . . . 0.0 111.193 -177.615 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 37.3 t -146.38 86.87 1.7 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.798 0.332 . . . . 0.0 111.236 176.68 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 202' ' ' GLY . . . . . . . . . . . . . . . 73.35 22.23 78.91 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 177.194 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . 100.84 -12.5 59.26 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 111.231 -0.747 . . . . 0.0 111.231 -178.154 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -100.62 165.07 11.59 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.738 0.304 . . . . 0.0 111.239 178.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 205' ' ' LEU . . . . . . . . . . . . . 96.5 mt -85.96 139.62 31.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.215 177.285 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -124.09 92.23 48.58 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.216 -179.385 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -76.26 138.75 20.43 Favored 'Trans proline' 0 N--CA 1.457 -0.672 0 C-N-CA 121.777 1.651 . . . . 0.0 111.244 -179.433 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 92.3 t -129.82 122.5 54.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.163 174.813 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 209' ' ' TRP . . . . . . . . . . . . . 91.8 m95 -86.8 126.46 34.63 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.166 178.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 69.5 t -131.62 113.54 23.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.213 176.244 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 211' ' ' LYS . . . . . . . . . . . . . 36.2 ttpt -103.51 136.0 44.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.225 -176.29 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 212' ' ' ARG . . . . . . . . . . . . . 80.4 ttt180 . . . . . 0 C--O 1.198 -1.611 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.18 177.708 . . . . . . . . 0 0 . 1 stop_ save_